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Even if the chirality and its consequences on the human body has been known for more than 
one century, the pharmaceutical industries have begun to be concerned about the different 
effects of the two enantiomers of active pharmaceutical ingredients only since the late 
eighties. The access to pure enantiomers has since become a considerable scientific and 
economical issue. In 2008, the European Community has launched a scientific program, 
called IntEnant, bringing together 13 academic groups and pharmaceutical industries working 
on different and complementary methods to obtain pure enantiomers. The SPCMIB laboratory 
of the University of Toulouse and the SMS laboratory of the University of Rouen, the two 
laboratories in which I worked during my PhD, were partners of this program. The main skills 
of these laboratory, respectively organic chemistry and purification by crystallisation, were 
combined to make a contribution to the access of pure enantiomers.  
  
Among all the methods to have access to pure enantiomers, the resolutions by crystallisation, 
such as pasteurian resolution, are generally productive processes but can not be applied to all 
the compounds. In order to increase the scope of this method, new chiral selectors must be 
synthesized. Cyclodextrins are chiral molecules known to form different inclusion complexes 
with the two enantiomers of a compound. Unfortunately the difference between the 
diastereomeric complexes is generally too small to lead to a chiral discrimination in the solid 
state. Therefore it is necessary to enhance this difference. From this perspective, a small 
library of monosubstituted β-cyclodextrins with an acidic or basic hook was synthesised and 
the study of the formation of diastereomeric complexes between these modified β-
cyclodextrins and a chiral guest was initiated. 
 
Another resolution method, called deracemisation or total symmetry breaking, was recently 
designed. Deracemisation is a powerful resolution method since the targeted pure enantiomer 
can be obtained with 100% yield in one step from its racemic suspension. Unfortunately, the 
limitations inherent in this process are significant: only compounds crystallising as 
conglomerates and racemisable in the same conditions can be candidate. 
The proportion of products crystallising as conglomerate is poor (≈5%) and such 
crystallisation are currently unpredictable. However, some families of organic compounds 
exhibit a higher tendency to crystallise as conglomerate. In this manuscript, two new families 
of compounds exhibiting this behaviour will be presented. One of these families is used in 
intermediate steps of the synthesis of the pure enantiomer of active pharmaceutical 
ingredients. 
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Moreover the deracemisation mechanism, leading the entire conversion of a racemic 
suspension into pure enantiomer, remains an open question. Many studies were carried out 
and the broad outline of the mechanism is known. The study presented in chapter 3 will 
provide some clarifications. 
In addition a new method of deracemisation, with a higher efficiency, will be presented. 
 
 
 
 
 
  
 
 
 
 
 
 
 
Chapter 1: Chirality and separation of 
enantiomers 
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I - Chirality 
 1. Definition 
The word “chiral” was first introduced by Lord Kelvin, Professor of Natural Philosophy at the 
University of Glasgow, in 1884: “I call any geometrical figure, or group of points, chiral, 
and say that it has chirality, if its image in a plane mirror,  ideally realized, cannot be 
brought to coincide with itself.” 1 The term “chiral” is derived from the greek “cheir” which 
means “hand” (Figure I - 1). 
A molecule and its image in a mirror are called “enantiomers” and are said “chiral” whereas 
the term “achiral” is used for molecules which can be superimposed with their mirror image. 
 
Figure I - 1. The right hand and the left hand are image of each other in a mirror but are not 
superimposed. 
 
Chiral molecules have the particular ability to interact with the polarised light: one of the two 
enantiomers rotates the plan of the polarized light to the right (or clockwise) whereas the other 
enantiomer rotates the plan of the polarized light to the left (or counter clockwise); 
Because chiral molecules are image of each other in a mirror, they have the same physical 
properties (melting point, solubility…) and the same reactivity towards achiral molecules. But 
the two enantiomers can have a different behaviour with chiral molecules (See paragraph I.3). 
 
 
 2. History
2
 
Even if the word “chiral” was first introduced in 1884, the phenomenon was observed for the 
first time by René-Just Haüy, a French mineralogist, in 1801.3 By comparing crystals of 
quartz, he noticed that there were two kinds of crystals, image of each other through a mirror, 
that he called “plagièdre droit” and “plagièdre gauche” (Figure I - 2). 
                                                 
1 Lord Kelvin; Baltimore Lectures on Molecular Dynamics and the Wave Theory of Light 1884. 
2 A. Collet, J. Crassous, J. P. Dutasta, L. Guy; Molécules chirales : stéréochimie et propriétés, EDP Sciences, 
CNRS editions: Les Ulis; Paris, 2006. 
3 R. J. Hauy; Traité de minéralogie: Paris, 1801. 
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Figure I - 2. Morphology of enantiomorphous crystals of quartz. 
 
In 1815, Jean-Baptiste Biot observed that molecules such as sucrose, tartaric acid and 
camphor are able to rotate the polarised light clockwise or counter clockwise at the solid state 
(crystal), at the liquid state or in solution.4 He assumed that this ability was directly correlated 
to the molecular properties. 
But the first major discovery in the field of chirality was made by Louis Pasteur in 1848. In 
1820 Kestner, an industrial researcher, synthesized a compound having exactly the same 
composition than the tartaric acid5 but which did not rotate the polarized light,6 contrary to the 
tartaric acid prepared from wine. Joseph Louis Gay-Lussac suggested naming this compound 
“racemic acid” (from the Latin “racemus” meaning “grapes”). In 1848, Kestner gave this 
racemic acid to Pasteur. He crystallised the sodium ammonium tartrate tetrahydrate and was 
disappointed when he realized that the salt did not rotate the polarised light. By looking more 
closely to the crystals he noticed that the sample was not composed of one but of two kinds of 
crystals with a symmetrical shape.7,8 He separated manually the two families of crystals then 
he checked their ability to rotate the polarised light. He noticed that the two kinds of crystals 
had an optical rotation with exactly the same intensity but with opposite signs.9 He deduced 
that these crystals were composed by two kinds of molecules, also image of each other in a 
mirror. Thus, just 26-year old, Louis Pasteur established the bases of the chirality in 
chemistry. 
In 1866, Desiré Gernez, a student of Pasteur, crystallized a pure enantiomer of sodium 
ammonium tartrate tetrahydrate by seeding a racemic supersaturated solution with 
                                                 
4 J. B. Biot; Bull. Soc. Philomatique, 1815, 190-192. 
5 J. L. Gay-Lussac; Schweigger’s journal, 1828, 48, 381. 
6 J. B. Biot; Annal. Chim.Phys. I,I, 1838, 69, 22. 
7 L. Pasteur; C. R. Acad. Sci. Paris, 1848, 26, 535-538. 
8 L. Pasteur; C. R. Acad. Sci. Paris, 1849, 28, 477-478. 
9 L. Pasteur; Annal. Chim.Phys., 1848, 24, 442-459. 
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enantiopure crystals.10 He discovered the basic principle of preferential crystallization but he 
did not experiment further on the subject. 
About ten years later, the next step in establishing the bases of stereochemistry was 
simultaneously taken by Jacobus Henricus van’t Hoff and Joseph Achille Le Bel.11,12 They 
proposed that the chirality was due to a spatial arrangement around a tetrahedral carbon. If a 
carbon is linked to four different substituents, the tetrahedron will be irregular and therefore 
become a chiral centre.  
 
 
 3. Nomenclature of chiral compounds 
To describe the chirality of an enantiomer, several nomenclatures can be used, each based on 
a different particularity of compound: 
• An enantiomer can be labelled (+) when it rotates the plan of the polarized light to the 
right, and (-) when it rotates the plan of the polarized light to the left. The (+) and (-) 
compounds have also been termed d- and l-, respectively for dextrorotatory and levorotatory. 
• The terms of R (rectus) and S (sinister), introduced by Cahn, Ingold and Prelog, describe 
the configuration of the asymmetric carbon.13 
 
Figure I - 3. Chemical structures of S- and R-alanine. 
 
• Amino acids and sugars can be labelled D- or L-, depending on whether the substituent 
with the highest priority is to the right or to the left in the Fisher projection of the molecule. 
 
Figure I - 4. Fisher projection of L- and D-alanine. 
 
 
 
                                                 
10 D. Gernez; C. R. Acad. Sci. Paris,, 1866, 63, 843. 
11 J.H. van't Hoff; Bul.l Soc. Chim. Fr., 1875, 23, 295. 
12 J. A. Le Bel; Bul.l Soc. Chim. Fr., 1874, 22, 337. 
13 R. S. Cahn, C. Ingold, V. Prelog; Angew. Chem. Int. Ed. Engl., 1966, 5, 385-415. 
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 4. Chirality around us 
  a. The biological homochirality 
The human body as well as the other living systems is made of many chiral molecules. 
Indeed, all the chiral proteinogenic amino acids are L and sugars building blocks of DNA and 
RNA are D. Therefore the human body can be considered as a chiral entity; the two 
enantiomers of a compound thus have a different biological activity. For example, the smell 
of two enantiomers can be different. (Figure I - 5)14,15,16 
 
Figure I - 5. Odours of the two enantiomers of a) Limonene: fresh citrus, orange-like/harsh, turpentine-
like, lemon note,
17
 b) cis-linalool oxide: earthy/sweet, floral, creamy,
15
  c) 2-methylbutanoic acid: cheesy, 
sweaty/fruity, sweet.
16 
 
  b. Chirality in the pharmaceutical industry 
The fact that the two enantiomers are seen as two different molecules by the human body is 
also valid for API (Active Pharmaceutical Ingredient). Their difference in behaviour can be 
insignificant or lead to disastrous consequences. For example, in the case of the: 
- Cocaine, the two enantiomers have similar effects. 
- Adrenaline, the S enantiomer is less active than the R enantiomer. 
- Ibuprofen, only the S enantiomer is active. 
- Thyroxin, the levothyroxin is used to treat the hypothyroidism, when the 
dextrothyroxin is used against the hypercholesterolemia.18 
- In other cases, one the two enantiomers can reduce the effect of the other enantiomer. 
                                                 
14 L. Friedman, J.G. Miller; Science, 1971, 172, 1044-1046. 
15 D. Wang, K. Ando, K. Morita, K. Kubota, A. Kobayashi; Biosci. Biotechnol. Biochem. 1994, 58 (11), 2050-
2053. 
16 M. H. Boelens, H. Boelens, L. J. van Gemert, P. & F., 1993, 18(6), 1-15. 
17 L. Friedman, J.G. Miller; Science, 1971, 172, 1044-1046. 
18 C. Bommer, E. Werle, I. Walter-Sack, C. Keller, F. Gehlen, C. Wanner, M. Nauck, W. März, H. Wieland, J. 
Bommer; J. Am. Chem. Nephrol., 2005, 16, 2789-2795. 
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One of the most infamous examples is the thalidomide. While the R enantiomer is a sedative 
drug, the S enantiomer is a teratogen compound.19 In the years 1950 and 1960, the effect of 
the S enantiomer was not known and the racemic thalidomide was typically used to cure 
morning sickness during pregnancy. The dramatic consequences were that more than 10,000 
children in 46 countries were born with deformities such as phocomelia. 
Even if the importance of the different behaviour between the two enantiomers of a drug was 
known for a long time, the interest for the use of pure enantiomer in pharmaceutical industry 
dates from a few decades. Until then, the scientists thought that the distomer was not used by 
the organism and eliminated without more complications. But in 1984, Everhardus Jacobus 
Ariëns compared the non-active enantiomer (i.e. the distomer) to an impurity.20 An impurity 
of 50%! He spoke about a “highly sophisticated scientific nonsense”. Since that day, the 
interest for enantiopur drugs has grown more and more until 2001 when no more drug were 
sold as a racemic mixture. (Figure I - 6)21 
 
Figure I - 6. Annual distribution of FDA-approved drugs according to chirality in the period 1991-2002. 
* Including diastereomeric mixtures. 
 
The need for pure enantiomers has become a major issue in the pharmaceutical industry for 
two main reasons. The first and the more important one is that the distomer can be toxic. 
Nobody wants the disaster of the thalidomide to happen again. The second reason is an 
economical reason; even if the distomer is not dangerous, its cost of production is not 
insignificant. The sooner it can be removed during the synthesis, the lower the cost, for the 
industry and for the customer. The sale of an enantiopure drug, initially available as a racemic 
mixture, also allows extending the term of the patent. 
Currently enantiopure drugs are obtained by:21 
 - Synthesis from the chiral pool, i.e. from easily available chiral molecules (45%). 
 - Enantioselective synthesis (9%). 
                                                 
19 B. K. Patel, A. J. Hutt; Chirality in Drug Design and Development 2004, Chap. 5, I. K. Reddy, R. Mehvar, 
Eds, New-York, Marcel Dekker Inc. 
20 E. J. Arien; Eur. J. Clin. Pharmacol., 1984, 26, 663-668. 
21 H. Caner, E. Groner, L. Levy; Discovery Drug Today, 2004, 9(3), 105-110. 
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 - Resolution of the racemic mixture, mainly from the crystallisation of diastereomeric 
salts (46%). 
Details about these methods will be given in paragraphs IV and V. 
 
 
 
II - Thermodynamics of chiral molecules 
 1. Thermodynamics 
A system is in equilibrium when it is in thermal, chemical and mechanical equilibrium. That 
means that for a system of n components, the intensive parameters, i.e. the temperature T 
(thermal equilibrium), the pressure P (mechanical equilibrium) and the chemical potentials µi 
(chemical equilibrium for the component i), are the same in all phases. 
In a system of n independent components, with φ phases in equilibriums, there are n + 2 
intensive parameters which are related to φ equations. The variance v defined by the Gibb’s 
rules (Equation I - 1) corresponds to the number of intensive variables which can be varied 
independently without changing the equilibrium between all the phases. 
ϕ-2v += n  Equation I - 1 
 
In some case, the variance can decrease when the intensive parameters are linked together. 
For example, the two enantiomers have the same chemical potential then the Gibbs-Scott 
phase rule22 must be applied. (Equation I - 2) 
2
'
--2
2
'
v
ϕ
ϕ++=
n
n  
Equation I - 2 
 
 
 
 2. Binary diagrams of racemic mixtures 
There are many possibilities for a racemic mixture to form condensed phases. 23 To simplify, 
if we assume the absence of partial solid solutions and solid-solid transitions, three 
possibilities exist. (Figure I - 7) 
                                                 
22 R. L. Scott; J. Chem. Soc., Faraday Trans. 2, 1977, 73, 356-360. 
23 G. Coquerel; Enantiomer, 2000, 5, 481-498. 
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Figure I - 7. Binary phase diagrams of an enantiomer pair in absence of partial solid solution and 
solid/solid transition. 
 
• Conglomerate (5-10% of the pair of enantiomers):24 the two enantiomers crystallise 
separately, as in a physical mixture. The binary diagram of a conglomerate is an eutectic and 
it is symmetric because of the properties of the enantiomers. Below the eutectic temperature 
(TE), the solid phase is composed of crystals of pure enantiomer whatever the composition of 
the mixture and there is a full chiral discrimination in the solid state. 
• Racemic compound (90-95% of the pair of enantiomers): there is a defined compound 
formed by a stoichiometric mixture of the two enantiomers. In the solid state there is a 
mixture of the racemic crystals and crystals of the pure enantiomer (R or S, depending on the 
composition of the system). This compound exhibits a congruent melting which can be higher 
(as it is the case in the example) or lower than the pure enantiomer melting. 
• Total solid solution (<1%): crystals are composed of the two enantiomers randomly 
distributed inside the structure. Each crystal is representative of the composition of the 
system, whatever its composition. The chiral discrimination is almost impossible in this case; 
only few cases of preferential enrichment were described in the literature.25 
Unfortunately these three cases are not the only one to exist and mixtures of them are 
frequently observed. 
Figure I - 8 represents a partial solid solution, a mixed situation between a conglomerate (the 
right diagram) and a complete solid solution (the left diagram). A part of the molecules of one 
enantiomer is substituted by the other enantiomer preventing the total discrimination at the 
solid state. 
                                                 
24 R.A. Sheldon; Chirotechnology : industrial synthesis of optically active compounds; Marcel Dekker: New 
York, 1993. 
25 R. Tamura, D. Fujimoto, Z. Lepp, K. Misaki, H. Miura, H. Takahashi, T. Ushio, T. Nakai, K. Hirotsu; J. Am. 
Chem. Soc., 2002, 124(44), 13139-13153. 
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Figure I - 8. Evolution of the discrimination at the solid state. 
 
Of course, many other possibilities can be encountered, as mixed situations between a 
conglomerate and a racemic compound, or polymorphic transition both for pure enantiomer 
and racemic compound. However, these cases require dedicated studies and will not be 
described in this manuscript. 
 
 
 3. Ternary diagrams of racemic mixtures 
Unfortunately, it is almost impossible to work up to the melting with organic molecules. 
Indeed, melting is often concomitant to degradation of the product. To prevent it, most of 
crystallisations are carried out in an achiral solvent, therefore a third component have to be 
added, transforming binary diagrams into ternary diagrams. Figure I - 9 depicts isothermic 
ternary phase diagrams of a conglomerate, a racemic compound and a complete solid solution, 
in the case where the solvent is liquid and the two enantiomers are solid at the considered 
temperature. Of course many other and more complicated cases are possible but they are not 
described in this manuscript.23 
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Figure I - 9. Ternary phase diagrams of a conglomerate (left), a racemic compound (middle) and a 
complete solid solution (right) in absence of partial solid solution and solid/solid transition. 
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• The isotherm associated with a conglomerate is divided into four domains. The 
monophasic domain 1 is composed by an undersaturated liquid phase and is located at the 
solvent apex of the triangle. Two symmetrical domains exist in which a solid phase composed 
by crystals of a pure enantiomer (the enantiomer R in the domain 2R and the enantiomer S in 
the domain 2S) is in equilibrium with a saturated liquid. The fourth domain is a three phase 
domain in which a polysaturated solution is in equilibrium with the two solid phases. 
• The isotherm associated with a racemic compound is divided into six domains. The 
domains 1, 2R and 2S are the same as in the ternary diagram of the conglomerate (respectively 
a liquid phase, pure crystals of R in equilibrium with a saturated liquid, and pure crystals of S 
in equilibrium with a saturated liquid). The racemic compound is present in three domains: 
2R/S, 3R and 3S. 2R/S is a biphasic domain composed by the racemic compound in equilibrium 
with a saturated liquid. 3R and 3S are three phase domains in which the racemic compound is 
in equilibrium with crystals of a pure enantiomer (the enantiomer R in 3R and the enantiomer 
S in 3S) and a polysaturated solution. The locations of the 3R and 3S domains are the key data 
for the enantiomeric separation from a racemic compound. 
• The isotherm associated with a complete solid solution exhibits only two domains. The 
monophasic domain 1 is composed by a liquid phase and is located at the solvent apex of the 
triangle. The domain 2 is a biphasic domain: the solid phase is in equilibrium with a saturated 
liquid. The composition of both phases in equilibrium is linked by tie lines represented by 
dashed lines in the diagram. 
 
The solvent can also modify the ternary diagram by stabilising a phase or ensuring the 
existence of news phases, as, for example, a stable conglomerate. 
Solvated conglomerate Solvated racemic compound
(R)(S)
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2S,svt 2R,svt
1
Solvent
3R/S
3S 3R
(S)svt (R)svt 3S 3R
2R/S,svt
1
2S 2R
Solvent
R/S,svt
 
Figure I - 10. Possible ternary phase diagrams when solvated solid phases exist 
 
Figure I - 10 depicts two cases in which the solvent modifies the crystallisation of the 
enantiomers by the presence of a solvated phase. 
• In the left diagram, the solvated phase crystallise as a conglomerate while the asolvated 
phase crystallises as a racemic compound. Domains 1, 2S,svt, 2R,svt and 3svt correspond to the 
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typical diagram of a conglomerate in which the conglomerate is a solvate; the chiral 
discrimination is possible in this solvent. The asolvated phases are only present in the 
domains 3S, 3R and 3R/S. 
• In the right diagram, the existence of a solvated racemic compound (R/S,svt) prevent the 
formation of the conglomerate between asolvated solids. In the three phases domain 3, 
asolvated R and S are in equilibrium with the solvated racemic compound. 
The separation of the two enantiomers is made easier when the compound crystallise as a 
conglomerate. Unfortunately, as seen previously, conglomerates are not prevalent in Nature 
and the prediction of the crystallisation of a compound as a conglomerate remains an open 
question. Therefore it is very important to detect the conglomerate. 
 
 
 
III - How to detect a conglomerate? 
 1. Comparison of spectroscopic data 
As said previously, a racemic molecule crystallising as a conglomerate has the particular 
property to be a physical mixture of single crystals of pure enantiomers. Indeed, all the solid 
phases in a conglomerate (the pure S or R crystals and the mixture of these two solids) exhibit 
the mirror image crystal packing whereas the crystal packing of the solid phases in the case of 
a racemic compound (the pure S or R enantiomers and the racemic compound) are different. 
As a consequence, the spectroscopic data (X-Ray diffraction, InfraRed or Raman 
spectroscopy and solid state NMR) of the racemic mixture and of the pure enantiomer are 
exactly the same in the case of a conglomerate (anomalous scattering is not considered here), 
whereas they are different in the case of a racemic compound. Comparison of spectroscopic 
data can prove the existence of a conglomerate. 
However, in the case of a total solid solution, there is only one single phase, so only one 
crystal packing. Spectroscopic data of a mixture of any composition of a total solid solution 
are almost the same (few weak differences are possible due to the substitution of one 
enantiomer by the other one) but should not be confused with a conglomerate.26 Nevertheless, 
complete solid solutions are unusual (less than 1%) and can be differentiated from 
conglomerate by using other analyses. 
 
                                                 
26 B. Chion, J. Lajzerowicz, D. Bordeaux, A. Collet, J. Jacques; J. Phys. Chem., 1978, 82, 2682-2688. 
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 2. Second Harmonic Generation 
Another problem concerning the use of spectroscopic data is the need to have access to the 
pure enantiomer. A new method to detect conglomerates, from racemic samples, has been 
designed in the laboratory: the SHG (Second Harmonic Generation). It is a nonlinear optic 
technique, in which photons interacting in a non centro symmetric material are combined to 
form new photons with twice energies (i.e. double frequence) of the initial photons. A powder 
sample is irradiated with a LASER (wave length λ) and the signal generated by the sample 
(diffused light) is analysed. (Figure I - 11) If the product crystallises in a non-centrosymmetric 
space group, a part of the signal generated will have a wave length divided by two (i.e. a 
double frequency),27 when the signal generated by a centrosymmetric space group is the same 
as that of the incident wave.28 All the conglomerates crystallise in a non centrosymmetric 
space group since in a centrosymmetric space group, the presence of an inversion centre 
induce the presence of the two enantiomers in the crystal packing. 
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Figure I - 11. Second harmonic generation set-up. 
 
Unfortunately, a positive signal in SHG (i.e. a wave length divided by two) is not a proof that 
the sample is a conglomerate. Indeed: (i) some racemic compound crystallise in a non 
centrosymmetric space group with Z’=2 (i.e. the two enantiomers are combined in the 
asymmetric unit), (ii) a racemic compound can crystallise in a non centrosymmetric but non 
chiral space group (e.g. Pca2, Pna2, Pc, Cc…). These cases remain in minor proportion, so the 
SHG remains a fast and accurate analysis to do a pre-screening of conglomerates. Additional 
spectroscopic data can be used to remove false positive. 
 
 
                                                 
27 S. K. Kurtz, T. T. Perry; J. Appl. Phys., 1968, 39, 3798-3813. 
28 A. Galland, V. Dupray, B. Berton, S. Morin-Grognet, M. Sanselme, H. Atmani, G. Coquerel; Cryst. Growth  
Des., 2009, 9, 2713-2718. 
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 3. Structural resolution 
The best method to know if the molecule crystallises as a conglomerate remains the X Ray 
diffraction on single crystal. Indeed, this method gives us, among other things, the space 
group of the crystal and the asymmetric unit, removing all the ambiguity. 
 
 
 
IV - Access to pure enantiomers 
Since chirality was discovered, and especially since it is known that the two enantiomers have 
a different behaviour toward another chiral system (such as molecules of the human body), 
researchers try to find methods to have access to pure enantiomers. Methods mainly used are 
summarised in Figure I - 12.24 A short description of these methods is given in the following 
paragraphs. 
Achiral substances
Assymetric synthesisNon enantioselective synthesis
Racemic mixture
Chiral pool
Biocatalytic process
Chiral chromatography
Crystallisation
Kinetical resolution
Pure enantiomer
 
Figure I - 12. Different routes to access to pure enantiomer 
 
The choice of the method depends on the enantiopure intermediate to obtain during the 
synthesis of the final compound, i.e. depends on its physico-chemical behaviour (solubility, 
stability…) and on the ratio time to reach pure enantiomer/cost of the method. A typical 
industrial decision tree for the resolution of a racemic mixture is presented below: 
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racemisable compound?
Economical advantages for 
the asymmetric synthesis?
Conglomerate?
Biocatalysis, 
chromatography 
and/or crystallisation
Asymmetric 
synthesis
Preferential 
crystallisation 
combined with 
racemisation
Chromatography 
combined with 
racemisation
Chromatography 
then crystallisation 
and racemisation
Anti-conglomerate?
No Yes
No Yes
No Yes
No Yes
 
Figure I - 13.  Decision tree for an industrial compound to resolve. 
 
In order to improve the research on enantiomeric substances, the European Community has 
launched a project called IntEnant29,30 (acronym for “Integrated synthesis and purification of 
Enantiomers”, Figure I - 14), a part of the seventh Framework Program (or FP7). This project 
lasted 3 years, from June 2008 to June 2011. IntEnant brought together 13 institutions, both 
academic groups (as the University of Rouen and the University of Paul Sabatier of Toulouse) 
and pharmaceutical companies, in 11 geographical locations in 6 countries (France, Germany, 
Italy, Sweden, Switzerland and United Kingdom). IntEnant aimed at designing new methods 
to obtain pure enantiomers or to improve the existing ones, or even to combine different 
methods by ensuring communication between the different groups. Several work packages 
were formed, bringing together the different specialities of each group such as crystallisation, 
organic synthesis, chromatography, biocatalytic processes, computer simulation… 
 
Figure I - 14. Logo of IntEnant. 
 
 
 
 
                                                 
29 H.-J. Federsel; Org. Proc. Res. Dev., 2012, 16, 260-261. 
30 IntEnant website: http://www.intenant.eu/ 
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 1. Non enantioselective synthesis from the chiral pool 
Chiral compounds can be prepared from the chiral pool, i.e. from chiral molecules readily 
available and inexpensive. Most of these molecules come from natural product, like amino-
acids, saccharides or alkaloids. The chirality already exists in the starting material and 
classical organic synthesis can be performed to achieve the production of the target 
compound. 
 
 
 2. Asymmetric synthesis from an achiral substrate 
When a chiral molecule cannot be synthesised from the chiral pool, the chiral centre can be 
created during steps of the synthesis from a prochiral precursor. The final chirality of the 
chiral centre can be controlled by the use of:31 
• Chiral reagent:32 chiral molecule used during the synthesis but not present on the product, 
such as a chiral reducing agent to perform a reduction. 
• Chiral auxiliary:33 temporary chiral compound added during a step of the synthesis of the 
API. This temporary chiral centre drives the selectivity of the second chiral centre during its 
formation. It is a step of diastereoselective synthesis. 
• Chiral catalyst:32,34 chiral compound involved in the formation of a chiral transition state 
from the prochiral precursor. Once the product is formed, the catalyst goes back into the 
reaction mixture without modification then can be used again. This method is mainly used at 
the industrial scale, because the amount of catalyst can be small and/or it can be recycled, 
therefore reducing the cost of the synthesis.31 
 
 
 3. Resolution of racemic mixtures 
When the synthesis of a single enantiomer is difficult to design (low yield, expensive catalyst 
or chiral auxiliary…), the synthesis of the racemic mixture, following by the resolution of the 
two enantiomers, can be the best option. Techniques mainly used to separate the two 
enantiomers are described below: 
                                                 
31 A. N. Collins, G. N. Sheldrake, J. Crosby; Chirality in industry: the commercial manufacture and applications 
of optically active compounds; Wiley: Chichester, 1992. 
32 E. J. Corey, S. Shibata, R. K. Baksi; J. Org. Chem., 1988, 53, 2861-2863. 
33 H. E. Ensley, C. A. Parnell, E. J. Corey; J. Org. Chem., 1978, 43, 1610-1612. 
34 H. Takaya, K. Mashima, K. Koyano, M. Yagi, H. Kumobayashi, T. Taketomi, S. Akutagawa, R. Noyori; J. 
Org. Chem., 1986, 51, 629-635. 
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• Chiral chromatography:35 mixture of enantiomer is eluted through a chiral stationary 
phase by a mobile phase. The chiral stationary phase is typically constituted by chiral 
molecule (like cyclodextrins, chiral amino acids…) grafted on silica. The two enantiomers 
have a different behaviour towards the stationary phase, therefore they have different 
retention time and they can be separated. A variant used at the industrial scale is the 
Simulated Moving Bed Chromatography (SMB chromatography).36 The SMB 
chromatography process employs several connected chiral columns. These are switched 
periodically against the fluid flow, which simulates a counter-current of liquid and solid 
phases, ensuring a continuous separation of the compounds, as illustrated in the Figure I - 15. 
The performance is often superior compared to a classical use of (chiral) columns. 
 
Figure I - 15.  General principle of SMB chromatography. 
 
Unfortunately, chromatographic methods are very expensive to set up because of the cost of 
columns, and a large amount of solvent is used. However, when the chromatographic method 
is well designed for a compound, it can be a very attractive way to obtain pure enantiomer, 
especially if the solvent can be recycled. 
• Kinetic resolution: this method plays with the kinetic of reaction of the two enantiomers. 
Indeed, in a chiral environment, one of the two enantiomers will react quickly than the other 
one. The final mixture is composed by the unreacted enantiomer and the product of the 
reaction, easier to separate than a racemic mixture. The chiral environment can be due to an 
enzyme (see the next paragraph)37 or a chiral catalyst.38  However, the maximal yield is 50%. 
                                                 
35 T.E. Beesley, R. P. W. Scott; Chiral chromatography; J. Wiley: Chichester, England; New York, 1998. 
36 G. Subramanian; Chiral Separation Techniques: A Pratical Approach, Wiley-VCH ed., 2006. 
37 A. Abate, E. Brenna, A. Constantini, C. Fuganti, F. G. Gatti, L. Malpezzi, S. Serra; J. Org. Chem., 2006, 71, 
5228-5240. 
38 S. E. Schaus, B. D. Brandes, J. F. Larrow, M. Tokunaga, K. B. Hansen, A. E. Gould, M. E. Furrow, E. N. 
Jacobsen; J. Am. Chem. Soc., 2002, 1307-1315. 
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• Dynamic Kinetic Resolution DKR:39 technique combining kinetic resolution and 
racemisation of the substrate in solution. As illustrated in the Figure I - 16, the kinetic of 
racemisation must be very fast compared to the kinetic of the reaction of the target compound 
(S)-B, ensuring a continuous supply in compound (S)-A 
 
Figure I - 16. General principle of DKR. 
 
For example, a reaction with a Grignard reagent can be catalyzed by chiral nickel complexes 
of β-aminoalkylphosphines with good yield and enantiomeric excess. (Figure I - 17) 
 
Figure I - 17. DKR applied to a Grignard reaction. 
 
• Biocatalysis: kinetic resolution ensured by an enzyme or a microorganism, like yeasts.40 
Biocatalysis DKR can also be performed, as illustrated in Figure I - 18: the two enantiomers 
of the N-benzoylphenylalanine can be prepared in 100% yield and 99% e.e. from the racemic 
2-phenyloxazolin-5-one. A porcine pancreatic lipase was used to synthesise the S enantiomer 
whereas a lipase from Aspergillus niger was used to prepare the R enantiomer.39 
 
Figure I - 18. Enzyme catalysed reactions. 
 
                                                 
39 R. S. Ward; Tetrahedron: Asymmetry, 1995, 6, 1475-1490. 
40 K. Leijondahl, L. Borén, R. Braun, J.-E. Bäckvall; J. Org. Chem., 2009, 75, 1988-1993. 
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Unfortunately, this process is limited by its moderate productivity (especially by the volume 
productivity) and by the difficulty to find the best enzyme or microorganism, but also by the 
experimental conditions. Most of them are efficient around 37°C and in an aqueous 
environment whereas organic solvents are often necessary to solubilise reagents and to 
promote synthesis. However, new enzymes and microorganisms can be designed by genetic 
manipulations in order to improve their performances. 
• Crystallisation: many resolution methods based on a crystallisation step have been 
designed. A brief overview of the separation techniques by crystallization is presented in the 
paragraph V. 
 
 
 4. Analysis methods 
To know if the asymmetric synthesis or the resolution of the two enantiomers have been 
efficient, it is necessary to have methods to determine the enantiomeric composition of the 
final product. 
 
  a. Chiral HPLC 
The chiral HPLC (High Performance Liquid Chromatography) is very similar to the chiral 
chromatography described above, but it is designed for an analytical use. It is not necessary to 
know the concentration of the analytical sample because the two enantiomers have the same 
behaviour towards a detector as UV detector or a symmetric behaviour towards detectors as a 
micropolarimetre or a circular dichroism detector. The peak areas are directly proportional to 
the relative percentage of the two enantiomers. Unfortunately, HPLC analyses are not 
instantaneous (10-30 minutes). HPLC cannot be used on-line to know the composition of the 
reaction mixture, but is a convenient method to analyse final products. 
 
  b. Polarimetry 
The measurement of the optical rotation was at the origin of the discovery of the chirality (see 
paragraph I.2) and it is still used to determine the enantiomeric excess of a sample. As said 
previously, the two enantiomers have the same specific optical rotation (α0) but with opposite 
signs. α0 is dependant on the temperature, on the wavelength of the polarized light and on the 
solvent. The optical rotation of the sample depends on the number of each molecule 
encountered by the light, therefore depends on the concentration of the sample and on the 
length of the measurement cell (Equation I - 3). The optical rotation can be related to the 
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enantiomeric excess thanks to a small modification of the Equation I - 3 (Equation I - 4). The 
polarimetry method has several inconvenients: the need to know the exact concentration of 
the sample and to perform a calibration, but also to have chemically pure samples. Indeed, if 
sample are contaminated by another chiral compound, the optical rotation will not only due to 
the target molecule. But the result is instantaneous and can be used to follow the evolution of 
the enantiomeric excess during an experiment. 
)C.(.0 −+ −= Clαα  Equation I - 3 
totC
ee ..
.0 lαα =  
Equation I - 4 
 
 
 
V - Purification by crystallisation 
The purification by crystallisation is one of the oldest methods to purify a product and still 
one of the most widely used. Crystallisation is used both for chemical and enantiomeric 
purification of molecules. Three kinds of purifications by crystallisations are described in the 
following paragraphs; their efficiency is directly linked to the properties of the molecule. 
 
 
 1. Pasteurian resolution 
This method, the oldest one, was designed by Louis Pasteur in 1853 and is based on the 
symmetry breaking between the two enantiomers. The principle of this method is to transform 
an enantiomer pair into a diastereomeric pair by adding a pure chiral agent to a solution of a 
racemic mixture in an achiral solvent. Contrary to enantiomeric compounds, diastereomeric 
compounds are not mirror images and therefore have different physico-chemical properties,41 
such as the difference of solubility, make it possible the separation of the two diastereomers. 
Then the pure enantiomer is separated from the chiral agent. Thus, Louis Pasteur added a 
chiral base to the racemic mixture of tartaric acid in order the form the two diastereomeric 
salts. Then he separated the two diastereoisomers by crystallisation, by using their difference 
in solubility. 
However, for this method to be interesting economically, the chiral agent must be cheap and 
easily available in large amount with a good enantiomeric purity, and/or be easily recycled. 
                                                 
41 J. Jacques, A. Collet, S. H. Wilen; Enantiomers, racemates, and resolutions 1981, New York, Wiley. 
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Therefore, most of chiral agents come from the chiral pool. Another limitation is the need to 
have a strong enough acidic or basic function on the pair of enantiomers to form the 
diastereomeric salt. Often, several diastereomeric salts must be formed in order to find the 
best combination, i.e. the best difference in solubility, the best yield and the easiest separation 
of the pure enantiomer and of the chiral agent. 
 
 
 2. Preferential crystallisation
42
 
  a. Definition and history 
Preferential crystallisation (hereafter PC) is a stereoselective crystallisation making possible 
the separation of the two enantiomers. From a racemic or nearly racemic supersaturated 
solution, and thanks to a careful management of the system, only one enantiomer crystallises. 
Historically, the first preferential crystallisation was carried out in 1866 by a Pasteur’s 
student, Desiré Gernez.10 He described to Pasteur the strange behaviour of a saturated solution 
of sodium ammonium tartrate tetrahydrate: 
 - A saturated solution of pure enantiomer seeded by small crystals of the other 
enantiomer does not give new crystals. 
 - A saturated solution of racemic mixture seeded by small crystals of the one of the 
two enantiomers gives bigger crystals of the same enantiomer. 
In 1882, Jungfleish43 emphasized the importance of the supersaturation on the success of the 
preferential crystallisation. In 1914, Werner described the first resolution of enantiomeric 
compounds: complexes of potassium cobalt trioxalate44 and in 1934, the resolution of the 
histidine mono chlorohydrate 45 was carried out. But it is only in 1959 that the proof of the 
large scale resolution was made by performing the resolution of the (1R,2R)-
chloramphenicol.46  Since the second part of the 20th century, with the publications of Secor47 
then Jacques and collaborators,48 the preferential crystallisation has become a widely used 
method to obtain pure enantiomers. 
 
 
                                                 
42 G. Levilain, G. Coquerel; Crystengcomm, 2010, 12(7), 1983-1992. 
43 M. E. Jungfleisch; J. Pharm. Chim., 1882, 5, 346-357. 
44 A. Werner; Chem. Ber., 1914, 47, 2171-2182. 
45 R. Duschinsky; Chem. Ind., 1934, 53, 10-20. 
46 G. Amiard; Experientia, 1959, 15, 1-7. 
47 R. M. Secor; Chem. Rev. 1963, 63, 297-309. 
48 A. Collet, M. J. Brienne, J. Jacques; Chem. Rev., 1980, 80, 215-230. 
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  b. General scheme of preferential crystallisation 
Typically, preferential crystallisation is a cyclic process, alternating the crystallisation of the 
two enantiomers (Figure I - 19). 
S R
S
 
Figure I - 19. Basic description of preferential crystallization. 
 
Starting from a slightly enriched mixture (typically 10% e.e.) in one enantiomer (e.g. the S 
enantiomer), this enantiomer is selectively crystallised. The solid is collected by filtration (or 
centrifugation) then racemic mixture, corresponding to the mass of pure enantiomer 
harvested, is added to the mother liquor in order to reach a mixture having exactly the mirror 
image composition than the starting mother liquor (i.e. a mixture slightly enriched in the R 
enantiomer). Then the R enantiomer is selectively crystallised. By adding racemic mixture, 
the mother liquor gets back to the initial situation and the S enantiomer is crystallised again. 
As the preferential crystallisation is a cyclic process and as the mother liquor is recycled, 
yields of this kind of resolution can be very good, and the two enantiomers are recovered. 
Several methods of preferential crystallisation were performed and are described below. 
 
  c. Seeded isothermal preferential crystallisation 
Seeded isothermal preferential crystallisation (SIPC) is the oldest method of preferential 
crystallisation. A saturated liquid enriched with one enantiomer (e.g. the enantiomer R) at the 
temperature Thomo is cooled down to TF in order to induce a sufficient supersaturation then 
seeds of pure crystals of R are added. Ideally, only the crystallisation of the R enantiomer 
takes place then the solid and the suspension are separated. The mother liquor, containing thus 
an excess of the S enantiomer, is heated to Thomo then racemic mixture is added to have a 
system with the exact opposite composition as the initial one. The mother liquor, enriched 
with the S enantiomer, is cooled down to TF and seeds of pure crystals of S are added. The 
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solid (ideally only the S enantiomer) and the liquid (containing an excess of the R enantiomer) 
are separated. The system is came back to the initial composition by adding racemic mixture 
to the mother liquor and by heating it to Thomo. The crystallisation of the R enantiomer can be 
performed again. 
 
  d. Auto-seeded polythermic programmed preferential crystallization 
Auto-seeded polythermic programmed preferential crystallization (AS3PC), 49 developed by 
the SMS laboratory, is similar to the SIPC mode but the initial system is composed of a 
saturated solution in equilibrium with crystals of a pure enantiomer (e.g. the enantiomer R). 
The crystallisation of the R enantiomer is ensured by a controlled cooling, thanks to a 
temperature ramp from Ti to Tf. In the ideal case, only the R enantiomer crystallises. The solid 
and the liquid are separated, before the crystallisation of the S enantiomer. Then, racemic 
solid is added and the system is heated to Ti to obtain a system with the exact opposite 
composition of the initial one; a saturated solution in equilibrium with crystals of the S 
enantiomer. 
 
  e. Auto-seeded preferential crystallisation induced by solvent evaporation 
Auto-seeded preferential crystallisation induced by solvent evaporation (ASPreCISE)50 is a 
new method of preferential crystallisation, developed by the SMS laboratory. The principle of 
this method is the same than in the AS3PC mode (i.e. a cyclic process with a saturated 
solution in equilibrium with crystals of a pure enantiomer as initial composition) but the 
supersaturation is generated and controlled by solvent evaporation and not by cooling. 
 
  f. Second-order asymmetric transformation 
Second-Order Asymmetric Transformation (SOAT) combines preferential crystallisation and 
in-situ racemisation.51,52,24 It is the ultimate version of the preferential crystallisation since 
starting from a racemic mixture, a single enantiomer can be quantitatively harvested in a 
single step. The initial system is composed by a saturated solution in equilibrium with crystals 
of a pure enantiomer at Ti. All along the controlled cooling, from Ti to Tf, crystals of pure 
enantiomer are in equilibrium with a racemic mixture. The in-situ racemisation erodes the 
chiral imbalance, making more difficult the crystallisation of the counter enantiomer. 
                                                 
49 WO9508522, 1995. 
50 WO2011/07330. 
51 US4417070 1983. 
52 S. N. Black, L. J. Williams, R. J. Davey, F. Moffat, R. V. H. Jones, D. M. McEwan, D. E. Sadler; 
Tetrahedron, 1989, 45, 2677-2682. 
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Therefore it is possible to decrease more the temperature or to evaporate a larger volume of 
solvent than in the case of AS3PC or ASPreCISE, increasing the yield. 
 
  g. Comparison between preferential crystallisation methods 
Usually, ASP3C mode gives better results than SIPC mode.53,54 The initial composition of the 
system is the major difference, seeding being not necessary in the AS3PC mode. Furthermore, 
the larger amount of solid in suspension in AS3PC mode compared with the seeds in SIPC 
mode, combined with the controlled cooling in AS3PC (in opposition with the initial 
supersaturation in SIPC), ensures a better yield and a better enantiomeric excess to the AS3PC 
mode. The slow cooling in presence of many crystals of pure enantiomer favours the crystal 
growth; the enantiopurity is increased and the filterability is improved. 
ASPreCISE is a recent technique, mainly used for thermally sensitive molecules and 
molecules with poor variation of solubility versus temperature. Only few examples are 
described in the literature, so it is difficult to compare its efficiency with the other ones. The 
main restriction of this method is the use a solvent easy to evaporate. But, if an appropriate 
solvent is found, the yield should be increased compare to the AS3PC mode; a solvent 
evaporation generally ensures a higher difference of solubility (and so, a higher theoretically 
harvested mass) than a cooling. 
Theoretically, the SOAT mode have non negligible advantages (e.g. yield > 50% in one step). 
However, it is not often used, mainly because the target compound must crystallise as a 
conglomerate and be quickly racemised in solution under the same operating conditions. 
 
 
 3. Inclusion complexes 
Formation of inclusion complexes is another way to have access to pure enantiomers by using 
the properties of diastereoisomers. As in the Pasteurian resolution, a chiral agent is added to 
the racemic mixture to break the symmetry, by the formation of diastereoisomeric entities. 
The main difference with the Pasteurian resolution is the nature of the chiral agent, and, 
consequently, the nature of the interactions with the two enantiomers. The formation of the 
diastereoisomeric entities is not ensured by salt formation but by formation of inclusion 
complexes thanks to weak interactions (hydrogen bond, van der Waals interactions…). In the 
                                                 
53 L. Courvoisier, E. Ndzié, M. N. Petit, U. Hedtmann, U. Sprengard,, G. Coquerel; Chem. Lett., 2001, 30, 364-
365. 
54 L. Courvoisier, L. Mignot, M.N. Petit, G. Coquerel; Org. Process Res. Dev., 2003, 7, 1007-1016. 
Chirality and separation of enantiomers 
 
 -53 - 
case of the inclusions complexes, two types of inclusions can be encountered, depending on 
the chiral agent used: 
 - Crystal-lattice inclusion: chiral cavities of a crystal lattice play the role of chiral host. 
 - Molecular inclusion: the host molecule is a chiral molecule. 
These two types of inclusions are described in the following paragraphs. 
 
  a. Crystal-lattice inclusion complexes 
As said previously, the symmetry breaking is ensured by the existence of chiral cavities inside 
the crystal packing. The chirality of these cavities is due to the chirality of the host molecule, 
or to the particular geometry (and so, to the specific interactions) of the cavity, even if the 
host molecule is achiral. Of course, it is necessary that the cavity and the guest molecule are 
compatible in terms of size and selectivity to have stable complex and an efficient resolution. 
(Figure I - 20) 
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Figure I - 20. General scheme of resolution by inclusion in a crystal lattice. 
 
Chiral cavities can be directly present inside the crystal lattice of the host molecule but 
sometimes, chiral cavities are created only when the host and guest molecule crystallise 
together. Few examples of structural inclusion complexes are described below. 
• Urea: it was the first case depicted in the literature.55 Although achiral, (Figure I - 21) this 
molecule is able to crystallize in the enantiomorphous space groups P6122/P6522 when 
appropriate molecules are present. The result is the formation of a conglomerate, and the two 
                                                 
55 W. Schlenk; Analyst 1952, 77, 870; Justus Liebigs; Ann. Chem., 1973, 1145; 1156; 1179; 1195. 
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enantiomers can be separated by using the classical method like preferential crystallisation.56 
Thus, by using inclusion complexes with urea, Schlenk performed the separation of the two 
enantiomers of the 2-chlorooctane, with a final enantiomeric excess of 95.6%.55 
 
Figure I - 21. Chemical formula of urea. 
 
• Tri-o-thymotide (TOT): this tricyclic lactone (Figure I - 22) exhibits a conformational 
chirality with a fast racemisation in solution. Like the urea, the TOT is able to form inclusion 
complexes with many different guests,56,57 (for example, the 2-bromobutane) and it crystallise 
in chiral space groups only in the presence of chiral molecules to give enantiomorphous 
crystals. 
 
Figure I - 22. Chemical formula of the Tri-o-thymotide. 
 
• Sterically hindered polyols: these molecules (Figure I - 23), derived from the BINOL 
(2,2’-dihydroxy-1,1’-binaphthyle) or the TADDOLs (α,α,α’,α’-tetraaryl-1,3-dioxolane-4,5-
diméthanol), were studied mainly by the team of Fumio Toda. 58,59,60 
                                                 
56 R. Arad-Yellin, B. S. Green, M. Knossow, G. Tsoucaris; Inclusion Compounds III, 1984, Academic Press, 
London, chap. 9, 278-284. 
57 H. M. Powell; Nature, 1952, 170, 155-155. 
58 F. Toda; Aust. J. Chem., 2001, 54, 573-582. 
59 Z. Urbanczyk-Lipkowska, F. Toda; Separations and reactions in organic supramolecular chemistry, 2004, J. 
Wiley & Sons: New York, Chapter 1. 
60 F. Toda; Enantiomer Separation: Fundamental and Practical Methods, 2004, Kluwer Academic Publisher: 
Dordrecht, Chapter 1, 1-47. 
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Figure I - 23. Chemical structure of BINOL (left) and TADDOL (right). 
 
In addition to the geometry of the cavity, the steric effect (aromatic groups) of this kind of 
molecules prevents the formation of intermolecular hydrogen bonds between two TADDOLs. 
However a small guest molecule is able to form H-bonds with two TADDOL units, bridging 
them (Figure I - 24), as it was demonstrated in the case of (R,R)-(-)-trans-2,3-
bis(hydroxydiphénylméthyl)-1,4-dioxaspiro[4.4]nonane (tBHDN) and methyl 3- 
hydroxybutanoate.61 
 
Figure I - 24. Schematical representation of the formation hydrogen bonds in the presence of a guest 
molecule. 
 
• (2R,3R)-(O,O’)-dibenzoyltartric acid (DBTA) : this chiral molecule was often used for the 
pasteurian resolution, but, in 1994, Hamato and collaborators studied the system formed by 
the DBTA and the racemic trans-bicyclo[2.2.1]heptane-2,3-diamine.62 They observed that 
instead of salt, a structural inclusion was formed. The possibility to form complexes with the 
DBTA was confirmed by different authors and the existence of a hydrophobic cavity was 
highlighted.63,64 
                                                 
61 F. Toda, A. Sato, L. R. Nassimbeni, M. L. Niven; J. Chem. Soc. Perkin Trans. 2, 1991, 1971-1975. 
62 K. Hatano, T. Takeda, R. Saito; J. Chem. Soc., Perkin Trans. 2, 1994, 579-584. 
63 B. Szczepanska, M. Gdaniec, U. Rychlewska; J. Incl. Phen. Mol. Recogn. Chem., 1995, 22, 211-219. 
64 K. Nemak, M. Acs, Z. M. Jaszay, D. Kozma, E. Fogassy; Tetrahedron, 1996, 52(5), 1637-1642. 
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Figure I - 25. Chemical formula of the (2R,3R)-DBTA. 
 
• Biliary acids: these natural molecules, like the cholic acid, are produced by the liver of 
mammals. A chiral channel exists inside the crystal lattice65 therefore they can also be used to 
form inclusion complexes.66 The chiral recognition is ensured buy a combination of van der 
Waals interactions and steric effects. For example, Bertolasi et al. described the resolution of 
cyclic ketone with e.e. > 65%. 
 
Figure I - 26. Chemical formula of the cholic acid. 
   
 
  b. Inclusion complex in a host molecule 
Contrary to the previous case, the cavity is not formed by the crystal lattice but by the 
molecule itself. The interactions involving the complex formation between the host entity and 
the guest molecule are the same in the two cases, but real diastereoisomeric complexes are 
formed in the case of molecular inclusion. (Figure I - 27) Consequently, this kind of 
complexes exists in the solvated state and the chiral discrimination is possible in solution. 
 
Figure I - 27. General principle of inclusion complexes. 
 
                                                 
65 O. Bortolini, G. Fantin, M. Fogagnolo; Chirality, 2005, 17, 121-130. 
66 V. Bertolasi, O. Bortolini, M. Fogagnolo, G. Fantin, P. Pedrini; Tetrahedron: Asymmetry, 2001, 12, 1479–
1483. 
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It is necessary for the host molecule to have a chiral cavity. These molecules are often 
depicted in the literature, for example, for the preparation of stationary phases for HPLC. Four 
examples of host molecules are described below. 
• Crown ethers: heterocycles which the main unit is the ethylene oxide (-CH2-CH2-O-). 
They are named following their total number of atoms x and of oxygen y to give x-crown-y or 
x-C-y. (Figure I - 28a) Basic crown ethers are achiral but they can be functionalised in order 
to make them chiral. (Figure I - 28b) They are mainly used for the separation of enantiomers 
by chromatography67 (there are grafted on the stationary phase) and there are few examples of 
resolution by crystallisation.68 
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Figure I - 28. Chemical formula of a) 21-C-7 and b) (+)-18-C-6 tetracarboxylic acid. 
 
• Cucurbiturils: achiral macrocyclic molecules made of glycoluril monomers 
(=C4H2N4O2=).69 Their name is derived from the resemblance with a pumpkin, of the family 
of the cucurbitaceae. Cucurbiturils are commonly written as cucurbit[n]uril (CB[n], or CBn) 
where n is the number of glycoluril units. (Figure I - 29) Until now, these molecules were 
mainly used for the complexation of cations.70 But recently, the first example of cucurbituril 
used for chiral recognition in solution was depicted.71  By complexing the CB6 with two 
different guest molecules, a chiral agent then the two enantiomers of the compound of interest 
(2-methylbutylamine), Rekharsky et al.  highlighted the different behaviour of the two 
enantiomers, ensuring a final enantiomeric excess of 95%. 
                                                 
67 L. R. Sousa, G. D. Y. Sogah , D. H. Hofmann, D. J. Cram; J. Am. Chem. Soc., 1978, 100, 4569-4576. 
68 H. Nagata, H. Nishi,  M. Kamigauchi, T. Ishida; Chem. Pharm. Bull., 2006, 54(4), 452-457. 
69 W. A. Freeman, W. L. Mock, N. Y. Shin; J. Am. Chem. Soc., 1981, 103, 7367-7368. 
70 D. Whang, J. Heo, J. H. Park, K. Kim; Angew. Chem. Int. Ed., 1998, 37(1-2), 78-80. 
71 V. M. Rekharsky, H. Yamamura, C. Inoue, M. Kawai, I. Osaka, R. Arakawa, K. Shiba, A. Sato, Y. Ho Ko, N. 
Selvapalam, K. Kim, Y. Inoue; J. Am. Chem. Soc., 2006, 128, 14871-14880. 
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Figure I - 29. Schematic representation with chemical formula of CBn (left) and structure of CB6 (right). 
 
• Calixarenes: macrocycles made of phenolic units. The word calixarene is derived from the 
greek “calix", meaning vase, and from the word “arene” used to refer to the aromatic groups. 
Calixarenes are commonly written as calix[n]arene where n is the number of phenolic units. 
(Figure I - 30) These molecules are achiral but they can be chemically modified to make them 
chiral.72 Most of examples of chiral recognition were made in solution,73,74 but few 
discriminations at the solid state were depicted in the literature.75,76,77 
 
Figure I - 30. Chemical formula of calix[n]arene (left) and calix[4]arene (right). 
 
• Cyclodextrins: cyclic oligosaccharides linked by α-1→4-glycosidic bonds. The more 
popular cyclodextrins are α-, β- and γ-cyclodextrins, respectively made of six, seven and eight 
glycosidic units.78 (Figure I - 31) Cyclodextrins are able to form complexes with many 
different molecules. Contrary to the previous compounds, cyclodextrins are chiral. Complexes 
made from cyclodextrins with a racemic mixture are thus diastereoisomers. This interesting 
property explains why many researchers are working on this subject.79,80 Additional details 
are given in the chapter II. 
                                                 
72 Z. Asfari, V. Böhmer, J. Harrowfield, J. Vicens; Calixarenes, 2001, Kluwer Academic Publishers: Dordrecht, 
Holland. 
73 U. Darbost, M.-N. Rager, S. Petit, I. Jabin, O. Reinaud; J. Am. Chem. Soc., 2005, 127, 8517-8525. 
74 L. Mutihac, J. H. Lee, J. S. Kim, J. Vicens; Chem. Soc. Rev., 2011, 40, 2777-2796.  
75 E. Weber, J. Ahrendt, A, Lohner, P. J. Reddy, K. K. Chacko; J. Incl. Phenom., 1993, 15, 231-245. 
76 J. L. Atwood, S. J. Dalgarno, M. J. Hardie, C. L. Raston; Chem. Commun., 2005, 337-339.  
77 P. R. Martinez-Alanis, I. Castillo; Tetrahedron Lett., 2005, 46, 8845-8848. 
78 W. Saenger; Angew. Chem., Int. Ed. Eng., 1980, 19, 344-362. 
79 A. Grandeury, E. Condamine, L. Hilfert, G. Gouhier, S. Petit, G. Coquerel; J. Phys. Chem. B, 2007, 111, 
7017-7026. 
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Figure I - 31. Chemical formula of β-cyclodextrin. 
 
 
 
VI - Spontaneous symmetry breaking 
The preferential crystallisation methods previously described are based on the alternate 
crystallisation of the two enantiomers of a conglomerate. Thus, for a molecule, both pure R 
and S are harvested even if only one is the target compound, engendering a maximum of 50% 
yield. Sometimes, the non-desired enantiomer can be racemised and then used again to reach, 
theoretically, 100% yield. Unfortunately, the number of additional steps increases the time 
and the cost of the production of the pure target enantiomer. 
Recently a new crystallisation process called deracemisation, combining in-situ racemisation 
and grinding (and preferential crystallisation) was designed. Contrary to classical preferential 
crystallisation, a racemising agent is added to the system in order to racemise the counter 
enantiomer during the crystallisation of the target one (e.g. the enantiomer R). Thus, pure 
crystals of S are “transformed” into pure crystals of R. This method, also called “spontaneous 
symmetry breaking”, allows to obtain only one enantiomer with a very good optical purity 
(>99%) and with a maximal yield, theoretically close to 100%. 
The first observations of the benefit of the grinding during the resolution by preferential 
crystallisation combined with in-situ racemisation were made by Viedma in 2005.81 
The discovery of this process, as well as the last improvements, is described in the following 
paragraphs. Hypothesis about the mechanism involved during the set-up will be also 
discussed. 
                                                                                                                                                        
80 Y. Amharar, A. Grandeury, M. Sanselme, S. Petit, G. Coquerel; J. Phys. Chem., 2012, 116(20), 6027-6040. 
81 C. Viedma; Phys. Rev. Lett., 2005, 94, 065504. 
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 1. History 
The first observations of the spontaneous symmetry breaking were made by Frank in 1953.82 
He suggested that an enantiomer was able to catalyse its own synthesis, suppressing that of its 
mirror image, with a nonlinear amplification of a small initial enantiomeric excess. 
Almost twenty years later, the spontaneous symmetry breaking of the 1,1’-binaphthyl was 
reported by Richard E. Pincock and Keith R. Wilson.83 One of the polymorphic form of the 
1,1’-binaphthyl is a conglomerate and its racemisation (i.e. the rotation around the single 
bond) is very fast at 150°C. Pincock and Wilson managed to do the resolution of the 
crystalline material from the melt by inducing the crystallisation at 150°C by touching the 
sample with dry ice. They also noticed that the use of seeds of pure enantiomer improved the 
final enantiomeric excess. Indeed, without seeds, “it is apparent that obtaining binaphthyl 
with an optical purity above 90 percent by this method would be a very exceptional event 
(observable about one in 150 tries)”. 
 
Figure I - 32. S-(+)- and R-(-)-1,1’-binaphthyl. 
 
 
 2. Theory of the mother crystal 
In 1990, Kondepudi et al. confirmed the observations made by Kipping and Pope almost one 
century before, about the particular crystallisation of the sodium chlorate NaClO3.84,85 This 
inorganic compound, though achiral, crystallise as two enantiomeric chiral crystals, D and L, 
in the cubic space group P213. Kipping and Pope noticed that, during the crystallisation of 
NaClO3 by evaporation of a saturated solution, without seeding, the difference between the 
number of D and L crystals was due to statistical fluctuations (from 17 different 
crystallisations, 525 L-crystals and 475 D-crystals were harvested), whereas seeds ensure a 
greater final enantiomeric excess. Kondepudi et al. also depicted for the first time the 
particular contribution of the stirring for the chiral symmetry breaking. They compared 
                                                 
82 F. C. Frank; Biochem. Biophys. Acta, 1953, 11, 459-463. 
83 R. E. Pincock, K. R. Wilson; J. Am. Chem. Soc., 1971, 93(5), 1291-1292. 
84 F. S. Kipping, W. J. Pope; J. Chem. Soc. Trans., 1898, 73, 606-617. 
85 D. K. Kondepudi, R. J. Kaufman, N. Singh; Science, 1990, 250, 975-976. 
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crystals obtained after evaporation of the solvent (water) with and without magnetic bar in the 
absence of seed. Crystals harvested from the experiment with stirring were smaller and more 
numerous than the ones obtained without stirring. Moreover, every try gave an enantiomeric 
excess greater than 99% under stirring whereas the enantiomeric excess obtained without 
stirring was close to 0%. To explain these observations, they put forward the hypothesis that 
secondary nuclei were quickly produced from a primary nucleus, called “mother crystal”, 
thanks to the stirrer. These new nucleus grew up then gave in turn new secondary nucleus, 
thus propagating the chirality of the mother crystal. Kondepudi et al. spoke about a “chirally 
autocatalytic” process. They also highlighted that secondary nucleation was not sufficient to 
explain the final enantiomeric excess. Indeed, during the time of the experiment, nucleus of 
the opposite enantiomer had time to appear, grow and form secondary nucleus. The 
proliferation of the first crystal of a particular chirality must be linked to a suppression of the 
nucleation of the opposite handedness. They explained this suppression of nucleation by the 
very weak supersaturation. Indeed, supersaturation was ensured by a slow evaporation of the 
solvent (around 25mL of water were evaporated in 4-5 days), so, when the first nucleus 
appeared, and with the contribution of the secondary nucleus, the rate of primary nucleation 
became very close to zero. Therefore, only crystals of the same handedness than the first 
nuclei grow during the experiment. The chirality of the first nucleus, and then of the final 
crystals, is stochastic. 
Few years later, two new studies of Kondepudi et al., 86,87 and another one of Martin et al.,88 
confirmed the important role of the stirring during the chiral symmetry breaking process, and 
particularly the role of the stirring rate. At the end of the century, they offered another proof 
by improving the resolution of the 1,1’-binaphthyl thanks to stirring.89 
 
 
 3. Reassessment of the theory of the mother crystal 
The theory of the “mother crystal” was called into question by Viedma in 2004.90 Indeed, he 
performed the total chiral symmetry breaking of the sodium chlorate from a high 
supersaturated solution, i.e. with a very high primary nucleation rate. Immediately after he 
began to stir a highly supersaturated solution (β>1.5 with 60°C of supercooling), the solution 
                                                 
86 D.K. Kondepudi, K. L. Bullock, J. A. Digits, J. K. Hall, J. M. Miller; J. Am. Chem. Soc., 1993, 115, 10211-
10216. 
87 D. K. Kondepudi, K. L. Bullock, J. A. Digits, P. D. Yarborough; J. Am. Chem. Soc., 1995, 117, 401-404. 
88 B. Martin, A. Tharrington, X.-I. Wu; Phys. Rev. Lett., 1996, 77(13), 2826-2829. 
89 D. K. Kondepudi, J. Laudadio, K. Asakura; J. Am. Chem. Soc., 1999, 121, 1448-1451. 
90 C. Viedma; J. Crystal Growth, 2004, 261, 118-121. 
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became milky, meaning the formation of many crystals. In spite of this catastrophic primary 
nucleation (the two enantiomers crystallised), and after 2 days of growth, 100% of the crystals 
were of the same handedness. Viedma concluded that “the results of our experiment suggest 
that the current explanation for chiral symmetry breaking via nucleation of a single “mother 
crystal” may explain some cases but not all, and as such, the mechanism to explain the chiral 
symmetry breaking in crystallisation remains as an open question.” 
These observations were confirmed the year after, when he performed the complete chiral 
symmetry breaking of the sodium chlorate from a suspension of racemic material.81 In this 
case, it was clear that the theory of the “mother crystal” was not valid and he proposed a new 
model of “complete chiral purity induced by nonlinear autocatalysis and recycling”. This 
theory will be detailed in the paragraph VI-6. 
 
 
 4. Benefits of grinding 
In the same publication,81 Viedma described the effect of stirring combined with the addition 
of 3mm diameter glass beads. The result was a significant increase of the kinetics, i.e. a 
significant decrease of the time to reach a complete resolution of sodium chlorate, depending 
on the number of glass balls and on the stirring rate (Figure I - 33).81 Indeed, glass beads have 
an abrasive effect, enhancing the effect of the stirring and then enhancing the rate of 
secondary nucleation. 
 
Figure I - 33. Solutions with initial symmetric mixtures of L and D crystals of NaClO3 and glass beads 
show total symmetry breaking and chiral crystal purity. The data show the necessary time to achieve 
chiral purity depending on: a) the number of balls in the system (600rpm) and b) the speed of agitation of 
the system (4g of balls). 
 
The discovery of benefits of the abrasive grinding for the obtaining of pure enantiomers was 
the major advance in the field of total symmetry breaking. Since 2005 and the publication of 
Viedma, the number of publications on the subject increases, as well as for the understanding 
of the mechanism than for the production of pure enantiomers. 
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 5. Total symmetry breaking of organic compounds 
In 2006, Crustats et al.91 following by Donna G. Blackmond92 in 2007 speculated that this 
crystallisation process might be extended to intrinsically chiral molecules which can be very 
quickly racemised when a racemising agent is present. Moreover, such a chiral molecule 
should crystallise as a conglomerate to imitate the enantiomeric chiral crystals of the NaClO3. 
(Figure I - 34) 
 
Figure I - 34. Illustration of solid-liquid equilibrium for systems forming chiral solids. a) achiral material 
in equilibrium with chiral crystals, b) chiral compound crystallising as a conglomerate. 
 
The first try was made jointly between the Blackmond research group and a Dutch 
consortium, composed by two chemical companies, Syncom and DSM, and the Radboud 
University of Nijmegen. They studied the behaviour of an amino-acid derivative, the N-(2-
methyl-benzylidene)-phenylglycine-amide, known to crystallise as a conglomerate. This kind 
of molecule can be easily racemised in solution in the presence of a catalytic amount of an 
organic base such as DBU (1,8-diazabicyclo[5.4.0]undec-ène). (Figure I - 35)93 They 
performed the complete deracemisation of the solid phase within approximately 30 days.94,95 
They also introduced for the first time the term of “chiral amnesia”. 
 
Figure I - 35. Chemical formula of N-(2-methyl-benzylidene)-phenylglycine-amide. 
 
                                                 
91 J. Crusats, S. Vientemillas-Verdaguer, J. M. Ribό; Chem. Eur. J., 2006, 12, 7776-7781. 
92 D. G. Blackmond; Chem. Eur. J., 2007, 13, 3291-3295. 
93 R. M. Kellogg, B. Kaptein, T. R. Vries; Top. Curr. Chem., 2007, 269, 159-197. 
94 W. L. Noorduin, T. Izumi, A. Millemaggi, M. Leeman, H. Meekes, W. J. P. Van Enckevort, R. M. Kellogg, B. 
Kaptein, E. Vlieg, D. G. Blackmond; J. Am. Chem. Soc., 2008, 130, 1158-1159. 
95 W. L. Noorduin, H. Meekes, W. J. P. van Enckevort, A. Millemaggi, M. Leeman, B. Kaptein,R. M. Kellogg, 
E. Vlieg; Angew. Chem. Int. Ed., 2008, 47, 6445-6447. 
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However they noticed that the result of the experiment was not random because only the R 
enantiomer was harvested. They did more than 100 experiments though, carried out in 
different laboratories. They suspected a contamination by a chiral impurity of the natural 
origin. This hypothesis was validated one year later by the addition of an enantiopure 
compound (R or S-phenylglycine).94 In 2009, it has been demonstrated that the use of 
enantiopure amino-acid allows to predict and then to choose the final chirality of the solid 
phase.96 
 
  a. Formation of Schiff bases: an efficient tool for the preparation of pure 
enantiomers of amino-acid derivatives 
Since this success, the total deracemisation of many other amino-acid derivatives were 
performed. The need of chiral amino acids is always a major issue for the pharmaceutical 
industries because they often are building blocks for the synthesis of new drugs. 
Unfortunately, amino acids crystallising as a conglomerate, and easily racemisable, are very 
uncommon. However, most of them can be modified into Schiff base. Schiff bases are 
compounds with aryl- or an alkylimine derived from an aldehyde and a primary amine. 
Amino acids can be converted into Schiff base (Figure I - 36) and a screening of aldehyde is 
performed in order to find a compound crystallising as a conglomerate. 
 
Figure I - 36. Synthesis of Schiff base from amino acids. 
 
The great advantage of the Schiff bases derivate from amino-acid is that they are easily 
racemisable: the hydrogen α to the imine is labile and an organic base like DBU is able to 
remove it. (See Figure I - 35) The second great advantage is that the synthesis of this kind of 
compound is reversible. Indeed, Schiff bases are not stable in the presence of acid and water, 
and are hydrolysed into the starting materials. (Figure I - 37). 
 
Figure I - 37. Hydrolysis of Schiff bases in the presence of acid. 
 
                                                 
96 P. S. M. Cheung, L. A. Cuccia; Chem. Commun., 2009, 1337- 1338. 
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N
OMe
O
Cl
Thus, even if the target compound does not crystallise as a conglomerate, it can be reversibly 
converted into a racemisable imine; a screening of aldehydes is therefore carried out to find a 
conglomerate and then the resolution can be performed. This process has ensured the 
resolution of several amino acid derivatives.97,98 
The deracemisation of the N-(4-chlorobenzylidene)phenylalanine (Figure I - 38a) also 
highlighted that epitaxy (Figure I - 38b) does not disturb the process, kinetic remaining 
exponential (Figure I - 39).99 
 
 
 
 
 
 
 
 
Figure I - 38. a) Chemical structure of the N-(4-cholorobenzylidene)phenylalanine, b) Partial dissolution 
of (RS)- N-(4-cholorobenzylidene)phenylalanine in a saturated solution of the S enantiomer (time interval 
between images: 10 minutes).
99
 
 
 
Figure I - 39. Typical change in the enantiomeric composition of the solid phase during grinding.
99
 
 
In 2009, the Dutch group described the synthesis of the pure enantiomer of Clopidogrel 
(Plavix, Figure I - 40), 100 a platelet aggregation inhibitor used for the treatment of ischemic 
strokes, heart attacks, atherosclerosis and also for the prevention of thrombosis after 
                                                 
97 W. L. Noorduin, P. van der Asdonk, H. Meekes, W. J. P. van Enckevort, B. Kaptein, M. Leeman, R. M. 
Kellogg, E. Vlieg; Angew. Chem. Int. Ed., 2009, 48(18), 3278-3280. 
98 M. Leeman, J. M. De Gooier, K. Boer, K. Zwaagstra, B. Kaptein, R. M. Kellogg; Tetrahedron: Asymmetry, 
2010, 21, 1191-1193. 
99 B. Kaptein, W. L. Noorduin, H. Meekes, W. J. P. van Enckevort, R. M. Kellogg, E. Vlieg; Angew. Chem. Int. 
Ed., 2008, 47(38), 7226-7229. 
100 M. W. van der Meijden, M. Leeman, E. Gelens, W. L. Noorduin, H. Meekes, W. J. P. van Enckevort, B. 
Kaptein, E. Vlieg, R. M. Kellogg; Org. Process. Res. Dev., 2009, 13, 1195-1198. 
a) b) 
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placement of intracoronary artery stents. Until that day, the pure (S)-Clopidogrel was prepared 
by pasteurian resolution.101,102103 
Cl
N
S
O OMe
(S)-clopidogrel  
Figure I - 40. Chemical formula of the (S)-Clopidogrel. 
 
The Dutch consortium performed a new synthesis of the Clopidogrel, in which an 
intermediate is reversibly converted into an imine, the N-(o-chlorobenzylidene)phenylglycine-
amide, and deracemised. Then, the benzaldehyde is removed by treatment of the imine with 
HCl. 
 
Figure I - 41. Synthesis of the (S)-Clopidogrel by deracemisation of the N-(o-
chlorobenzylidene)phenylglycine-amide. a) benzaldehyde, Na2SO4, CH2Cl2; b)DBU, glass beads, 
acetonitrile; c) HCl/acetone; d) H2SO4/MeOH, e) acetonitrile. 
 
 
  b. Naproxen 
The same year, the same Dutch group performed the synthesis of the (S)-Naproxen, a non-
steroidal anti-inflammatory drug.104 This molecule crystallises as a racemic compound but the 
methyl and ethyl ester derivatives crystallise as conglomerate and they can be easily 
racemised under basic conditions. Pure enantiomers of the ester derivative were thus obtained 
                                                 
101 a) U.S. Patent 6,800,759, 2004, b) U.S. Patent 6,737,411, 2004. c) U.S. Patent 4,847,265, 1989 d) U.S. Patent 
6,074,242, 2006. 
102 L. Wang, J. Shen, Y. Tang, Y. Chen, W. Wang, Z. Cai, Z. Du; Org. Process Res. Dev., 2007, 11, 487-489. 
103 a) U.S. Patent 2004073057, 2004, b) WO2006003671, 2006, c) U.S. Patent 2007225320, 2007. 
104 W. L. Noorduin, B. Kaptein, H. Meekes, W. J. P. Van Enckevort, R. M. Kellogg, E. Vlieg; Angew. Chem. 
Int. Ed., 2009, 48, 4581-4583. 
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by deracemisation by using NaOMe in methanol with grinding then the pure (S)-naproxen 
was synthesised. 
 
Figure I - 42. Chemical structure of the (S)-naproxen. 
 
 
  c. Racemisation thanks to a chemical equilibrium 
Sometimes, the racemisation of the target compound is not as easy as in the previous cases. In 
2008, Viedma and Blackmond et al. reported the total resolution of aspartic acid.105 Aspartic 
acid is one of only two proteinogenic amino acid which can crystallise directly as a 
conglomerate. Unfortunately, as all the natural amino acid, its racemisation is very slow on a 
laboratory time scale. But Yoshioka recently designed an efficient method for racemisation of 
amino acid by using a catalytic amount of aldehyde in an acidic media.106 Therefore Viedma 
and Blackmond et al. performed the resolution of aspartic acid by using salicylaldehyde in 
acetic acid. (Figure I - 43) 
 
Figure I - 43. Aspartic acid solid phase in equilibrium with a solution under racemising conditions. 
 
They also highlighted the benefit of grinding ensured by glass beads and the impact of the 
temperature on the kinetic of the process, as illustrated in the Figure I - 44. 
                                                 
105 C. Viedma, J. E. Ortiz, T. De Torres, T.Izumi, D. G. Blackmond; J. Am. Chem. Soc., 2008, 130, 15274-
15275. 
106 R. Yoshihoka; Top. Curr. Chem., 2007, 269, 83-132. 
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Figure I - 44. Evolution of solid-phase ee for D and L aspartic acid under racemizing conditions. Filled 
symbols: gradient heating to 160 °C. Open symbols: isothermal at 90 °C. Positive e.e. values are assigned 
to the naturally occurring L-asp. 
 
More recently, Tsogoeva et al. described the enantioenrichment by symmetry breaking of an 
amino acid derivative using a reversible Mannich type reaction to racemise the chiral 
compound. The enrichment occurs via an iterative retro-aldol/aldol reaction in the presence of 
an achiral or racemic secondary amine catalyst. (Figure I - 45)107 They performed 
deracemisation both with and without glass beads and they noticed that even if glass beads 
increased the kinetic, the benefit was weak. 
 
Figure I - 45. Deracemisation experiment with a Mannich type reaction at room temperature with an 
achiral secondary amine catalyst. 4-Br-Bz = 4-bromobenzoyl. 
 
 
  d. Combination of grinding, racemisation and controlled cooling 
In 2009, we,108 and the Dutch consortium100,109 described a process mixing the Kondepudi’s 
experiments (slow cooling rate, stirring and seeding) with the Viedma ripening (abrasive 
grinding ensured by glass beads). This new type of deracemisation can also be considered as a 
combination between the preferential crystallisation mode SOAT and Viedma’s ripening. The 
                                                 
107 S. B. Tsogoeva, S. Wei, M. Freund, M. Mauksch; Angew. Chem. Int Ed., 2009, 48(3), 590-594. 
108 G. Levilain, C. Rougeot, F. Guillen, J.-C. Plaquevent, G. Coquerel; Tetrahedron: Asymmetry, 2009, 20, 2769-
2771. 
109 M. Leeman, W. L. Noorduin, A. Millemaggi, E. Vlieg, H. Meekes, W. J. P. van Enckevort, B. Kaptein, R. M. 
Kellogg; CrystEngComm, 2010, 12 (7), 2051-2053. 
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Dutch consortium applied this new process to their amino acid derivatives with a great 
success: the time of the reaction was significantly decreased and the enantiopurity still 
remains over 99.5%. We depicted the total resolution of a new kind of compound: a 
triazoylketone. (Figure I - 46). 
 
Figure I - 46. Chemical formula of the triazoylketone, 1-(4-chlorophenyl)-4,4’-dimethyl-2-(1H-1,2,4-
triazol-1-yl)pentan-3-one. 
 
The resolution of this compound by preferential crystallisation combined with in-situ 
racemisation was previously described by Black et al.52 Nevertheless, the yield was low 
(20%) and a soft cooling profile (1°C.h-1) was required to avoid the nucleation of the 
antipode. The addition of glass beads in the process ensured an increase of the yield (70%) 
without modifying the final enantiomeric excess and permitted to work with a rapid and deep 
cooling profile (15°C.h-1): 2h were sufficient to reach the final state. (Figure I - 47) 
 
Figure I - 47. Evolution of the enantiomeric excess of the solid on fast cooling (the lines are a guide) 
 
 
 6. Deracemisation mechanisms: the current hypotheses 
  a. Introduction 
The theory of the “mother” crystal was the first described to explain the spontaneous 
symmetry breaking phenomena (see paragraph VI.2.). This theory may be valid for processes 
starting from a relatively highly supersaturated solution, with or without seeding and/or 
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abrasive grinding, but it can not be used to explain what happens in the cases of a racemic 
suspension in equilibrium with a saturated solution. Therefore, many research groups 
attempted to find another mechanism to explain why racemic suspensions in contact with a 
saturated solution and a racemising agent are able to evolve toward an enantiopure final state. 
Basic knowledge on crystallisation mechanism often named in these various explanations is 
described below: 
• Primary nucleation: spontaneous nucleation from a saturated solution (dissolved 
molecules aggregate to from nucleus) 
• Secondary nucleation: formation of nucleus from already existing crystals. When a crystal 
is submitted to shear stress or collisions (with another crystals, the wall of the reactor or the 
stirrer…) it is broken and small parts, called “daughter crystals”, are generated.110 From a 
chiral point of view, daughter crystals have the same handedness than the mother crystal.111 
• Gibbs-Thomson effect: in the middle of the 19th centrury, Gibbs noticed that small 
particles have a higher solubility than the large ones. This difference is a direct consequence 
of the minimization of the surface energy of the particles since the ratio surface area/volume 
is higher for small particles than for the large ones. 
• Ostwald limit: due to the activation energy required to generate the first nucleus, a 
supersaturated solution spontaneously crystallizes only if the supersaturation exceeds a certain 
threshold. In 1897, Friedrich W. Ostwald defined the first concept of metastable zone. (Figure 
I - 48)112,113 The biphasic domain (crystals in equilibrium with a saturated solution) is 
separated into two domains by the Ostwald limit. When the concentration is between the 
solubility line and the Ostwald limit (green domain), no primary nucleation spontaneously 
occurs and the supersaturated solution remains clear unless it is seeded. When the 
concentration of the solution is higher than the Ostwald limit (red domain), primary nucleus 
appears spontaneously from the clear supersaturated liquid. The location of the Ostwald limit 
depends of the supersaturation, of the increasing rate of the supersaturation (i.e. the cooling 
rate, the evaporation rate of the solvent…), the stirring rate, the stirring mode, the nature of 
the reactor… 
                                                 
110 W. L. McCabe, J. C. Smith; Unit operations of chemical engineering; McGraw-Hill Book Co.: New York, 
1956 
111 D. K. Kondepudi, C. Sabanayagam; Chem. Phy. Lett., 1994, 217, 364-368. 
112 F. W. Ostwald; Z. Phys. Chem., 1897, 22, 289-330. 
113 F. W. Ostwald; Z. Phys. Chem., 1900, 34, 495-503. 
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Figure I - 48. Ostwald limit representation in a binary diagram. 
 
• Ostwald ripening: it a ubiquitous phenomenon in a stagnant solution. The larger crystals 
became larger at the expense of the small crystals, 114 which progressively disappear or 
denucleate. The Ostwald ripening is directly linked to the Gibbs-Thomson effect and the end 
state of such system is only one single crystal in equilibrium with a saturated solution. Figure 
I - 49 illustrates the Ostwald ripening.115 Single crystals of NaClO3 are in contact with a 
saturated solution. Smaller crystals progressively shrink and, after two months, and with only 
the diffusion process, only one large single crystal is present. 
 
Figure I - 49. Polarized light microscope images showing the process of Ostwald ripening of NaClO3 
leading to a single chiral solid phase. 
 
• Meyerhoffer double solubility rule: the solubility of a racemic conglomerate is roughly 
double than the solubility of pure enantiomers. Indeed, each enantiomer is in equilibrium with 
its own liquid phase (in an ideal mixture, each type of liquid phase exhibits its own vapour 
pressure, independent of the other). But in the case of an achiral compound crystallising as 
two enantiomeric chiral crystals (e.g. NaClO3), the double solubility rule cannot be applied; 
crystals are in equilibrium with only one achiral molecule. 
                                                 
114 W. Ostwald; Lehrbuch der Allgemeinen Chemie, Vol. 2, Part 1; Leipzig, Germany, 1896. 
115 W. L. Noorduin, E. Vlieg, R. M. Kellogg, B. Kaptein; Angew. Chem. Int. Ed., 2009, 48, 9600-9606. 
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  b. Cairns-Smith’s experiment 
Cairns- Smith performed an experiment using balls of two colours to explain how, from a 
racemic mixture (each enantiomer corresponding to one colour of the balls), it was possible to 
reach a pure chiral final state (i.e. only balls of one colour).116 They put 100 balls in a box; 50 
of one colour, 50 of the other one. At each step, they throw away at random half of the balls 
and duplicate those that remain. After some time, all of the balls in the box have the same 
colours, as it is illustrated in the Figure I - 50. 
x2 x2÷2 ÷2
x2 x2÷2÷2
 
Figure I - 50. Cairns-Smith’s experiment. 
 
The Cairns-Smith’s model is not representative of the deracemisation process because a ball 
of one colour keeps its colours all along the experiment without having the possibility to 
change, i.e. without having the possibility to be “racemised”. But this model can give us an 
idea on the process which enables the random imbalance created from a racemic mixture. 
 
  c. Model based on Ostwald ripening 
Another model described to explain the phenomena of total symmetry breaking from a 
suspension is based on the Ostwald ripening.115,117 Indeed, besides the fact that only one 
single crystal is present at the end, Figure I - 49 exhibits that the final end state is only one 
handedness. The thermodynamic stable state is one enantiopure crystal, i.e. a result similar to 
the one of the deracemisation process. 
Ostwald ripening also emphasize that smaller crystals progressively disappear until reaching 
the denucleation step. This phenomenon is absolutely necessary to reach the enantiopure final 
suspension both starting from a suspension or a clear warm solution. Indeed, even in the 
second case and with a very slow cooling rate, it is very difficult to assume that only one 
primary nucleus appears at the beginning and that no other is formed during the cooling 
                                                 
116 A. G. Cairns-Smith; Chemistry in Britain, 1986, 22, 559-561. 
117 J. H. E. Cartwright, O. Piro, I. Tuval; Phys. Rev. Lett., 2007, 165501. 
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process. Without the Ostwald ripening, since a crystal cannot disappear once it has formed, 
the chiral mixture present at the end is derived from the crystals independently nucleated. But 
the sole Ostwald ripening process takes a long time to reach the final state, typically months 
or even longer (See Figure I - 49), depending on the system volume, the solubility of the 
compound, its rate of racemisation and its surface energy. In a suspension, for an initial 
crystal size distribution (CSD) with a large number of small crystals, Ostwald ripening is 
relatively fast, but it rapidly decreases when crystals become bigger. A vigorous stirring and 
more the abrasive grinding ensured by glass beads decrease the crystal size distribution, 
speeding up the Ostwald ripening. 
In order to better understand how the Ostwald ripening and the abrasive grinding interact to 
produce a single chiral state with many small crystals, a computer model was developed.118 A 
system composed by a saturated solution in equilibrium with the two CSDs of the 
enantiomers was subjected to a Monte Carlo simulation. This simulation considered the 
changes in the CSDs and the racemisation that took place in solution, with keeping constant 
the total number N of molecules. The flow diagram of the Monte Carlo simulation takes in 
account other parameters like the probability of an attrition event, Pattr, and the probability of 
an Ostwald event, Post. 
 
Figure I - 51. Flow diagram of the Monte Carlo simulation modelling the combined processes of Ostwald 
ripening and attrition. 
                                                 
118 W. L. Noorduin, H. Meekes, A. A. C. Bode, W. J. P. Van Enckevort, B. Kaptein, R. M. Kellogg, E. Vielg; 
Cryst. Growth Des., 2008, 8(5), 1675-1681. 
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This simulation exhibits that the system always evolves into a single chiral end state and that 
once this state is reached, it persists, even if the stirring is stopped. The results also 
highlighted that the time to reach the final state depends on the attrition-ripening ratio (the 
more intense the attrition, the faster the process, until a threshold) and on the solution 
racemisation efficiency. This simulation exhibits that the initial enantiomeric excess is 
amplified exponentially, where the constant k depends on the attrition-ripening ratio and the 
racemisation efficiency. (Equation I – 5) 
ee(t)=ee(t0).exp(kt)     Equation I - 5 
 
However, another behaviour was highlighted: when the racemisation in solution is 
instantaneous and even if enantiomeric excess is present at the beginning, deracemisation time 
decreases and the final handedness is stochastic. 
To conclude, it had been demonstrated that Ostwald ripening is a non linear dynamical 
process able to drive symmetry breaking to the final enantiopure system with an exponential 
kinetic. Ostwald ripening thus plays a key role in the deracemisation process. 
 
  d. Models based on clusters 
In 2004, Uwaha proposed a model based on a simple reaction-type that produces complete 
chiral symmetry breaking in crystallisation.119 This model assumes that: 
• The perpetual mixing of the solution and the abrasion of the crystals enable to describe the 
system by simple reaction-type equations. In classical crystallization, it impossible to do it 
because it requires a complex description of transport of the molecules and surface kinetics. 
• A minimal size of cluster that possesses chirality exists in solution. These clusters are 
smaller than the critical size of nucleus. Clusters, as well as achiral molecules, can be 
incorporated to a chiral crystal to grow it. 
• The decay of chiral units and crystals also occurs. 
Uwaha used masses of five components (achiral molecules, the two kinds of chiral clusters 
and the two kind of chiral crystals of various sizes) to described the time evolution of the 
system. The Uwaha’s model ensure a total symmetry breaking once a small symmetry 
breaking occurred by chance or by an external trigger (e.g. seeds). They assume that “the 
existence of clusters is the origin of the autocatalysis and the perpetual disturbance of the 
system makes the decay processes efficient and assures the realization of complete chirality.” 
                                                 
119 M. Uwaha; J. Phys. Soc. Jpn, 2004, 73(10), 2601-2603. 
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Grinding is thus the origin of many chiral clusters, the growth unit of chiral crystals, and their 
incorporation to the major crystal type accelerates the kinetic of crystallisation. 
Crusats et al. linked the deracemisation process to a thermodynamic equilibrium which can 
only occur when the system is perturbed, by formation of chiral clusters.91 The stable state of 
crystals in equilibrium with a saturated solution under perturbation (i.e. grinding) is only one 
solid state with 100% enantiomeric excess. 
This model was also supported by McBride and Tully,120 and then Saito and Hyuga121 adapted 
it for the total symmetry breaking of intrinsically chiral molecules, emphasising that a back 
reaction (i.e. crystal and/or cluster decay) is essential to produce achiral components. 
 
  f. Discussion 
In 2008, Uwaha and Katsuno compared these two models. For them, Ostwald ripening is not 
the essential mechanism which occurs under grinding, because the crystal size distribution 
must be almost steady during the grinding process.119,122 To clarify the role of Ostwald 
ripening during deracemisation, Uwaha and Katsuno proposed a mathematical model based 
on an extended Becker-Döring model, in which clusters reaction and the grinding effect are 
implemented,123 i.e. which described the change on cluster size distribution. They studied 
both achiral molecules and chiral molecules with a racemising agent. The results of their 
simulations were that Ostwald ripening, without grinding, can cause the chirality conversion 
only if the initial CSD is different for the two enantiomers. In the case of grinding and with a 
similar CSD for the two enantiomers, the total symmetry breaking occurs only with the 
crystallisation of chiral clusters, in addition to the usual monomers. Ostwald ripening does not 
have a key role in this mechanism. 
In contrary, T. Izumi and D. G. Blackmond affirmed that “invoking clusters of molecules to 
insure chiral identity of the species adding to growing crystals is therefore not required to 
rationalize the mechanism of the evolution of solid-phase homochirality in conglomerate 
systems of enantiomers.”124 They also highlighted that even in the case of a molecules 
crystallising as conglomerate, the Meyerhoffer double solubility rule is followed whereas 
Crusats et al. claimed the opposite.125 
                                                 
120 J. M. McBride, J. C. Tully; Nature, 2008, 452, 161-162. 
121 Y. Saito, H. Hyuga; J. Phys. Soc. Jpn, 2004, 73, 33-35. 
122 M. Uwaha; J. Phys. Soc. Jpn, 2008, 77, 083802. 
123 Y. Saito, H. Hyuga; J. Phys. Soc. Jpn, 2005, 74, 535-537. 
124 T. Izumi, D. G. Blackmond; Chem. Eur. J., 2009, 15, 3065-3068. 
125 J. Crusats, S. Veintemillas-Verdaguer, J. M. Ribó; Chem. Eur. J., 2007, 13, 10303-10305. 
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As for McBride and Tully,120 Ostwald ripening combined with a step of molecular recognition 
(i.e. clusters incorporation) is imperative to explain the autocatalytic properties of the 
deracemisation. 
In 2010, the Dutch group in association with McBride and Tully proposed a mechanism 
combining Ostwald ripening and reincorporation of chiral clusters.126 They have found 
experimental evidences for the existence of clusters. Thus, they conclude that four processes 
are necessary to explain the deracemisatioon of a racemic conglomerate: 1) racemisation in 
solution, 2) Ostwald ripening, 3) incorporation of chiral clusters and 4) attrition. 
In 2011, two studies about a mathematical model describing the deracemisation process were 
carried out. Peter J. Skrdla modelled the deracemization process by an exponential equation 
describing the sigmoidal-shaped (or “S”-shaped) kinetic (Figure I - 52), but without removing 
uncertainty about the details.127 
 
Figure I - 52. Exponential kinetic for deracemisation described by P. J. Skrdla. 
 
The second study was performed by Iggland and Mazzotti.128 They assumed a mechanism 
based on the propositions of several authors, including racemisation in solution, growth and 
dissolution due to a size-dependent solubility (i.e. Ostwald ripening), agglomeration (clusters) 
and attrition. Each of these propositions was modelled by mathematical equations: 
• Growth and dissolution of particles subject to size-dependent solubility: Equation I - 6 
gives the critical size xc, beyond which a nuclei is stable and can grow, where ka and kv are 
volume shape factors, γ the surface tension, Vm the molar volume, R the universal gas 
constant, T the absolute temperature and S the supersaturation of the solution. c represents the 
concentration in the solution and c∞, the bulk solubility, that is to say the solubility of an 
infinitely large particle.  
                                                 
126 W. L. Noordiun, W. J. P. Van Enckevort, H. Meekes, B. Kaptein, R. M. Kellogg, J. C. Tully, J. M. McBride, 
E. Vlieg; Angew. Chem. Int. Ed., 2010, 49(45), 8435-8438. 
127 P. J. Skrdla; Cryst. Growth Des., 2011, 11, 1957-1965. 
128 M. Iggland, M. Mazzotti; Cryst. Growth Des., 2011, 11, 4611-4622. 
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As the solubility of a crystalline material depends on its size, the concentration of a particle of 
size x, c*(x), can be obtained from the Equation I - 7, and then can be simplified to give the 
Equation I - 8: 
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• Agglomeration: it can be described by using two different equations. In Equation I - 10, 
agglomeration is slowest for combination of two small particles while in Equation I - 11, 
agglomeration is slowest for combination of two large particles. 
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• Attrition: in this model, the attrition is a U-shaped and is symmetric in volume-space, thus 
gives only two fragments, and is characterized by a single adjustable, integer parameter q (the 
larger the value of q, the larger the difference in size between the two resulting fragments) 
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η and x represent the sizes of the original particle and of the formed fragment, respectively. 
The rate of the breakage by attrition of particles of size x is given by the following equation, 
where k and β are adjustable parameters and x0 is a scaling factor: 
β
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• Racemisation: it is a first order reaction and the two enantiomers have the same constant of 
reaction so kD=kL=kr. 
The results of this modelling confirmed the necessity to have racemisation, growth and 
dissolution due to size dependent solubility and agglomeration to perform deracemisation. 
Moreover, kinetics obtained by the modelling are very similar to the experimental ones, 
whatever the initial conditions (CSD, initial e.e., racemisation rate...). However, they pointed 
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out that attrition is not necessary to reach the complete chiral purity but it increased the 
deracemisation rate, and therefore the kinetics. 
 
  g. Conclusion 
In spite of the numerous studies and computer simulations carried out on the deracemisation 
process, the mechanism is still under vigorous discussion. However, it seems to be clear that 
production of chiral clusters and small crystals by attrition is a key step. Clusters can be 
reincorporated to crystals of the same handedness or be dissolved and racemised. Small 
crystals can also be dissolved or grow (i.e. to be subjected to Ostwald ripening) by 
reincorporation of chiral clusters or chiral molecules, propagating the chirality of its “mother 
crystal”. Moreover, all the researchers are to agree that deracemisation is a nonlinear 
autocatalytic process following an exponential kinetics. 
However, this process remains a paradox in the chemistry world, as was pointed out by 
Viedma et al. in 2010: “the key driving force for the evolution of solid-phase homochirality is 
solution racemisation – a process that conventionally erodes chiral discrimination.” 
 
 
 
VII - Conclusion 
Since the discovery of the chirality and its vital role for living systems, many methods to give 
access to pure enantiomer were designed by researchers. In this chapter, an overview of these 
techniques, such as asymmetric synthesis, kinetic resolution of a racemic mixture, resolution 
by chromatography or by crystallisation, was depicted. Each method has its advantages and its 
drawbacks. The more effective method depends on the target compound and need to be 
adapted to give the best productivity. 
The recent technique of chiral symmetry breaking by crystallisation was studied with great 
details. Even if this method is limited to conglomerates that can be quickly racemised in 
conditions compatible with its crystallisation, it remains a very promising technique because 
the yield and the final enantiomeric excess are very good. Moreover, no chiral auxiliary are 
necessary. 
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I - Introduction 
The separation of the enantiomers in the solid state is an important economical issue; in most 
of cases, less solvents and less expensive equipments are necessary than for the purification 
by chromatography for example. However, the separation in the solid state can not be applied 
to all the compounds. Therefore, the acess to new chiral auxiliaries is became a major issue in 
order to enlarge the range of enantiomers which can be separated by crystallisation. 
Cyclodextrins are macrocyclic molecules able to form inclusion complexes with organic 
compounds and are also known in literature to be chiral selectors. This ability to discriminate 
enantiomers is widely used in chromatography but only few successes were poined out in the 
solid state, mainly because the difference between the complexes formed from the two 
enantiomers of a molecule is not sufficient to lead to a chiral separation. 
In order to increase the chiral discrimination between the two enantiomers, monosubstituted 
β-cyclodextrins with a “hook” were synthesized. This hook, with an acidic or basic function, 
may create strong bonds with a basic or acidic guest, increasing the cohesion energy in the 
complex. This hook may also force the direction of the inclusion of the guest inside the cavity 
of the cyclodextrin, and therefore to induce a higher energy difference between the two 
enantiomers, making possible their separation. 
In this chapter, the synthesis of a small library of monosubstituted β-cyclodextrins is 
described, as well as the study of a few complexes. But first, an overview on cyclodextrins, 
history, functionalisation, and formation of complexes, is given. 
 
 
 
II - Synthesis of mono-substituted cyclodextrins: state of the art 
 1. Cyclodextrins 
  a. History 
The earliest reference to cyclodextrins in the scientific literature was made in 1891 by 
Villiers.129,130 They appeared as by-product of the fermentation of potato starch by Bacillus 
amylobacter. He noticed that two different crystalline forms existed, most probably due to 
two different molecules. However, he could not determine the exact composition of these 
molecules. He could only state that the empirical formula was a multiple of C12H20O10.3H2O. 
                                                 
129 A. Villiers; Comptes Rendus Hebdomadaires des Séances de l’Académie des Sciences, 1891, 112, 536-538. 
130 J. Szejtli; Chem. Rev., 1998, 98(5), 1743-1754. 
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Twelve years later, Schardinger,131 who sought to isolate bacteria that cause food poisoning, 
published a report on the formation of crystalline compounds resulting from the digestion of 
starch by bacteria. These compounds appeared to be identical to those previously described by 
Villiers. Schardinger isolated a bacterium, which he named Bacillus macerans, which seems 
to be the cause of the formation of these crystalline compounds. He found that these products 
reacted differently with iodine: he called them α- and β-dextrins. 
In the early ‘30s, Pringsheim and his group published several articles on cyclodextrins but 
most of them contained only speculations based on non-reproducible experiments and 
irrelevant analyses. However, they found that these dextrins were able to form complexes 
with many organic compounds.132,133 
Shortly after, Freudenberg and his group discovered that the Schardinger’s dextrins were 
made of maltose units, connected between them by α-1,4-glycosidic bonds.134,135 In the late 
‘30s, the γ-cyclodextrin was discovered and its structure was elucidated.136 
In the early ‘50s, groups of French and Cramer studied the enzymatic production of 
cyclodextrins and characterised their chemical and physical properties. 
In 1953, a first patent was filed on application of cyclodextrins in the pharmaceutical field, 
stabilizing the active ingredients in the human body. This patent paved the way for intensive 
researches on complexes made of cyclodextrins. 
But, in the end of the ‘60s, cyclodextrins were suspected to be toxic, restricting their uses in 
pharmaceutical and food processing industries. It was only in the early ‘70s that further 
analyses showed that this toxicity was due to impurities complexed in cyclodextrins rather 
than cyclodextrins themselves. 
Since these results, studies on cyclodextrins grew exponentially (Figure II - 1) as well as the 
quantities produced, resulting in lower cost (divided by 1000 in 30 years). 
                                                 
131 F. Z. Schardinger; Unters. Nahr. u. Genussm., 1903, 6, 865-880. 
132 H. Pringsheim: A Comprehensive Survey Of Starch Chemistry, Ed. Chemical CatalogueCo, R. Walton, New 
York, 1928. 
133 H. Pringsheim; Chemistry of the Saccharides, McGraw-Hill, New York, 1932. 
134 P. Karrer, C. Nageli; Helv. Chim. Acta 1921, 4, 169-173. 
135 A. Miekeley; Ber. Dtsch. Chem. Ges. 1932, 65, 69. 
136 K. Freudenberg, G. Blomquist, L. Ewald, K. Soff; Ber. Dtsch. Chem. Ges. 1936, 69, 1258-1266. 
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Figure II - 1. The three stages in development of CD technology.
Erreur ! Signet non défini.
 
 
 
  b. Structure and nomenclature 
Cyclodextrins (or cyclohexa/hepta/octaamylose, cyclomaltohexa/hepta/octaose...) are cyclic 
oligosaccharides. There are considered as natural compounds since they are produced by the 
digesting of starch by bacteria. 
Cyclodextrins are made of glucopyranose units connected between them by α-1,4-glycosidic 
bonds. Different size of cycles exists and the most commonly studied are made of six, seven 
and eight units, respectively named α-, β- and γ-cyclodextrins (Figure II - 2). 
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Figure II - 2. Chemical structure of β-cyclodextrin 1. 
 
All glycosidic units adopt a chair-type conformation (4C1), all the alcohols being in the 
equatorial position (Figure II - 3). 
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Figure II - 3. Chair-type conformation of the glucose units and numbering of carbons. 
 
Consequently, all the alcohol groups are rejected outside the cyclodextrin. One of the most 
important properties of the cyclodextrins directly results of this conformation: cyclodextrins 
exhibit the shape of a truncated cone (Figure II - 4). The primary face (with the primary 
alcohols) is smaller than the secondary face (with the secondary alcohols) and the cavity is 
hydrophobic. 
 
Figure II - 4. Schematic representation of the hydrophobic cavity of β-cyclodextrins. 
 
The size of cavity depends on the number of glucose units as shown in Table II - 1. 
 α-CD β-CD (1) γ-CD 
Number of glucose units 6 7 8 
Molecular weight (g.mol-1) 972.84 1134.98 1297.12 
Internal diameter of cavity (Ǻ) 5.7-13.7 7.8-15.3 9.5-16.9 
Heigh of cavity (Ǻ) 7.8 7.8 7.8 
Volume of cavity (Ǻ3) 174 262 427 
Table II - 1. Approximate dimensions of cavities of α-, β- et γ-cyclodextrins. 
 
Native cyclodextrins are molecules exhibiting an axis of symmetry with an order equal to the 
number of units that composed them. For example, the β-cyclodextrins exhibits a C7 axis. 
Therefore, the 1H RMN spectra is relatively simple (Figure II - 5). The importance of peak of 
water is due to the particular hygroscopicity of cyclodextrins. For example, the hydration rate 
of the commercial β-cyclodextrin is ≈14% and its entire cavity is filled with water molecules. 
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Figure II - 5. 1H NMR spectra of β-cyclodextrins in DMSO-d6. 
 
 
  c. Reactivity 
The reactivity of cyclodextrins is mainly due to the alcohol groups. The functionalisation of 
these alcohols gives cyclodextrins with different properties. For example, the native 
cyclodextrins, which has only OH groups, are completely insoluble in organic solvents such 
as dichloromethane or ethyl acetate, whereas the permethylated cyclodextrins are soluble in 
most of them. 
The totally modified cyclodextrins can be easily synthesized by using a large excess of 
reagent. Thus, the methyl-β-cyclodextrins (Me-β-CD) and the hydroxypropyl-β-cyclodextrins 
(HP-β-CD) are easily available. On the other hand, it is more difficult to modify only one of 
the twenty one alcohols of the molecules (in the case of the β-cyclodextrin). The secondary 
alcohols are less reactive than the primary ones; they are involved in hydrogen bonds between 
them and they rotation is restricted, whereas the rotation of the secondary alcohols is free. It is 
therefore possible to discriminate these two kinds of alcohols, but it is generally difficult to 
obtain a controlled functionalisation (Figure II - 6); the results are often a mixture of different 
polysubstituted cyclodextrins. 
 
Figure II - 6. Possible positions of the substituents of a difunctionalised β-cyclodextrin. 
 
Polysubstituted cyclodextrins (on the same kind of position, 2, 3 or 6) are generally difficult 
to purify. They are almost insoluble in conventional organic solvent. Classical purification by 
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liquid-liquid extraction and chromatography on silica gel are therefore particularly 
complicated to carry out, eluents being generally composed of viscous solvents such as water 
or butanol. 
And yet, it is essential to be able to purify and characterise the synthesized compounds, 
particularly for pharmaceutical and food industries. Therefore numerous studies were carried 
out to control the substitution of cyclodextrins.129 Key steps are generally based on the 
different reactivity of the alcohols (the ratio of reagent can be optimised to obtain the desired 
compound) or on protection/deprotection reactions. 
Methods exist to selectively functionalise several positions on one cyclodextrin but they are 
not described in this manuscript. Only the selective monosubstitution is studied in the 
following paragraph.137 
 
 
 2. Synthesis of monosubstituted cyclodextrins 
  a. Monosubstitution at the 2-position of cyclodextrins 
One of the methods used to prepare monosubstituted cyclodextrin at the 2-position is the 
group transfer strategy (Figure II - 7 I and II). A complex is first formed then the functional 
group, commonly a tosyl group (coming from m-nitrophenyl tosylate)138 is transferred 
preferentially at the 2-position due to the orientation of the reagent within the host molecule. 
Then nucleophilic substitutions can be carried out to have access to a large number of 
monosubstituted cyclodextrins. 
The hydroxyl groups at the 2-position are also more acidic (due to the proximity of two 
oxygen atoms) than those at the 6-position. NaH under anhydrous conditions is able to 
selectively deprotonated the alcohol at the 2-position and therefore only this position is 
tosylated (Figure II - 7 III).139 
If the substitution of the primary alcohols is favoured, they can be protected (e.g. by a silyl 
group) then the substitution of the 2-position can be performed. After a deprotection step, the 
desired compound is obtained (Figure II - 7 IV, V and II).140 
However, the selectivity at the 2-position is generally not complete and an additional step of 
purification if necessary. 
                                                 
137 A. R. Khan, P. Forgo, K. J. Stine, V. T. D’Souza; Chem. Rev., 1998, 98, 1977-1996. 
138 A. Ueno, R. Breslow; Tetrahedron Lett., 1982, 23, 3451-3454. 
139 D. Rong, V. T. D’Souza, Tetrahedron Lett., 1990, 31, 4275-4278. 
140 E. V. van Dienst, B. H. M. Snellink, I. Von Piekartz, M. H. B. Gansey, F. Venema, M. C. Feiters, R. J. M. 
Nolte, J. F. J. Engbersen, D. N. Reinhoudt, J. Org. Chem., 1995, 60, 6537-6545. 
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Figure II - 7. Strategies for modification at the 2-position of cyclodextrins. n = 6 for α-CD , n = 7 for β-CD 
and n = 8 for γ-CD.
137
 
 
 
  b. Monosubstitution at the 3-position of cyclodextrins 
Direct substitution at the 3-position is a very complicated and difficult process because of the 
higher reactivity of the 2- and 6-hydroxyl groups. However, two reagents, the 2-
naphtalenesulfonyl chloride and the 3-nitrobenzenesylfonyl chloride give a higher yield of the 
3-substituted cyclodextrins.141,142 
Most modifications at the 3-position are obtained by reaction of manno-mono-2,3-
epoxycyclodextrin with a nucleophile as illustrated on Figure II - 8. This epoxycyclodextrin is 
obtained by elimination of the tosyl group at the 2-position by the hydroxyl group at the 3-
position. In most of the cases, the ring opening with a nucleophile, such as ammoniac or 
hydroxylamine, leads to the formation of the monosubstituted cyclodextrin at the 3-
position.143,144,145,146 However, imidazole is an exception since it has been reported that it 
attacks both the 2- and the 3-position of the 2,3-epoxycyclodextrin.147 
                                                 
141 K. Fujita, S. Nagamura, T. Imoto, T. Tahara, T. Koga; J. Am. Chem. Soc., 1985, 107, 3233-3235. 
142 K. Fujita, T. Tahara, Y. Egashira, T. Imoto, T. Koga; Tetrahedron Lett., 1992, 33, 5385-5388. 
143 M. Kojima, F. Toda, K. Hattori; J. Chem. Soc., Perkin Trans 1, 1981, 1647-1651. 
144 T. Ikeda, R. Kojin, C. J. Yoon, H. Ikeda, M. Iijima, F. Toda; J. Inclusion Phenom. Mol. Recognit. Chem., 
1987, 5, 93-98. 
145 K. Fujita, Y. Egashira, T. Imoto, T. Fujoka, K. Mihashi, K. Tahara, T. Koga; Chem. Lett., 1989, 429-432. 
146 A. M. Mortellaro, A. W. Czarnik; Bioorg. Med. Chem. Lett., 1992, 2, 1635-1638. 
147 D.-Q. Yuan, K. Ohta, K. Fujita; J. Chem. Soc., Chem. Commun., 1996, 821-822.  
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Figure II - 8. Reactions of mono-2-tosylcyclodextrin.
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  c. Monosubstitution at the 6-position of cyclodextrins 
The 6-position is the easiest to functionalise, primary alcohols being the most reactive. The 
most popular method to access to monomodified cyclodextrins is the nucleophilic 
substitutions, with various reagents, on the 6-O-p-toluenesulfonyl-β-cyclodextrine CDOTs 2 
(Figure II - 9 and Figure II - 10 I). This compound is relatively easy to obtain with an 
acceptable purity (90-95%) without purification and with a quite satisfactory yield (50%). 
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Figure II - 9. Chemical structure and schematic representation of 6-O-p-toluenesulfonyl-β-cyclodextrin 
CDOTs 2. 
 
CDOTs is generally prepared from the native cyclodextrin and the p-toluenesulfonyl chloride 
TsCl. In order to prevent the polytosylation (tosylation is a non selective process because both 
primary and secondary alcohols can react, giving di- or tritosylated cyclodextrins), numerous 
studies were carried out to find the best conditions to obtain only the monosubstituted 6-O-p-
toluenesulfonyl-β-cyclodextrin. Good results were obtained by using p-toluenesulfonyl 
chloride and native cyclodextrin in pyridine. Even if the work-up of the synthesis was 
complicated (formation of complexes with pyridinium which is difficult to remove), the direct 
monosubstitution of the 6-position is widely favoured. But as pyridine is not a user-friendly 
solvent, the method of choice to prepare the 6-O-p-toluenesulfonyl-β-cyclodextrin is a 1:1 
ratio of native cyclodextrin and TsCl in aqueous alkaline medium for a short time. The 
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product is obtained with a fairly good purity and repeated crystallisations or chromatography 
on a charcoal column can increase its purity. 
Another important intermediate is the monoaldehydic cyclodextrin because they provide a 
route for further modifications. The monoaldehydic cyclodextrin can be obtained by oxidation 
of the CDOTs (Figure II - 10 VI) but it can also directly be obtained with a better yield (85-
100%) from the native cyclodextrin by reaction with Dess-Martin periodinane (Figure II - 10 
IX). 
 
Figure II - 10. Overwiev of methods for monosubstitution at the 6-position of cyclodextrins. R1 = -I, -N3, -
SCOCH3, alkyl or polyalkyl amines, thioalkyl, R2 = derivatives of β-D-glucose, β-D-galactose, α-D-
mannose, β-D- and β-L-fructose, R3 = -OH, -NHPh.
137
 
 
The ether derivatives cannot be easily prepared from native cyclodextrins or by substitution of 
the tosyl group; alkoxide ions act as strong bases and not as nucleophiles. A multi-steps 
synthesis with protection/deprotection steps is necessary to obtain the desired compound. 
 
 
 3. Inclusion complexes 
  a. In industries 
Thanks to their hydrophobic cavity, cyclodextrins are able to easily form inclusion complexes 
with organic molecules as guests. Moreover, large amounts of cyclodextrins are industrially 
produced and so they are often used for pharmaceutical and food industries. Indeed, the 
formation of inclusion complexes with cyclodextrins has a lot of advantages:148  
 - Increasing of the solubility of the guests in water. This property is probably the most 
widely used in pharmaceutical industry; formation of complexes increasing the bioavailability 
of API, making them more soluble in physiological environment. 
                                                 
148 A.R. Hedges; Chem. Rev., 1998, 98(5), 2035-2044. 
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 - Increasing of the chemical stability of the guest molecules (e.g. photosensitive 
compounds or compounds unstable in acidic media such as stomach). 
 - Modification of the reactivity. In most cases, the reactivity decreases, the guest being 
stabilised by the cavity. But in few cases, the cyclodextrins may act as an artificial enzyme, 
speeding up or modifying a reaction. 
 - Manipulation of volatile or liquid compounds or compounds having an unpleasant 
odour as powders. 
 - Gradual release of a compound (drug, flavour…) 
Pharmaceutical industry 
Itraconazole Increased solubility 
Piroxicam/Brexin Reduce irritation 
Hydrocortisone Increased solubility 
garlic oil Mask odour 
  
Food industry 
peppermint-flavoured chewing gum Flavour delivery 
Acetic acid Convert to a powder 
lemon-flavoured sugar Flavour stabilization 
flavoured tea Flavour stabilization 
aloe-containing beverage Mask bitterness 
  
Cosmetics and Personal Care Items 
powdered hair bleach Stability 
Cold Cream Increased solubility 
Table II - 2. Examples of industrial use of cyclodextrins.
148
 
 
 
  b. Complexes formation 
An important factor to obtain inclusion complexes is the structural compatibility between the 
guest molecule and the cavity of the host, ensuring the formation of a maximum of 
interactions. In the case of complexes with cyclodextrins, only hydrogen bonds and low 
energy interactions, such as van der Waals interactions, are brought into play. The presence of 
seven alcohols on one side of the cyclodextrins and fourteen alcohols on the other side (in the 
case of the β-cyclodextrin) leads to the existence of an important dipolar moment. Therefore 
electrostatic interactions (dipole/dipole) also contribute to the formation and the stabilisation 
of the complexes. 
Furthermore, even if the cavity of cyclodextrins is hydrophobic, the entire cavity is filled of 
water molecules. These water molecules do not have the possibility to adopt the most stable 
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configuration and can be considered as high-energy molecules. Thus, the inclusion of a 
hydrophobic molecule instead of water gives a complex with a lower energy and stabilises the 
system. This is one of the driving forces of the formation of complexes. 
For example, a molecule such as toluene can be included in α- and β-cyclodextrins but not in 
γ-cyclodextrin. Naphthalene can form complexes with β- and γ-cyclodextrins while 
anthracene can be included only in γ-cyclodextrin, being to large to be included in the cavity 
of the smaller cyclodextrins. All this complexes exhibit a 1:1 stoichiometry but, different 
combinations of host and guest also exist.80 For example, the salicylic acid forms 1:2 and 1:4 
(host/guest) complexes with the γ-cyclodextrin.149 
These complexes are generally prepared in water. The cyclodextrin is dissolved in water then 
the guest is added. After stirring, the complex may be recovered by precipitation or 
evaporation of the solvent. To help the formation of the complex, an increase of the 
temperature or an addition of solvent may be used to increase the solubility of the host. The 
cyclodextrin is also generally close to the saturation. 
However, several different methods can be used:148 
 - Slurry method: cyclodextrin is suspended in water up to a 40-50% w/w 
concentration. This method can be used when the complex is less soluble in water than the 
cyclodextrin. 
 - Paste method: a minimum of water is used (20-30% w/w) then the host is added and 
the paste is mixed. This method is generally used in industry. 
 - Dry mixing method: no solvent are used. Cyclodextrin and the host molecule are 
mixed together. This method is efficient when the host is liquid. 
 
  c. Characterisation of complexes 
Many techniques can be used to characterize the complexes. As all the techniques give 
different information, they are generally complementary. Separate analyses of host and guest 
are also necessary to fully characterise the complexes. The classical analyses in solution 
(NMR, mass spectrometry, IR and UV spectroscopies, fluorimetry…) and in the solid state 
(XRPD, IR and Raman spectroscopies, DSC/TGA-DSC, solid state NMR…) can be used.150 
X ray diffraction on single crystal and the 2D NMR are analyses given the most important 
details. Indeed, these methods allow having access to structural information. However, the 
                                                 
149 K. Higashi, Y. Tozuka, K. Moribe, K. Yamamoto; J. Pharm. Sci., 2010, 4192-4200. 
150 H.-J. Schneider, F. Hacket, V. Rüdiger; Chem. Rev., 1998, 1755-1785. 
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analyses in solution and in the solid state may give contradictory information: in solution, the 
complex can be stabilised (or destabilised) by the interactions with the solvent. 
 
 
 4. Cyclodextrins and chiral recognition 
Besides their ability to form inclusion complexes, cyclodextrins are chiral and thus, they are 
able to discriminate the two enantiomers of a molecule. 
This property for cyclodextrins to be a chiral selector is widely used in chromatography; 
cyclodextrins are grafted on the stationary phase, leading a different retention time for the two 
enantiomers which can be separated. Numerous researches were and are still carried out in 
order to improve the efficiency of the separation, particularly for gas chromatography and 
capillary electrophoresis.151 
 
  a. Chiral recognition in the solid state 
However, except in the field of chromatography, only few studies were carried out on the 
ability of cyclodextrins to discriminate enantiomers. In the ‘80s, the first structures of 
complexes were resolved by Harata et al.152,153  and Hamilton and Chen.154 Harata et al. 
studied the system formed by the β-cyclodextrin and the flurbiprofene (Figure II - 11) by 
resolving the crystalline structures of the racemic and of the diastereomeric complexes. The 
structures of the two diastereomeric complexes were characterized by the existence of dimers 
of cyclodextrins, in which two guest molecules were included. The two enantiomers of the 
guest formed different interactions with the host. For example, the R-flurbiprofene crystallised 
as a monohydrate with the β-CD whereas the S-flurbiprofene crystallised as an anhydrate with 
the β-CD. However, these differences were not sufficient to induce a chiral discrimination; 
the resolution of the structure of the racemic complex revealed that the two enantiomers are 
present in the dimers. 
 
Figure II - 11. Chemical structure of the Flurbiprofene. 
 
                                                 
151 W. Tang, S.-C. Ng; J. Spe. Sci., 2008, 31, 3246-3256. 
152 K. Harata; Bull. Chem. Soc. Jpn, 1982, 55, 1367. 
153 K. Uekama, F. Hirayama, T. Imai, M. Otagiri, K. Harata; Chem. Pharm. Bull., 1984, 33, 1662. 
154 J. A. Hamilton, L. Chen; J. Am. Chem. Soc. 1988, 110, 4379. 
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A similar study was carried out by Hamilton and Chen with the β-CD and the fenoprofene.154 
As for the previous case, the structures obtained from the racemic mixture and from the two 
enantiomers are isomorphous and are characterized by the formation of dimers. However, the 
geometry of inclusion is totally different for the two enantiomers (Figure II - 12). In a dimer, 
the two molecules of S-fenoprofene were in the same direction (head-to-tail) whereas the two 
molecules of R-fenoprofene faced each other (head-to-head). 
Crystals obtained from the racemic mixture exhibited an enantiomeric excess over 50% (for 
the S enantiomer). This chiral discrimination was attributed to the different geometry of 
inclusion of the two enantiomers inside the cavity of the β-CD. 
 
Figure II - 12. Schematic representation of the dimers formed with the S-fenoprofene (left) and with the 
R-fenoprofene (right) with the β-CD. 
The chiral recognition induced by cyclodextrins can also be detected in solution by NMR.150 
Some NMR studies, and especially 2D NMR, showed the splitting peaks in two of the guest 
molecule,155 proving that the two enantiomers interact differently with the cavity of the 
cyclodextrin. Computer simulations also demonstrated that the optimal configuration of the 
complex depends on the enantiomer: interactions between both enantiomers and the 
cyclodextrin are different leading to a different positioning inside the cavity and therefore 
different association constants.156 Microcalorimetric analyses also demonstrated that the chiral 
recognition was possible with the native β-cyclodextrin.157 However, these studies highlighted 
that the energy difference between the more and the less stable complexes was generally not 
sufficient to perform a chiral separation at the solid state. 
 
 
 
                                                 
155 B. S. Jursic, P. K. Patel; Tetrahedron, 2005, 61, 919-926. 
156 C.-J. Núñez-Agüero, C.-M. Escobar-Llanos, D. Díaz, C. Jaime, R. Garduño-Juárez; Tetrahedron, 2006, 62, 
4162-4172. 
157 M. Rekharsky, Y. Inoue; J. Am. Chem. Soc., 2000, 122, 4418-4435. 
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  b. Permethylated β-cyclodextrins/(±)p-fluorophenylethanol complexes 
Very recently, Amharar et al. described the unusual case of the permethylated β-
cyclodextrins/(±)-p-fluorophenylethanol complexes, and the resulting separation of the two 
enantiomers.80 This study follows the work carried out by Grandeury et al., on the 
permethylated cyclodextrins/(±)-phenylethanol derivatives complexes.158159 
The study of the β-cyclodextrins/(±)-p-fluorophenylethanol/water system revealed that two 
different solid phases exist, with unusual features. On the one hand, a stable complete solid 
solution with two idependent complexes per asymmetric unit exibits a limited chiral 
recognition, and on the other hand, two metastable partial solid solutions with 1:2 host:guest 
stoichiometries behave as diastereomeric complexes. The structural study of these 1:2 
complexes show that the chiral recognition is ensured both by the cavity of the cyclodextrin 
and by the crystal lattice; one of the guest molecule is included in the cavity while the second 
guest molecule do not have direct interaction with the cyclodextrins. It was the first time that 
such a hybrid mechanism of chiral recongnition was reported in the literature. 
However, even if the separation of the two enantiomers is possible, successive 
recrystallisations are necessary to obtain a high enantiomeric excess, decreasing the yield of 
the separation: three recrystallisations must be carried out to obtain the S-1:2 (diastereomeric 
excess d.e.>98%) with 12.5% yield and eight recrystallisations must be carried out to obtain 
the R-1:2 (d.e.>95%) with ≈1% yield. 
Therefore it is necessary to increase the discrimination between the two enantiomers. In this 
perspective, monosubstituted cyclodextrins with a hook were synthesized. 
 
 
 
III - Synthesis of monosubstituted β-cyclodextrins 
 1. 6-O-p-toluenesulfonyl-β-cyclodextrin β-CDOTs 
  a. Synthesis of 6-O-p-toluenesulfonyl-β-cyclodextrin 
The method widely used to synthesize the β-CDOTs involves TsCl (see paragraph II). 
However, different tosylate derivatives can also be used. 
                                                 
158 A. Grandeury, S. Tisse, G. Gouhier, V. Peulon, S. Petit, G. Coquerel; Chem. Eng. Technol., 2003, 26, 354-
358. 
159 A. Grandeury, S. Petit, G. Gouhier , V. Agasse, G. Coquerel; Tetrahedron: Asymm., 2003, 14, 2143-2152. 
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In 1998, Zhong et al. described the preparation of β-CDOTs from the p-toluenesulfonic 
anhydride Ts2O.160 Pure β-CDOTs was obtained with 61% yield without any purification step. 
However, tosic acid-free p-toluenesulfonic anhydride is difficult to prepare. The synthesis, 
described in the publication of Zhong et al., was tested in the laboratory. The reaction 
between TsCl and TsOH in CH2Cl2 did not give Ts2O; the reagents were recovered. Another 
synthesis was tested by using TsOH and SOCl2. This time, the Ts2O was observed in 1H NMR 
but it was not pure; the solid harvested at the end of the synthesis was a mixture of Ts2O and 
TsOH. As the purification was difficult, this route of synthesis was not pursued further. 
 
In 2000, the same authors published a more efficient synthesis of β-CDOTs by using 1-(p-
toluenesulfonyl)imidazole ImTs 3 (Figure II - 13).161 The yield was lower (40% instead of 
61%) but the selectivity was higher; multi-tosylation was not observed even with four 
equivalents of ImTs. 
 
Figure II - 13. Synthesis of β-CDOTs 2 from native β-cyclodextrin and 1-(p-toluenesulfonyl)imidazole 
ImTs 3. 
 
Actually, the purity of β-CDOTs obtained from p-toluenesulfonic anhydride Ts2O was not 
perfect as described in the publication dated from 1998; a significant amount of native and 
disubstituted β-cyclodextrins were also synthesized.161 Other advantages of ImTs are its 
stability (it is more resistant to hydrolysis at room temperature than TsCl and Ts2O) and its 
solubility in water (ImTs exhibits a higher solubility than TsCl and Ts2O). Moreover, ImTs is 
easy to synthesize and to purify. 
The synthesis of β-CDOTs from ImTs was then tested in the laboratory. The synthesis of 
ImTs was carried out with success: pure ImTs was obtained with yields between 72% and 
97% (Figure II - 14). 
                                                 
160 N. Zhong, H.-S. Byun, R. Bittman; Tetrahedron Lett., 1998, 39, 2919-2920. 
161 H.-S. Byun, N. Zhong, R. Bittman; Org. Synth., 2000, 77, 225-227. 
Synthesis of monosubstituted β-cyclodextrins for chiral separation 
 
- 96-  
 
Figure II - 14. Synthesis of 1-(p-toluenesulfonyl)imidazole ImTs 3. 
 
The first synthesis of β-CDOTs from ImTs was carried out following the same procedure than 
the one descried the by Byun et al.,161 but from 1.14g (1mmol) of native β-cyclodextrin 
instead of 40g. Unfortunately, the results were disappointing: even if the β-CDOTs was 
predominantly obtained, mass spectrometry and thin layer chromatography (hereafter TLC) 
revealed that significant amounts of native and disubstituted cyclodextrin β-CD(OTs)2 were 
also formed. Different methods of purification were tested: 
 - Successive recrystallisations in hot water: the purity seemed to be slightly improved 
but to the detriment of the yield. Recrystallisation must be carefully carried out to avoid the 
hydrolysis of the tosylate. 
 - Recrystallisation in a 1/1 water/ethanol mixture: the purity was not significantly 
increased. 
 - Purification on silicagel by using mixtures of water and acetone (from 1/6 to 1/5) as 
eluent. A fraction enhanced in β-CDOTs was collected but with a very low yield (≈ 3%). 
Moreover, a large volume of solvents was necessary to perform this purification. 
 
As the results were not satisfying with 1-(p-toluenesulfonyl)imidazole ImTs, synthesis of β-
CDOTs from p-toluenesulfonyl chloride TsCl was tested (Figure II - 15). The experiment was 
carried out in water with sodium hydroxide. Unfortunately, but in accordance with the 
literature, the purity of the final product was worse than with ImTs. 
 
Figure II - 15. Synthesis of β-CDOTs 2 from native β-cyclodextrin and p-toluenesulfonyl chloride TsCl. 
 
Therefore the synthesis of β-CDOTs was continued with ImTs and 10g of native β-CD were 
involved in the reaction. Surprisingly, the purity of the final product seemed to be better than 
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previously and the yield was satisfying (47%). This product was then used without further 
purification in the next steps. 
As the purity seemed to be increased when the amount of starting material increased, a 
synthesis on a larger scale was carried out. The same masses of reagents were used than those 
used by Byun et al.161 Therefore, 40g of native β-CD were involved. Once again, the purity of 
the final product was increased compared to the previous synthesis and the yield was quite 
good (32%). Native β-CD and β-CD(OTs)2 was almost no more visible on the mass 
spectrometry analyses. Of course, this analytical method is qualitative and not quantitative, 
but the comparison of spectra of different experiments carried out in the same conditions may 
give information on the relative purity of products. 
The synthesis of β-CDOTs by using ImTs seems to be, at present, the best method to obtain 
satisfying purity and yield. This experiment was reproduced several times and the yield was 
increased up to 56%, without decreasing the purity. 
 
  b. 2 dimensions NMR analysis 
After each synthesis, mass spectrometry analyses were carried out to determine if the 
monofunctionalisation was efficient or not, but did not give information about which alcohol 
was substituted. Therefore 2D NMR experiments were performed. 
The HSQC (Heteronuclear Single Quantum Correlation) NMR analysis seemed to be the 
more relevant method to determine which kind of alcohol was substituted; direct correlations 
between carbon and attached hydrogen(s) are visible. 
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Figure II - 16.  HSQC NMR of β-CDOTs (left) and magnification of the red square (right). 
 
In this case, the 13C NMR is a Jmod analysis, in which C and CH2 are on a side of the base 
line of the spectrum (here, to the left) and CH and CH3 are on the other side (to the right). On 
β-CDOTs, only two kinds of CH2 exist; those linked to the free primary alcohols and the one 
linked to the tosyl group. Therefore, it is easy to attribute the CH2 peaks, as drawn on the right 
spectrum of the Figure II - 16: six carbons give a signal at ≈60ppm while another single one is 
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at ≈70ppm. Moreover, we can notice that the carbon at 70ppm is correlated to two different 
hydrogens, that is typical of diastereotopic hydrogens. 
Combining mass spectrometry analysis and HSQC NMR analysis, it is clear that the 
monosubstitution occurred on a primary alcohol. 
 
 
 2. Synthesis of 6-deoxy-6-azido-β-cyclodextrin and its derivatives 
  a. Synthesis of 6-deoxy-6-azido-β-cyclodextrin β-CDN3 
The 6-deoxy-6-azido-β-cyclodextrin β-CDN3 4 can be easily synthesized from of β-CDOTs 
by nucleophilic substitution by using N3- as nucleophile (Figure II - 17).  
N3
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Figure II - 17. Synthesis of 6-deoxy-6-azido-β-cyclodextrin β-CDN3 4. 
 
The synthesis and the purification were carried out according to the protocol described by 
Jicsinszky et al.162 The nucleophilic substitution was a success, but not the purification. A 
purification by recrystallisation in a 10/1 acetone/water mixture was described but the product 
seemed to be almost insoluble in this mixture, even at high temperature. However, as this 
nucleophilic substitution is quantitative, the purity of the final product depends on the purity 
of the starting material. So, as the starting material was quite pure, the purity of β-CDN3 was 
satisfying. 
 
Actually, the main impurities were not native β-CD or polysubstituted CD, but were DMF, 
the solvent of the reaction, and a tosylate derivative: most probably TsONa. This impurity 
was encountered in all the syntheses of cyclodextrin derivatives by nucleophilic substitution 
(see the following paragraphs). TsONa seemed to give a stable complex with the substituted 
cyclodextrins, making its removal difficult. The presence of a tosylate derivative is clearly 
visible by 1H NMR; peaks at δ ≈ 7 ppm cannot belong to the cyclodextrins 4 (Figure II - 18). 
                                                 
162 L. Jicsinszky, R. Iványi; Carbohyd. Polym., 2001, 45, 139-145. 
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Integration of peak areas gave the proof that the amount of TsONa is thus absolutely not 
negligible. 
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Figure II - 18. 
1
H NMR of the crude β-CDN3 in DMSO-d6.  
 
To remove the DMF, the product was suspended in methanol and was stirred over night at 
RT. The solid was then analysed by 1H NMR: as expected DMF almost disappeared but the 
amount of TsONa also significantly decreased (Figure II - 19). After an additional stirring in 
fresh methanol, peaks of DMF and TsONa were not detected. 
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Figure II - 19. 
1
H NMR of β-CDN3 in DMSO-d6 after stirring one night in methanol. 
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  b. Synthesis of 6-deoxy-6-amino-β-cyclodextrin CDNH2 
The 6-deoxy-6-amino-β-cyclodextrin β-CDNH2 was synthesized by hydrolysis of β-CDN3 by 
using triphenyl phosphine and water in DMF with a good yield (Figure II - 20).163  
 
Figure II - 20. Synthesis of 6-deoxy-6-amino-β-cyclodextrin β-CDNH2 5. 
 
β-CDNH2 can be synthesized both from the crude and the purified β-CDN3; the presence of 
TsONa did not disturb the reaction. However, it was still present at the end of the synthesis 
but it can be easily removed by using the same method as that used for β-CDN3 (Figure II - 
21). 
   
Figure II - 21. 
1
H NMR of β-CDNH2 in D2O of the crude product (left) and after stirring twice in methanol 
(right). 
 
 
  c. Synthesis of 6-deoxy-1,2,3-triazole-β-cyclodextrin derivatives 
The β-CDN3 can also be involved in coupling reactions. The Huisgen [2+3] cycloaddition can 
be carried out with various alkyne precursors to give the 6-deoxy-1,2,3-triazole-β-
cyclodextrin derivatives (Figure II - 22). This kind of reactions is named “Click-chemistry” 
and is widely used to graft cyclodextrins on silica to prepare the stationary phases of chiral 
chromatography columns.164 
                                                 
163 I. W. Muderawan, T. T. Ong, T. C. Lee, D. J. Young, C. B. Chinga, S. C. Ng; Tetrahedron Lett., 2005, 46, 
7905-7907. 
164 Z., Y. Jina, T. Lianga, Y. Liua, Q. Xua, X. Lianga, A.  Lei; J. Chromatogr. A, 2009, 1216, 257-263. 
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Figure II - 22. Synthesis of 6-deoxy-1,2,3-triazole-β-cyclodextrin derivatives. 
 
Various functionalised cyclodextrins can be synthesized from β-CDN3 by Click-chemistry. 
The first alkyne tested for this reaction was the propargyl alcohol. The reaction was carried 
out in DMSO, following the procedure of Mourer et al.; this solvent seemed to be more 
efficient in terms of yields than DMF.165 Unfortunately, even if the desired product 6a was 
synthesized (β-CDN3 was not detected by the mass spectrometry analysis), the purification 
was difficult, and DMSO was particularly difficult to remove. Moreover, the crude product 
was green, due to the copper used as catalyst. But the purification described by Mourer et al. 
(chromatography on silicagel with water as eluent) was not efficient. 
Therefore, a second experiment was made in DMF and with the propragyl amine in order to 
purify the product on an ion-exchange resin. An Amberlite IR-120 H+ form was used and the 
copper-free 6-deoxy-(4-aminoethyl-1,2,3-triazole)-β-cyclodextrin 6b was obtained with 37% 
yield. Another ion-exchange resin, the Dowex 50Wx 8H+ form, gave similar results. 
Nevertheless, the purification was not very efficient and the yield significantly decreased 
when the purification was performed on a larger scale (≈1%). Chromatography with ion-
exchange resin as stationary phase was also tested without success: the cyclodextrin was not 
retained enough in the column. 
 
Figure II - 23. Schematic representation of 6-deoxy-(4-hydroxymethyl-1,2,3-triazole)-β-cyclodextrin 6a 
and 6-deoxy-(4-aminomethyl-1,2,3-triazole)-β-cyclodextrin 6b. 
 
 
 
 
                                                 
165 M. Mourer, F. Hapiot, S. Tilloy, E. Monflier, S. Menuel; Eur. J. Org. Chem., 2008, 5723-5730. 
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 3. Synthesis of diamino-β-cyclodextrins 
A small library of diamino-β-cyclodextrins was synthesized to have access to basic 
cyclodextrins with different length of “hook”, in order to increase the possibility for a 
molecule to form a stable complex with one of this modified cyclodextrins (Figure II - 24). 
 
Figure II - 24.  Synthesis of diamino-β-cyclodextrins. 
 
 
  a. Synthesis of 6-deoxy-(2-aminoethylamino)-β-cyclodextrin 
The 6-deoxy-(2-aminoethylamino)-β-cyclodextrin 7 was easily synthesized from β-CDOTs by 
nucleophilic substitution with ethylenediamine as nucleophile. According to Liu et al., 
ethylenediamine was used as solvent.166 The ratio β-CDOTs/ethylenediamine can be 
decreased compare to the Liu’s procedure, from 115 to 50 equivalents. However, it is difficult 
to use a lower ratio, the amount of diamine being not sufficient to dissolve β-CDOTs. 
The position of the substituent was confirmed by HSQC, the two diastereotopic hydrogens 
linked on the functionalised secondary carbon are clearly visible. 
As β-CDN3 4 and β-CDNH2 5, the tosyl derivative gave a complex with 7. Stirring in 
methanol were also able to purify the product. 
 
  b. Synthesis of 6-deoxy-(aminoalkylamino)-β-cyclodextrin 
This monosubstituted cyclodextrins 8 et 9 were synthesized following the same procedure 
than 7 by using 1,3-diaminopropane and 1,6-diaminohexane as solvent, respectively. 
The monosubstituted cyclodextrin 10 was synthesized by using N-methyl-2-pyrrolidone NMP 
as solvent with 4 equivalents of 1,8-diaminooctane (1,8-diaminooctane is a solid, and so can 
not be used as solvent).167 The monosubstituted cyclodextrin 9 can also be carried out in NMP 
with 4 equivalents of 1,6-diaminohexane with similar results than with 1,6-diaminohexane 
only. 
                                                 
166 Y.-Y. Liu, X.-D. Fan, L. Gao; Macromol. Biosci., 2003, 3, 715-719. 
167 J. S. Lock, B L. May, P. Clements, J. Tsanaktsidis, C. J. Easton, S. F. Lincoln; J. Chem. Soc., Perkin Trans. 1, 
2001, 3361–3364. 
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The substitution at the 6-position was confirmed by an HSQC NMR analysis and the tosylate 
derivative can be removed by stirring in methanol. 
 
  c. Synthesis of 6-deoxy-6-benzylamino-β-cyclodextrin 
The 6-deoxy-6-benzylamine-β-cyclodextrin 11 was synthesized and purified following the 
same procedure than 7 by using benzylamine as solvent (50 equivalents). 
 
Figure II - 25. Synthesis of the 6-deoxy-benzylamino-β-cyclodextrin 11. 
 
 
 4. Synthesis of acid derivatives 
A small library of amino acid derivatives was prepared to have access to cyclodextrins with 
an acidic hook. Aliphatic amino acids with different chain length were synthesized to increase 
the possibility to form a stable complex with a basic guest. 
Polyacidic monosubstituted β-cyclodextrins were also prepared; the three acidic moieties may 
act as a polydentate complexing agent. 
 
  a. Synthesis of aliphatic amino acid derivatives 
These derivatives were synthesized from the β-CDOTs. An organic base, such as triethyl 
amine (TEA) had to be added to make the nitrogen nucleophile. Indeed, amino acids exist as 
NH3+-CHR-COO- form (and not as NH2-CHR-COOH form). The nitrogen is therefore not 
nucleophile. The addition of a base is therefore necessary to form the nucleophile entity NH2-
CHR-COO-. 
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Figure II - 26. Synthesis of aliphatic amino acid derivatives. 
 
First, reactions were carried out in NMP and DMF, but the substitution did not occur. Then 
water was used and the conversion was complete. However, some optimisations were 
necessary; when the amount of amino acid was too low, a significant amount of by-product 
appeared. On mass spectra, the peak corresponding to the mass of native cyclodextrin minus 
18 (a water molecule) was visible. As this peak has never been observed before on the mass 
spectra of the other compounds (mass spectrometry analyses were carried out in the same 
conditions than the previous one), this peak corresponded to a by-product and not to a 
fragmentation of the native cyclodextrin. An excess of triethylamine was used compared to β-
CDOTs, so alcohols may be deprotonated and an intramolecular substitution may occur. 
According to the literature,168 the alcohol at the 3-position can be responsible of this 
substitution and the cyclodextrin 13a was formed. However, the compound 13b, resulting 
from the elimination of the tosylate, has also the same molecular mass. As the by-product had 
not been isolated, it was impossible to know which one was the by-product. To avoid the 
formation of 13a and/or 13b, 10 equivalents of amino acid had to be used. 
Moreover, the final products were not pure; free amino acids are still present, as if they were 
complexed inside the cyclodextrins. 
 
Figure II - 27. Chemical structure of the by-products 13a and 13b. 
                                                 
168 J. A. Faiz, N. Spencer, Z. Pikramenou; Org. Biomol. Chem., 2005, 3, 4239-4245. 
Synthesis of monosubstituted β-cyclodextrins for chiral separation 
 
- 105-  
  b. Synthesis of the L-phenylalanine derivative 
The L-phenylalanine derivative was also synthesized to give the possibility to form π 
interactions between the host and the guest molecules. The same procedure as for the aliphatic 
amino acid derivatives was used. 
 
Figure II - 28. Synthesis of the L-phenylalanine derivative. 
 
 
  c. Synthesis of polyacid derivatives 
The amino-β-CD 5 and the diamino-β-CDs 7-10 can be modified by addition of chloroacetic 
acid to have access to poly acid cyclodextrins (Figure II - 29 and Figure II - 30). Pham et al. 
described the use of these compounds to combine the effect the EDTA 
(ethylenediaminetetraacetic acid), known to complex metallic ions, with the ability of 
cyclodextrin to be a chiral selector.169 
 
Figure II - 29.  Synthesis of the amino-β-CD derivative. 
 
Figure II - 30. Synthesis of the diamino-β-CD derivatives. 
 
                                                 
169 D.-T. Pham, P. Clements, C. J. Easton, S. F. Lincoln; Tetrahedron: Asymmetry, 2008, 19, 167-175. 
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IV - Study of the crystallisation of monosubstituted β-
cyclodextrins and of inclusion complexes 
 1. Crystallisation of monosubstituted β-cyclodextrins 
After purification by stirring overnight in methanol to remove the tosylate included in the 
cavity of the cyclodextrins, XRPD analyses were performed. Figure II - 31 exhibits the 
superimposition of β-CDN3, β-CDNH2 and β-CDNH(CH2)nNH2. 
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Figure II - 31. Superimposition of XRPD patterns of β-CDN3, β-CDNH2, and β-CDNH(CH2)nNH2. 
 
Each β-CD derivative exhibits a poor crystallinity. That can be explained by the purification 
work-up of these compounds: after stirring in methanol and filtration, powders are dried 
overnight in an oven at 50°C. This temperature may be sufficient to remove water to the 
crystal lattice and therefore to decrease its crystallinity. 
 
The amino acid β-CD derivatives (12a-d and 14) also exhibit a poor crystallinity and two of 
them (12a and 12d) are amorphous. 
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Figure II - 32. Superimposition of the XRPD patterns of the amino acid β-CD derivatives. 
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  a. β-CDN3 
After purification, the β-CDN3 exhibits a poor crystallinity that can be enhanced by 
recrystallisation in water from 40°C to room temperature (the red pattern of Figure II - 33). 
However, after maturation in water, a new phase appeared, probably due to the crystallisation 
of a hydrate with a different stoichiometry. When the temperature of the system is decreased 
to 10°C, a third phase appeared. 
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Figure II - 33.  Superimposition of XRPD patterns of β-CDN3 after purification (in black), after 
recrystallisation in water (from 40°C to RT, in red), after  maturation (in blue) and after 72h at 10°C (in 
green). 
 
The crystallisation of the β-CDN3 seems be very sensitive to the temperature and to the 
presence of water. The existence of efflorescent hydrate was confirmed by microscopy; 
crystals of β-CDN3 were obtained in water (Figure II - 34), but, after few minutes at room 
conditions, they became white, due to loss of water. Unfortunately, no single crystal with a 
sufficient quality was obtained. Furthermore, no structure of β-CDN3 is register in the CSD 
(Cambridge Structural Database). A comparison between the phases obtained in the 
laboratory and the compounds described in the literature is therefore impossible. 
 
Figure II - 34. Crystals of β-CDN3 in water. 
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  b. β-CDNH2 
After purification, the β-CDNH2 exhibits a poor crystallinity but it can be enhanced by 
recrystallisation in water from 40°C to room temperature as shown on Figure II - 35.  
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Figure II - 35. Superimposition of XRPD patterns of the β-CDNH2 after purification (in black) and after 
recrystallisation in water from 40°C to RT (in red). 
 
Cooling of a saturated solution of β-CDNH2 in water led to the formation of crystals (Figure 
II - 36). Unfortunately, no single crystal was obtained. Moreover, these crystals were not 
stable in room conditions; as β-CDN3, crystals became quickly white because of an 
efflorescent phase. Also in this case, no structure data are available on CSD and comparison 
with the literature was impossible. 
 
Figure II - 36. Crystals of β-CDNH2 in water, from 50°C to 20°C for 5h then 20°C for 16h. 
 
A TG-DSC analysis of the β-CDNH2 obtained after purification was carried out. Only one 
phenomenon occurred between circa 50°C and 150°C, corresponding to dehydration. 10.11% 
of mass were lost, that correspond to the loss of seven molecules of water. 
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Figure II - 37. TGA-DSC analysis of β-CDNH2. Heating rate: 5°C.min
-1
. 
 
A DVS (Dynamic Vapor Sorption) analysis was also carried out to study the behaviour of β-
CDNH2 toward the relative humidity. If stoichiometric hydrates exist, they can be detected by 
DVS, and their relative stability can be determined. Unfortunately, by looking at the result 
(Figure II - 38), no hydrate with a clear defined stoichiometry was detected; the percentage of 
water increased in the same time than the relative humidity increased without reaching a 
threshold. Moreover, the anhydrous β-CDNH2 was hydrated as soon as the RH was different 
than zero. 
0
10
0 10 20 30 40 50 60 70 80 90 100
% RH
%
 m
a
s
s
%
 m
a
s
s
 
Figure II - 38. DVS analysis of the β-CDNH2. 
 
DVS analysis of the native β-cyclodextrins showed the same behaviour: hydration rate 
increased when the relative humidity was increasing; it was totally dependant of the moisture. 
If all the cyclodextrins behave similarly, it is not surprising that crystals obtained in water are 
not stable at room conditions. 
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  c. β-CDNH(CH2)6NH2 
The β-CDNH(CH2)6NH2 is the only one of the series of compounds described in this chapter 
for which the crystalline structure was available in the literature. Mentzafos et al. obtained 
suitable single crystals from recrystallisation in water and slow evaporation of the solvent 
(two months).170 These crystals were not stable at room conditions. The structure resolution 
was therefore performed in a capillary with mother liquor. They found that β-
CDNH(CH2)6NH2 crystallised in the P212121 space group with 9.68 molecules of water per 
molecules of β-CDNH(CH2)6NH2. The corresponding crystal data are available under the 
reference code TEVCUS on the CSD database. 
The calculated XRPD pattern corresponding to this crystal structure and the XRPD pattern of 
our β-CDNH(CH2)6NH2 stored at room conditions were superimposed; as expected, they are 
totally different (Figure II - 39). 
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Figure II - 39. Superimposition of calculated (black) and experimental (red) XRPD pattern of  β-
CDNH(CH2)6NH2. 
 
 
 
 2. Inclusion complexes 
  a. Native β-cyclodextrin and 1-(p-toluenesulfonyl)imidazole  
First, the complex formed by the native β-CD and the 1-(p-toluenesulfonyl)imidazole ImTs 
was studied in order to understand the high selectivity of the substitution at the 6-position; 
ImTs may adopt a specific configuration inside the cavity to make possible only one 
substitution. 
                                                 
170 D. Mentzafos, A. Terzis, A. W. Coleman, C. de Rango; Carbohydr. Res., 1996, 282, 125-135.  
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The complex was prepared in water: the native β-CD cyclodextrin was suspended in water 
then ImTs (1 equivalent) was added. The mixture was stirred for one day at room temperature 
when the solid was filtered, washed with acetone then dried at 40°C. 1H NMR analysis of the 
powder confirmed the 1:1 stoichiometry (Figure II - 40). 
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Figure II - 40. 
1
H NMR of the complex between native β-CD and ImTs. 
 
The XRPD pattern of this powder was compared to those of the native β-CD and of the ImTs; 
these three diffractograms were different; the existence of a new phase confirmed the 
formation of the complex (Figure II - 41). 
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Figure II - 41.  Superimposition of XRPD patterns of ImTs (in black), of the native β-CD (in red) and of 
the complex (in blue). 
 
Crystallisation experiments were carried out in order to obtain single crystals. Unfortunately, 
no suitable crystals were obtained to perform the resolution of the structure. 
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  b. β-CDNH2 and ibuprofen 
The complex formed between the native β-CD and ibuprofen was previously described by 
Núñez-Agüero et al.156 They studied the energetic and conformational preferences involved in 
the formation of inclusion complexes, mainly by performing 2D NMR experiments and 
molecular mechanics simulations. However, the analysis revealed that a small energy 
difference (about 1kcal/mol) existed between the complexes formed by the two enantiomers. 
Therefore chiral separation of the two enantiomers was impossible by using the native β-CD. 
 
Figure II - 42. Chemical structure of ibuprofen. 
 
In order to increase the energy interaction between the host and the guest, or to force a 
direction for the complexation, and therefore to induce a higher energy difference between the 
two enantiomers, a monosubtituted cyclodextrin with a “basic hook” was used. 
A first test was performed by using the β-CDNH2. β-CDNH2 was dissolved in water then 
ibuprofen was added. As ibuprofen was not soluble in water, it tended to be included inside 
the hydrophobic cavity of the cyclodextrin to minimize the energy. 
To see if a chiral discrimination was possible in these conditions, two equivalents of 
ibuprofen were used. After filtration, the mass of the harvested solid corresponded to one 
equivalent of ibuprofen, giving the proof that a 1:1 complex was formed. 1H NMR confirmed 
the stoichiometry. Moreover, the “free” ibuprofen was racemic. 
 
A recent study of Grandeury et al. described that the chiral recognition of the permethylated 
β-cyclodextrin/phenylethanol derivatives complexes progressively decreased with the 
duration of stirring.159 Several experiments with different duration of stirring, between 10 
minutes and 16 hours, were carried out but no enantiomeric excess was observed; if a chiral 
recognition exists, the energy difference between the two enantiomers is not sufficient to 
discriminate them in these conditions. 
 
The complex was studied by X ray diffraction on powder. As expected, a new phase 
appeared, different from β-CDNH2 and ibuprofen. However, as the other cyclodextrin 
derivatives, the crystallinity was poor. 
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Figure II - 43. Superimposition of the XRPD patterns of ibuprofen (in black), β-CDNH2 (in red) and the 
complex (in blue). 
 
To determine if a chiral recognition exists at the solid state, crystallisation of single crystals 
was performed. Crystals were obtained in water, unfortunately, even after several experiments 
in different conditions, no crystal with a sufficient size and quality was obtained. The best 
results are shown on Figure II - 44, but these rather well-shaped particles were found to be not 
single crystals. 
 
Figure II - 44. Crystals of β-CDNH2/ibuprofen complex. 
 
Moreover, these crystals are efflorescent. As the other cyclodextrins, different solvates may 
exist. The chiral separation is maybe possible with a solvate but of a different (nature) 
composition. The study of the liquid-solid quaternary phase diagram (R-ibuprofen/S-
ibuprofen/β-CDNH2/water) could give relevant information to perform a chiral separation, 
assuming that a chiral discrimination exist at the solid state for a solvate with a particular 
stoichiometry. 
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V- Conclusion 
Monosubstituted cyclodextrins with various “hooks” were synthesized with success (Table II 
- 3) and with a quite good purity; the major impurity, tosylate derivatives, were easily 
removed. However, other impurities such as native β-cyclodextrin or disubstituted β-
cyclodextrin are difficult to remove. Therefore it is very important to avoid the formation of 
these compounds during the step of synthesis of the monosubstituted β-CDOTs. The synthesis 
at the 40g scale of native β-cyclodextrin by using of 1-(p-toluenesulfonyl)imidazole gave the 
best results. 
The sensitivity of cyclodextrins derivatives toward water was highlighted, more particularly 
by DVS analyses, and may explain why the crystallisation of cyclodextrins and their storage 
under room conditions are difficult. 
Experiments gave the proof that formation of complexes between β-CDNH2 and ibuprofen 
was possible but did show any chiral discrimination. Of course, further studies are necessary 
on this topic to determine if a chiral recognition exists at the solid state. 
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2 
β-CDOTs 56% 
 
4 
β-CDN3 
71% 
 
5 
β-CDNH2 
85% 
 
6b 92% 
 
7   β-
CDNH(CH2)2NH2 
82% 
 
12a 
β-CDNHCH2COOH 
Not 
pure* 
8   β-
CDNH(CH2)3NH2 
93% 12b   β-CDNH(CH2)2COOH 
Not 
pure* 
9   β-
CDNH(CH2)6NH2 
Quant. 12c    β-CDNH(CH2)3COOH 
Not 
pure* 
10  β-
CDNH(CH2)8NH2 
97% 12d   β-CDNH(CH2)4COOH 
Not 
pure* 
 
11 
β-CD 
benzylamine 
Quant. 
NH
(OH)7(OH)7
HO 6
COOH
 
14 
L-phenyl glycine β-
CD 
Not 
pure* 
N
(OH)7(OH)7
HO 6
COOH
COOH
 
15 77% 
 
16a 85% 
16b Quant. 
16c 89% 
Table II - 3. Summary table of monosubstituted β-cyclodextrins synthesized in this chapter. *The 
impurity is the amino acid used for the synthesis. 
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In the previous chapter, mono-substituted β-cyclodextrins were synthesized in order to purify 
enantiomers thanks to the formation of complexes. In this part, pure enantiomers will be 
obtained by using a totally different method combining crystallisation and racemisation, 
called deracemisation, or total symmetry breaking.115 The historical aspects of this discovery 
and related bibliographic data are developed in Chapter 1. 
We decided to study the deracemisation of the 1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-
triazol-1-yl)pentan-3-one ClTAK Cl-17 (Figure III - 1). The choice of this molecule resulted 
from the context of my PhD, which was a part of the European project IntEnant (see chapter 
1). One of the partners of this project previously worked on this molecule and wished to 
perform additional studies on it. Therefore there was a need for the racemic mixture as well as 
to the pure enantiomers. As Cl-17 meets the dual conditions required for the deracemisation 
process (crystallisation as a conglomerate and racemisation are compatible in the same 
medium171), pure enantiomers will be prepared by deracemisation, studying at the same time 
other aspects of this process such as the evolution of the crystal size distribution. Furthermore, 
except few exceptions, only amino acid derivatives were described in the literature (see 
Chapter 1). Cl-17 and few other derivatives will thus be other examples of compounds 
possible to deracemise. 
 
Figure III - 1. Chemical Structure of Cl-17. 
 
In the last part of this chapter, a new deracemisation process will be described in which glass 
beads are replaced by ultrasounds. The efficiency of the two variants will be compared 
leading to new hypotheses on the mechanism of the deracemisation. 
 
 
 
 
 
 
                                                 
171 S. N. Black, L. J. Williams, R. J. Davey, F. Moffat, R. V. H. Jones, D. M. McEwan, D. E. Sadler; 
Tetrahedron, 1989, 45(9), 2677-2682. 
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I - Introduction 
Paclobutrazol 18 (Figure III - 2) is a plant growth inhibitor.52 The pure enantiomer was 
obtained by diastereoisomeric salt.172 Unfortunately, the unwanted enantiomer was difficult to 
recycle and the final product was thus expensive. 
 
Figure III - 2. Chemical structure of Paclobutrazol. 
 
Twenty years ago, Black et al. studied the 1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-
triazol-1-yl)pentan-3-one Cl-17, a precursor of Paclobutrazol. They noticed that Cl-17 
crystallised as a stable conglomerate, in the P212121 space group, and thus that it was possible 
to obtain the target enantiomer by preferential crystallization. Then the S-Cl-17 can be 
stereospecifically reduced to give only the (2S,3S)-paclobutrazol without further 
enantiopurification steps (Figure III - 3). Moreover, they noticed that Cl-17 was easily 
racemisable: “Addition of 1% w/w sodium hydroxide resulted in racemization which was too 
rapid to measure it. At much lower concentration of base (0.001%), the observed optical 
rotation fell to half its initial value in 30 minutes.”171 The unwanted enantiomer can be 
recycled, increasing the overall yield and thus, decreasing the cost of the synthesis. As 
preferential crystallisation and racemisation can be carried out in the same experimental 
conditions (methanol/water mixtures), they combined them to perform a process named 
“crystallisation-induced asymmetric transformation” also called “second order asymmetric 
transformation” (SOAT, see Chapter I), increasing the productivity of the purification to 83% 
yield with 99% enantiomeric excess. Unfortunately, a slow cooling profile (1K.h-1, from 30°C 
to 24.5°C) must be applied to prevent the heteronucleation of the counter enantiomer (mainly 
by epitaxy). Similar results were obtained when the cooling was replaced by a controlled 
evaporation of solvent or addition of water as anti-solvent. 
 
Figure III - 3. Synthesis of Paclobutrazol with a preferential crystallisation step. 
                                                 
172 US4243405A1. 
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One of the first works for my PhD was to synthesize Cl-17 to establish a collaboration 
between the SPCMIB laboratory at the University of Toulouse, in which I spent the first part 
of my PhD, and the SMS laboratory at the University of Rouen, in which I spent the second 
part of my PhD. After synthesis, Cl-17 was provided to Guillaume Levilain, a student of the 
SMS laboratory. He worked on the design of the new process combining the experiments of 
Black et al. (that is to say cooling and in-situ racemisation) and the Viedma Ripening 
(deracemisation by using glass beads). The combination of all this conditions increased the 
productivity of the purification; the effect of glass beads makes it possible to apply a high 
cooling rate (15K.h-1) from 50°c to 20°C, keeping the final enantiomeric excess at circa 99% 
(See Chapter I).108 
In the literature, a compound with a very similar crystal structure was described: the 1-(2-
fluoro-4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-one 2F-4Cl-17.173 
Both Cl-17 and 2F-4Cl-17 crystallise in the P212121 space group with very close cell 
parameters. Therefore we decided to synthezise a series of compounds to study the effect of 
the substitution of the aromatic group on the crystal packing (Figure III - 4). We wanted to 
know if a kind of pocket exists inside the crystal structure in which it was possible to put 
“almost everything” with similar size and/or similar kind of interactions without modifying 
the stereoselective packing. Then, the deracemisation of compounds crystallising as a 
conglomerate could be applied. 
  
Figure III - 4. Chemical structures of the five synthesised derivates of TAK. 
 
 
 
 
                                                 
173 S. K. Branch, I. W. Nowell; Acta Cryst. , 1986, C42, 440-442. 
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II - Synthesis of the triazolyl ketones 
 1. Synthesis of 1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl) 
pentan-3-one ClTAK 
The synthesis of ClTAK Cl-17 was described in the patent concerning the preparation and the 
application of fungicidal compounds such as Paclobutrazol. In this patent, heterocyclic 
compounds containing an imidazole or a 1,2,4-triazole and a substituted aromatic cycle were 
studied (Figure III - 5).172 
 
Figure III - 5. Patented heterocyclic compounds. 
 
The syntheses of only two compounds were described in the patent: the synthesis of 18 and 
therefore of Cl-17 and the synthesis of the unsubstituted ketone H-17. Moreover, two 
different routes were published. 
In the first route, only three steps were necessary to access to the final compound 18 (Figure 
III - 6). In the first step, the α-1,2,4-triazol-1-yl-pinacolone 19 was prepared by nucleophilic 
substitution from the bromopinacolone and the 1,2,4-triazole. Then another substitution with 
the p-chlorobenzylchloride gives the ClTAK Cl-17. Finally, the Paclobutrazol was obtained 
by reduction by using NaBH4. 
 
Figure III - 6. First synthetic route of Paclobutrazol. 
 
In the second synthetic route, five steps were necessary to obtain the final product (Figure III - 
7). First, an adolisation-crotonisation of the p-chlorobenzaldehyde with the pinacolone was 
carried out. The chalcone 20 was then reduced to give the hydrogenated compound 21. The 
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ketone was brominated in α position then a nucleophilic substitution with the 1,2,4-triazole 
gave the ClTAK Cl-17. The last step was a reduction by NaBH4, as described in the first 
route. 
 
Figure III - 7. Second synthetic route of Paclobutrazol. 
 
The second route is longer than the first one but reagents are cheaper; the starting material of 
the first route, the bromopinacolone, is an expensive product. It can be prepared by 
bromination of the pinacolone but it is difficult to control the number of substitutions and a 
significant amount of dibromopinacolone is formed. Its purification is quite difficult, making 
the compound expensive. Moreover, even after purification, a small amount of 
dibromopinacolone remains, giving by-products for the synthesis. On the contrary, reagents of 
the second route are cheaper and easy to find with a good purity. 
In the patent, the experimental protocol is well described for these syntheses: stoechiometries 
of the reagents, volumes of solvent and reaction times are given as well as the purification 
steps. However, the yield and the analyses of intermediates and final products, such as 1H 
NMR, 13C NMR or mass spectrometry, are not given. Moreover, the synthesis of only two 
compounds, ClTAK Cl-17 and the unsubstituted derivative HTAK H-17 are depicted. 
To perform the synthesis of Cl-17, we chose to follow the second route of the synthesis 
because all the reagents were available in the laboratory. A small modification of the protocol 
was made: the bromination step was carried out with tetrabutylammonium tribromide 
TBA.Br3 in acetic acid instead of Br2 in CCl4 (Figure III - 8). The solvent is toxic and Br2 is 
quite difficult to manipulate. 
Stochastic chiral symmetry breaking of a conglomerate forming system 
 
- 124 - 
 
Figure III - 8. Synthetic route used in the laboratory. 
 
The TBA.Br3 can be easily synthesized from tetrabutylammonium TBA.Br (Figure III - 9).174 
TBA.Br instantaneously reacts with sodium bromate NaBrO3 and hydrobromic acid HBr to 
give TBA.Br3, an orange power. Purification by recrystallisation in a 1:1 CH2Cl2/Et2O 
mixture gives pure orange crystals of TBA.Br3. Moreover, this product can be recycled after 
the bromination step of the synthesis of compounds Cl-17 by adding the right amount of 
sodium bromate and hydrobromic acid. 
 
Figure III - 9. Synthesis of the tetrabutylammonium tribromide. 
 
Some by-products are formed during this route of synthesis but a single purification at the 
final stage is sufficient to easily obtain pure compounds with an acceptable yield. In fact, two 
by-products were detected. During the hydrogenation step, a small percentage of Ar-Cl bonds 
were broken, giving at the end of the synthesis the dechlorinated compounds H-17. During 
the last step, the elimination of HBr can occur to give the intermediate Cl-20. These two by-
products are very soluble in diisopropylether and/or methanol compared to the target 
compound, simple washings of the solid with these solvents are thus sufficient to purify it. 
 
 
 2. Synthesis of the triazoyl ketone derivatives 
Four other TAK derivatives (Figure III - 4) were synthesized following the same procedure 
than the ClTAK, even if the work-up had to be modified in some cases (see experimental 
part). 
The synthesis of the BrTAK Br-17 was more complicated. Indeed, during the hydrogenation 
step, the proportion of debrominated product was significant. Of course, the presence of this 
                                                 
174 S. Kajigaeshi, T. Kakinami, T. Okamoto, S. Fujisaki; Bull. Chem. Soc. Jpn., 1987, 60, 1159-1160. 
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by-product was not surprising, the Ar-Br bond being easier to break than the Ar-Cl bond 
under these experimental conditions. But this phenomenon seemed to be coupled with a 
decreasing of the efficiency of the catalyst; even by increasing the amount of hydrogen, the 
reaction was stopped before the total conversion, at circa 50%. When the crude product was 
hydrogenated again, with fresh Raney nickel, the conversation did not increase significantly 
when breakage of Ar-Br bond was substantial, giving a mixture of four compounds (Figure III 
- 10). Unfortunately, the purification by chromatography was complicated because all the 
compounds were similarly eluted. 
 
Figure III - 10. Molecules in the crude product after hydrogenation of Br-20. 
 
The crude product was used without purification in the next step. Mixture of products was 
thus obtained. The presence of Br-22 was confirmed by 1H NMR and by mass spectrometry 
(characteristic peaks of a compounds having two bromines atoms and corresponding to the 
mass of Br-22 were visible). The crude product was used in the final step then the desired 
compound Br-17 was purified by crystallisation. 
A different hydrogenation method was tested, using zinc and ammonium chloride in a mixture 
of methanol and water.175 This method was described to be softer than the hydrogenation 
catalysed by Raney nickel but was not efficient in our case. As the final amount of Br-17 
(around 5g) was sufficient to study its behaviour in crystallisation and deracemization 
process, no alternative synthetic route was designed. 
However, the first synthetic route described in the patent would have been beneficial since no 
reduction step is necessary. 
 
 
 
 
 
 
 
 
                                                 
175 J.-P. Li, Y.-X. Zhang, Y. Ji; J. Chin. Chem. Soc., 2008, 55(2), 390-393. 
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III. Characterisation of the solid phases 
 1. Solubility data 
Solubilities of the TAK derivatives were determined by using the gravimetric method in 
various methanol/water mixture. This mixture of solvents was the one used by Black et al. in 
1989 for the preferential crystallisation of ClTAK in which both, crystallisation and 
racemisation, were compatible. The results are summarized in Table III - 1. The evolution of 
the solubilities of TAK derivatives depending on the ratio of methanol/water is represented in 
a ternary phase diagram (Figure III - 11). 
Methanol/water 
w/w 0/100 45/55 47/53 50/50 60/40 65/35 75/25 80/20 90/10 100/0 
ClTAK 0.0% -  0.6% - - 4.1%* 5.5% - 14.4% 
HTAK 0.1% 4.0% 4.7% 7.4% 20.6% - - - - 68.3% 
MeTAK 0.0% -  1.5% 3.3% 6.0% 11.5% 15.2% - 34.9% 
BrTAK - -  0.5% - - - 3.3% 5.2% 8.3% 
Table III - 1. Solubilities of the racemic composition of TAK derivatives in various methanol/water 
mixtures. *The ratio of methanol and water was 76/24. 
 
 
Figure III - 11. Evolution of the solubilities of the racemic composition of TAK derivatives  in different 
ratios of methanol and water. ClTAK in pink, HTAK in blue, MeTAK in red and BrTAK in purple. Lines 
are given as a guide to the eye. 
 
In the case of tBuTAK, demixions appear whatever the methanol/water system (Figure III - 
12). The solubility of the tBuTAk was thus impossible to measure. In this condition, it seems 
to be difficult to perform deracemisation with this compound in this solvent. 
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Figure III - 12.  Demixion of tBuTAK in a 65/35 methanol/water mixture. 
 
 
 
 2. Thermal anaylses 
The melting points of the racemic composition of these derivatives were determined by 
differential scanning calorimetry (DSC) and are summarized below. 
 ClTAK Cl-17 HTAK H-17 MeTAK Me-17 BrTAK Br-17 tBuTAK tBu-17 
Tmelt (°C) 126.1 71.2 104.1 139.3 47.3 
M (g.mol-1) 291.8 257.3 271.4 336.2 313.4 
Table III - 2.  Melting points of TAK derivatives by DSC analyses. 
 
TAK derivatives with a high molecular mass had a higher melting point that was not 
surprising. Once again, the tBuTAK exhibited a different behaviour from the other 
derivatives; its melting point was much lower than the other one whereas its molecular mass 
was higher. 
40 60 80 100 120 140
Temperature /?C
-5
-4
-3
-2
-1
0
DSC /(mW/mg)
Complex Peak: 
Area:
Peak*:
Onset:
End:
-49.7 J/g
51.3 ?C
47.3 ?C
53.9 ?C
Complex Peak: 
Area:
Peak*:
Onset:
End:
-88.12 J/g
76.2 ?C
71.2 ?C
79.0 ?C
Complex Peak: 
Area:
Peak*:
Onset:
End:
-109.8 J/g
106.3 ?C
104.1 ?C
107.3 ?C
Complex Peak: 
Area:
Peak*:
Onset:
End:
-114.3 J/g
128.5 ?C
126.1 ?C
129.5 ?C
Complex Peak: 
Area:
Peak*:
Onset:
End:
-112.3 J/g
140.9 ?C
139.3 ?C
142.3 ?C
[1.2][2.2][3.1]
[4.4][5.3]↑ exo
Area: -49. g
Peak: 51.3°C
Onset: 47.3°C
End: 53.9°C Area: -88.1J/g
Peak: 76.2°C
Onset: 71.2°C
End: 79.0°C
Area: -109.8J/
Peak: 106.3°C
Onset: 104.1°C
End: 107.3°C
Area: -1 4. /g
Peak: 128.5°C
Onset: 126.1°C
End: 129.5°C
Area: -112.3J/g
Peak: 140.9°C
Onset: 139.3°C
End: 142.3°C
Temperature / °C
40 60 80 100 120 140
-
-
-
-2
-
0
tBuTAK
HTAK
MeTAK
ClTAK
BrTAK
 
Figure III - 13. DCS analyses of the five racemic composition of TAK derivatives. 
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 3. X ray powder diffraction (XRPD) 
The five TAKs were analysed by X ray diffraction on powder and were compared. Figure III - 
14 exhibits the superimposition of the five patterns. 
XRPD patterns of ClTAK, MeTAK and BrTAK were very similar. This result suggested that 
these three TAKs were isomorphous. As ClTAK crystallised in the chiral space group 
P212121, it was likely that MeTAK and BrTAK also crystallised in the P212121 space group, 
corresponding to the conglomerate. Moreover, these compounds must be easily racemised in 
the same conditions as that used for ClTAK (the chiral centre should not be greatly affected 
by the nature of the substituent), thus MeTAK and BrTAK could probably be deracemised. 
The XRPD patterns of HTAK and tBuTAK were different to the other ones. They must 
crystallise in a different crystal packing and so, it was impossible to predict if they crystallised 
as a conglomerate or not. 
L
in
 (
C
o
u
n
ts
)
0
10000
20000
2-Theta - Scale
6 10 15 20 25
tBuTAK
HTAK
BrTAK
MeTAK
ClTAK
 
Figure III - 14. XRPD analyses of the five TAK derivatives. 
 
 
 4. Conclusion 
Because of the high similarity between their XRPD patterns, MeTAK and BrTAK were likely 
to crystallise in the same space group than ClTAK: P212121. Thus, they should be 
deracemisable. Of course, these hypotheses will be checked by using other methods such as 
resolution on single crystals (see paragraph IV) and by completing deracemisation (see 
paragraph V) 
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IV- Structural studies 
 1. Structural resolution of 1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-
triazol-1-yl)pentan-3-one ClTAK 
The structure of ClTAK was already resolved by Black et al. in 1989.176 The calculated 
diffractogram was compared to our experimental XRPD and they match perfectly. 
However, for MeTAK and BrTAK, the tBu group exhibits a statistical disorder (see the 
following paragraphs). In the Black’s resolution, this disorder was not mentioned. So, a new 
resolution of the structure was carried out to determine if this disorder was inexistent or 
simply not detected. 
 
  a. Crystallisation from racemic mixture 
First, crystallisations were carried out from the racemic mixture of ClTAK. Unfortunately, 
whatever the system of crystallisation (solvents, temperature, supersaturation) rod particles 
appears and no single crystals were observed. This compound was known to crystallise with 
epitaxy, making difficult the formation of single crystals. 
 
Figure III - 15. Crystals of ClTAK obtained from saturated solution in a) acetonitrile from 40°C to RT, b) 
ethanol at RT, c) MeOH at RT, d) MeOH/water 50/50 from 50°C to 20°C for 15h, e) MeOH/water 75/25 
from 50°C to 20°C for 15h. 
 
During the crystallisation experiments with a high initial surpersaturation, a layer of solid was 
formed, preventing the evaporation of solvent, decreasing the growth rate. After few days at 
room temperature (hereafter RT), the crystals were observed by optical microscopy. No single 
                                                 
176 S. N. Black, L. J. Williams, R. J. Davey, F. Moffat, D. M. McEwan, D. E. Sadler, R. Docherty, D. J. 
Williams; J. Phys. Chem., 1990, 3223-3226. 
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crystals were seen but large crystals with hourglass defects and hollow crystals were 
observed.177 
 
Figure III - 16. Crystal with macroscopic hourglass defects and hollow crystals. 
 
 
  b. Crystallisation from pure enantiomer 
As ClTAK crystallised as a conglomerate, the racemic solid was just composed of crystals of 
the pure enantiomers. Crystallisation from pure enantiomer could prevent the epitaxial 
growth, making easier the formation of single crystals. 
Suspensions of ClTAK in different systems of solvent were prepared at given temperatures 
(25°C or 35°C). The saturated liquid phase was taken, filtered then put at room temperature. 
After few days, crystals appeared. The results are summarized below. In a methanol/water 
mixture at 25°C, single crystals with sufficient size and quality were obtained. 
Methanol Methanol/water 80/20 
35°C 25°C 35°C 25°C 
    
Figure III - 17. Crystals obtained from the pure enantiomer of ClTAK. 
 
 
  c. Structure 
The resolution of the structure had been performed and the main crystal data are given in 
Table III - 3. 
 
 
                                                 
177 C. Gervais, S. Beilles, P. Cardinael, S. Petit, G. Coquerel; J. Phys. Chem. B, 2002, 106 (3), 646-652. 
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 Our data Black’s data176 
Chemical Formula C15H18ClN3O C15H18ClN3O 
Molecular Weight / g.mol-1 291.77 291.77 
Crystal System Orthorhombic Orthorhombic 
Space group P212121 P212121 
Z , Z’ (asymmetric units per unit cell) 4, 1 4,1 
a / Å 5.8076(5) 5.799(1) 
b / Å 19.661(2) 19.654(3) 
c / Å 13.553(1) 13.552(2) 
V / Å3 1547.5(2) 1545 
R factor (with I>2σI) 
R1 = 0.0367 
wR2 = 0.0871 
R1 = 0.049 
wR2 = 0.057 
dcalc / g.cm
-3 1.252 1.25 
Table III - 3. Crystal data of ClTAK 
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Figure III - 18. Superimposition of calculated (red) and experimental (black) XRPD patterns of ClTAK. 
 
As expected, our results were very close to those obtained by Black et al. But, by looking 
closely the residual densities around the tertbutyl group, we noticed that two positions existed 
for this group. The tertbutyl extremity was split into two positions within statistical occupancy 
factors of 78% and 22% (Figure III - 19). Next pictures will be drawn with the most probable 
conformation. 
When the structure was solved by taking into account the two positions of the tertbutyl group, 
the R1 value dropped down from 5.0% to 3.7%, and the residual electronic density from 
0.306/-0.192e-.Å-3 to 0.123/-0.135 e-.Å-3. Indeed, the quite good R1 factor of 5.0% might have 
been sufficient; however the three highest residual electronic densities (~0.3e-.Å-3) were 
located between the atoms of carbon of the tertbutyl moiety and displayed a tertbutyl-like 
arrangement, so they were included in the structure solution as partial tertbutyl moiety, and 
led to the final R1 of 3.7%. 
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Figure III - 19. Asymmetric unit of ClTAK, in ellipsoid thermal representation (50% of probability). 
The two positions of the tBu are represented in grey (sof: 78%) and light grey (sof: 22%). 
 
 
 
 2. Structural resolution of 4,4-dimethyl-1-phenyl-2-(1H-1,2,4-triazol-1-
yl)pentan-3-one HTAK 
  a. Crystallisation from pure enantiomer 
First crystallisation experiments were carried out from the racemic mixture of HTAK but no 
single crystals were obtained; rod crystals appeared whatever the system of crystallisation but 
they were not suitable for structure resolution. Whereas when the crystallisations tests were 
performed from the pure enantiomer of HTAK, single crystals with a sufficient size and 
quality were easily obtained (Figure III - 20). 
 
Figure III - 20. Single crystals of HTAK. 
 
 
  b. Structure 
The resolution of a single crystal obtained from the pure enantiomer had been performed and 
the main crystal data are given in Table III - 4. 
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 HTAK 
Chemical formula C15H19N3O 
Molecular Weight / g.mol-1 257.33 
Crystal System Monoclinic 
Space group P21 (n°4) 
Z , Z’ (asymmetric units per unit cell) 4, 2 
a / Å 5.747(1) 
b / Å 19.183(1) 
c / Å 13.437(1) 
β 96.561(1) 
V / Å3 1471.8(2) 
R factor (with I>2σI) 
R1 = 0.0623 
wR2 = 0.1142 
dcalc / g.cm
-3 1.161 
Table III - 4. Crystal data of HTAK. 
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Figure III - 21. Superimposition of calculated (red) and experimental (black) XRPD patterns of HTAK. 
 
HTAK crystallised in a chiral space group, P21. The asymmetric unit (Figure III - 22) was 
composed of two molecules and no disorder was observed with the tertbutyl group. In fact 
one molecule of the asymmetric unit differed to the other one mainly by the position of the 
tertbutyl group as shown on Figure III - 23, mimicking a 50/50 disorder. 
Stochastic chiral symmetry breaking of a conglomerate forming system 
 
- 134 - 
 
Figure III - 22. Asymmetric unit of HTAK, in ellipsoid thermal representation (50% of probability). 
 
Figure III - 23. Superimposition of the two molecules of the asymmetric unit. 
 
 
 
 3. Structural resolution of 4,4-dimethyl-1-(p-toluyl)-2-(1H-1,2,4-triazol-
1-yl)pentan-3-one MeTAK 
  a. Crystallisation from racemic mixture 
Single crystals of the MeTAK were the easiest to obtain. Indeed, even if MeTAK crystallised 
as rod crystals in almost all the solvents used, this compound had the particularity to 
crystallise with a different morphology in acetonitrile. (Figure III - 24). Comparison between 
XRPD patterns confirmed that the same phase was present in each solvent (Figure III - 25), 
and therefore that only the morphology of crystals was different. 
 
Figure III - 24. Crystals of MeTAK in MeOH/water 75/25 from 50°C to RT (left) and in acetonitrile from 
50°C to RT (right). 
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Figure III - 25. XRPD analyses of MeTAK in three different solvents. 
 
During the crystallisation experiments in methanol/water mixture with a high supersaturation, 
crystals with hourglass defects and hollow crystals were observed. 
 
Figure III - 26. Crystal with hourglass defects and hollow crystals obtained from the racemic mixture in 
8/2 methanol/water. a) from 30°C to RT, b) and c) slow evaporation of a saturated solution at RT. 
 
  
  b. Structure 
In acetonitrile, single crystals with a sufficient size and quality were obtained. The resolution 
of the structure had been made. The main crystal data are given in Table III - 5. 
 MeTAK 
Chemical Formula C16H21N3O 
Molecular Weight / g.mol-1 271.36 
Crystal System Orthorhombic 
Space group P212121 
Z , Z’ (asymmetric units per unit cell) 4, 1 
a / Å 5.808(1) 
b / Å 13.641(1) 
c / Å 19.789(1) 
V / Å3 1567.9(2) 
R factor (with I>2σI) 
R1 = 0.0483 
wR2 = 0.0938 
dcalc / g.cm
-3 1.150 
Table III - 5. Crystal data of MeTAK. 
 
a) 
 
b) 
 
b) 
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Figure III - 27. Superimposition of calculated (red) and experimental (black) XRPD patterns of MeTAK. 
 
The structural data confirmed that XRPD patterns had predicted: MeTAK crystallised in the 
P212121 space group with similar cell parameters than ClTAK. The asymmetric unit was also 
built from one molecule and the tertbutyl was split into two positions within statistical 
occupancy factors of 69% and 31%.  
 
Figure III - 28. Asymmetric unit of MeTAK, in ellipsoid thermal representation (50% of probability). 
The two positions of the tertbuthyl are represented in grey (sof: 69%) and light grey (sof: 31%). 
 
 
 
 4. Structural resolution of 1-(4-bromophenyl)-4,4-dimethyl-2-(1H-1,2,4-
triazol-1-yl)pentan-3-one BrTAK 
  a. Crystallisation from racemic mixture 
As in the other cases, crystals obtained from the racemic mixture crystallised as needles and 
did not exhibit a sufficient quality to resolve the structure (Figure III - 29). 
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Figure III - 29. Crystals of BrTAK obtained in a) acetone from 40°C to RT for 4h, b) acetone form 40°C to 
RT, c) methanol from 40°C to RT, d) methanol/water 75/25 from 40°C to RT for 4h. 
 
 
  b. Crystallisation from pure enantiomer 
Suspensions of BrTAK in methanol and methanol/water mixture were prepared at 25°C. The 
saturated liquid phase was taken, filtered then left at room temperature. After few days, 
crystals appeared (Figure III - 30). 
 
Figure III - 30. Crystals of BrTAK obtained from the pure enantiomer, from 25°C to RT in a) methanol b) 
methanol/water 80/20. 
 
  c. Structure 
Single crystals with a sufficient size and quality were obtained in the methanol/water mixture. 
The resolution of the structure has been made. The main crystal data are given in Table III - 6. 
 BrTAK 
Chemical Formula C15H18BrN3O 
Molecular Weight / g.mol-1 336.23 
Crystal System Orthorhombic 
Space Group P212121 
Z , Z’ (asymmetric units per unit cell) 4, 1 
a / Å 5.7875(5) 
b / Å 13.629(1) 
c / Å 19.882(2) 
V / Å3 1568.3(2) 
R factor (with I>2σI) 
R1 = 0.0544 
wR2 = 0.0913 
dcalc / g.cm
-3 1.424 
Table III - 6. Crystal data of BrTAK. 
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Figure III - 31. Superimposition of calculated (red) and experimental (black) XRPD patterns of BrTAK. 
 
As for the MeTAK derivative, the structural data confirmed what XRPD patterns led to 
predict: BrTAK crystallised in the P212121 space group with similar cell parameters as ClTAK 
and MeTAK. The asymmetric unit was also built from one molecule and the tertbutyl was 
split into two positions within statistical occupancy factors of 68% and 32%.  
 
Figure III - 32. Asymmetric unit of BrTAK, in ellipsoid thermal representation (50% of probability). 
The two positions of the tertbuthyl are represented in grey (sof: 68%) and light grey (sof: 32%). 
 
 
 
 5. Case of 1-(4-tert-butylphenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl) 
pentan-3-one tBuTAK 
Crystallisations of tBuTAK were tested in several solvents. In methanol/water mixtures, 
demixion appeared (Figure III - 12). In solvents such as CH2Cl2 or ethyl acetate, the 
evaporation of solvent led to the formation of an oil which became crystalline few days after. 
Therefore no single crystals were obtained. 
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Moreover, as this compound had no signal in SHG and as no solid-solid transitions are 
observed in DSC at low temperature (that is to say: no possibility to have a conglomerate at 
low temperature), attempts to obtain single crystals were stopped. 
The difficulty to crystallise tBuTAK can be due to disorders of the two tertbutyl groups, 
instead of only one tertbutyl group, making its crystallisation more difficult. 
 
 
 6. Comparison between the different crystal packings 
  a. Comparison between ClTAK, MeTAK and BrTAK 
In the previous paragraphs, we had already highlighted that ClTAK, MeTAK and BrTAK 
crystallise in the same space group. The crystallographic data were brought together in the 
following table; cell parameters of these three molecules were very close and confirmed the 
high similarity observed with the XRPD patterns. 
 ClTAK MeTAK BrTAK 
Chemical Formula C15H18ClN3O C16H21N3O C15H18BrN3O 
Molecular Weight / g.mol-1 291.77 271.36 336.23 
Crystal System Orthorhombic Orthorhombic Orthorhombic 
Space group P212121 P212121 P212121 
Z , Z’ (asymmetric units per unit cell) 4, 1 4, 1 4, 1 
a / Å 5.8076(5) 5.808(1) 5.7875(5) 
b / Å 13.553(1) 13.641(1) 13.629(1) 
c / Å 19.661(2) 19.789(1) 19.882(2) 
V / Å3 1547.5(2) 1567.9(2) 1568.3(2) 
dcalc / g.cm
-3 1.252 1.150 1.424 
Table III - 7. Cell parameters of ClTAK, MeTAK and BrTAK. 
 
Then the crystal packing of the three TAK derivatives were compared. 
First, we can observe that the asymmetric units are almost superimposable (Figure III - 33); 
the three structures are isomorphous. 
 
 
Figure III - 33. Superimposition of the asymmetric units. ClTAK in white, MeTAK in red and BrTAK in 
green. 
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Secondly, we can see that in each case, the aromatic rings are interacting with their adjacent 
equivalents along b axis by means of π interactions in T shape, generating infinite chains of 
molecules in [100] direction (Figure III - 34 and Figure III - 35). The angle between two 
consecutive aromatic rings involved into the interaction is circa 60°. The distance between 
two consecutive rings is 3.9Å. The cohesion between chains is ensured through Van der 
Waals interactions. 
a) b) c)
 
Figure III - 34.  π stacking in T shape (dashed green lines). a) ClTAK, b) MeTAK, c) BrTAK. 
 
a) b) c)
 
Figure III - 35. The interactions in T-shape generate double chains that are spreading along the [100] 
direction. a) ClTAK, b) MeTAK, c) BrTAK. 
 
The chains are stacked along c and give rise to slices (blue and red). 
However, we can notice that the representation of these three packing is not exactly identical; 
the cell edges are shifted from a compound to another. These shifts are only due to the choice 
of the origin during the resolution of the structure and not to a different packing. By 
translating the cell edges of MeTAK with a c/2 vector and the cell edges of BrTAK with a 
b/2+c/2, the origin of these crystal packings will be the same than for ClTAK. 
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a) b)
c)
 
Figure III - 36. Projections along a axis. a) ClTAK, b) MeTAK, c) BrTAK. One chain is circled in black. 
 
Figure III - 37 exhibits projections along b axis of the three TAK derivatives and Figure III - 
38 exhibits projections along c axis. Infinite chains of molecules, created by π interactions in 
T shape, are clearly visible on these pictures (one chain in red, the other one in blue). 
a) b)
c)
 
Figure III - 37. Projections along b axis. a) ClTAK, b) MeTAK, c) BrTAK.  
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a) b) c)
 
Figure III - 38. Projections along c axis. a) ClTAK, b) MeTAK, c) BrTAK. 
 
Another common point between these compounds is the disorder induced by the tertbutyl 
group; in the three cases, two positions exist for this group with statistical occupancy factor of 
circa 70% and 30%. However, the structure resolution at room temperature did not give 
information about the nature of this disorder: is it a statistical disorder or a dynamical 
disorder? If it is a dynamical disorder, a decreasing of the temperature could stop the rotation 
of the tertbutyl group. If such phenomenon occurs, it should be visible by DSC analysis. DSC 
analyses of ClTAK, MeTAK and BrTAK were therefore carried out at low temperature 
(Figure III - 39); in each case, a slight endothermic phenomenon occurs at circa -30°C, which 
is probably due to the “freeze” of the tertbutyl group. The reversibility of this phenomenon (a 
slight exothermic phenomenon exists at circa -30°C when the temperature increased) 
confirmed this hypothesis. 
Complex peak
Area: -1.096 J/g
Peak: -33.0 C
Onset: -32.5 C
End: -32.5 C
Complex peak
Area: 0.2094 J/g
Peak: -265.8 C
Onset: -32.4 C
-60 -50 -40 -30 -20 -10
Temperature / C
-0.15
-0.10
-0.05
0.00
0.05
0.10
0.15
DSC /(mW/mg)
exo
BrTAK
Complex peak
Area: -0.6366 J/g
Peak: -31.3 C
Onset: -30.3 C
End: -25.6 C
-60 -50 -40 -30 -20 -10 0
Temperature / C
-0.10
-0.05
0.00
0.05
0.10
DSC /(mW/mg)
exo
Complex peak
Area: 0.2157 J/g
Peak: -26.3 C
Onset: -21.2 C
End: -19.7 C
ClTAK
-60 -50 -40 -30 -20 -10
Temperature / C
-0.10
-0.05
0.00
0.05
0.10
0.15
0.20
DSC /(mW/mg)
exo Complex peak
Area: -0.9573 J/g
Peak: -41.9 C
Onset: -34.4 C
Complex peak
Area: 0.03068 J/g
Peak: -26.2 C
Onset: -35.7 C
End: -31.3 C
MeTAK
 
Figure III - 39. DSC analysis at low temperature of ClTAK, MeTAK and BrTAK. Heating rate: 5K.min
-1
. 
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  b. Comparision between the crystal packings of HTAK and ClTAK 
HTAK crystallises in a different crystal packing than the other TAK derivatives since it 
crystallises in the monoclinic P21 space group and not in the orthorhombic P212121 space 
group. Moreover, the asymmetric unit is composed of two molecules of HTAK. However, 
some similarities can be observed. 
We demonstrated in the previous paragraph that the structures of ClTAK, MeTAK and 
BrTAK were isomorphous therefore similarities between HTAK and the other TAKs will be 
only described from ClTAK. 
First, the crystal data are compared (Table III - 8). In the two cases, the unit cell is composed 
of four molecules and the cell parameters are very close. The parameters b and c are inverted 
but it is due to a convention; in the monoclinic system, the angle which is different from 90° 
is the β angle and the cell parameters a, b and c are given according to this angle. 
 HTAK ClTAK 
Chemical Formula C15H19N3O C15H18ClN3O 
Molecular Weight / g.mol-1 257.33 291.77 
Crystal System Monoclinic Orthorhombic 
Space group P21 (n°4) P212121 
Z , Z’ (asymmetric units per unit cell) 4, 2 4, 1 
a / Å 5.747(1) 5.8076(5) 
b / Å 19.183(1) 13.553(1) 
c / Å 13.437(1) 19.661(2) 
β 96.561(1) - 
V / Å3 1471.8(2) 1547.5(2) 
dcalc / g.cm
-3 1.161 1.252 
Table III - 8. Crystal data of HTAK and ClTAK. 
 
Cohesion of molecules in the crystal packing is also ensured by means of π interactions in T 
shape, generating infinite chains of molecules in [100] direction. The angle between two 
consecutive aromatic rings involved into the interaction is circa 60°. The distance between 
two consecutive rings is 3.9Å. π interactions link together the asymmetric units. 
c)a) b)
 
Figure III - 40. π stacking in T shape (dashed green lines). a) HTAK, b) HTAK with colour differentiation 
of the asymmetric units, c) ClTAK. 
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c)a) b)
 
Figure III - 41. The interactions in T-shape generate double chains that are spreading along the [100] 
direction. a) HTAK, b) HTAK with colour differentiation of the asymmetric units, c) ClTAK. 
 
However, the chains are not identical: the triazol moieties are at the endo position for HTAK 
whereas they are at the exo position for ClTAK. 
Projections along a axes give another proof of the similarity existing between the crystal 
structures of HTAK and ClTAK; the chains are stacked along b direction (c for ClTAK). 
Along c (b for ClTAK), these slices are shifted by ½ c
r
 vector (or ½ b
r
 vector). 
b)a)
 
Figure III - 42. Projections along a axis a) HTAK, one asymmetric unit is circled in red and one chain is 
circled in black, b) ClTAK, one chain is circled in black. 
 
Projection along c axis of HTAK is also similar to the projection along b axis of ClTAK; 
infinite chains of molecules are clearly visible on these pictures. 
b)
c
a
a)
b
a
 
Figure III - 43. Projections along a) c axis for HTAK, one asymmetric unit is circled in red and b) b axis 
for ClTAK. 
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  c. Comparision between the crystal packings of 2F-4ClTAK and MeTAK 
The crystal structure of another TAK derivative, the 2F-4ClTAK (Figure III - 44), was 
described in the literature.173 This compound also crystallised in the P212121 space group with 
very close cell parameters (Table III - 9). The comparison will be made between MeTAK and 
2F-4ClTAK. 
 
Figure III - 44. Chemical structure of 2F-4ClTAK. 
 MeTAK 2F-4ClTAK173 
Chemical Formula C16H21N3O C15H17ClFN3O 
Molecular Weight / g.mol-1 271.36 309.77 
Crystal System Orthorhombic Orthorhombic 
Space group P212121 P212121 
Z , Z’ (asymmetric units per unit cell) 4, 1 4, 1 
a / Å 5.808(1) 5.777(3) 
b / Å 13.641(1) 13.699(6) 
c / Å 19.789(1) 19.813(8) 
V / Å3 1567.9(2) 1567.9(1) 
Table III - 9. Crystal data of MeTAK and 2Cl-4FTAK. 
 
The superimposition of these two structures reveals that they both exhibit the same packing: 
the aromatic rings are interacting with their adjacent equivalents along b axis, and by means 
of π interactions in T shape (Figure III - 45), generate infinite chains of molecules in [100] 
direction. 
 
Figure III - 45. Superimposition of a slice, 2F-4ClTAK in blue and MeTAK in white. 
 
Figure III - 46. Superimposition of projections along a axis. 2F-4ClTAK in blue and MeTAK in white. 
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No disorder was described for the tertbutyl group. However, as it was the case for the first 
resolution of the structure of ClTAK, it is possible that Branch and Nowell missed the 
disorder, the quality of the single crystal being maybe not sufficient.   
 
 
 7. Conclusion 
The resolution of structures has confirmed what have been predicted from comparisons 
between XRPD patterns: ClTAK, MeTAK and BrTAK crystallise in the same crystal packing, 
the non centrosymmetric space group P212121, with a dynamic disorder of the tertbutyl group. 
A fourth compound, the 2F-4ClTAK, also exhibits the same structure. The substitution of the 
aromatic ring of this series of molecules seems to have some degrees of freedom. These 
compounds behave as if a kind of pocket exists around the aromatic ring in which we can 
change substituents without changing the crystal packing. 
However, the size of this pocket seems to be limited: if the substituent is too large, as it is 
probably the case for the tBuTAK, another packing becomes more stable. 
In the case of HTAK (i.e. without substituent on the aromatic ring) the crystal packing is 
different, P21, but it shows extensive similarities with the P212121 structures. No disorder of 
the terbutyl group was detected but the two molecules of the asymmetric unit differ mainly by 
the position of the tertbutyl group, mimicking a 50/50 disorder. 
We can also imagine that acid or basic subtituents, or substituents with a strong electronic 
effect (CF3, NO2, OMe…), can prevent the formation of this kind of structure. 
It should be interesting to study the crystallisation of other compounds within this series to 
find the limit of this pocket. 
 
 
 
V - Viedma ripening on TAK derivatives 
 1. Deracemisation of 1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-
triazol-1-yl)pentan-3-one ClTAK 
Even if the resolution of this compound was already described, the access to the pure 
enantiomer from the racemic suspension had never been studied. Therefore, the 
deracemisation of ClTAK was studied at constant temperature to evidence that ClTAK 
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exhibited the same Viedma ripening than the other compounds described in the literature (i.e. 
an autocatalytic deviation from the 50-50 mixture). 
 
  a. Experimental conditions 
The experimental conditions described here were applied to all TAK derivatives, except for 
the solvent. The ratio of methanol and water had to be adjusted for each compound in order to 
keep similar masses of TAKs in the liquid and in the solid phase. The composition of the 
solvent was chosen according to the solubility data (Table III - 1) and is given in weight 
fraction. 
It should be noted that the enantiomeric excess of the starting material was checked before its 
partial dissolution. Therefore, any small imbalance would be increased by the dissolution of 
the racemic mixture. The first point of each experiment should not be taken in account for the 
shape of kinetics. Furthermore, all the points are connected together by a line but this line 
does not represent the real kinetic of the deracemisation. 
A suspension of ClTAK was prepared by adding 1g of ClTAK and 5g of glass beads (Ø2mm) 
into 5g of an 80/20 methanol/water mixture at 25°C. As the solubility of ClTAK at 25°C is 
5.5%, 0.29g of ClTAK was dissolved and 0.71g of ClTAK remained as solid phase in the 
suspension. Sodium hydroxide (0.1g) was added then the suspension was vigorously stirred 
by using a cross magnetic stirrer. 
All along the experiment, samples were taken with a plastic pipette, immediately filtered, 
washed with a large amount of water to remove all traces of sodium hydroxide then dried 
overnight at 40°C. 
The evolution of the enantiomeric excess was monitored by chiral HPLC. The column was a 
Chiralcel OD and the eluent was a 95/5 heptane/ethanol mixture at 1.5mL/min. The retentions 
times of the two enantiomers were at circa 8.3 and 10 minutes (Figure III - 47). 
 
Figure III - 47. Chromatogram of the racemic ClTAK. 
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  b. Results 
The results of the first experiment are summarized in Figure III - 48. These graphics show that 
around five days were necessary to complete the deracemisation of ClTAK in these 
conditions. Furthermore, ClTAK seems to have exactly the same behaviour than the other 
compounds described in the literature: the enantiomeric excess exponentially evolves toward 
the high values (Figure III - 48). The curve ln(e.e.)=f(t) is linear and the corresponding 
exponential trend line perfectly matches with the experimental points. However, the number 
of experimental values was not sufficient to have a good accuracy. Therefore, other 
experiments were carried out, with more sampling, to confirm the exponential evolution of the 
enantiomeric excess. 
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Figure III - 48. Evolution of the enantiomeric excess versus time (left) and ln(e.e.) versus time (right). In 
black, the exponential trend line (left) and the corresponding linear trend line (right). Red lines are given 
as a guide to the eyes. 
The achievement of the deracemisation points out the absence of impact of epitaxy. Indeed, in 
classical preferential crystallisation, epitaxial growth is a limiting factor, the counter 
enantiomer can grow from crystals of the seeded enantiomer. But it is not the case for 
deracemisation. Kaptein et al. previously described that the epitaxial growth does not disturb 
the deracemisation process, and it is also the case for ClTAK (Black et al. previously 
described the epitaxial crystallisation).171 
 
Figure III - 49 shows another experiment, carried out in the same conditions than the first one, 
but with more sampling. When the e.e. of the solid is below 80%, the evolution of the e.e. is 
definitively exponential, as evidenced the representation of ln(e.e.) as a function of time. This 
experiment also highlighted the existence of a slowdown of the kinetics when the e.e. 
approached 100%. This phenomenon can easily be explained by i) the decreasing of the 
amount of the minor enantiomer to transform and ii) the increasing of the amount of the major 
enantiomer that increased its kinetics of racemisation. As the exponential kinetics, the 
slowdown was also described in the literature.128 
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But, this experiment highlighted a new phenomenon: the exponential evolution of the 
enantiomeric excess did not start as the same time as the stirring. After 50h, the enantiomeric 
excess was almost racemic, as if a threshold must be reached to make the process 
“irreversible”. 
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Figure III - 49. Evolution of the enantiomeric excess versus time (left) and ln(e.e.) versus time (right). In 
black, the exponential trend line (left) and the corresponding linear trend line (right). Blue line is given as 
a guide to the eyes. 
 
In order to know if this latent period (i.e. the delay in the evolution of the enantiomeric 
excess) was due to an experimental problem (e.g. stirring) or due to the deracemisation 
process itself, another experiment was carried out and many samples were taken for 100h. 
The results are shown below. 
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Figure III - 50. Comparison of the evolution of the enantiomeric excess for three experiments carried out 
in the same experimental conditions. 
 
By looking at the evolution of the e.e., it is clear that the deracemisation process did not start 
as the same time as the stirring. The first and the second experiment were quite similar 
whereas the time to complete the deracemisation was much longer in the case of the third 
experiment; for the first 3 days, the enantiomeric excess stayed very close to 0%. Though, 
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nothing was changed during all the experiments: the number of glass beads as well as the 
stirring rate and the temperature were kept constant. 
It is known that without unbalanced initial e.e. or CDS,128 the final chirality obtained after a 
deracemisation process is randomly distributed between the (+) and the (-) enantiomers. The 
“irreversible” evolution seems to have a certain threshold, below which the enantiomeric 
excess can go back toward the racemic composition. Contrary, once this threshold is 
overcome, the enantiomeric excess quickly evolves toward 100%. 
Unfortunately, this threshold was difficult to estimate precisely. A first error is inherent in the 
HPLC method; the accuracy of the result is generally estimated at ±0.2%. The second error 
comes from the sample; around 0.5mg of TAK was dissolved in 1mL of eluent. As the 
compounds crystallise as conglomerates, it is possible that this 0.5mg was not representative 
of the whole sample. 
 
 
 2. Deracemisation of 4,4-dimethyl-1-phenyl-2-(1H-1,2,4-triazol-1-yl) 
pentan-3-one HTAK 
  a. Experimental conditions 
The experimental conditions were similar as the ones used for ClTAK: 1g of HTAK for 5g of 
solvent (a mixture of 47% of methanol and 53% of water) and 5g of glass beads (Ø2mm) with 
0.10g of NaOH at 25°C. Samples were prepared in the same way and the same chiral column 
was used. However, the eluent had to be changed: a 98/2 heptane/ethanol mixture was used. 
The retentions times of the two enantiomers were at circa 23 and 25.7 minutes. 
 
Figure III - 51. Chromatogram of the racemic HTAK. 
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  b. Results 
A first experiment was carried out to determine if the deracemisation was possible and 
therefore if the compound crystallised as a conglomerate or not (at this stage, the structure of 
HTAK was not resolved yet.) After twenty days, the enantiomeric excess of the solid was 
checked by chiral HPLC: only one peak was detected. The conversion of the racemic mixture 
toward the pure enantiomer was thus also possible with HTAK. 
An additional experiment was carried out to monitor the kinetics of this deracemisation. The 
evolution of the enantiomeric excess is shown in Figure III - 52: the kinetics of 
deracemisation was exponential with a slow down when the e.e. is close to 100%. Moreover, 
the e.e. stayed close to 0% for the first three days; the latent seems to be a recurrent 
phenomenon. 
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Figure III - 52. Evolution of the e.e. for the deracemisation of HTAK. In black, the exponential trend line 
(left) and the corresponding linear trend line (right). Red lines are given as a guide to the eyes. 
 
 
 
 3. Deracemisation of 4,4-dimethyl-1-(p-toluyl)-2-(1H-1,2,4-triazol-1-yl) 
pentan-3-one MeTAK 
  a. Experimental conditions 
The experimental conditions were similar as the ones used for ClTAK: 1g of MeTAK for 5g 
of solvent (a mixture of 65% of methanol and 35% of water) and 5g of glass beads with 0.10g 
of NaOH at 25°C. Samples were prepared in the same way and the same chiral column was 
used as ClTAK. The retentions of time the two enantiomers are at circa 7.4 and 8.9 minutes, 
with a return to base line in-between (Figure III - 53). 
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Figure III - 53. Chromatogram of racemic MeTAK. 
 
  b. Results 
For MeTAK, the resolution of the structure was made before the deracemisation experiments 
so we knew that MeTAK crystallises as a conglomerate and so that the deracemisation should 
work. A first experiment was carried out to confirm this and, after 5 days, the enantiomeric 
excess was around 99%. 
An additional experiment was carried out to monitor the evolution of the enantiomeric excess 
(Figure III - 54). The convertion was also exponential with a slow down when the e.e. reached 
high values. 
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Figure III - 54. Evolution of the enantiomeric excess versus time (left) and ln(e.e.) over time (right). In 
black, the exponential trend line (left) and the corresponding linear trend line (right). Blue line is given as 
a guide to the eyes. 
 
To compare kinetics of deracemisations of all TAK derivatives, we tried to keep the solubility 
constant for all the TAK derivatives. However, the solubility of MeTAK in the solvent used 
above (65/35 w/w methanol/water mixture) was 6.0% whereas the solubility of ClTAK for the 
deracemisation experiments (80/20 methanol water mixture) was 5.5%. So, the influence of 
the solubility of MeTAK was also studied. Two experiments were carried out in parallel, with 
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the same experimental conditions (temperature, stirring rate…) except for the solvent: a 65/35 
methanol/water mixture and a 60/40 methanol/water mixture were used. 
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Figure III - 55. Influence of the solubilty of MeTAK on the kinetics of deracemisation depending on the 
solvent: 65/35 methanol/water mixture (purple) and 60/40 methanol water mixture (orange). Lines are 
given as a guide to the eyes. 
 
As expected, a modification of the solubility did not influence the shape of the kinetics: both 
enantiomeric excess evolved exponentially toward 100%. But these experiments highlighted 
two facts: i) it was clear that the deracemisation did not start as the same time as the 
mechanical treatment, ii) the solubility had an influence on the deracemisation duration, 
probably because the amount of solid in suspension was higher when the solubility was lower 
(the same initial mass of MeTAK was used in both cases), iii) the solubility seemed to have 
an influence on the end of the process; the evolution of the enantiomeric excess seemed to 
slow down earlier when the solubility is lower. 
However, the durations of these two deracemisations were not so different; experiments with 
6.0% solubility can be used for the comparison with the other TAK derivatives. 
 
 
 4. Deracemisation of 1-(4-bromophenyl)-4,4-dimethyl-2-(1H-1,2,4-
triazol-1-yl)pentan-3-one BrTAK 
  a. Experimental conditions 
The experimental conditions were the similar as the ones used for ClTAK: 1g of BrTAK for 
5g of solvent (a mixture of 90% of methanol and 10% of water) and 5g of glass beads 
(Ø2mm) with 0.10g of NaOH at 25°C. Samples were prepared in the same way and the same 
chiral column was used than for ClTAK. The retentions of time the two enantiomers are circa 
8.3 and 10.4 minutes with a clear return to base line in-between (Figure III - 56). 
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Figure III - 56. Chromatogram of racemic BrTAK. 
 
 
  b. Results 
The first experiment carried out with BrTAK aimed at knowing if it crystallises as a stable 
conglomerate or not (at this stage, the structure of BrTAK was not resolved yet). The results 
of this first experiment are detailed below: 
y = 0.0031e0.0255x
R2 = 0.9832
0%
20%
40%
60%
80%
100%
0 48 96 144 192 240 288 336 384 432 480
Time (h)
E
v
o
lu
ti
o
n
 o
f 
th
e
 e
.e
.
 
y = 0.0255x - 5.765
R2 = 0.9832
-6
-5
-4
-3
-2
-1
0
0 48 96 144 192 240 288 336 384 432 480
Time (h)
ln
(e
.e
.)
 
Figure III - 57. Evolution of the enantiomeric excess versus time (left) and ln(e.e.) over time (right). In 
black, the exponential trend line (left) and the corresponding linear trend line (right). Red line is given as 
a guide to the eyes. 
 
This experiment had shown that the deracemisation was possible and therefore confirmed that 
BrTAK crystallised as a conglomerate. This preliminary result suggested that the 
deracemisation could take more time than for the other TAK derivatives. Therefore, another 
experiment was carried out, with more sampling (Figure III - 58). 
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Figure III - 58. Evolution of the enantiomeric excess versus time (left) and ln(e.e.) over time (right). In 
black, the exponential trend line (left) and the corresponding linear trend line (right). Blue line is given as 
a guide to the eye. 
 
Even if the shape of the kinetics was less visible than for the other compounds, the evolution 
of the enantiomeric excess was also exponential. 
The process seemed to be slower than for the other TAK derivatives. This point will be 
discussed in the following paragraph where the kinetics of the deracemisation of the four 
TAKs will be compared. 
 
 
 5. Comparison between kinetics 
The deracemisation of the four TAK derivatives, ClTAK, HTAK, MeTAK and BrTAK, were 
carried out with success. In all cases, the evolution of the enantiomeric excess was 
exponential, with a slow down when the e.e. approached 100%. To make easier the 
comparison between the kinetics, the origins of the deracemisation were shifted: the latent 
periods before the “irreversible” evolutions of the enantiomeric excess were removed (Figure 
III - 59). 
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Figure III - 59. Comparison between the kinetics of deracemisation of ClTAK, HTAK, MeTAK and 
BrTAK. Lines are given as a guide to the eyes. The origins of the deracemisations were shifted to remove 
the latent period. 
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The shape of the evolution of the enantiomeric excess against time was very similar for 
ClTAK, HTAK and MeTAK; around three days were necessary to complete the total 
symmetry breaking and the autocatalytic shape of the curve was obvious. For BrTAK, more 
than five days were necessary to reach 100% e.e. and the autocatalytic shape of the kinetics 
was less visible. This behaviour iss also visible when the curves ln(e.e.) versus time are 
compared (Figure III - 60). 
 
Figure III - 60. Comparison between the evolution of ln(e.e.) versus time for ClTAK, HTAK, MeTAK and 
BrTAK. Lines are given as a guide to the eyes. 
 
The kinetics of deracemisation of ClTAK was a little bit slower than the deracemisations of 
MeTAK and HTAK. The difference with MeTAK can be explained by a difference of 
solubility. Indeed, it has been demonstrated that the solubility affects the kinetics of 
deracemisation (see paragraph V-3.b) and, in spite of the modifications of the solvent system, 
the solubilities of ClTAK and MeTAK derivatives were not absolutely identical (5.5% and 
6.0% respectively). HTAK crystallised in a different crystal packing that can explain the 
differences observed between ClTAK and HTAK. 
Nevertheless, neither the difference of solubility nor the crystal packing can explain the 
slowest evolution of the enantiomeric excess of BrTAK. 
 
 
 
 
 
 
 
Stochastic chiral symmetry breaking of a conglomerate forming system 
 
- 157 - 
VI - Evolution of the crystal size distribution 
One of the key steps of the mechanism of the deracemisation process seems to be the 
reduction of the size of crystals, increasing the transfer of matter.128 
However, a very recent study, conducted by Hein et al., described a new aspect of the 
deracemisation: “a transient growth in crystal size”.178 By monitoring the crystal size during 
deracemisation experiments, they noticed that “a broadening of the distribution commenced 
at the onset of the evolution of the solid-phase CEE (crystal enantiomeric excess) [...] and 
endured through the ermergence of homochirality”. 
 In order to confirm these observations, the evolution of the CSD was monitored by scanning 
electron microscopy (SEM) for the four TAK derivatives. Crystal size distribution 
measurement by LASER diffraction could not be applied because the TAK derivatives are 
soluble in the solvent usually used for this analysis (n-heptane). Therefore water must be used 
but the dispersion of particles is not sufficient to perform accurate analyses. Moreover the 
harvested mass of each sample was not sufficient to perform this analysis. 
 
 
 1. 1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-
one ClTAK 
  a. Starting material 
First, the CSD of the starting material and the shape of crystals were observed by SEM 
(Figure III - 61). Initial powder of ClTAK was made of rod crystals with a scattered CSD; the 
lengths of particles were between 1µm and 200µm. The edges were clearly visible. 
 
Figure III - 61. SEM pictures of the starting material of ClTAK. 
 
 
 
                                                 
178 J. E. Hein, B. H. Cao, C. Viedma, R. M. Kellogg, D. G. Blackmond; J. Am. Chem. Soc., 2012, 134, 12629-
12636. 
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  b. Evolution of the CSD 
The evolution of the CSD was monitored by SEM; six samples were chosen depending on 
their e.e. and on the time of sampling: 
 - Two samples with e.e. ≈ 0%, during the latent period. 
- Three samples during the increasing of the e.e. (exponential part). 
- One sample when the deracemisation was complete. 
These six samples are indicated by arrows on Figure III - 62. 
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Figure III - 62. Evolution of the enantiomeric excess versus time during deracemisation with glass beads. 
Arrows indicate time of sampling for SEM pictures shown in Figure III - 63 and Figure III - 64. Line is 
given as a guide to the eyes. 
 
SEM pictures of these six samples, at two different magnifications (x1000 and x5000, 
respectively Figure III - 63 and Figure III - 64) are presented below. 
 
Figure III - 63. SEM pictures of samples during deracemisation of ClTAK with glass beads. Labels A-F 
correspond to arrows indicated on Figure III - 62. Magnification x1000. 
A B C 
D E F 
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Figure III - 64. SEM pictures of samples during deracemisation of ClTAK with glass beads. Labels A-F 
correspond to arrows indicated on Figure III - 62. Magnification x5000. 
 
The shape of particles was different compare to the starting material. Crystal length was much 
shorter (between 1 and 10µm) but the width was quite similar. Edges were almost not visible; 
they were eroded because of the attrition ensured by glass beads. 
The amount of small crystals was not negligible and was in line with the currently accepted 
mechanism. We can indeed easily imagine their dissolution to the benefit of the growth of the 
larger ones and the exchange of matter between the two enantiomers. 
Another interesting point shown by these pictures is that the CSD was roughly the same from 
the first sample to the last one, that is to say during: the latent period, the increasing e.e. 
period and at the final state. The steady state of the size of particles seems to be quickly 
reached and be independent of the enantiomeric excess. We can thus conclude: 
 - The grinding ensured by glass beads is definitely efficient all along the experiment 
and therefore, the latent period is not due to an experimental problem. The reason for the 
existence of this latent period must involve another phenomenon (for example, a stochastic 
variation of the e.e.). 
 - The evolution of the e.e. is not due to a specific size of particles. The CSD depends 
on the abrasive power produced by glass beads and not on the enantiomeric excess of the 
solid phase, contrary to that C. Viedma, R. M. Kellogg and D. G. Blackmond described.178 
 
 
 
A B C 
D E F 
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 2. Evolution of the CSD for the other TAK derivatives 
The aim of the following parts is to determine if the behaviour of the other TAK derivatives is 
the same as for ClTAK. The evolution of the CSD is studied from SEM pictures then the size 
of particles is compared to know if the nature of the compound has an influence. 
For the three TAK derivatives, SEM pictures of three samples were taken: 
 - One sample with e.e. ≈ 0%. 
 - One sample during the increasing of the e.e. 
 - One sample when the deracemisation was complete. 
The times of sampling are indicated by arrows on the corresponding representation of the 
evolution of the enantiomeric excess versus time: 
 
  a. 4,4-dimethyl-1-phenyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-one HTAK 
As for ClTAK, the initial powder of HTAK was made of rod shaped crystals with a scattered 
CSD; the length of particles was between 5µm and 200µm. 
 
Figure III - 65. SEM pictures of the initial powder of HTAK. 
The crystal size distribution of three samples was observed by SEM. 
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Figure III - 66. Evolution of the enantiomeric excess versus time for HTAK. Arrows indicate time of 
sampling for SEM pictures. Line is given as a guide to the eyes. 
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We can observe that the CSD was much narrower than the starting material (with a significant 
amount of small particles) and crystals were more elongated. Moreover, no edges were 
visible. As for ClTAK, the steady state of particles size was quickly reached and then no 
evolution was observed; it was also independent of the enantiomeric excess. 
A B C 
 
Figure III - 67. SEM pictures of samples during deracemisation of HTAK with glass beads. Labels A-C 
correspond to arrows indicated on Figure III - 66. Magnification x 1000 and x5000. 
 
 
  b. 4,4-dimethyl-1-(p-toluyl)-2-(1H-1,2,4-triazol-1-yl)pentan-3-one MeTAK 
The initial powder of MeTAK was made up by ill-defined particles, with a scattered CSD; rod 
crystals with a length higher than 200µm, or particles with diameter between 1µm and 200µm 
(Figure III - 68). The edges were not clearly visible on all particles. 
   
Figure III - 68. SEM pictures of the initial powder of MeTAK. 
 
The crystal size distribution of three samples was observed by SEM. 
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Figure III - 69. Evolution of the enantiomeric excess versus time. Arrows indicate time of sampling for 
SEM pictures. Line is given as a guide to the eyes. 
 
The shape of crystals was homogeneous, with a narrow CSD (particles between 1 and 10µm, 
Figure III - 70). A lot of small particles were present and edges were not visible (some 
particles look like ball). In this case, the steady state of size particles seemed also to be 
quickly reached. 
A B C 
   
   
Figure III - 70. SEM pictures of samples during deracemisation of MeTAK with glass beads. Labels A-C 
correspond to arrows indicated on Figure III - 69Figure III - 66. Magnification x1000 and x5000. 
 
  c.1-(4-bromophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-one 
BrTAK 
The initial powder of BrTAK was made of ill particles, with a scattered CSD; needles, rod 
crystals with a length higher than 500µm, or 1µm particles (Figure III - 71). The edges were 
clearly visible. 
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 Figure III - 71. SEM pictures of the initial powder of BrTAK. 
 
The crystal size distribution of three samples was observed by SEM. The shape of crystals 
was homogeneous, with a narrow CSD (particles between 1 and 5µm, Figure III - 73). A lot 
of small particles were present and edges were not visible. The steady state of the size of the 
particles was quickly reached. 
0%
20%
40%
60%
80%
100%
0 24 48 72 96 120 144 168
Time (h)
E
v
o
lu
ti
o
n
 o
f 
th
e
 e
.e
.
A
B
C
 
Figure III - 72. Evolution of the enantiomeric excess versus time. Arrows indicate time of sampling for 
SEM pictures. Line is given as a guide to the eyes. 
A B C 
   
   
Figure III - 73. SEM pictures of samples during deracemisation of BrTAK with glass beads. Labels A-C 
correspond to arrows indicated on Figure III - 72. Magnification x1000 and x5000. 
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 3. Comparisons between the sizes of particles 
In this paragraph, the particles sizes of the four TAK derivatives were compared to understand 
why the behaviour of BrTAK was slower than the three others. The study focused on samples 
with an enantiomeric excess at circa 100% (Figure III - 74). 
ClTAK HTAK 
  
  
MeTAK BrTAK 
Figure III - 74. SEM pictures of samples with a high e.e. of ClTAK, HTAK, MeTAK, BrTAK. 
Magnification x2000. 
 
A first interesting point was that there was a good correlation between the CSD and the 
deracemisation kinetics for ClTAK, MeTAK and HTAK (relatively close CSDs and similar 
kinetics). 
The deracemisation duration was longer for BrTAK than for the other TAK derivatives. As all 
the experimental parameters were identical (same mass of crystals in suspension, same mass 
concentration, same mass of sodium hydroxide, isomorphous crystal lattices for MeTAK, 
ClTAK and BrTAK, same set-up, same attrition energy...), larger particles were expected for 
BrTAK. But SEM pictures shew the opposite: particles of BrTAK were much smaller than 
particles of ClTAK, HTAK and MeTAK, that was in contradiction with the currently accepted 
mechanism. BrTAK behaves as if the transfert of matter was inhibited, limiting the growth of 
particles and slowing down the evolution of the enantiomeric excess. 
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But no evidence was found to confirm this theory; the slow evolution of the enantiomeric 
excess of BrTAK remains an open question. 
 
 
 
VII – Deracemisation by using ultrasounds 
Very recently, a few experiments using ultrasounds instead of glass beads were carried out to 
perform the deracemisation of sodium chlorate NaClO3. Song et al. Provoked the 
crystallisation of NaClO3 from a supersaturated solution by applying ultrasounds, both with 
and without seeding.179,180 In both cases the final enantiomeric excess was close to 100% and 
without seeding, the final chirality was stochastic, as for glass beads. Following their first 
study, P. Cintas attributed the effect of the ultrasounds on the deracemisation to their ability to 
promote the formation of secondary nuclei and/or to increase the mechanical effects,181 two 
processes known to be very important in the mechanism of the deracemisation. 
Up to now, several experiments combining ultrasounds and glass beads were performed by 
the Dutch consortium to complete deracemisation of amino acid derivatives but ultrasounds 
have never been used alone in these cases.95,100,104,126 Moreover, even if an increase of the 
kinetics was noticed, the role of the ultrasounds has never been specifically studied. 
In order to study the effect of ultrasounds without any glass beads, experiments of 
deracemisation of ClTAK were carried out. 
 
 
1. Deracemisation in an ultrasonic bath 
Preliminary experiments in a simple ultrasonic bath showed that ultrasounds were indeed able 
to perform deracemisation of ClTAK without the help of glass beads (Figure III - 75). In the 
first experiment (solid curve), the vial was just put down inside the US bath and naturally 
went in a corner, whereas in the second experiment (dotted curve), the vial was fixed in the 
middle of the bath. In both cases the enantiomeric excess was over 40% after 6h. 
                                                 
179 Y. Song, W. Chen, X. Chen; Cryst. Growth Des., 2008, 8(5), 1448-1450. 
180 Y. Song, W. Chen, X. Chen; Cryst. Growth Des., 2012, 12(1), 8-11. 
181 P. Cintas; Cryst. Growth Des., 2008, 8(8), 2626-2627. 
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Figure III - 75. . Evolution of the enantiomeric excess during the ultrasonic treatment in an ultrasonic 
bath. ♦ “free” vial, ■ fixed vial. 
However, in the first case, the evolution of the enantiomeric excess was slowest whereas the 
initial e.e. was higher. That is in contradiction with the exponential evolution of the e.e. (the 
experimental parameters, such as temperature and initial crystal size distribution, were kept 
constant). This difference can maybe be explain by the non homogeneity of ultrasounds in the 
entire bath as the appearance of the surface of water shows; the vial in the middle get more 
power than the vial in the corner of the bath. The amount of ultrasounds seemed to have a 
significant effect on the kinetics of the deracemisation. 
Moreover, another encountered problem was the difficulty to control the temperature inside 
the suspension because of the overheating provokes by ultrasounds. 
 
 
2. Deracemisation in controlled conditions: use of an ultrasonic probe 
  a. Experimental results 
To perform deracemisations in controlled conditions (power and temperature), a different set-
up was used; an ultrasonic probe was immerged into a suspension of ClTAK in a double-
walled thermostated reactor (Figure III - 76). The generator connected to the probe was able 
to deliver different powers of ultrasounds and the temperature of the system was monitored by 
a temperature probe. A magnetic stirrer was added in order to ensure a good homogeneity of 
the suspension inside the reactor. Indeed, with low powers, ultrasounds were not sufficient to 
homogenize the system. As stirring was also able to provoke deracemisations, the same 
stirring rate (750rpm) was used for all the experiments to make possible the comparison 
between the results. 
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Figure III - 76. The ultrasonic probe immerged into the suspension of ClTAK. 
 
The evolution of the enantiomeric excess was monitored by chiral HPLC for four different 
powers (50kJ.h-1, 130kJ.h-1, 170kJ.h-1 and 325kJ.h-1). The results are shown on Figure III - 77. 
In the four cases, the enantiomeric excess evolved autocatalytically towards the high values 
up to a final e.e. close to 100%. Moreover, we can observe that the necessary time to complete 
deracemization depends on the power delivered by the ultrasonic probe: the higher the power, 
the faster the kinetics. 
It should be noted that almost two months were necessary to complete the deracemisation 
without ultrasonic radiation in the same conditions (i.e. stirring rate at 750rpm, 25°C), which 
proved that the effect of the stirring itself can be neglected. 
Moreover, the maximum continuous irradiation which can be programmable by the generator 
was 10h. In consequences, the generator was turn off all the evening and the system had to be 
“frozen” to not modify the size of the crystals and the enantiomeric excess. The temperature 
of the thermostat was therefore adjusted to 25°C and the stirring was stopped. 
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Figure III - 77. Evolution of the enantiomeric excess during deracemisation by using ultrasounds with 
four different powers. Lines are given as a guide to the eyes. 
 
The study of the size of the particles by SEM revealed that the higher the power (and so the 
faster the kinetics), the smaller the crystals (Figure III - 78). 
This result combined to the exponential evolution of the enantiomeric excess seemed to give 
the proof that the mechanism of the deracemisation is the same for glass beads as for 
ultrasonic waves. Therefore these two kinds of deracemisation were compared. 
50kJ.h-1 5µm 130kJ.h-1 5µm
170kJ.h-1 5µm 325kJ.h-1 5µm  
Figure III - 78. SEM pictures of final particles for the four different powers of ultrasounds. Magnification 
x5000. 
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  b. Comparison between glass beads and ultrasounds: a different mechanism? 
First, kinetics of the evolution of the enantiomeric excess were compared. As illustrated on 
Figure III - 79, the reaction durations were shorter using ultrasonic irradiations, even at the 
lowest power. 
It should be noted that the two kinds of experiments were not performed at the same scale: 
when attrition was ensured by glass beads, 1g of ClTAK was used whereas 20g were 
deracemised with ultrasounds. Indeed, because of the size of the ultrasonic probe 
(≈10x200mm), it was difficult to perform the experiment on a smaller scale than 20g of 
substrate. As for glass beads, the necessary amount of beads was too large (100g) and make 
very difficult the stirring of the suspension. Moreover, the workup of the reaction was not 
easy; the product and the glass beads must be separated. However, to make possible the 
comparison between the two processes, the substrate/base/solvent proportions and the 
temperature were kept constant. 
 
Figure III - 79. Comparison of the evolution of the enantiomeric excess by using glass beads and with two 
different powers of ultrasounds. The origin of the deracemisation by using glass beads was shifted (the 
latent period was removed). Lines are given as a guide to the eyes. 
 
This difference of the kinetics can be explained by the energy provided in the system; 
ultrasonic irradiation is a very energetic technique, as the overheating of the suspension 
showed. Moreover, ultrasounds are known to produce a high number of clusters. As 
reincorporation of clusters seems to be one of the key steps of the deracemisation process, it 
was not surprising that deracemisations under ultrasounds proceeded faster than 
deracemisations induced by glass beads. Pedro Cintas also pointed out in his publication181 
that cavitations produced by the ultrasonic waves can create a strong mechanical effect. Inside 
a cavitational bubble, the pressure and the temperature can reach very high values (over 
5000K and 1000 bar). When bubbles collapsed, a high energy is released in the system, 
inducing shear forces, shock waves and high speed liquid jets, responsible for pitting, erosion 
and abrasion. Thus, ultrasounds seemed to have a similar effect than glass beads, faster 
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kinetics due to the high energy and/or their higher rate of attrition and/or to the high number 
of clusters. 
So, if the mechanism is the same for the two processes, the crystals obtained after ultrasonic 
treatment should be smaller than those obtained using glass beads. Surprisingly, it is not that 
can be observed on the SEM pictures (Figure III - 80). 
50kJ.h-1 5µm 325kJ.h-1 5µm Glass beads 5µm  
Figure III - 80. SEM pictures of final particles of ClTAK obtained after attrition ensured by ultrasounds 
or glass beads. Magnification x5000. 
The enantiomeric excess evolved faster with ultrasounds than with glass beads but crystals 
were larger, that was in contradiction with the current mechanism. The high mechanical effect 
produced by ultrasonic waves cannot explain why this process was so efficient. 
 
Moreover, by looking at the evolution of the crystal size distribution during an ultrasonic 
treatment (Figure III - 81), another difference appeared. The CSD did not evolve significantly 
after 14h (e.e. = 2%), as with glass beads, but all the particles have the same size; the CSD 
was narrow and only few small crystals are present. 
So it was difficult to understand how the Ostwald ripening can occur and how it can be 
responsible of the so fast kinetics if only few small crystals were present in suspension. 
Stochastic chiral symmetry breaking of a conglomerate forming system 
 
- 171 - 
Starting material 50µm t = 14h, e.e. = 2% 5µm
t = 39h, e.e. = 24.7% 5µm
0%
20%
40%
60%
80%
100%
0 10 20 30 40 50 60
e
.e
.
Time (h)
50kJ/h
t = 8h, e.e. = 0.5% 5µm
t = 58h, e.e. = 96% 5µm
 
Figure III - 81. SEM pictures of the evolution of the CSD during deracemisation using the slowest power 
of ultrasounds (50kJ.h-1, corresponding to the blue curve on the Figure III - 79). 
 
A different aspect of the surfaces of the crystals can also be observed: after an ultrasonic 
treatment, surfaces are quite rough, as if small “flakes” were blown off from the mother 
crystal (Figure III - 78 and Figure III - 80) whereas after attrition ensured by glass beads, the 
particles were eroded, with smooth surfaces (Figure III - 80). These flakes can be quickly 
dissolved, increasing the dissolution/recrystallisation rate and therefore increasing the kinetics 
of the process. 
 
 
3. Conclusion 
This study allowed to shed some light to the deracemisation mechanism: 
 - The role of the mechanical effects and of the Ostwald ripening was confirmed (the 
higher the power of the ultrasonic irradiation, the smaller the particles and the faster the 
kinetics). But, they are not sufficient to explain how the process proceeds: for the same 
compound, particles obtaining by deracemisation using ultrasounds are larger than particles 
particles obtaining by deracemisation using glass beads and the evolution of the enantiomeric 
excess is faster. 
 - The important role of clusters was confirmed: a high number of clusters are produced 
by ultrasounds, speeding up the transfert of matter (clusters can be dissolved or recaptured by 
docking on the surfaces of crystal of the same handedness). 
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 - The local overheating produced when the cavitational bubbles collapsed lead to the 
creation of a local supersaturation. This surpersaturation combined with the “instantaneous” 
racemisation of the compound make possible a significant entrainment effect. As the thermal 
effect induced by the ultrasonic waves is much higher than the one due to glass beads, the 
entrainment is also promoted, leading to a faster evolution of the enantiomeric excess. This 
effect can also explain the difference between the sizes of particles obtained by using 
ultrasounds or by using glass beads. 
 
 
 
VIII – Conclusion 
In this chapter, we first demonstrated that several TAK derivatives exhibit the same crystal 
structure. A kind of pocket seems to exist around the aromatic ring in which the substituents 
can be changed without modifying the crystal packing: ClTAK, MeTAK, BrTAK and 4Cl-
2FTAK crystallise in the P212121 space group with Z’=1 and with disorder. Limited 
modulations in the crystal structure are even possible without destroying the full chiral 
discrimination as exemplified by HTAK (P21, Z’=2, without disorder). tBuTAK is an 
example of the limitation of this pocket. 
The fairly high degrees of freedom of the pocket (additional experiments are necessary to 
study its limits) can increase the number of deracemisable chiral intermediates. 
 
The successful deracemisation experiments with glass beads as well as with ultrasounds 
improved the understanding of the mechanism: 
 - A random delay to the “irreversible” evolution of the enantiomeric excess exists at 
the beginning of the process if there is no initial imbalance between the two enantiomers. A 
threshold needs to be overcome prior making the transformation “irreversible”. This 
emphasises the stochastic behaviour of the deracemisation. 
 - The crystal size distribution is dependent on the mechanical energy given to the 
system, but not on the enantiomeric excess of the solid phase, both with glass beads and with 
ultrasounds. This observation does not confirm the general charactec of the”transient growth” 
described by Hein et al.178 
 - The Ostwald ripening and the mechanical effect are necessary to ensure the total 
symmetry breaking but they are not sufficient to explain how the evolution proceeds. 
 - The importance of the reincorporation of clusters was confirmed. 
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 - The role of the entrainment effect was highlighted and might explain, at least 
partially, the different kinetics observed when using glass beads or ultrasounds. 
In addition, a recent study, conjointly made with the Flood’s research group in Thailand, gave 
the proof that total symmetry breaking can be achieved by thermal cycling only (successive 
heating and cooling cycles) without any mechanical attrition.182 These results gave another 
proof of the importance of the entrainment effect. 
 
Nevertheless, the case of BrTAK messes up: even if its deracemisation was carried out in 
similar conditions as ClTAK, MeTAK (quasi identical crystal lattices, very similar mass 
concentrations in the saturated solutions, same mass of solid in the suspensions, same 
temperature, same set-up, same attrition energy injected in the systems...), kinetics are slower 
and particles are smaller. The current accepted mechanism cannot explain this behaviour, 
showing that more investigations are needed for a full elucidation of deracemisation. 
                                                 
182 K. Suwannasang , A. E. Flood, C. Rougeot, G. Coquerel; Oral presentation at CGOM10, June 2012, 
Limerick, Ireland. 
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I - Introduction 
SYNCOM is a chemical company founded in 1988 and based in Groningen, in the north of 
the Netherlands. Syncom is a global leader in supplying pharmaceutical (such as Pfizer) and 
biotech (Phillips) industries with custom synthesis solutions. 
My work in Syncom was to design a synthesis of pure enantiomer of Prasugrel, a platelet 
aggregation inhibitor, by deracemisation. 
 
Prasugrel is a α-amino acid derivative with a chiral centre located in the α position. Numerous 
methods were described in the literature to have access to pure enantiomer of α-amino acid 
derivatives. Crystallisation methods, and particularly the Pasteurian resolution, are often used 
and were described in Chapter 1. A quick view of organic synthesis methods was also 
described. In this Chapter, additional examples will be given on the enzymatic dynamic 
kinetic resolution (here after enzymatic DKR), an efficient method frequently used to obtain 
enantiomerically pure amino acid derivatives. 
 
 
 1. Enzymatic dynamic kinetic resolution of amino acid derivatives 
Numerous DKR were carried out by using an enzyme to selectively convert only one 
enantiomer. As natural substrates of enzymes are generally proteins, enzymes are particularly 
efficient to selectively transform amino acids derivatives. Therefore, a lot of examples of 
enzymatic dynamic kinetic resolution were described in the literature. In this paragraph, a 
brief overview of these methods is depicted. 
 
Tessaro et al. proposed the synthesis of pure enantiomer of N-Boc-amino acid amides from 
R,S-N-boc-amino acid thioethyl esters (Figure IV - 1).183 Alcalase® (an endoprotease from 
Bacillus licheniformis) transformed only the S enantiomer. In the experimental conditions, the 
chemical aminolysis that may limit the success of the DKR is not efficient and therefore does 
not disturb the resolution; final yields are circa 80% after purification with an enantiomeric 
excess >98%. 
                                                 
183 D. Tessaro, L. Cerioli, S. Servi, F. Viani, P. D’Arrigo;  Adv. Synth. Catal., 2011, 353, 2333-2338. 
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Figure IV - 1. DKR of N-Boc-amino acid thioesters. 
 
Another use of the Alcalase® was described by Schichl et al. to obtain pure L enantiomer of 
free amino acids from the corresponding ester derivative (Figure IV - 2).184 The racemisation 
was ensured by a catalytic amount of 3,5-dinitrosalicylaldehyde. The purpose for the 
synthesis of pure natural amino acid was limited because they were easily available but the 
obtaining of enantiomerically pure non natural amino acids was an important issue for the 
pharmaceutical industry. 
 
Figure IV - 2. DKR of α-amino acid ethyl esters with Alcalase
®
 in acetonitrile/water (1:1) at 35 °C with  
3,5-dinitrosalicylaldehyde as racemising agent. [b] Reaction was continued for an additional 1 d to give 
94% yield and 95%ee. 
 
Enzymatic DKR can also be performed by combining the selectivity of an enzyme with the 
racemisation by using metal catalysts.185 In the case presented below (Figure IV - 3), the 
                                                 
184 D. A. Schichl, S. Enthaler, W. Holla, T. Riermeier, U. Kragl, M. Beller; Eur. J. Org. Chem., 2008, 20, 3506-
3512. 
185 Y. Kim, J. Park,M.-J. Kim; Chem. Cat.Chem., 2011, 3, 271-277. 
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enzyme is the Candida antarctica lipase B (CALB) and the racemising catalyst is palladium 
trapped in aluminium oxyhydroxide Pd/AlO(OH).  
 
Figure IV - 3. DKR of phenylglycine amide catalysed by Pb/AlO(OH). 
 
Because only L-amino acids are natural, most of enzymes selectively transform derivatives 
having the same configuration. The access to enantiomerically pure D-amino acids derivatives 
is therefore more difficult. However, some examples of enzymes which are able to selectively 
convert D-amino acids derivatives exist. In the case presented here (Figure IV - 4), the 
racemisation is ensured by an enzyme, the ACL racemase (α-amino-ε-caprolactam racemase, 
from Achromobacter obae), and the final configuration of the free amino acid depends on the 
enzyme used for the conversion; the D-aminopeptidase (from Ochrobactrum anthropi C1-38) 
or the L-amino acid amidase (from Brevundimonas diminuta TPU 5720).186 D and L-amino 
acids are obtained with yields > 99% and with enantiomeric excesses >99%. 
 
Figure IV - 4. DKR of amino acid amides. 
 
The enzymatic dynamic kinetic resolution is an efficient method to have access to pure 
enantiomers of free amino acids and amino acids derivatives. Even if the productivity is 
limited by the optimal conditions to use the enzymes (water is often necessary and the 
temperature may generally be maintained around 30-35°C), amino acids derivatives are 
generally compatible with these conditions. 
 
 
 
                                                 
186 K. Yasukawa, R. Hasemi, Y. Asano; Adv. Synth. Catal., 2011, 353(13), 2328-2332. 
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 2. Clopidogrel and Prasugrel 
Clopidogrel (23, Figure IV - 5), commercially available under the name Plavix, is a platelet 
aggregation inhibitor used for treatment of ischemic strokes, heart attacks, atherosclerosis and 
also for the prevention of thrombosis after placement of intracoronary artery stents. Its market 
was reported to be US$9.3 billons in 2010187 (US$7.3 billions in 2007188) 
 
Figure IV - 5. Chemical structure of S-Clopidogrel. 
 
Prasugrel (24, Effient, Figure IV - 6) is the next generation of Clopidogrel, approved for the 
use in Europe on February 2009189 and in the USA by the FDA on July 2009. It has 
approximately 10 times greater potency than Clopidogrel (measures were made by ex vivo 
inhibition of platelet aggregation and in vivo inhibition in animal models).190 
 
Figure IV - 6. Chemical structure of Prasugrel. 
 
Prasugrel and Clopidogrel are prodrugs, members of the thienopyridine class of ADP receptor 
inhibitors. These compounds are known to reduce the aggregation of platelets by irreversibly 
binding to P2Y12 receptors. For Clopidogrel the first step of the metabolism is a cytochrome 
P450-dependent oxidative step to generate the active metabolite. For Prasugrel the active 
metabolite is 25. It is stated in the literature190 that Prasugrel is more efficient than 
Clopidogrel because only one cytochrome P450 is needed rather than the two for Clopidogrel 
in order to obtain the active intermediate. We note, however, that the chemical transformation 
                                                 
187 Pharmactua, from www.pharmactua.com. 
188 MS Global insights, from www.inshealth.com. 
189 EMEA/117561/2009. 
190 J. A. Jakubowskin C. D. Payne, J. T. Brandt, G. J. Weerakkody, N. A. Farid, D. S. Small, H. Naganuma, G. 
Y. Li, K. J. Winters; J. Cardiovasc. Pharmacol., 2006, 47(3), 377-384. 
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of Prasugrel 24 to active intermediate 25 involves only a hydrolysis followed by ring opening.  
There is no oxidative step. 
These two drugs are commonly used in combination with aspirin. 
 
Figure IV - 7. Active metabolite of the Prasugrel. 
 
The active enantiomer of Clopidogrel, S-Clopidogrel S-23, was obtained by resolution of the 
camphorsulfonic acid salt191 or by resolution of an intermediate with tartaric acid.192 Three 
years ago, a new synthesis of the pure enantiomer of Clopidogrel was designed by Syncom 
BV by attrition-enhanced deracemisation (Figure IV - 8).100 This new synthesis exhibits two 
key steps: 
 - A deracemisation step: a small library of imines (Schiff bases) was synthesized to 
perform a screening of conglomerate by using various aromatic aldehydes. The compound 26 
derived from benzaldehyde was found to be a conglomerate and was used to complete the 
resolution step by deracemisation in acetonitrile with DBU (1,8-Diazabicyclo[5.4.0]undec-7-
ene) as racemising agent. Then the pure enantiomer of the amine 27 was obtained by 
hydrolysis of the imine S-26. 
 - The final step: the enantiopure amine S-28 reacts with a dibromothiophene 29 
previously prepared to give S-Clopidogrel, with a final enantiomeric excess of >99%. 
                                                 
191 US6800759, 2004. 
192 US2004073057, 2004. 
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Figure IV - 8. Synthesis of S-Clopidrogrel (S-23) developped by Syncom B.V. a) SOCl2, MeOH (95%), b) 
NH3 30% in water (81%), c) benzaldehyde, NaSO4, CH2Cl2 (90%), d) DBU, glass beads, acetonitrile (80%, 
e.e. > 99.5%), e) HCl, acetone (95%), f) H2SO4, methanol (94%), g) 7, acetonitrile (95%, e.e. > 99%). 
 
The synthesis of the racemic Prasugrel was described in a patent in 2009 (Figure IV - 9 and 
Figure IV - 10).193 The Grignard reagent, prepared from the 1-(bromoethyl)-2-fluorobenzene 
30, reacted with the cyclopropyl cyanide to give the ketone 31. A bromination step followed 
by a substitution led to the formation of 33. A final acetylation step gave Prasugrel 24. 
 
Figure IV - 9. Patented synthesis of Prasugrel. a) Mg, cyclopropyl cyanide, ether, b) Br2, CCl4, c) K2CO3, 
DMF, d) Ac2O, NaH, DMF. 
 
The compound 34 was synthesized by oxidation of the thiophene by the tri-n-butyl borate 
(BuO)3B with butyl lithium n-BuLi and H2O2 in dry THF. The amine had to be protected by a 
trityl group.194 
                                                 
193 WO2009062044A2 
194 US4740510. 
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Figure IV - 10. synthesis of 34. a) Trityl chloride, b) n-Buli, (BuO)3B, H2O2, THF, c) Formic acid, HCl, 
diethyl ether. 
 
Up to now, the Prasugrel has been commercially available as the racemic mixture. However, 
the activity of the two enantiomers is a little bit different and the S enantiomer seems to be 
more active. A workable synthesis of pure S-Prasugrel is therefore a potentially important 
economical issue. 
 
 
 
II - First synthestic route: synthesis of 2-amino-1-cyclopropyl-2-
(2-fluorophenyl)ethanone 
The aim of my work in Syncom BV was to design a new synthesis of S-Prasugrel with a step 
of deracemisation, which is an efficient and relatively cheap method to obtain pure 
enantiomer. 
This synthesis is based on the synthetic route of Clopidogrel developed by Syncom B.V., 
bringing into play the same two key steps: 
 - The formation of the ring by reaction of the pure enantiomer of the amino ketone 37 
with the dibromothiophene derivative 38 (Figure IV - 11). 
 
Figure IV - 11. Retrosynthesis of the pure enantiomer of S-Prasugrel. 
 
 - Deracemisation of the imine 39 by attrition enhanced deracemisation: a screening of 
substituted benzaldehyde will be performed to find a conglomerate (Figure IV - 12). 
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Figure IV - 12. Retrosynthesis of the pure S-enantiomer of the intermediate amine 37. 
 
 
 1. Synthesis of 2-amino-1-cyclopropyl-2-(2-fluorophenyl)ethanone 
The racemic intermediate 2-amino-1-cyclopropyl-2-(2-fluorophenyl)ethanone 37 can be 
synthesized from the racemic 2-fluorophenylglycine 40. The amine group had to be first 
protected195 then the Weinreb amide can be formed by a coupling reaction.196 The cyclopropyl 
ketone was then obtained by reaction with the corresponding Grignard reagent, the 
cyclopropyl magnesium bromide.197 Finally, a deprotection step gave the target amine 
37.HCl. 
 
Figure IV - 13. Synthetic route of the racemic 2-amino-1-cyclopropyl-2-(2-fluorophenyl)ethanone 
hydrochloride. a) Boc2O, NaHCO3, THF, water (quant.), b) CDI, TEA, THF (80%), c) 
cyclopropylmagnesium bromide, THF (83%), d) HCl, methanol (85%). 
 
The synthesis of the Weinreb amide intermediate was necessary to obtain the desired ketone. 
In classical Grignard reactions, ketones are more reactive than the starting carbonyl 
derivatives and, once formed, they are immediately involved in second Grignard reaction to 
give a tertiary alcohol (Figure IV - 14). 
                                                 
195 D. M. Shendage, R. Fro1hlich, G. Haufe; Org. Lett, 2004, 6(21), 3675-3678. 
196 D. E. Levy, F. Lapierre, W. Liang, W. Ye, C. W. Lange, X. Li, D. Grobelny, M. Casabonne, D. Tyrrell, K. 
Holme, A. Nadzan, R. E. Galardy; J. Med. Chem., 1998, 41, 199-223. 
197 M. K. Ghorai, A. Kumar, D. P. Tiwari; J. Org. Chem., 2010, 75, 137-151. 
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Figure IV - 14. Reaction between a carbonyl derivative and a Grignard reagent. 
 
Thanks to the Weinreb amide, the over-addition is avoided by the formation of a stable 
complex involving the methoxy group as drawn on Figure IV - 15.198 
 
Figure IV - 15. Formation of the stable intermediate during the addition of a Grignard reagent on a 
Weinreb amide. 
 
More recently, reactions using the morpholine instead of the Weinreb amide were described. 
The morpholine seemed also to be able to stabilise the intermediate complex and so to avoid 
the formation of the tertiary alcohol. In our case, the same experimental conditions as with the 
Weinreb amide were applied to synthesize the target amine 44, with similar yields. As the 
morpholine was less expensive than the Weinreb amine, the morpholine was used for the 
synthesis. 
 
Figure IV - 16. Modified synthetic route of the racemic 2-amino-1-cyclopropyl-2-(2-fluorophenyl)ethanone 
hydrochloride. a) Boc2O, NaHCO3, THF, water (quant.), b) CDI, TEA, THF (90%), c) magnesium 
turnings, cyclopropyl bromide, THF (83%), d) HCl, methanol (90%). 
 
The amino ketone 37 can be reversibly converted to imines by reaction with aldehydes. 
Compounds derived from an aromatic aldehyde (Schiff bases 39) can be easily racemised by 
using an organic base such as DBU. Therefore a screening of conglomerate with various 
                                                 
198 S. Nahm, S. M. Weinreb; Tetrahedron Letters, 1981, 22(39), 3815-3818. 
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substituted benzaldehyde was carried out and the corresponding imines were analysed by 
SHG. 
 
Figure IV - 17. Reversible synthesis of imines into amide with a deracemisation step. a) RCHO, Na2SO4, 
CH2Cl2, b) BDU, glass beads, acetonitrile, c) HCl, methanol. 
 
Imines 39 can be synthesized from both the hydrochloride salt 37.HCl and the free amine 37. 
As a base, such as triethylamine (TEA), must be added when the hydrochloride salt is used, 
leading to an additional purification step, the free amine 37 was prepared. 37 was easily 
obtained by dissolution of the hydrochloride salt in aqueous NaOH (around 2M). After 
extraction with an organic solvent and evaporation, a pale yellow solid was obtained. 
Unfortunately, 1H NRM analysis revealed that the peak corresponding to the hydrogen of the 
chiral centre is missing (Figure IV - 18). 
 
Figure IV - 18. 
1
H NMR of the hydrochloride amine in methanol-d4 (left), and of the pale yellow solid in 
CDCl3 (right). Peak corresponding the hydrogen of the chiral centre is indicate by an arrow. 
 
Furthermore, peaks of all the other hydrogens are still present and no supplementary peaks are 
visible. Therefore we suspected the formation of the dimer (Figure IV - 19), hypothesis 
supported by the mass spectrometry analysis. 
Water 
Methanol 
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Figure IV - 19. Chemical structure of the dimer. 
 
The dimer was recrystallised in acetonitrile, and some large crystals were cropped. Under a 
microscope, these single crystals exhibited sufficient size and quality for single crystal 
diffraction (Figure IV - 20). 
 
Figure IV - 20. Single crystals of dimer. 
The resolution of the structure was performed and confirmed the existence of the dimer. 
Crystal data are summarized in Table V - 1. The crystal packing presented an uncommon 
feature: the asymmetric unit was composed of two “half” molecules, that is to say  
Z’=2x0.5.199 Each molecule was centred on an inversion centre (located in the centre of the 
pyrazin ring, Figure IV - 21). On one molecule (Mol-A, Figure IV - 21), the fluorine atom 
exhibited a partial disorder on the benzene cycle. The statistical occupancy factor (s.o.f.) for 
this fluorine atom spread over two positions was respectively of 79 % and 21%. 
 
 
 
 
 
 
 
 
                                                 
199 A. J. C. Wilson; Acta Cryst A49, 1993, 795-806. 
250µm 
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 Dimer 46 
Chemical Formula C22H20F2N2 
Molecular Weight / g.mol-1 350.40 
Crystal System Triclinic 
Space group P-1 (n°2) 
Z , Z’ (asymmetric units per unit cell) 2, 2x0.5 
a / Å 9.2668(10) 
b / Å 9.6027(10) 
c / Å 11.3518(12) 
α 65.849(2)° 
β 77.487(2)° 
γ 86.079(2)° 
R factor (with I>2σI) 
R1 = 0.0514 
R2 = 0.134 
V / Å3 899.61(17) 
Table V - 1. Crystal data of the dimer. 
 
 
Figure IV - 21. The two fully regenerated molecules of the asymmetric unit (in light grey the part 
regenerated by the inversion centre - red dot). The molecule to the left exhibits a partial disorder on the 
fluorine atom which is divided onto two positions with s.o.f. of 79% and 21%. 
 
In fact, the instability of the free amino ketone 37 was not surprising, both the carbonyl group 
and the free amine being reactive enough to form the diamine 47. Then the aromatisation 
occurs, being the transformation irreversible (Figure IV - 22). As the hydrochloride salt was 
stable, it was used for the screening of conglomerate. 
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Figure IV - 22. Formation of the dimer. 
 
First, only three different imines were synthesized (39a-c, Figure IV - 23). After evaporation 
of the solvent, mixtures of solid and brown oil were obtained. The 1H NMR analyses revealed 
that the crude product was a mixture of the desired amine 39, the unreacted benzaldehyde and 
the dimer 46 (probably the solid). Moreover, after few hours, imine was totally converted into 
dimer. Both free amino ketone and imines were not stable; the deracemisation of these 
compounds was thus impossible. 
 
Figure IV - 23. Three cyclopropyl imines. 
 
 
 2. Screening of conglomerate 
To avoid the formation of the dimer, a screening of conglomerate was performed by using a 
compound with a less reactive carbonyl group; the morpholine derivative 48. The Boc-
morpholine derivative was first deprotected then amines were synthesized. 
 
Figure IV - 24. Screening of conglomerate from morpholine derivatives. a) HCl, 1,4-dioxane, 94%, b) 
NaOH, water, quant., c) substituted benzaldehyde, NaSO4, CH2Cl2. 
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Before performing the screening of conglomerate, the stability of the free amine 48 was 
tested. The compound was refluxed overnight in acetonitrile then the solvent was evaporated. 
No signals of dimer or degradations were visible on 1H NMR analyses. The stability of this 
compound was thus sufficient for the screening. Ten benzaldehydes, with different 
substituents (nature, number and/or position, Figure IV - 25), were involved in reaction of 
formation of imines. The choice of these benzaldehydes was arbitrary. 
 
Figure IV - 25. Various benzaldehyde derivatives used for the screening of conglomerate. 
 
Compounds with a good purity were easily obtained after synthesis without purification step 
and they were stable (no trace of dimer was visible on 1H NMR analyses). Unfortunately, in 
each case, oil was obtained. Even after one year, samples were still oils. It was thus 
impossible to perform deracemisation. 
Synthesis of imines with the Weinreb amide instead of the morpholine was also carried out 
(Figure IV - 26). Unfortunately, they also were obtained as oils. 
 
Figure IV - 26. Imines synthesised from the Weinreb amide derivative. 
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III - Alternative synthetic route 
 1. Synthesis of 2-fluorophenylglycinamide 
For the synthesis of Clopidogrel, all the amines prepared for the screening of conglomerate 
were crystalline. These compounds were obtained from the 2-chlorophenylglycinamide 27. 
Therefore we decided to modify the synthesis to include the screening of conglomerates from 
the 2-fluorophenylglycinamide 51, hoping to have the same crystalline behaviour for the 
fluorinated imines than for the chlorinated imines. 
 
Figure IV - 27. Screening of conglomerates from the 2-chlorophenyglycinamide (left) and of the 2-
fluorophenyglycinamide (right). 
 
The same synthetic route was followed to carry out the screening of conglomerate (see Figure 
IV - 8): the 2-fluorophenylglycine 40 was first converted to the 2-fluorophenylglycinamide 51 
then a small library of imines was synthesized by using various substituted benzaldehydes 
(52a-j, Figure IV - 28). 
 
Figure IV - 28. Screening of conglomerate from the 2-fluorophenylglycinamide. a) SOCl2, MeOH (95%), 
b) NH3 30% in water (70%), c) substituted benzaldehyde, NaSO4, CH2Cl2, d) DBU, glass beads, 
acetonitrile, e) HCl, acetone. 
 
 
 
 2. Screening of conglomerates 
Ten benzaldehydes with different substituents (nature, number and/or position, Figure IV - 
25) were arbitrary chosen then involved in reaction of formation of imines. The results of 
SHG measurements are summarized in Table V - 2: 
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 52a 52b 52c 52d 52e 
Aromatic 
aldehyde 
     
SHG positive signal 
negative 
signal 
negative signal 
weak positive 
signal 
positive signal 
 
 52f 52g 52h 52i 52j 
Aromatic 
aldehyde 
    
 
SHG negative signal oil positive signal 
weak positive 
signal  
negative signal 
Table V - 2. SGH measurements of the small library of imines. 
 
Among the ten imines, three exhibited a positive signal in SHG, 52a, 52e and 52h, and could 
therefore crystallise as conglomerate.  
Unfortunately, because a lack of time and product (SHG analyses were performed one week 
before I went back in France), we had the possibility to try the deracemisation (and so to 
confirm the crystallisation as a conglomerate) of only one of these three compounds. We 
decided to work with the benzaldehyde derivative for two reasons: 
 - Benzaldehyde was cheaper than the 4-(trifluoromethyl)benzaldehyde and the 2,4-
dichlorobenzaldehyde. 
 - The imine 26, derived from the 2-chlorophenylglycinamide and benzaldehyde 
crystallised as a conglomerate. As we demonstrated in the previous chapter that it was 
possible for a series of compounds to exhibit the same crystal packing. We hoped that a same 
kind of pocket also exists for this series. 
After synthesis of the imine 52a, its deracemisation was tested. The compound 52a (1g) was 
dissolved in acetonitrile (5g) at 50°C then BDU (17%) and glass beads (Ø2mm, 2.5g) were 
added. The reaction mixture was vigorously stirred and the temperature was slowly decreased 
to 20°C for 5h. The mixture was stirred an additional night at 20°C; the enantiomeric excess 
of the final solid phase was >99%. The deracemisation has been achieved; 52a did crystallise 
as a conglomerate. Furthermore, XRPD patterns of the racemic mixture and of the pure 
enantiomer were superimposable (Figure IV - 29). 
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Figure IV - 29. Superimposed XRPD patterns of the racemic (in black) and of the pure enantiomer (in 
red) of 52a. 
 
However, the yield of the deracemisation was very low since only 138mg (14%) of solid were 
harvested. This experiment was carried out just to determine if the deracemisation of this 
imine was possible without optimising the experimental conditions. The solubility was not 
known, that may explain the low yield. The optimisation of parameters was carried out in 
Rouen and are described in the following paragraph. 
 
 
 
IV - Deracemisations 
 1. Determination of the solubility of the imine 
One of the first experiments was the determination of the solubility of the imine 52a in 
several solvent, and particularly in acetonitrile, to optimise the parameters of the 
deracemisation. 
 
  a. Solubility in acetonitrile 
The solubility of 52a was determined by using the gravimetric method, at two different 
temperatures: 25°C (Table V - 3) and 50°C (Table V - 4). 
 
Mass of 
saturated solution 
Mass of solid Solubility 
Average 
solubility 
1 0.79170g 0.08904g 11.25% 
11.1% 2 0.87911g 0.09658g 10.99% 
3 0.88336g 0.09824g 11.12% 
Table V - 3. Solubility of 52a in acetonitrile at 25°C. 
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Mass of 
saturated solution 
Mass of solid Solubility 
Average 
solubility 
1 0.84660g 0.27906g 32.96% 
32.9% 2 0.95627g 0.31537g 32.98% 
3 0.95914g 0.31491g 32.83% 
Table V - 4. Solubility of 52a in acetonitrile at 50°C. 
 
29a has a solubility of 11.1% in acetonitrile at 25°C. This value can explain why the yield of 
the preliminary deracemisation was so low. 1g of 52a and 5g of acetonitrile were used. At 
25°C, and assuming that the DBU did not modify the solubility, 632mg of 52a was dissolved 
and so only 368mg were in the solid phase. Therefore the theoretical maximal yield is 36.8% 
at 25°C and so higher at 20°C, the final temperature of the preliminary experiment. However, 
the yield was 14%. The solubility alone cannot explain the low yield and the origin of the 
problem must be finding elsewhere. 
 
  b. Solubility in tertbutylmethylether 
The tertbutylmethylether (TBME) was used to wash the solid to remove all the DBU. If the 
solubility of the imine in TBME was not negligible, a part of the solid phase was dissolved, 
decreasing the yield of the deracemisation. The solubility of 52a in TBME was thus measured 
at 25°C. 
 
Mass of 
saturated solution 
Mass of solid Solubility 
Average 
solubility 
1 0.64165g 0.00041g 0.06% 
0.1% 2 0.61730g 0.00040g 0.06% 
3 0.70429g 0.00034g 0.05% 
Table V - 5. Solubility of 52a in TBME at 25°C. 
 
The imine was almost insoluble in TBME. TBME was so a good solvent to remove the DBU 
without dissolving the imine. 
 
 c. Solubilities in other solvents 
The solubility of imine 52a was studied at 25°C for four additional solvents: ethyl acetate, 
ethanol, n-heptane and tetrahydrofurane THF (Table V - 6). 
Solvent Solubility 
n-Heptane 0.0% 
Ethanol 4.7% 
Ethyl acetate 5.8% 
THF 23.6% 
Table V - 6. Solubilities of 52a in different solvents at 25°C. 
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The solubility of 52a in ethyl acetate and ethanol is around 5%; these values of solubilities are 
acceptable to perform a deracemisation; the amount of product in solution at the end of the 
experiment being quite low, but sufficient to ensure the exchange of matter. 
The imine is totally insoluble in n-heptane which can be therefore used as anti-solvent if 
necessary. The solubility in THF is too high to perform deracemisation in good conditions; 
too much product is dissolved in the liquid phase. 
 
 
 2. Optimisation of the experimental conditions 
In acetonitrile, the solubility is 32.9% at 50°C, that is to say that, for example, that 2.454g of 
52a can be dissolved in 5g of solvent. If the final temperature of the deracemisation is 25°C 
(solubility = 11.1%), the solid phase is composed of 1.898g of 52a, giving a theoretical 
maximal yield of 77%. The next deracemisations were carried out by using these conditions. 
2.454g of 52a were dissolved in 5g of acetonitrile at 52-53°C then the temperature was 
adjusted to 50°C. Glass beads (5g) and DBU (0.425g) were added then the mixture was 
cooled down to 25°C in 5h (5°C.h-1) under a vigorous stirring. After 30 additional minutes at 
25°C, the solid was filtered, washed with TBME (3x) then dried. 1.059g of solid was 
harvested, giving a yield of 58%, with an enantiomeric excess over 97%. 
The yield increased compare to the first deracemisation but it was always lower than the 
theoretical yield (77%). 30 minutes at 25°C were maybe not sufficient to reach the 
equilibrium state; the entire solid had no had time to precipitate. 
Two other experiments, A and B, were carried out in parallel, in the same conditions, except 
for the duration of the stirring at 25°C: the deracemisation A was stirred for one night whereas 
the deracemisation B was stirred for 3 days at 25°C (Table V - 7). 
 52a DBU 
Blass 
beads 
CH3CN 
Cooling rate 
50°C → 25°C 
Time at 25°C Yield e.e. 
A 4.908g 0.3eq 10g 10g 5°C.h-1 One night 29% >96% 
B 4.908g 0.3eq 10g 10g 5°C.h-1 3 days 58% >99.5% 
Table V - 7. Experimental conditions of the two deracemisations A and B. 
 
In the two cases, the final enantiomeric excess was very good; the peak of the second 
enantiomer was not detected in the case B in chiral HPLC. However, the yield of the 
deracemisation was not improved. It was even twice lower in the case A, experimental 
conditions (starting material, temperature…) being the same. Moreover, these results 
contradicted themselves: yields were the same when the mixture was stirred for 30 minutes or 
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for 3 days at 25°C but it was lower when the mixture was stirred for one night. The duration 
of stirring at 25°C was therefore not a factor affecting the yield but it was necessary to reach 
an enantiomeric excess of 100%. 
Other experiments were carried out from 50°C to 20°C (keeping identical the other 
experimental conditions) in order to increase the yield. Unfortunately, it was not increased; 
yields between 20% and 55% were obtained. Moreover, in one case, no solid had precipitated, 
even after seeding at 20°C then evaporation of a part of the solvent. 
Furthermore, it was impossible to isolate the imine from the filtrate. When the solvent was 
evaporated, oil was obtained: a mixture of imine and DBU. Addition of anti solvent (such as 
TMBE or n-heptane) to the filtrate or trituration of the oil with solvents did not ensure the 
crystallisation of the compound. 
The imine seemed to be difficult to separate from the DBU. The amount of base was thus 
decreased; 0.15 equivalent of base was used instead of 0.30 equivalent. Unfortunately, after 
four days at 20°C, the enantiomeric excess was only 75% with 38% yield and that did not 
make easier the separation of the imine and the DBU. Furthermore, besides the fact that the 
yield was not improved, the enantiomeric excess of the solid phase was low. A diminution of 
the ratio of base was thus not the key factor to increase the productivity of the process. 
 
 
 
V - Study and characterisation of the different solid phases of the 
2-(benzylideneamino)-2-(2-fluorophenyl)acetamide 
For all these experiments, synthesis and deracemisations, the powders were analysed by X ray 
diffraction. In most cases, 52a crystallised as a conglomerate. Nevertheless, in two cases, 
different XRPD patterns were obtained, resulting in the crystallisation of different phases: a 
monohydrate and an undetermined phase. These different phases were analysed by TGA-DSC 
and thermal TR-XRPD (temperature resolved X-ray powder diffraction). Moreover, the 
crystal structures of the conglomerate and of the monohydrate were resolved. 
The existence of these two phases could disturb the crystallisation of the pure enantiomer for 
deracemisations and therefore could explain the low yields. 
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 1.  Study of the conglomerate 
  a. Resolution of the structure 
No single crystals of the conglomerate were obtained. However, the structure of a similar 
compound, the 2-(benzylideneamino)-2-(2-chlorophenyl)acetamide 26, was already described 
in the literature.100  
 
Figure IV - 30. Chemical structures of the 2-(benzylideneamino)-2-(2-chlorophenyl)acetamide 26 and of 
the 2-(benzylideneamino)-2-(2-fluorophenyl)acetamide 52a. 
 
The crystal data were downloaded on the CSD database (available under the reference code 
OHODUL) then the chlorine atom was replaced by a fluorine atom in the crystal structure. If 
these two compounds crystallised in similar crystal packings, the calculated XRPD of the 
fluorinated compound 52a resulting of the refinement of the structure parameters were the 
same than the experimental one. If XRPD were not superimposable, that means that the 
fluorinated compound 52a did not crystallise in the same packing that the chlorinated 
compound 26. The superimposition of the calculated and the experimental XRPD are shown 
on Figure IV - 31: they match perfectly. Therefore these two compounds crystallised in the 
same crystal packing. The cell parameters of 26 and 52a are summarised in Table V - 8.  
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Figure IV - 31. Superimposition of experimental (in blue) and calculated (in red) XRPD patterns of the 2-
(benzylideneamino)-2-(2-fluorophenyl)acetamide 52a, and of the calculated XRPD pattern of the 2-
(benzylideneamino)-2-(2-chlorophenyl)acetamide 26 (in black). 
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 26 52a 
Chemical Formula C15H13ClN2O C15H13FN2O 
Molecular Weight / g.mol-1 272.73 256.27 
Crystal System Monoclinic Monoclinic 
Space group P21 P21 
Z , Z’ (asymmetric units per unit cell) 2, 1 2, 1 
a / Å 8.454(7) 8.814(5) 
b / Å 5.082(4) 5.105(12) 
c / Å 14.886(13) 14.509(18) 
β / ° 102.430(13) 103.821(0) 
V / Å3 624.559 633.937 
dcalc / g.cm
-3 1.45 1.34 
Table V - 8. Unit cell parameters of 26 (from CSD database) and 52a (obtain from routine XRPD). 
 
The unit cell parameters of the fluorinated imine 52a are bigger than the cell parameters of the 
chlorinated imine 26, that is in contradiction with the relative length of the halogens-carbon 
bonds; C-F bonds are shorter than C-Cl bonds. The refinement of the structure was limited by 
the quality of the XRPD pattern, which was sufficient to obtain the crystal lattice but not to 
obtain the best cell parameters. 
The asymmetric unit was built from one molecule of the 2-(benzylideneamino)-2-(2-
fluorophenyl)acetamide 52a (Figure IV - 32). 
 
Figure IV - 32. Asymmetric unit of the 2-(benzylideneamino)-2-(2-fluorophenyl)acetamide 52a in the P21 
space group. 
 
The asymmetric units interacted together by means of hydrogen bonds formed with -C=O and 
-NH2 of amide groups of two different molecules. In one molecule, both C=O and NH2 group 
were involved in hydrogen bonds with two different molecules, generating infinite ribbons 
along b axis (Figure IV - 33). The length of the hydrogen bonds was 2.0 Å. 
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Figure IV - 33. Infinite ribbons along b axis generates by means of hydrogen bonds (dashed pink lines). 
 
The cohesion between molecules in these ribbons was reinforced by means of two kinds of π-
interactions between two consecutive unsubstituted rings and two consecutive fluorinated 
rings (Figure IV - 34). The distance between to consecutive cycles was 3.6 Å. 
 
Figure IV - 34. π-interactions between two aromatic rings. 
 
Ribbons were connected between them by means of π-interactions in T-shape (Figure IV - 
35). The unsubstituted aromatic rings were interacting in the (001) plan (dashed green lines) 
whereas the fluorinated aromatics rings were interacting along the b axis (dashed blue lines). 
The distances between two consecutive rings were 3.97 Å and 3.84 Å, respectively and the 
angles were 78° and 81°, respectively. 
 
Figure IV - 35. π-interactions between ribbons. One ribbon is encircled in red. 
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  b. Thermal analysis 
DSC analyses of the pure enantiomer and of the racemic conglomerate were performed 
(Figure IV - 36). As expected, the melting point of the pure enantiomer (117.5°C) was higher 
than the melting point of the racemic conglomerate (113.2°C). However, the difference 
between these two temperatures was lower than usual since only 4.2°C were detected. Both 
racemic conglomerate and pure enantiomer were stable up to the melt. 
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Figure IV - 36. DSC analyses of the racemic conglomerate (in red) and of the pure enantiomer (in black). 
Heating rate: 5K/min from 30°C to 140°C. 
 
 
 2. Study of the unknown phase 
  a. X Ray diffraction analyses 
At the end of one synthesis of the imine, a different XRPD pattern was obtained. The 
superimposition of XRPD patterns revealed that it was a mixture of phases: the conglomerate 
and an unknown phase (Figure IV - 37). 
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Figure IV - 37. Superimposition of XRPD of the conglomeate (in black), the monohydrate (in red) and of 
the mixture of conglomerate and of the new phase (in blue). 
Peak: 117.3°C 
Onset: 113.2°C 
End: 120.0°C 
Peak: 120.8°C 
Onset: 117.5°C 
End: 122.6°C 
Synthesis of pure enantiomer of Prasugrel by deracemisation 
 
- 201 - 
1H NMR revealed that additional peaks were present in the aromatic zone. The imine was thus 
not pure. But only ≈5% of impurity(ies) were present so it was difficult to assume that the 
additional peaks on the XRPD pattern, and most particularly concerning the first large peak, 
were due to this impurity only. 
The stability of this phase was then studied in acetonitrile. A suspension of this powder was 
stirred in acetonitrile at 25°C. After three days, the powder was analysed: no evolution was 
visible. Therefore the unknown phase was also stable in acetonitrile and cannot be easily 
converted into the conglomerate. 
As this phase was not pure, it was impossible to have access to structural characteristics and 
no single crystals were obtained. 
 
  b. Thermal analyses 
In order to determine the thermal behaviour of this mixture of phases, a DSC analysis was 
carried out and was compared to the DSC curve of the racemic conglomerate. 
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Figure IV - 38. Superimposition of DSC analyses of the racemic conglomerate (in red) and of the mixture 
of phases (in blue), from 30°C to 140°C (5°C/min). 
 
Two phenomena occurred and something rather surprising appeared: the melting point of the 
conglomerate was missing while the conglomerate was present in the starting material. In 
order to better understand what happened during the heating, the evolution of the crystalline 
structure was monitored by TR-XRPD (Figure IV - 39). 
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Figure IV - 39. Evolution of the crystalline phase over temperature. Superimposition with the 
conglomerate (in black). In red, the XRPD pattern of the mixture between the conglomerate and the 
unknown phase. 
 
Between 81°C and 91°C, a first phenomenon occurred. The unknown phase disappeared but 
seemed not to be converted into the conglomerate phase; the base line of the diffractogramme 
became less well defined, most probably due to the melting of the unknown phase. The 
melting of the conglomerate occurred between 91° and 101°C. 
These two phenomena and their corresponding temperatures were in accordance with the 
DSC analysis of the mixture of phases; the second endothermique peak on the DSC curve was 
therefore due to the melt of the conglomerate. However it was different than the melting point 
of the pure racemic conglomerate (Figure IV - 36); the chemical impurity may sufficiently 
disturb the behaviour of the conglomerate to decrease its melting point. 
 
 
 3. Study of the monohydrate 
  a. Resolution of the structure 
The imine 52a used for the solubility was recovered in a large beaker by using acetonitrile. 
The solvent was then evaporated under room conditions and single crystals appeared (Figure 
IV - 40).  
 
Figure IV - 40. Crystals appears in the beaker. 
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Few of them were kept for the resolution of the structure, the rest was milled. X ray 
diffraction analyses on the powder highlighted the existence of a new phase which did not 
match with the conglomerate, as expected (Figure IV - 41).  
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Figure IV - 41. XRPD patterns of conglomerate (in black) and of the monohydrate (in red). 
 
The resolution of the structure from single crystals revealed that this phase corresponds to the 
crystallisation of the monohydrate of the imine 52a. The asymmetric unit was made of one 
molecule of imine and one molecule of water (Figure IV - 42). 
 
Figure IV - 42. Asymmetric unit of the monohydrate. 
 
The crystal data are given in Table V - 9. The monohydrated form crystallised in P21/c space 
group, a centrosymmetric space group. Therefore the monohydrated form did not crystallise 
as a conglomerate. 
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 52a.H2O 
Chemical Formula C15H15FN2O2 
Molecular Weight / g.mol-1 274.29 
Crystal System Monoclinic 
Space group P21/c 
Z , Z’ (asymmetric units per unit cell) 4, 1 
a / Å 13.9829(14) 
b / Å 6.6374(7) 
c / Å 15.8034(15) 
β / ° 100.202(2) 
V / Å3 1443.5(3) 
R factor (with I>2σI) 
R1 = 0.0659 
wR2 = 0.1907 
dcalc / g.cm
-3 1.262 
Table V - 9. Crystal data of the monohydrate form. 
 
Imines were connected between them through hydrogen bonds with H2O: homochiral ribbons 
were generated by the 21 screw axis parallel to the b axis (Figure IV - 43). One imine was 
interacting with three molecules of water, and one molecule of water formed hydrogen bonds 
with three different molecules of imine. The length of hydrogen bonds was circa 2 Å. 
 
Figure IV - 43. Infinite homochiral ribbons along b axis generates by means of hydrogens bonds with 
water (dashed pink lines). 
 
Homochiral ribbons were connected between them by means of π-interactions (dashed green 
lines) and π-interactions in T-shape (dashed blue lines). Heterochiral dimers were formed by 
these two kinds of π-interactions (Figure IV - 44). 
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Figure IV - 44. Interactions between homochiral ribbons by means of π-interactions. One homochiral 
ribbon is circled in red and one heterochiral dimer is circled in black. 
 
The infinite ribbons, connected together by means of π-interactions, were creating 
heterochiral slices parallel to the (102) plane of the crystal lattice (Figure IV - 45). 
 
Figure IV - 45. Heterochiral slices creating by hydrogen bonds and π-interactions. 
 
 
  b. Relative stability in solution 
The stability of the monohydrate was studied in acetonitrile, the solvent of the deracemisation. 
A suspension of monohydrate was stirred in acetonitrile at 25°C. After three days, the powder 
was analysed: the monohydrate was totally converted into the conglomerate. Therefore the 
monohydrate was not stable in the conditions of the deracemisation and mustn’t be the reason 
why the yields are so low. 
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Figure IV - 46. Superimposition of the XRPD patterns of the conglomerate (in blue) and of the 
monohydrate before (in red) and after (in black) the stirring in acetonitrile. 
 
 
  c. Thermal analyses 
The TGA-DSC of the monohydrate was carried out. The mass of the sample decreased during 
the analysis, corresponding to the departure of water molecules. However, the mass loss was 
only 5.7% whereas the theoretical mass loss was 6.5%. The monohydrate was most probably 
not pure which may explain a part of the number of phenomena that occurred during the 
analysis. 
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Figure IV - 47. TGA-DSC analysis of the monohydrate from 30°C to 140°C (5°C/min). 
 
To better understand what happened during the heating, the evolution of the crystalline 
structure was followed by X ray diffraction. The results are drawn on Figure IV - 48 
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Figure IV - 48. Evolution of the crystalline phase over temperature. Superimposition with calculated 
XRPD patterns of the monohydrate (in red) and of the conglomerate (in black). In blue, the XRPD pattern 
of the mixture between the conglomerate and the unknown phase. 
 
First, we can notice that the starting monohydrate phase was not pure since additional peaks 
are visible compared to the calculated XRPD. Several phenomena on the DSC curve were 
therefore not only due to the thermal behaviour of the monohydrate phase. The main impurity 
was clearly detected by a peak at circa 6θ; one peak disappeared when another one 
(corresponding to the conglomerate) appeared. This peak may correspond to the unknown 
phase. However, as the characteristics of this phase remained undetermined, it was difficult to 
conclude. 
Secondly, all the starting material, that is to say the monohydrate and the impurity, was 
converted into the conglomerate at 80°C. Therefore the conglomerate can be considered as the 
stable form at high temperature. 
The DSC analyses of the monohydrate and of the racemic conglomerate were compared 
(Figure IV - 49): as the monohydrate was converted into the conglomerate, the last 
phenomenon should correspond to the melt of the racemic conglomerate (113.2°C). 
Unfortunately, it was not the case since the last phenomenon occurred at 109.5°C. This 
difference may be explained by the presence of impurities not detected on XRPD patterns. 
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Figure IV - 49. Superimposition of DSC analyses of the racemic conglomerate (in red) and of the 
monohydrate (in blue), from 30°C to 140°C (5°C/min). 
 
 
 
 4. Comparisons between structures 
TR-XRPD of the monohydrate has shown that the monohydrate was converted into the 
conglomerate at circa 80°C. Therefore, structures of these two phases were compared to 
understand how the conversion can occur; if filiations exist between the two structures or if it 
is a total destructive/reconstructive mechanism. 
By comparing the projections along the b axis, high similarities were observed: ribbons along 
the b directions were generated by a 21 screw axis and molecules were connected by means of 
hydrogen bonds (Figure IV - 50). 
 
Figure IV - 50. Projections along b axes of the conglomerate (left) and of the monohydrate (right). One 
ribbon is encircled in red and one “dimer” is encircled in black. 
 
No dimer existed in the structure of the conglomerate but the relative position of the aromatic 
rings shew similarities with the structure of the monohydrate: π interactions between the two 
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unsubstituted rings also existed. We can imagine that the departure of water molecules move 
closer the molecules of imine to form hydrogen bonds between the amide groups, breaking 
the dimers. However, such mechanism cannot lead to the crystallisation of a conglomerate 
since the two enantiomers are present inside the crystal structure. 
 
The case of this imine is very similar to another one previously studied in the laboratory. In 
2011, Amharar et al. described the dehydration mechanism of a hydantoin derivative, the 5-
methyl-5-(4’-ethylphenyl)hydantoin.200 This compound crystallises as an anhydrous 
conglomerate (called C-18H) and a monohydrate racemic compound (HR-18H). A third 
phase, an anhydrous racemic compound (AR-18H) also exists. The three structures exhibit 
homochiral molecular ribbons generated by hydrogen bond networks (Figure IV - 51).  
 
Figure IV - 51. Hydrogen bond networks and resulting molecular ribbons in the crystal structures of the 
anhydrous conglomerate (left) and the monohydrate racemic compound (middle) and of the anhydrous 
racemic compound (right).
200
 
 
The authors studied the relative stability of these three phases. HR-18H can be reversibly 
converted to AR-18H, but the both transformation toward C-18H is irreversible (Figure IV - 
52). 
 
Figure IV - 52. Experimental conditions required for solid-solid transformations between HR-18H, AR-
18H and C-18H.
200 
 
To explain the reversible transformation from HR-18H to AR-18H, Amharar et al. proposed a 
zip-mechanism; a nondestructive and cooperative mechanism as illustrated on Figure IV - 53. 
                                                 
200 Y. Amharar, S. Petit, M. Sanselme, Y. Cartigny, M.-N. Petit, G. Coquerel; Cryst. Growth Des., 2011, 11(6), 
1453-2462. 
Synthesis of pure enantiomer of Prasugrel by deracemisation 
 
- 210 - 
The departure of water along the b axis enable the two parts of the ribbon initially hydrated to 
join them to form a new anhydrous ribbon, inducing a persistence of the main structural 
features of the crystal lattice. 
 
Figure IV - 53. Schematic representation of the probable dehydration mechanism from HR-18H to AR-
18H through a zip-mechanism. 
 
One the other hand, a destructive/reconstructive mechanism was proposed to explain the 
transformation of HR-18H into C-18H, in which water molecules acts as plasticizer (Figure 
IV - 54). “The progressive departure of water produces a highly defective crystal packing of 
18H that can be assimilated to an amorphous phase, and the presence of residual water in 
this intermediate zone could facilitate the crystallisation of the conglomerate.” 
 
Figure IV - 54. Schematic representation of the hypothetical mechanism for the transformation between 
HR-18H and C-18H. The bold arrow indicates the direction of propagation of the interface.
200
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These mechanisms could explain the solid-solid transition observed by TR-XRPD analyses, 
the similarities between the imine 52a and the 18H being significant: 
 - Existence of three phases including an anhydrous conglomerate and monohydrate 
racemic compound. 
 - The conglomerate is the stable phase. 
 - Formation of homochiral molecular ribbons generated by hydrogen bond networks. 
However, additional experiments, such as DVS analysis and study of the relative stability of 
the three phases of 52a must be carried out to conclude. The determination of the structure of 
the unknown phase could also give relevant information. 
 
 
 
VI - Conclusion 
The synthesis of Prasugrel as pure enantiomer was found more difficult than anticipated, 
mainly because the instability of the amino ketone 37 leading to the formation of the stable 
dimer 46 and because of the formation of oils (48a-j and 48a-c). 
The deracemisation by attrition of the imine 52a has been achieved; the final enantiomeric 
excess was very good (>95%) but the yield was poor (between 20% and 55%). A screening of 
organic base could be carried out to find better experimental conditions, but the main issue is 
most probably the existence of the undetermined phase which is also stable in acetonitrile. 
The determination of the stability domains of the conglomerate and of the undetermined phase 
in acetonitrile, and the building of the ternary phase diagram could be a good way to improve 
the experimental conditions of the deracemisation. 
Two other imines, 52e and 52h, gave a positive signal in SHG. If these two compounds 
effectively crystallise as conglomerate, they could be a good alternative to by-pass the 
existence of several competitive solid phases of 52a and to increase the productivity of the 
deracemisation step. 
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This work was dedicated to chirality, and how crystallisation can be an efficient tool for the 
discrimination and the production of pure enantiomers of active pharmaceutical ingredients. 
 
A small library of β-cyclodextrins with an acidic or basic hook was synthesized with success. 
The selectivity of the syntheses was satisfactory but the purification was quite difficult, 
probably due to the ability to the cyclodextrins to form inclusion complexes. Analyses 
highlighted that a large range of hydrates exists for these cyclodextrins derivatives that can 
explain the difficulty to obtain well crystalline phases as well as suitable single crystals. The 
study of inclusion complexes by using the monosubstituted β-cyclodextrins has only just 
started and no chiral discrimination was yet observed even if the formation of inclusion 
complexes was confirmed. The optimisation of experimental conditions, and particularly the 
determination of the host/guest/solvents phase diagrams, may rationalise the chiral 
discrimination. 
 
The second part of the thesis was devoted to the enantioamplification by means simultaneous: 
i) Crystallisation of a stable conglomerate. ii) Fast racemisation in solution and iii) 
Breakage/dissolution/recrystallisation of particles in suspension undergoing a flux of energy 
(glass beads or ultrasounds or temperature cycling). 
Unfortunately, it is currently impossible to predict if a racemic mixture crystallises as a 
conglomerate or not, but it appears that limited modifications of the substituents of a 
compound which crystallises as a stable conglomerate can lead to a series of conglomerate 
forming systems. If they are not isostructural, they, at least, show extensive structural 
similarities in their crystal packings. Compounds of a such series behave as if a pocket exists, 
in which substituents can be modulated without impairing the full chiral discrimination of the 
crystal packing. 
The study of the evolution of the crystal size distribution during the deracemisation process 
with glass beads or with ultrasounds led to spot the following features: 
 - A random delay in the “irreversible” evolution of the enantiomeric excess exists at 
the beginning of the process (if there is no initial enantiomeric excess and if the crystal size 
distribution of the two enantiomers is identical). This emphasises the stochastic character of 
the deracemisation. 
 - The crystal size distribution is dependent on the mechanical energy transfered to the 
system but not on the enantiomeric excess of the solid phase. 
General Conclusion 
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 - The fast kinetics induced by ultrasounds are consistent with the important role of the 
formation and recapture of the clusters, i.e. a high number of clusters are produced by 
ultrasounds and they can be immediately dissolved or be recaptured by docking on the 
surfaces of crystals with the same handedness, therefore speeding up the transfer of matter. 
 - The effect of the supersaturation induced by the local heating due to ultrasounds, and 
more, by the temperature cycles, cannot be neglected. The resulting entrainment effect must 
be taken in account to explain how the deracemisation process works and is particularly 
consistent with its autocatalytic character. 
In order to achieve the total symmetry breaking, the use of ultrasounds instead of glass beads 
makes easier the process (the kinetics are faster, the size of reactor is reduced and the work up 
is easier) and the final size of the particles can be chosen. Those features are important for an 
industrial application. 
 
 
 - 217 - 
 
 
 
 
 
 
 
Résumé en français 
 
 

Résumé en français 
 
- 219 - 
Introduction Générale 
Même si la chiralité et ses conséquences sur les êtres vivants sont connues depuis de 
nombreuses années, les industries pharmaceutiques n’ont commencé à s’intéresser aux 
différents effets des deux enantiomères d’un composé actif que depuis la fin des années 80. 
L’accès aux énantiomères purs est alors devenu un enjeu scientifique et économique 
considérable. C’est dans ce cadre que l’Union européenne a lancé en 2008 un programme 
appelé IntEnant, rassemblant les différentes compétences de plusieurs laboratoires européens. 
Le laboratoire SPCMIB de l’Université de Toulouse et le laboratoire SMS de l’Université de 
Rouen, dans lesquels j’ai effectué ma thèse, étaient tous deux membres de ce programme. 
Leurs principales compétences, respectivement la synthèse organique et la purification par 
cristallisation, ont ainsi été combinées afin d’apporter une nouvelle contribution à l’accès 
d’énantiomères purs. 
Les voies d’obtention d’énantiomères purs les plus utilisées et les plus productives sont les 
dédoublements de mélanges racémiques par cristallisation, telles que le dédoublement 
pasteurien. Afin d’élargir le champ d’action de ce type de purification, de nouveaux sélecteurs 
chiraux, basés sur des cyclodextrines monosubstituées, ont été synthétisés. Un motif acide ou 
basique a été greffé sur les cyclodextrines afin d’augmenter la discrimination entre les deux 
énantiomères. L’étude de la formation de complexes d’inclusion a été initiée. 
Une autre méthode d’obtention d’énantiomères purs, appelée déracémisation ou rupture totale 
de symétrie, a récemment été décrite. Cette méthode est très prometteuse car elle permet 
d’obtenir l’énantiomère désiré avec un rendement de 100% en une seule étape. 
Malheureusement, les limitations inhérentes à ce procédé sont importantes et seuls les 
composés cristallisant comme des conglomérats (environ 5% des composés) et facilement 
racémisables dans les mêmes conditions peuvent être utilisés. 
La cristallisation sous forme de conglomérat est actuellement imprévisible. Cependant, 
certaines familles de composés organiques ont une grande tendance à cristalliser de cette 
façon. Dans ce manuscrit, deux nouvelles familles de molécules ayant un tel comportement 
seront présentées. 
De plus, le mécanisme rendant possible la transformation progressive d’une suspension 
racémique en une suspension d’énantiomère pur, n’a toujours pas été totalement élucidée. Le 
troisième chapitre de cette thèse y apportera quelques éclaircissements, notamment grâce à la 
mise au point et à l’étude de la déracémisation par les ultrasons. 
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I - La chiralité et la séparation d’énantiomères 
 1. Généralités 
Le mot “chiral” a été introduit pour la première fois par Lord Kelvin, en 1884: “J’appelle 
chiral toute figure géométrique ou tout ensemble de points qui n’est pas superposable à son 
image dans un miroir. Je parle alors de chiralité. “201 
Une molécule et son image dans un miroir sont appelées “énantiomères“ et sont dites 
“chirales“ lorsqu’elles ne sont pas superposables. Dans le cas contraire, elles sont dites 
“achirales“. 
 
Figure 1. La main droite et la main gauche sont images l’une de l’autre dans un miroir mais ne sont pas 
superposables ; elles sont donc chirales. 
 
Comme deux énantiomères sont images l’un de l’autre dans un miroir, ils possèdent les 
mêmes propriétés physiques (température de fusion, solubilité…) et les même réactivités 
envers des molécules achirales. Par contre, ils peuvent posséder des réactivités différentes vis 
à vis d’autres molécules chirales. 
Le corps humain est composé de nombreuses molécules chirales (protéines, ADN...). Deux 
énantiomères pourront donc avoir un comportement différent. Par exemple leurs odeurs 
pourront être différentes. 
OH
H
O
HO
H
O
(R)-(-)-methylbutanoic
acid
(S)-(+)-methylbutanoic
acid
(R) (S)
 
Figure 2. Les différentes odeurs des deux énantiomères de l’acide 2-methylbutanoïque.
 202
 
 
Ce comportement est aussi valable pour les composés pharmaceutiques et l’administration 
d’un mélange racémique peut avoir des conséquences graves. Un cas tristement célèbre est 
celui de la thalidomide.203 Ce médicament a été la cause de nombreuses malformations graves 
de foetus dans les années 1950 et 1960, l’un des énantiomères étant tératogène. 
 
                                                 
201 Lord Kelvin; Baltimore Lectures on Molecular Dynamics and the Wave Theory of Light 1884. 
202 M. H. Boelens, H. Boelens, L. J. van Gemert, P. & F., 1993, 18(6), 1-15. 
203 B. K. Patel, A. J. Hutt; Chirality in Drug Design and Development 2004, Chap. 5, I. K. Reddy, R. Mehvar, 
Eds, New-York, Marcel Dekker Inc. 
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Les médicaments énantiomériquement purs sont principalement obtenus par : 
 - Synthèse à partir du pool chiral (45%). 
 - Synthèse énantiosélective (9%). 
 - dédoublement d’un mélange racémique : cristallisation, chromatographie... (46%) 
 
 
 2. La déracémisation 
La déracémisation, aussi appelée rupture totale de symétrie, est une méthode d’obtention 
d’énantiomères purs récemment developpée. Elle permet la transformation progressive d’un 
mélange racémique en énantiomère pur désiré, en une seule étape, avec un rendement de 
100%. C’est donc une technique de dédoublement très puissante. Malheureusement, les 
limitations inhérentes à cette méthode sont importantes car trois conditions doivent être 
respectées : 
 - le composé doit cristalliser sous forme de conglomérat, 
 - le composé doit être facilement racémisable en solution, 
 - ces deux conditions doivent être compatibles dans les mêmes conditions opératoires. 
Dans un conglomérat, les deux énantiomères cristallisent séparément, rendant possible la 
discrimination totale à l’état solide. Malheureusement, ce type de cristallisation représente 
moins de 10% des cas et il est souvent difficile à combiner avec une racémisation en solution. 
 
  a. La découverte de la déracémisation 
La première observation de rupture totale de symétrie a été faite par Kipping et Pope en 1898 
en étudiant la cristallisation de NaClO3.204,205 Ce composé inorganique, bien qu’achiral, 
cristallise dans le groupe d’espace chiral P213, donnant deux types de cristaux chiraux. Si la 
cristallisation du NaClO3 par évaporation du solvant à partir d’une solution saturée donne bien 
un mélange racémique de cristaux, la cristallisation à partir de germes énantiopurs conduit 
majoritairement à la formation de cristaux de ce même énantiomère, avec un excès de plus de 
90%. Un siècle plus tard, Kondepudi et al. confirmèrent ces observations et mirent en 
évidence l’importance de l’agitation : avec et sans ensemencement, un seul type de cristaux 
étaient obtenus après évaporation du solvant. Ils expliquèrent ce phénomène par "la théorie du 
cristal mère" c’est à dire par la propagation de la chiralité de premier nucleus. 
 
                                                 
204 F. S. Kipping, W. J. Pope; J. Chem. Soc. Trans., 1898, 73, 606-617. 
205 D. K. Kondepudi, R. J. Kaufman, N. Singh; Science, 1990, 250, 975-976. 
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  b. Le mûrissement de Viedma 
En 2004,206 puis en 2005,207 Viedma remit en cause cette théorie en réalisant tout d’abord la 
déracémisation du NaClO3 à partir d’une solution hautement sursaturée (apparition de 
nucléation primaire catastrophique) puis à partir d’une suspension racémique. Il effectua cette 
dernière en présence de billes de verre, augmentant considérablement la vitesse du procédé. 
Depuis, le nombre de publications concernant la déracémisation a fortement augmenté, aussi 
bien pour la compréhension du mécanisme que pour l’obtention d’énantiomères purs de 
composés organiques intrinsèquement chiraux. 
N
NH2
O
N
NH2
O
Cl
MeO
OH
O
N
O
N
N
OH
HO
O NH2
O
a) b) c) d)
e)
 
Figure 3. Différents composés organiques déracémisables.  a) N-(2-methyl-benzylidene)-phenylglycine 
amide
208
, b) N-(benzylidene)-2-chlorophenylglycine-amide
209
, c) ClTAK
210
, d) Naproxène
211
, e) Acide 
aspartique
212
. 
 
Dans certains cas,209,210 le mûrissement de Viedma a été combiné avec une rampe de 
refroidissement, augmentant encore plus la productivité du procédé. 
 
 
 3. Mécanisme 
  a. L’expérience de Cairns-Smith 
Cairns-Smith décrivit une expérience (Figure 4) utilisant des balles de deux couleurs 
différentes permettant d’expliquer comment un énantiomère pur (i.e. une seule couleur de 
balles) pouvait être obtenu à partir d’un mélange racémique (i.e. un mélange comportant le 
même nombre de balles des deux couleurs). Cependant cette expérience ne reflète pas la 
réalité du mécanisme de déracémisation puisque les balles n’ont pas la possibilité de changer 
                                                 
206 C. Viedma; J. Crystal Growth, 2004, 261, 118-121. 
207 C. Viedma; Phys.Rev. Lett., 2005, 94, 065504. 
208 W. L. Noorduin, T. Izumi, A. Millemaggi, M. Leeman, H. Meekes, W. J. P. Van Enckevort, R. M. Kellogg, 
B. Kaptein, E. Vlieg, D. G. Blackmond; J. Am. Chem. Soc., 2008, 130, 1158-1159. 
209 M. W. van der Meijden, M. Leeman, E. Gelens, W. L. Noorduin, H. Meekes, W. J. P. van Enckevort, B. 
Kaptein, E. Vlieg, R. M. Kellogg; Org. Process. Res. Dev., 2009, 13, 1195-1198. 
210 G. Levilain, C. Rougeot, F. Guillen, J.-C. Plaquevent, G. Coquerel; Tetrahedron: Asymmetry, 2009, 20, 2769-
2771.  
211 W. L. Noorduin, B. Kaptein, H. Meekes, W. J. P. Van Enckevort, R. M. Kellogg, E. Vlieg; Angew. Chem. 
Int. Ed., 2009, 48, 4581-4583.  
212 C. Viedma, J. E. Ortiz, T. De Torres, T.Izumi, D. G. Blackmond; J. Am. Chem. Soc., 2008, 130, 15274-
15275. 
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de couleur (i.e. d’être racémisées). Elle permet toutefois d’illustrer comment un déséquilibre 
peut être créé à partir d’un mélange racémique. 
x2 x2÷2 ÷2
x2 x2÷2÷2
 
Figure 4. L’expérience de Cairns-Smith: à partir de 100 balles (50 rouges et 50 bleus), la moitié des balles 
est aléatoirement enlevée à chaque étape puis la moitié restante est multipliée par deux. Après plusieurs 
étapes, une seule couleur de balles est présente, correspondant à un excès énantiomérique de 100%. 
 
 
  b. Le mûrissement d’Ostwald 
De nombreuses études menées sur le mécanisme de la déracémisation ont conduit les 
scientifiques à déclarer le mûrissement d’Ostwald comme l’un procédé clé de la 
déracémisation. Grâce à ce phénomène, les petits cristaux se dissolvent spontanément au 
profit de la croissance des plus gros.213 Le cas présenté sur la Figure 5 illustre bien ce 
phénomène,214 mais montre aussi que, dans le cas particulier du NaClO3, l’état final 
correspond à une seule des deux phases chirales possibles, comme dans le cas de la 
déracémisation. 
 
Figure 5. Images au microscope à lumière polarisée du procédé de mûrissement d’Ostwald de cristaux de 
NaClO3. 
 
Le mûrissement d’Ostwald est un procédé très lent, dépendant largement de la taille des 
particules : plus les particules sont grosses, plus elles sont lentes à se dissoudre. Mais 
l’attrition provoquée par l’action des billes de verre permet de fortement diminuer la taille des 
particules et donc d’accélérer le phénomène du mûrissement d’Ostwald. 
                                                 
213 W. Ostwald; Lehrbuch der Allgemeinen Chemie, Vol. 2, Part 1; Leipzig, Germany, 1896. 
214 W. L. Noorduin, E. Vlieg, R. M. Kellogg, B. Kaptein; Angew. Chem. Int. Ed., 2009, 48, 9600-9606. 
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De nombreuses études et simulations ont été publiées afin d’expliquer comment le 
mûrissement d’Ostwald pouvait, à partir d’un très faible déséquilibre énantiomérique, 
conduire à l’obtention d’une phase solide énantiomériquement pure.215,216 
 
  c. Modèle basé sur la réincorporation de clusters 
D’autres scientifiques, ont suggéré que le procédé clé de la déracémisation était la 
réincorporation de clusters chiraux. En 2004, Uwaha publia une étude dans laquelle il 
modélisa l’évolution de l’excès énantiomérique par une simple réaction-type d’échange de 
matière entre les différents constituants de la suspension.217 Les résultats de cette modélisation 
montrèrent que la réincorporation de clusters était nécessaire mais aussi que le murissemment 
d’Ostwald avait un rôle insignifiant en présence d’attrition. 
Ce modèle a été soutenu par d’autres publications,218 dont celle de McBride et Tully,219 ainsi 
que celle de Saito et Hyuga220 qui adaptèrent le modèle aux composés chiraux. 
 
  d. Discussion 
D’autres études ont été effectuées, comparant ces deux hypothèses, certaines confirmant le 
rôle des clusters,221,222 d’autres confirmant le rôle le rôle du mûrissement d’Ostwald.223 
Cependant, en 2010, un groupe de scientifiques hollandais, en association avec McBride et 
Tully proposèrent un mécanisme combinant ces deux procédés.224 Ils donnèrent la preuve de 
la production de clusters grâce à l’action des billes de verre et conclurent que quatre 
phénomènes étaient nécessaires à l’évolution de l’excès énantiomérique : i) la racémisation en 
solution, ii) le mûrissement d’Ostwald, iii) la réincorporation de clusters et iv) l’attrition. 
Depuis, d’autres groupes ont modélisé avec succès le procédé de déracémisation en tenant 
compte à la fois la réincorporation de cluster et du mûrissement d’Ostwald.225,226 
Cependant, malgré tous les efforts faits pour comprendre le mécanisme responsable de 
l’évolution spontanée de l’excès énantiomérique lors du procédé de déracémisation, toutes les 
                                                 
215 J. H. E. Cartwright, O. Piro, I. Tuval; Phys. Rev. Lett., 2007, 165501 
216 W. L. Noorduin, H. Meekes, A. A. C. Bode, W. J. P. Van Enckevort, B. Kaptein, R. M. Kellogg, E. Vielg; 
Cryst. Growth. Des., 2008, 8(5), 1675-1681. 
217 M. Uwaha; J. Phys. Soc. Jpn, 2004, 73(10), 2601-2603. 
218 J. Crusats, S. Vientemillas-Verdaguer, J. M. Ribό; Chem. Eur. J., 2006, 12, 7776-7781. 
219 J. M. McBride, J. C. Tully; Nature, 2008, 452, 161-162. 
220 Y. Saito, H. Hyuga; J. Phys. Soc. Jpn, 2004, 73, 33-35. 
221 M. Uwaha; J. Phys. Soc. Jpn, 2008, 77, 083802. 
222 Y. Saito, H. Hyuga; J. Phys. Soc. Jpn, 2005, 74, 535-537. 
223 T. Izumi, D. G. Blackmond; Chem. Eur. J., 2009, 15, 3065-3068. 
224 W. L. Noordiun, W. J. P. Van Enckevort, H. Meekes, B. Kaptein, R. M. Kellogg, J. C. Tully, J. M. McBride, 
E. Vlieg; Angew. Chem. Int. Ed., 2010, 49(45), 8435-8438. 
225 P. J. Skrdla; Cryst. Growth Des., 2011, 11, 1957-1965. 
226 M. Iggland, M. Mazzotti; Cryst. Growth Des., 2011, 11, 4611-4622. 
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incertitudes n’ont pas été levées et, comme le souligne Viedma, un paradoxe reste à 
expliquer : “la force motrice de l’évolution de l’homochiralité de la phase solide est la 
racémisation en solution - un procédé qui traditionnellement érode la discrimination chirale.” 
 
 
 
II - Synthèse de β-cyclodextrines monofonctionnalisées 
 1. Introduction 
Les cyclodextrines sont des molécules cages chirales227,228 largement utilisées en 
chromatographie, pour la préparation de phases stationnaires chirales. Cependant leur capacité 
de discrimination chirale n’est généralement pas suffisante pour assurer la séparation 
d’énantiomères à l’état solide et seulement quelques exemples d’obtention énantiomères purs 
par formation de complexes hôte/invité ont été décrits dans la littérature.229,230,231  
 
Figure 6. Structure de la β-cyclodextrine à gauche, et sa représentation schématique à droite. 
 
Afin d’augmenter les différences d’inclusion, et donc les chances de discrimination entre les 
deux énantiomères, il nous est apparu nécessaire de synthétiser de nouvelles cyclodextrines 
possédant un motif acide ou basique. Ces motifs pourraient permettre de modifier la façon 
dont la molécule invitée est incluse dans la cavité de la cyclodextrine et ainsi d’augmenter la 
discrimination entre les deux énantiomères. 
 
 
 2. Synthèse de β-cyclodextrines monosubstituées 
Différentes β-cyclodextrines monosubstituées ont donc été synthétisées à partir de la β-
cyclodextrine monotosylée β-CDOTs. Celle-ci a été obtenue avec un rendement satisfaisant 
(40%) et une très bonne pureté à partir de la β-cyclodextrine native et du tosylate 
                                                 
227 A. Villiers ; Comptes Rendus Hebdomadaires des Séances de l’Académie des Sciences, 1891, 112, 536-538. 
228 K. Freudenberg, G. Blomquist, L. Ewald, K. Soff; Ber. Dtsch. Chem. Ges. 1936, 69, 1258-1266. 
229 A. Grandeury, S. Tisse, G. Gouhier, V. Peulon, S. Petit, G. Coquerel Chem. Eng. Technol. 2003, 26, 354-358. 
230 A. Grandeury, S. Petit, G. Gouhier , V. Agasse, G. Coquerel; Tetrahedron: Asymm. 2003, 14, 2143-2152. 
231 Y. Amharar, A. Grandeury, M. Sanselme, S. Petit, G. Coquerel; J. Phys. Chem., 2012, 116(20), 6027-6040. 
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d’imidazole.232 La substitution en position 6 a été confirmée par  des analyses RMN à deux 
dimensions. 
 
Figure 7. Synthèse de la β-cyclodextrine monotosylée β-CDOTs. 
La plupart des autres β-cyclodextrines monosubstituées ont été obtenues par substitutions 
nucléophiles à partir de la β-CDOTs. Les cyclodextrines 5 et 6b ont été synthétisées à partir 
de la β-CDN3 4, respectivement, par réduction et par réaction de cycloaddition de Huisgen. 
Les cyclodextrines 14 et 15 ont quant à elles été obtenues par alkylation des amines 
correspondantes, en utilisant l’acide chloroacétique. 
Tableau 1. Récapitulatif des différentes cyclodextrines synthétisées. 
 
2 
β-CDOTs 
 
4 
β-CDN3 
 
5 
β-CDNH2 
 
6b 
 
7   β-CDNH(CH2)2NH2 
 
12a β-CDNHCH2COOH 
8   β-CDNH(CH2)3NH2 12b   β-CDNH(CH2)2COOH 
9   β-CDNH(CH2)6NH2 12c    β-CDNH(CH2)3COOH 
10  β-CDNH(CH2)8NH2 12d   β-CDNH(CH2)4COOH 
 
11 
β-CD benzylamine NH
(OH)7(OH)7
HO 6
COOH
 
13 
L-phenyl glycine β-CD 
N
(OH)7(OH)7
HO 6
COOH
COOH
 
14 
 
15a 
15b 
15c 
 
 
 
                                                 
232 H.-S. Byun, N. Zhong, R. Bittman; Org. Synth., 2000, 77, 225-227. 
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 3. Etude de la cristallisation des β-cyclodextrines monosubstituées et des 
complexes d’inclusion 
  a. Cristallisation des β-cyclodextrines monosubstituées : influence de l’eau 
Après synthèse, les cyclodextrines ne sont pas très cristallines, comme le montre la Figure 
8Figure 1. 
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Figure 8. Superposition des diffractogrammes des rayons X sur poudres de différentes cyclodextrines. 
 
Cependant, certaines ont pu être cristallisées dans l’eau (Figure 9). Toutefois, les cristaux se 
sont révélés instables une fois séparés de la solution saturée : ils sont rapidement devenus 
blanc, traduisant la cristallisation d’une phase efflorescente. 
Des analyses DVS (dynamic vapor sorption, Figure 10) ont montré que le taux d’hydratation 
des cyclodextrines dépendait largement du taux d’humidité, et qu’aucun hydrate 
stoechiométrique n’existait. 
 
Figure 9.  Cristaux de β-CDNH2 dans 
l’eau. 
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Figure 10. Analyse DVS de la β-CDNH2. 
 
 
  b. Etude du complexe β-CDNH2/ibuprofène 
Le complexe β-CDNH2/ibuprofène a été étudié. La β-CDNH2 a été dissoute dans l’eau puis 2 
équivalents d’ibuprofène ont été ajoutés. L’ibuprofène n’étant pas soluble dans l’eau, il va se 
complexer avec la cavité hydrophobe de la cyclodextrine, et ainsi passer en phase aqueuse. La 
formation d’un complexe de stoechiométrie 1/1 a été mise en évidence par RMN, 
malheureusement, aucune discrimination chirale n’a pu être obtenue dans ces conditions. 
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Des essais d’obtention de monocristaux ont été effectués afin de déterminer si une 
discrimination chirale était possible à l’état solide. Malheureusement, aucun cristal de qualité 
suffisante n’a été obtenu ; ceux présentés sur la Figure 11 se sont révélés polycristallins. 
 
Figure 11. Cristaux du complexe β-CDNH2/ibuprofène 1/1 dans l’eau. 
 
 
 4. Conclusion 
Une  petite librairie de cyclodextrines monosubstituées a été synthétisée avec succès et avec 
une assez bonne pureté. Les analyses DVS ont montré que le taux d’hydratation des 
cyclodextrines dépendait grandement du taux d’humidité, ce qui pourrait expliquer la 
difficulté d’obtention de phases solides bien cristallisées. 
De premières expériences ont montré qu’il était possible de former des complexes d’inclusion 
avec ces cyclodextrines. Toutefois, aucune discrimination chirale n’a pu être observée pour le 
moment. 
 
 
 
III - Déracémisation d’une famille de conglomérats   
 1. Introduction 
Ce chapitre est consacré à l’étude d’une famille de composés dérivés du 1-(4-chlorophényl)-
4,4-diméthyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-one, ClTAK. Ce composé, un précurseur du 
Placobutrazol,233  un inhibiteur de croissance des plantes, cristallise sous forme de 
conglomérat et est facilement racémisable en solution dans les mêmes conditions ;234 il peut 
donc être déracémisé.210 
Dans la littérature, un composé très similaire a été décrit : le 2H-4ClTAK, isomorphe à 
ClTAK. Afin de déterminer si le fait que ces deux composés cristallisent de façon identique 
soit une propriété de cette famille ou une coïncidence, quatre autres dérivés ont été 
synthétisés : BrTAK, MeTAK, HTAK et tBuTAK. 
                                                 
233 US4243405A1. 
234 S. N. Black, L. J. Williams, R. J. Davey, F. Moffat, R. V. H. Jones, D. M. McEwan, D. E. Sadler; 
Tetrahedron, 1989, 45(9), 2677-2682. 
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Figure 12. Structures des composés dérivés du ClTAK synthétisés au laboratoire. 
 
 
 2. Etude structurale 
D’après la superposition des diffractogrammes sur poudre de ces cinq composés, ClTAK, 
MeTAK et BrTAK, semblent isomorphes (Figure 13). L’étude de tBuTAK à, quant à elle, été 
rapidement abandonnée : le composé forme des démixtions avec de nombreux solvants et les 
analyses SHG (second harmonic generation) ont montré qu’il cristallise dans un groupe 
d’espace centrosymétrique, et donc qu’il ne forme pas de conglomérat. 
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Figure 13. Superposition de DRXP des dérivés du TAK. 
 
La résolution structurale de ClTAK, MeTAK, BrTAK et HTAK a confirmé les résultats 
obtenus par diffractions de rayons X sur poudre : ClTAK, MeTAK et BrTAK sont 
isomorphes. Cependant, elle a aussi pu montrer que, même si HTAK cristallise dans un 
groupe d’espace différent (P21 au lieu de P212121), sa structure présente de grandes 
similitudes avec celle des trois autres composés, notamment au niveau des paramètres de 
mailles. 
Tableau 2. Paramètres de maille de ClTAK, MeTAK, BrTAK et HTAK. 
 ClTAK MeTAK BrTAK HTAK 
Système cristallin Orthorhombique Orthorhombique Orthorhombique Monoclinique 
Groupe d’espace P212121 P212121 P212121 P21 
Z , Z’ (unités asymétrique par maille) 4, 1 4, 1 4, 1 4, 2 
a / Å 5.8076(5) 5.808(1) 5.7875(5) 5.747(1) 
b / Å 13.553(1) 13.641(1) 13.629(1) 19.183(1) 
c / Å 19.661(2) 19.789(1) 19.882(2) 13.437(1) 
β - - - 96.561(1) 
V / Å3 1547.5(2) 1567.9(2) 1568.3(2) 1471.8(2) 
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dcalc / g.cm
-3 1.252 1.150 1.424 1.161 
Dans le cas de ClTAK, MeTAK et BrTAK, l’unité asymétrique est composée d’une seule 
molécule présentant un désordre au niveau du groupement tert-butyl, alors que l’unité 
asymétrique de HTAK est composée de deux molécules ne présentant aucun désordre. 
Cependant, la superposition de ces deux molécules montre qu’elles ne diffèrent quasiment que 
par la position du tert-butyl, mimant ainsi un désordre de 50/50. 
 
Figure 14. Superposition des unités 
asymétriques de ClTAK (en blanc), MeTAK 
(en rouge) et BrTAK (en vert). 
 
Figure 15. Unité asymétrique de HTAK. 
 
Figure 16. Superposition des deux molécules 
de l’unité asymétrique de HTAK. 
 
La Figure 17 montre les projections des quatre structures selon l’axe a, il est ainsi facile de 
voir que ClTAK, MeTAK et BrTAK sont isomorphes. Pour ces trois composés, des chaînes 
sont formées selon a, les molécules étant reliées entre elles par des liaisons π en forme de T, 
les groupements triazoles étant rejetés vers l’extérieur. Dans le cas de HTAK, des chaînes 
similaires sont formées, mais les groupements triazoles sont dirigés vers l’intérieur de la 
chaîne. 
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Figure 17. Projections selon l’axe a. a) ClTAK, b) MeTAK, c) BrTAK et d) HTAK. Une chaîne est 
entourée en noir et les liaisons π en forme de T sont représentées en pointillés verts. 
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 3. Le mûrissement de Viedma 
Les déracémisations de ClTAK, MeTAK, BrTAK et HTAK ont été étudiées. Toutes les 
expériences ont été menées dans des conditions les plus similaires possibles : 
  - TAK : 1 g    - Billes de verre (diamètre 2 mm) : 5 g 
  - Solvant (MeOH/eau): 5 g  - Agitateur magnétique en forme de croix 
  - Température : 25°C   - Vitesse d’agitation : 1000 rpm 
  - NaOH : 0.1 g 
Afin de garder des solubilités similaires pour tous les composés, les proportions de méthanol 
et d’eau ont du être modulées (Tableau 3). 
Tableau 3. Solubilités des dérivés du TAK dans les mélanges de solvants utilisés lors des déracémisations. 
 ClTAK MeTAK HTAK BrTAK 
MeOH/eau (m/m) 80/20 65/35 47/53 90/10 
Solubilité 5.5% 6.0% 4.7% 5.2% 
 
 
  a. ClTAK 
Plusieurs expériences de déracémisations de ClTAK ont été effectuées. Des échantillons ont 
été régulièrement prélevés et analysés par HPLC chirale. Les résultats obtenus pour trois 
expériences sont présentés sur la Figure 18. 
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Figure 18. Comparaison de 3 déracémisations de ClTAK conduites dans les mêmes conditions opératoires. 
A gauche: évolution de l’excès énantiomérique en fonction du temps. A droite: évolution de ln(e.e.) en 
fonction du temps. 
 
Dans chaque cas, l’évolution de l’excès énantiomérique est exponentielle, comme le prouve la 
représentation de ln(e.e.) en fonction du temps. Cependant, on peut remarquer que les trois 
expériences ne démarrent pas au même moment, même si leurs cinétiques sont identiques. Ce 
phénomène est clairement visible sur la courbe rose : durant les 2-3 premiers jours, l’excès 
énantiomérique n’évolue pas. 
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Afin de déterminer si  ce retard à l’évolution de l’e.e. n’est pas dû à un problème 
expérimental, par exemple une mauvaise efficacité des billes de verre, différents échantillons 
ont été analysés par microscopie électronique à balayage (MEB). Cependant, comme le 
montre les photos (Figure 19), l’attrition a bien été efficace tout au long de l’expérience, et ne 
peut donc pas expliquer pourquoi la déracémisation n’a pas démarré à t = 0. De plus, on peut 
observer que la taille des particules ne dépend pas de l’e.e.  
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Figure 19. Photos prises au MEB de trois échantillons lors d’une expérience de déracémisation de ClTAK. 
 
 
  b. ClTAK, MeTAK, BrTAK et HTAK 
Les cinétiques de déracémisation de quatre dérivés sont comparées. Là encore, on peut 
observer des retards à l’évolution de l’e.e., et les cinétiques de ClTAK, MeTAK et HTAK 
sont très similaires. Cependant, le comportement de BrTAK est différent : bien que les 
conditions expérimentales soient comparables à celles des autres expériences, la vitesse est 
beaucoup plus lente. 
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Figure 20. Comparaison des cinétiques d’évolution de l’excès énantiomérique des quatres TAK. ClTAK 
en rouge, MeTAK en vert, BrTAK en bleu et HTAK en violet. 
 
De plus, comme le montre la Figure 21, les particules de BrTAK sont plus petites que celles 
des autres TAK, ce qui est en désaccord avec le mécanisme préalablement décrit. Aucune 
condition expérimentale ne peut expliquer cette différence. BrTAK semble se comporter 
comme si les échanges de matière entre les particules étaient inhibés, les empêchant ainsi de 
croître et donc ralentissant l’évolution de l’e.e. 
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ClTAK MeTAK BrTAK HTAK 
    
Figure 21. Photos prises au MEB des particules à la fin des déracémisations. 
 
 
 
 5. Déracémisation par les ultrasons 
Les ultrasons sont connus pour réduire la taille des particules, produire un nombre élevé de 
clusters ainsi qu’augmenter les effets mécaniques grâce à l’implosion des bulles de cavitations 
qui induissent des forces de cisaillement et des jets de liquides à très grande vitesse. Les 
ultrasons pourraient donc être utilisés pour remplacer l’action des billes de verre.235 
En 2008, Song et al.236,237 cristallisèrent le NaClO3 sous ultrasons, et obtinrent un excès 
énantiomérique proche de 100%. Mais jusqu’à présent, et mis à part les expériences de Song 
et al., les ultrasons n’ont jamais été utilisés seuls pour déracémiser des molécules organiques. 
Ils ont en effet souvent été utilisés en combinaison avec les billes de verre, mais, même si une 
augmentation de la vitesse de déracémisation avait été remarquée, leurs effets n’ont jamais été 
étudiés. La déracémisation de ClTAK par les ultrasons a donc été effectuée (Figure 22). 
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Figure 22. Montage de déracémisation 
par ultrasons 
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Figure 23. Comparaison de l’évolution de l’e.e. pour quatre 
différentes puissances d’ultrasons avec les billes de verre. 
 
 
 
 
                                                 
235 P. Cintas; Cryst. Growth Des., 2008, 8(8), 2626-2627. 
236 Y. Song, W. Chen, X. Chen; Cryst. Growth Des., 2008, 8(5), 1448-1450. 
237 Y. Song, W. Chen, X. Chen; Cryst. Growth Des., 2012, 12, 8-11. 
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Sur la Figure 23, plusieurs points sont à noter : 
• L’évolution de l’e.e. est exponentielle, 
• Plus la puissance des ultrasons augmente, plus l’évolution de l’e.e. est rapide. L’analyse de 
la taille des particules montre que les particules sont aussi de plus en plus petites, ce qui est en 
accord avec le mécanisme précédemment décrit, 
• La déracémisation par ultrasons est plus efficace que la déracémisation utilisant les billes 
de verre. 
Cependant, la comparaison des tailles des particules entre ces deux méthodes montre que les 
particules sont plus grosses lors des déracémisations par ultrasons, ce qui est en contradiction 
avec le mécanisme précédemment décrit. Les effets mécaniques induits par les ultrasons et le 
mûrissement d’Ostwald ne peuvent donc pas expliquer pourquoi les ultrasons sont si 
efficaces ; d’autres phénomènes doivent être à l’origine de cette rapide évolution. 
50kJ.h-1 5µm 325kJ.h-1 5µm Glass beads 5µm  
Figure 24. Comparaison de taille des particules après déracémisations par les ultrasons à 50 kJ.h-1 (à 
gauche) et à 325 kJ.h-1 (au milieu) et par des billes de verre (à droite). 
 
 
 
 6. Mécanisme 
L’étude de la déracémisation des dérivés du TAK par les ultrasons a permis de préciser le 
mécanisme mis en jeu lors de la déracémisation : 
• La réduction de la taille des particules par effet mécanique est responsable d’une 
accélération de l’évolution de l’e.e. puisque pour un même composé et un même mode 
opératoire, de plus petites particules sont liées à une évolution plus rapide. 
• L’importance de la réincorporation des clusters : les ultrasons sont décrits dans la 
littérature pour produire un très grand nombre de clusters, qui pourraient être responsables 
d’une accélération de l’évolution de l’e.e. en favorisant les échanges de matière. 
• L’entraînement pourrait aussi expliquer pourquoi la déracémisation par ultrasons est si 
efficace et pourquoi les particules sont plus grosses. En effet, les ultrasons sont responsables 
d’un échauffement du système (le réacteur doit être réfrigéré pour maintenir la température du 
système à 25°C.) Localement, les particules vont donc se dissoudre du fait de la hausse de 
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température. Une sursaturation va donc se créer lorsque la température redescendra à 25°C, 
rendant alors possible le phénomène d’entraînement et donc la croissance des particules. 
D’autres expériences permettent de confirmer l’effet de l’entraînement sur la déracémisation, 
comme par exemple celles combinant le mûrissement de Viedma avec une rampe de 
refroidissement.209,210 Mais l’exemple le plus flagrant est celui permettant la déracémisation 
en utilisant seulement des cycles de température.238 
• La taille des particules est indépendante de l’excès énantiomérique, contrairement à ce que 
a été très récemment décrit par Hein et al. ;239 ils observèrent une "croissance transitoire" des 
particules au cours de la déracémisation. 
 
 
 
IV - Synthèse de l’énantiomère pur du Prasugrel 
Le Prasugrel (Effient) est un antiagrégant plaquettaire.240 Il représente la nouvelle génération 
d’un médicament très largement utilisé, le Clopidogrel (Plavix), donc le marché était estimé à 
9.3 milliards de dollars en 2010. 241 La mise au point d’une voie de synthèse économique de 
l’énantiomère pur du Prasugrel est un enjeu important pour l’industrie pharmaceutique. Il 
nous est donc apparu judicieux d’obtenir ce composé en introduisant une étape de 
déracémisation au cours de la synthèse. 
 
Figure 25. Structures du S-Prasugrel et du S-Clopidogrel 
 
 
 
 
 
 
 
 
                                                 
238 K. Suwannasang , A. E. Flood, C. Rougeot, G. Coquerel; Oral presentation at CGOM10, June 2012, 
Limerick, Ireland. 
239 J. E. Hein, B. H. Cao, C. Viedma, R. M. Kellogg, D. G. Blackmond; J. Am. Chem. Soc., 2012, 134, 12629-
12636. 
240 EMEA/117561/2009. 
241 Pharmactua, from www.pharmactua.com. 
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 1. Synthèse de la 2-amino-1-cyclopropyl-2-(2-fluorophényl)éthanone 
  a. Rétrosynthèse 
La première voie de synthèse imaginée est décrite ci-dessus : 
 
Figure 26. Rétrosynthèse de l’énantiomère S du Prasugrel. 
 
Le Prasugrel pourrait être obtenu par cyclisation du composé dibromé 18 sur l’amine 19. 
L’énantiomère pur de l’amine 19 pourrait être obtenu par déracémisation de la base de Schiff 
correspondante. Une recherche de conglomérats pourra être effectuée en modulant les 
substitutants du cycle aromatique apportés par le benzaldéhyde. 
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Figure 27. Rétrosynthèse de l’énantiomère pur de l’amine 19. 
 
Le composé dibromé 18 pourrait, être synthétisé à partir du thiophène éthanol, en trois étapes. 
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Figure 28. Rétrosynthèse du composé dibromé 18. 
 
  b. Synthèse 
L’amine 19 a été synthétisée en 4 étapes à partir de la (2-fluorophényl)glycine 24. L’amine 
primaire de la (2-fluorophényl)glycine est tout d’abord protégée par un groupement Boc, puis 
une réaction de couplage est effectuée avec la morpholine. Le groupement cyclopropyle est 
ensuite introduit grâce à une réaction de Grignard puis une réaction de déprotection conduit 
au produit attendu sous forme de sel. 
 
Figure 29. Synthèse du mélange racémique de la 2-amino-1-cyclopropyl-2-(2-fluorophényl)éthanone 
hydrochloride. a) Boc2O, NaHCO3, THF, eau (quant.), b) CDI, TEA, THF (90%), c) copeaux de 
magnésium, bromure de cyclopropyle, THF (83%), d) HCl, méthanol (90%). 
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L’amine 19 n’est pas stable sous la forme libre : deux molécules vont réagir ensemble pour 
former la pyrazine 28. La structure de ce composé a été confirmée par RMN du proton, 
spectrométrie de masse et résolution de structure cristalline sur monocristal. 
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Figure 30. A gauche: structure, au milieu: monocristaux, à droite: résolution structurale de la pyrazine 28. 
 
Cependant l’amine est stable sous forme de sel. La recherche de conglomérats peut donc être 
effectuée à partir de 19.HCl. Malheureusement, même si les bases de Schiff ont pu être 
formées, leurs stabilités n’étaient pas suffisantes pour espérer pouvoir faire une 
déracémisation, la pyrazine 28 se formant rapidement dans chaque cas.  
Afin d’empêcher la formation de ce dimère, une recherche de conglomérats a été effectuée à 
partir d’un composé possédant un groupement carbonyle moins réactif : le composé 30. Cette 
fois, toutes les bases de Schiff obtenues se sont montrées stables. Malheureusement, elles ont 
aussi toutes étaient obtenues sous forme d’huile et étaient donc impossibles à déracémiser. 
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Figure 31. Recherche de conglomérats. a) HCl, 1,4-dioxane (94%), b) NaOH, eau (quant.), c) 
benzaldéhyde substitué, NaSO4, CH2Cl2. 
 
 
 1. Synthèse de la (2-fluorophényl)glycinamide 
  a. Synthèse 
La recherche de conglomérats s’étant révélée infructueuse à partir de la 2-amino-1-
cyclopropyl-2-(2-fluorophényl)éthanone 19, une nouvelle voie de synthèse à été envisagée 
mettant en jeu la (2-fluorophényl)glycinamide 32. Celle-ci peut être facilement obtenue en 
deux étapes à partir de la (2-fluorophényl)glycine. 
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Figure IV - 55. Criblage de conglomérats à partir de la (2-fluorophényl)glycinamide. a) SOCl2, MeOH 
(95%), b) NH3 30% dans l’eau (70%), c) benzaldéhyde substitué, NaSO4, CH2Cl2. 
 
 
  b. Recherche de conglomérats 
Une recherche de conglomérats à ensuite pu être effectuée à partir de la (2-
fluorophényl)glycinamide et de dix benzaldéhydes différemment substitués. Neuf des dix 
composés se sont révélés cristallins et trois d’entre eux ont donnés un signal positif en SHG. 
Tableau 4. Résultats de l’analyse SHG des dix bases de Schiff synthétisées à partir de la (2-
fluorophenyl)glycinamide. 
 33a 33b 33c 33d 33e 
Aldéhyde 
aromatique 
     
SHG Signal positif - - Faible signal positif Signal positif 
 
 33f 33g 33h 33i 33j 
Aldéhyde 
aromatique 
    
 
SHG - huile Signal positif Faible signal positif - 
 
Le composé dérivé du benzaldéhyde, 33a, a alors été synthétisé, le benzaldéhyde étant le plus 
économique et très peu toxique. 
 
 
 2. Déracémisation 
Une première déracémisation de 33a a été effectuée et un résultat encourageant a été obtenu 
puisqu’un excès de 99.1% a été obtenu. Cependant, le rendement n’était que de 14%. 
Toutefois, les conditions expérimentales n’avaient pas été optimisées, et notamment, la 
solubilité de la base de Schiff 33a dans le solvant de déracémisation était inconnue. 
Des essais d’optimisation des conditions expérimentales ont donc été effectués, en adaptant la 
quantité de solvant à la quantité de produit à déracémiser, en modulant la quantité de solvant 
ou le programme de refroidissement. Malheureusement, le meilleur rendement obtenu n’a été 
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que de 58% (avec un excès énantiomérique supérieur à 99.5%), un résultat très décevant pour 
une déracémisation. 
 
D’autres optimisations de conditions expérimentales pourraient être envisagées, notamment 
un changement d’agent racémisant, jusqu’alors le DBU (1,8-diazabicyclo[5.4.0]undec-ène) ou 
un changement de solvant (acétonitrile). La déracémisation des deux autres bases de Schiff 
ayant données un résultat positif en SHG pourraient aussi envisagée. 
 
 
 
Conclusion générale 
Le travail décrit dans cette thèse est dédié à la chiralité, et plus particulièrement à l’obtention 
d’énantiomères purs de composés actifs par cristallisation. 
 
Dans un premier temps, une petite librairie de β-cyclodextrines monofonctionnalisées a été 
synthétisée afin de servir d’agent de résolution par formation de complexes d’inclusion. 
Même si la formation de complexes a été mise en évidence, aucune discrimination chirale n’a 
pour l’instant été observée. L’importance du taux d’humidité sur la cristallisation des 
cyclodextrines a été observée et pourrait expliquer la difficulté d’obtention de phases bien 
cristallisées et de monocristaux. 
 
La seconde partie de cette thèse est dédiée à l’étude d’un phénomène d’énantioamplification 
autocatalytique, la déracémisation, mettant en jeu : i) une cristallisation sous forme de 
conglomérat, ii) une racémisation rapide en solution, iii) une dissolution/recristallisation des 
particules due à une diminution de leur taille par l’action d’un flux d’énergie (broyage, 
ultrasons, cycles de température) 
Malheureusement, il est, pour l’instant, impossible de prédire si un produit va cristalliser sous 
forme de conglomérat ou non. Cependant, dans cette étude, deux nouvelles familles de 
composés ayant une grande tendance à cristalliser sous forme de conglomérats ont été 
décrites. Des modifications limitées des subtituants ne modifiaient pas (ou très peu) 
l’empilement cristallin. 
L'étude de l'évolution de la distribution de la taille des cristaux au cours du processus de 
déracemisation en utilisant des billes de verre ou des ultrasons a conduit à repérer les 
caractéristiques mécanistiques suivantes: 
Résumé en français 
 
- 240 - 
 - Un retard à l’évolution spontanée de l’excès énantiomérique peut avoir lieu (à 
condition qu’aucun déséquilibre ne soit préalablement établi entre les deux énantiomères), 
confirmant le caractère aléatoire du mécanisme responsable de la déracémisation. 
 - La distribution de taille des particules dépend de l’énergie mécanique donnée au 
système mais pas de l’excès énantiomérique de la phase solide. 
 - L’évolution rapide de l’excès énantiomérique en utilisant les ultrasons est cohérente 
avec la formation et la recapture de clusters, les nombreux clusters produits par les ultrasons 
favorisant l’échange de matière entre les particules. 
 - L’effet d’entraînement produit par l’échauffement du système dû aux ultrasons peut 
expliquer pourquoi les particules sont plus grosses qu’avec les billes de verre et serait 
cohérent avec le caractère autocatalytique de la déracémisation. 
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I - Generality 
All reagents and solvents were purchased from Fisher Scientific, Alfa Aesar, Sigma Aldrich 
and VWR and were used without further purification. 
 
The NMR spectra were recorded on a Bruker spectrospin 300 Instrument (300MHz and 
75MHz for 1H and 13C, respectively) and were calibrated with the solvent (CDCl3: 7.26ppm 
for 1H NMR and 77.00 for 13C NMR, MeOD: 3.31ppm for 1H NMR and 49.05 for 13C NMR 
and DMSO-d6: 2.50ppm for 1H NMR and 39.43 for 13C NMR). NMR spectra were analyzed 
by using the software MestRec. 
 
The mass spectroscopy analyses were carried out by electrospray ionisation by using a 
Thermo Fisher Scientific LCQ Advantage Max and the Qual Browser software. The chemical 
ionisations (NH3) were carried out on a Thermo Fisher Scientific DSQ. 
 
Elementary analyses were performed on a Thermo Scientific Flash 2000 CHNS Series 
Organic Elemental Analyzers. 
 
Chiral HPLC were carried out by a chiralcel OD connected to a HPLC Finnigan SURVEYOR 
- LC Pump Plus. The apparatus was controlled by the ChromQuest® software. 
 
The X ray powder diffractograms were recorded on a Diffractometers Siemens D5005 and 
Siemens D5000 with θ/θ configuration or on a Bruker D8 Advance with a -θ/-θ configuration, 
by using a Cupper anti cathode. The Eva® Software was used for the processing data. 
 
The resolution of structure was carried out by using a Bruker SMART APEX diffractometer 
with a CCD area detector. The cell parameters and the orientation matrix of the crystal were 
preliminary determined by using SMART Software. Data integration and global cell 
refinement were performed with SAINT Software. Intensities were corrected for Lorentz, 
polarisation, decay and absorption effects (SAINT and SADABS Softwares) and reduced to 
FO2. The program package WinGX3 was used for space group determination, structure 
solution and refinement. 
 
DSC and TGA-DSC analyses were recorded respectively on DSC 204 F1 Phoenix 
NETZSCH® and on TGA-DSC NETZSCH® STA 449C. Measurements are performed in an 
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open aluminum crucible under helium, with a heating rate between 5 and 10K.h-1 and the 
Netzsch–TA Proteus® Software were used for the processing data. 
 
The melting points were determined on a Kofler bench Fisher Scientific®, calibrated with 
standard compounds.  
 
The DVS analyses were carried out by using a DVS-1 type and a DVS Advantage plus type, 
Surface Measurement System. The partial vapour pressure is controlled by continuous gas 
flow containing pure nitrogen and solvent vapour in adequate proportions. 
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II - Synthesis of monosubstituted β-cyclodextrins for chiral 
separation 
S
O
N
O
N
3
 
3 1-(p-toluenesulfonyl)imidazole 
Imidazole (65g, 950mmol) was dissolved in CH2Cl2 (250mL). The solution was cooled at 0°C 
then tosyl chloride (80g, 420mmol), dissolved in CH2Cl2 (250mL), was added dropwise to the 
solution over a period of 1h30. The reaction mixture was stirred for 2h at room temperature 
(RT) then the solution was filtered through a pad of silica gel, which was washed with a 1/1 
mixture of ethyl acetate/petroleum ether (500mL). The solvents were evaporated then the 
solid was dissolved in ethyl acetate (100mL) and petroleum ether (500mL) was added. The 
solid was filtered, washed with petroleum ether then dried to give 78,6g (353mmol, 84%) of 3 
as a white solid. 1H NMR (300MHz, CDCl3): δ (ppm) = 2.44 (s, 3H), 7.08 (m, 1H), 7.28-
7.29 (t, J=1.38Hz, 1H), 7.34-7.37 (d, J=8.6Hz, 2H), 7.81-7.84 (d, J=8.4Hz, 2H), 8.01 (s, 1H). 
13
C NMR 
13
C (75MHz, CDCl3): δ (ppm) = 21.50, 117.26, 121.26, 127.14, 130.24, 131.17, 
134.65, 146.17. Chemical Ionisation MS+ (calc. for C10H10N2O2S 222.05): m/z=223.0 
[M+H] +. Melting point: 77°C. 
 
2 6-O-p-toluenesulfonyl-β-cyclodextrin β-CDOTs 
Native β-cyclodextrin hydrate (≈14% H2O by weight, 40g, 30,3mmol) was suspended in 
water (900mL) then the mixture was stirred at 60°C until complete dissolution of the β-CD. 
After cooling at RT, 1-(p-toluenesulfonyl)imidazole (31.3g, 141.4mmol) was added. The 
reaction mixture was stirred 2h at room temperature then NaOH (18g, 450mmol) in water 
(50mL) was added over 20 minutes. After 10 minutes at RT, the reaction mixture was filtered. 
NH4Cl (48,4g, 900mmol) was added to the filtrate then the mixture was stirred for 2h at RT. 
The solid was filtered, washed with cold water (2x100mL) then with acetone (200mL), and 
dried under vacuum to give 22.03g (17.1mmol, 56%) of β-CDOTs 2 as a white powder. 1H 
OTs
(OH)7(OH)7
HO 6
O
OH
HO
OH
O
O
OH
HO
O
O
OOH
OH
OH
O
O
OH
OH
OH
OO
OH
OH
HO
O
O
OH
OH
H
O
O
O
OH
HO
HO
O
S
O
O
2 
Experimental part 
 
- 246 - 
NMR (300MHz, DMSO-d6): δ (ppm) = 2.40 (s, 3H), 3.22-3.64 (overlap with HDO, m, 40H), 
4.16-4.21 (m, 1H, CH2OTs), 4.31 (m, 1H, CH2OTs) 4.35-4.51 (m, 6H, CH2OH), 4.77-4.84 
(m, 7H, H1), 5.64-5.83 (m, 14H, OH1 et OH2), 7.42-7.44 (d, J=8.1Hz, 2H), 7.74-7.76 (d, 
J=8.1Hz, 2H). 13C NMR 13C (300MHz, DMSO-d6): δ (ppm) = 21.24 (CH3), 59.27-60.03 
(6xCH2OH), 69.77 (CH2OTs), 72.06-73.09 (21xCH), 80.75-81.67xCH), 101.27-102.24 
(7xC1H), 127.59 (2xCArH), 129.91 (2xCArH), 132.66 (CAr), 144.85 (CAr). MS ESI+ (calc. 
for C49H76O37S 1288.4): m/z = 1311.2 [M+Na]+. 
 
4 6-deoxy-6-azido-β-cyclodextrin β-CDN3 
β-CDOTs 2 (5g, 3.88mmol) was dissolved in dried DMF (35mL) then sodium azide (0.3g, 
4.65mmol) was added. The reaction mixture was stirred at 105°C for 1h. After cooling at 
room temperature, acetone (200mL) was added then the solid was filtered and washed with 
acetone (3x50mL). The product was suspended in methanol (50mL) and the mixture was 
stirred overnight at room temperature. The product was filtered, washed with methanol 
(10mL) and acetone (2x10mL) then dried under vacuum to give 3.21g (2.75mmol, 71%) of β-
CDN3 4 as a white powder. 1H NMR (300MHz, DMSO-d6): δ (ppm) = 3.26-3.43 (m, 18H 
augmenté par HDO), 3.55-3.70 (m, 27H), 4.45-4.56 (m, 6H, 6xCH2OH), 4.81-4.88 (m, 7H, 
H1), 5.63-5.75 (m, 14H, OH1 et OH2) (DMSO = 2.51). MS ESI+ (calc. for C42H69N3O34 
1159,38) : 1182.3 [M+Na]+. 
  
5 6-deoxy-6-amino-β-cyclodextrin β-CDNH2 
β-CDN3 4 (8.32g, 7.17mmol) was dissolved in DMF (41mL) then triphenylphosphine (2.07g, 
7.89mmol) was added. The reaction mixture was stirred 4h at RT then water (2.58mL, 
143mmol) was added and the reaction mixture was stirred at reflux for 30 minutes. After 
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cooling at RT, the product was precipitated in acetone (400mL) then quickly filtered. The 
solid was washed with acetone (3x75mL) then dried under vacuum. The crude product was 
suspended in methanol (30mL) and the mixture was stirred overnight at RT. The product was 
filtered, washed with methanol (10mL) and acetone (2x10mL) then dried under vacuum to 
give 6.90g (6.09mmol, 85%) of β-CDNH2 5 as a white powder. 1H NMR (300MHz - D2O): δ 
(ppm) = 2.71-2.78 (m, 1H), 2.96-3.01 (m, 1H), 3.33-3.40 (m, 1H), 3.49-3.57 (m, 14H), 
3.7779-3.90 (m, 28H), 4.98 (s, 7H). MS ESI+ (calc. for C42H71NO34 1133,39): 1134.7 
[M+H]+, 1156.8 [M+Na]+.  
N
(OH)7(OH)7
HO 6
O
OH
HO
OH
O
O
OH
HO
N
O
OOH
OH
OH
O
O
OH
OH
OH
O
O
OH
OH
HO
O
O
OH
OH
HO
O
O
OH
HO
HO
O
NN
N
N
NH2
NH2
 
6b 6-deoxy-(4-(aminomethyl)-1,2,3-triazole)-β-cyclodextrin 
β-CDN3 4 (10.0g, 8.6mmol) was dissolved in DMF (75mL) then CuSO4 (1.51g, 9.5mmol) 
and propargyl amine (1.18g, 12.9mmol) were added. The sodium ascorbate (5.12g, 
25.9mmol) was dissolved in water (15mL) then was added dropwise. The reaction mixture 
was stirred 20h at room temperature then the solvents were evaporated. The residue was 
dissolved in water (125mL) then HCl 1N (30mL) was added. The mixture was stirred 
overnight at RT then half of the solvent was evaporated. The product was then precipitated in 
acetone, filtered, washed with acetone (3x) then dried under vacuum to give 9.68g 
(7.91mmol, 92%) of 6b as a white powder. 1H NMR (300MHz - D2O): δ (ppm) =2.76-2.82 
(m, 1H), 3.00-3.04 (m, 1H), 3.29-3.59 (m, 14H), 3.60-3.90 (m, 21H), 4.04-4.10 (m, 1H), 4.21 
(s, 1H), 4.62-4.70 (m, overlap with H2O), 4.87-4.93 (m, 6H), 5.04-5.05 (m, 1H), 8.05 (s, 1H). 
MS ESI
+ (calc. for C45H74N4O34 1214.42): 1215.6 [M+H]+, 1237.6 [M+Na]+. 
6b 
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7 6-deoxy-(2-aminoethylamino)-β-cyclodextrin β-CDNH(CH2)2NH2 
β-CDOTs 2 (5.0g, 3.9mmol) was dissolved in ethylenediamine (195mmol, 13.0mL) then the 
reaction mixture was stirred 4h at 75°C. After cooling at room temperature, the product was 
precipitated in acetone (250mL) then filtered. The solid was washed with acetone (3x50mL) 
then dried under vacuum. The powder was suspended in methanol then the mixture was 
stirred overnight at room temperature. The solid was filtered then dried under vacuum to give 
3.77g (3.2mmol, 82%) of 7 as a white solid. 1H NMR (300MHz - D2O): δ (ppm) = 2.49-2.67 
(m, 8H), 2.87-2.91 (m, 3H), 3.23-3.29 (t, 2H), 3.37-3.748 (m, 59H), 4.89 (m, 7H). 13C NMR 
(D2O - 75MHz): δ (ppm) = 39.70, 49.23, 50.47, 57.38, 60.21, 71.4-72.01, 73.13, 81.02-81.15, 
83.64, 101.64-101.89. MS ESI+ (calc. for C44H76N2O34 1176.43): 1177.8 [M+H]+, 1199.8 
[M+Na]+. 
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8 6-deoxy-(3-aminopropylamino)-β-cyclodextrin β-CDNH(CH2)3NH2 
β-CDOTs 2 (5.0g, 3.9mmol) was dissolved in diaminopropane (195mmol, 16.2mL) then the 
reaction mixture was stirred 4h at 75°C. After cooling at room temperature, the product was 
precipitated in acetone (250mL) then filtered. The solid was washed with acetone (3x50mL) 
then dried under vacuum. The powder was suspended in methanol then the mixture was 
7 
8 
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stirred overnight at room temperature. The solid was filtered then dried under vacuum to give 
4.27g (3.6mmol, 93%) of 8 as a white solid. 
1
H NMR(300MHz - D2O): δ (ppm) = 1.93-2.10 (m, 2H), 3.00-3.05 (t, 2H), 3.09-3.14 (m, 
2H), 3.26-3.33 (m, 1H), 3.41-3.62 (m, 13H), 3.60-3.93 (m, 21H), 4.06-4.13 (m, 1H), 4.98-
5.044 (m, 6H). 13C NMR (75MHz - D2O): δ (ppm) = 23.54, 36.57, 45.26, 48.38, 60.34-
60.69, 67.44, 71.72-72.39, 72.84-73.11, 80.40-83.14, 101.07-101.80. MS ES+ (calc. for 
C45H78N2O34 1190.4): m/z = 1191.4 [M+H]+, 1213.4 [M+Na]+. 
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9 6-ddeoxy-(6-aminohexylamino)-β-cyclodextrin β-CDNH(CH2)6NH2 
β-CDOTs 2 (10.0g, 7.8mmol) was dissolved in NMP (150mL) then diaminohexane (3.60g, 
31mmol) was added. The reaction mixture was stirred overnight at 75°C. After cooling at 
room temperature, the product was precipitated in acetone (500mL) then filtered. The solid 
was washed with acetone (3x100mL) then dried under vacuum. The powder was suspended in 
methanol then the mixture was stirred overnight at room temperature. The solid was filtered 
then dried under vacuum to give 9.60g (7.8mmol, 100%) of 9 as a white solid. 1H NMR 
(300MHz - D2O): δ (ppm) = 1.03-1.32 (m, 14H), 1.99-2.07 (m, 2H), 2.49 (m, 7H+DMSO), 
2.86 (m, 3), 3.32-3.99 (m, 60H), 4.81 (m, 7H). 13C NMR (75MHz - D2O): δ (ppm) = 18.69, 
26.63, 27.01, 29.57, 32.25, 41.18, 49.50, 50.80, 56.56, 60.28, 72.43-72.60, 73.39, 81.87, 
102.33. MS ESI+ (calc. for C48H84N2O34 1232.49): 1233.7 [M+H]+, 1255.8 [M+Na]+. 
9 
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10 6-deoxy-(8-aminooctylamino)-β-cyclodextrin β-CDNH(CH2)8NH2 
β-CDOTs 2 (10.0g, 7.8mmol) was dissolved in NMP (150mL) then diaminohexane (4.48g, 
31mmol) was added. The reaction mixture was stirred overnight at 75°C. After cooling at 
room temperature, the product was precipitated in acetone (500mL) then filtered. The solid 
was washed with acetone (3x100mL) then dried under vacuum. The powder was suspended in 
methanol then the mixture was stirred overnight at room temperature. The solid was filtered 
then dried under vacuum to give 9.47g (7.5mmol, 97%) of 10 as a white solid. 1H 
NMR (300MHz - DMSO-d6) : δ (ppm) = 1.50-1.51 (m, 2H), 2.28-2.31 (m, 2H), 2.46-2.48 
(m, 2H), 2.64-2.69 (m, 2H), 2.75-2.80 (m, 2H), 2.94-2.98 (m, 2H), 3.28-3.31 (m, 2H), 3.45-
3.80 (m, 49H), 4.7 (m, overlap with H2O) 4.94-5.00 (m, 7H). MS ESI+ (calc. for 
C48H84N2O34 1260.50): 1261.8 [M+H]+, 1283.7 [M+Na]+. 
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11 6-deoxy-(benzylamino)-β-cyclodextrin β-CDNHCH2Ph 
β-CDOTs 2 (5.0g, 3.9mmol) was dissolved in benzylamine (195mmol, 21.3mL) then the 
reaction mixture was stirred 4h at 75°C. After cooling at room temperature, the product was 
10 
11 
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precipitated in acetone (250mL) then filtered. The solid was washed with acetone (3x50mL) 
then dried under vacuum to give 4.96g (quant.) of 11 as a white solid. 1H NMR (300MHz - 
DMSO-d6) : δ (ppm) = 2.68-2.77 (m, 1H), 2.88-2.94 (m, 1H), 3.12-3.25 (m, 2H), 3.40-3.79 
(m, 42H), 4.91 (s, 7H), 7.23-7.32 (m, 5H). MS ESI+ (calc. for C48H84N2O34 1260.50): 
1224.20 [M+H]+, 1246.33 [M+Na]+. 
 
General synthesis of amino acid derivatives: 
β-CDOTs 2 (5g, 3.9mmol) was dissolved in water (75mL) then triethyl amine (10.81mL, 
78mmol) and the corresponding amino acid (39mmol) were successively added. The reaction 
mixture was stirred overnight at 70°C. After cooling at room temperature, the product was 
precipitated in acetone (500mL). The solid was filtered, washed with acetone (3x100mL) then 
dried under vacuum. 
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12a 6-carboxymethylamino-6-deoxy-β-cyclodextrin 
From 5.0g (3.9mmol) of β-CDOTs 2, 7.51g (y>100% because of glycine) of crude product 
was collected. 1H NMR (300MHz - D2O): δ (ppm) = 3.39-3.52 (m, 26H overlap with 
glycine), 3.73-3.85 (m, 21H), 4.69 (m, 67H overlap with H2O), 4.92 (s, 7H). MS ESI- (calc. 
for C44H73NO36 1191.39): 1190.6 [M-H]-. 
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12b 6-(2-carboxyethylamino)-6-deoxy-β-cyclodextrin 
From 5.0g (3.9mmol) of β-CDOTs 2, 8.19g (y>100% because of presence of β-alanine) of 
crude product was collected. 1H NMR (300MHz - D2O): δ (ppm) = 2.412-2.46 (t, J=6.67Hz, 
2H), 3.04-3.09 (t, J=6.67Hz, 2H), 3.45-3.57 (m, 21H), 3.74-3.89 (m, 28H), 4.96-4.97 (m, 7H), 
4.70 (m, overlap with H2O. MS ESI- (calc. for C45H75NO36 1205.41): 1204.7 [M-H]-. 
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12c 6-(3-carboxypropylamino)-6-deoxy-β-cyclodextrin 
From 5.5g (4.27mmol) of β-CDOTs 2, 9.45g (y>100% because of presence of aminobutyric 
acid) of crude product was collected. 1H NMR (300MHz - D2O): δ (ppm) = 1.80-1.88 (m, 
2H), 2.15-2.27 (m, 2H), 3.04-3.06 (m, 2H), 3.23-3.30 (m, 1H), 3.43-3.64 (m, 14H), 3.73-3.72 
(m, 28H), 4.71 (m, overlap with H2O), 4.99-5.07 (m, 7H). MS ESI- (calc. for C46H75NO36 
1219.42): 1218.8 [M-H]-. 
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12d 6-(4-carboxybutylamino)-6-deoxy-β-cyclodextrin 
From 8.44g (6.55mmol) of β-CDOTs 2, 8.12g (y≈100%,  presence of aminovaleric acid) of 
crude product were collected. 1H NMR (300MHz - D2O): δ (ppm) = 1.48-1.50 (m, 4H), 2.05-
2.10 (m, 2H), 2.83-2.87 (m, 2H), 3.40-3.52 (m, 14H), 3.69-3.84 (m, 28H), 4.70 (m, overlap 
with H2O), 4.92-4.92 (m, 7H).  MS ESI- (calc. for C47H79NO36 1233.44): 1232.7 [M-H]-. 
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14 6-(1-benzyl-1-carboxymethylamino)-6-deoxy-β-cyclodextrin 
From 5.0g (3.9mmol) of β-CDOTs 2, 6.72g (y>100%) of crude product were collected. 
1
H NMR (300MHz - D2O): δ (ppm) = 1.24 (m, 1H), 1.55-1.56 (m, 2H), 2.80-2.89 (m, 2H), 
3.09-3.68 (m, 42H), 4.83-4.84 (m, overlap with H2O), 5.66-5.77 (m, 7H), 7.21-7.29 (m, 5H). 
MS ESI
+
 (calc. for C51H79NO36 1281.44): 1282.1 [M+H]+, 1304.3 [M+Na]+. 
 
General synthesis of polyacid monosubstituted β-CD: 
0.6mmol of cyclodextrins was dissolved in water (5mL) then the solution was cooled to 0°C.  
Chloroacetic acid (5mmol) and NaOH (5mmol) each dissolved in water (2mL) then both 
solutions were combined and cooled at 0°C and added to the solution of cyclodextrin. pH was 
adjusted to 10-11 using a solution of NaOH in water (1M) then the reaction mixture was 
stirred at 80°C for 24h. pH was regularly adjusted to 10-11 with the solution of NaOH. After 
cooling to room temperature, the product was precipitated in absolute ethanol. The solid was 
filtered, washed with absolute ethanol (5mL) then dried under vacuum. 
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15 6-[bis(carboxylatomethyl)amino]-6-deoxy-β-cyclodextrin 
14 
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From 0.60mmol (0.68g) of β-CDNH2 5, 0.58g (0.46, 77%) of a white solid was collected. 1H 
NMR (300MHz - D2O): δ (ppm) =2.72 (m, 1H), 3.00-3.05 (m, 1H), 3.18 (s, 2H), 3.42-3.51 
(m, 14H), 3.72-3.85 (m, 28H), 4.87-4.99 (m, 7H) . MS ESI- (calc. for C46H75NO38 1249.4): 
1248.9 [M-H]-. 
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16a 6-[tris(carboxylatomethyl)(2-aminoethyl)amino]-6-deoxy-β-cyclodextrin 
From 3.20mmol (3.77g) of β-CDNH(CH2)2NH2 7, 3.66g (2.71mmol, 85%) of a white solid 
were collected. 1H NMR (300MHz - D2O): δ (ppm) = 2.49-3.23 (m, 1H), 3.43-3.51 (m, 
14H), 3.73-3.81 (m, 8H), 3.92 (s, 7H). MS ESI- (calc. for C50H82N2O40 1350.44): 1349.6 [M-
H]-. 
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16b 6-[tris(carboxylatomethyl)(3-aminopropyl)amino]-6-deoxy-β-cyclodextrin 
From 0.6mmol (0.71g) of β-CDNH(CH2)3NH2 8, 0.95g (r>100%) of crude product was 
collected. 1H NMR (300MHz - D2O): δ (ppm) =3.24-3.33 (m, 6H), 3.34-3.54 (m, 14H), 3.60-
3.88 (m, 28H), 4.05 (s, 1H), 4.13-4.23 (m, 1H), 4.26 (s, 1H), 4.38-4.50 (m, 2H), 4.92-5.06 (m, 
7H). MS ESI- (calc. for C51H84N2O40 1364.46):  1363.9 [M-H]-. 
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16c 6-[tris(carboxylatomethyl)(6-aminohexyl)amino]-6-deoxyβ-cyclodextrin 
From 3.49g (2.8mmol) of β-CDNH(CH2)6NH2 9, 3.52g (2.49mmol, 89%) of a white solid was 
collected. 1H NMR (300MHz - D2O): δ (ppm) = 1.18-1.53 (m, 8H), 2.47-2.78 (m, 3H), 2.91-
3.22 (m, 6H), 3.45-3.52 (m, 14H), 3.63-3.95 (m, 21H), 4.83-5.05-m, 7H). MS ESI- (calc. for 
C54H90N2O40 1406.51): 1406.1 [M-H]-, 702.8 [M-2H]2-. 
 
Native β-cyclodextrin/ImTs inclusion complex 
10g (8.8mmol) of native β-cyclodextrin was suspended in water (400mL) then ImTs 3 (1.96g, 
8.8mmol) was added. The suspension was stirred for 24h at RT then the solid was filtered, 
washed with acetone (3x) then dried overnight at 40°C to give 7.7g (5.6mmol, 64%) of 
complex as a white solid. 1H NMR (300MHz - DMSO-d6): δ (ppm) = 3.40 (s, 3H), 3.27-
3.38 (m, 40H overlap with H2O), 3.54-3.70 (m, 21H), 4.45-4.49 (m, 7H), 4.82-4.83 (m, 7H), 
5.68-5.75 (m, 14H), 7.12 (s, 1H), 7.49-7.51 (d, J=8.35Hz, 2H), 7.74 (s, 1H), 7.96-7.99 (d, 
J=8.38Hz, 2H), 8.36 (s, 1H). 
 
β-CDNH2/ibuprofen inclusion complex 
0.585g (0.5mmol) of β-CDNH2 was dissolved in water (50mL) then ibuprofen (0.206g, 
1mmol) was added. The reaction mixture was stirred for 10 minutes at RT then was filtered. 
The aqueous layer was concentrated then the solid was dried overnight at 40°C to give 0.607 
g (0.44mmol, 88%) of inclusion complex as a white solid. 1H NMR (300MHz - D2O): δ 
(ppm) =0.78-0.80 (d, J=6.57Hz, 6H), 1.22-1.25 (d, J=6.24Hz, 3H), 1.70-1.79 (m, 1H), 2.27-
2.39 (d, 6.43Hz, 2H), 3.18-3.23 (m, 1H), 3.28-3.35 (m, 1H), 3.41-3.80 (m, 40H), 4.91-4.92 
(m, 7H), 6.93-6.95 (d, J=7.77Hz, 2H), 7.07-7.09 (d, 7.55Hz, 2H). 
16c 
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III - Stochastic chiral symmetry breaking of a conglomerate 
forming system; study of a series of triazoyl ketone   
 
20-Cl (E)-1-(4-chlorophenyl)-4,4-dimethylpent-1-en-3-one  
NaOH (8g, 200mmol) was dissolved in water (14mL) then ethanol (30mL) was added. The 
reaction mixture was placed in an ice-bath then a solution of 4-chlorobenzaldehyde (28.11g, 
200mmol) and pinacolone (20.03g, 200mmol) in ethanol (40mL) was added dropwise. The 
ice-bath was removed and the reaction mixture was vigorously stirred at room temperature for 
4h then filtered. The solid was washed with water (3x75mL) then dried under vacuum. 36.18g 
(81%) of 20-Cl was obtained as a pale yellow solid. 1H NMR (300MHz, CDCl3): δ (ppm) =  
1.21 (s, 9H), 7.06-7.11 (d, J=15.6Hz), 7.31-7.35 (m, 2H), 7.46-7.50 (m, 2H), 7.58-7.63 (d, 
J=15.6Hz). 13C NMR (75MHz, CDCl3): δ (ppm) = 26.19, 43.19, 121.08, 129.02, 129.36, 
133.35, 136.92, 141.37, 203.86 Chemical ionisation MS+ (calc. for C13H15ClO 222.71): m/z 
= 223.0 [M+H]+, 225.0 [M+H+2]+, 240.0 [M+NH4]+, 242.1 [M+NH4+2]+. Melting point: 
85°C. 
 
20-H (E)-4,4-dimethyl-1-phenylpent-1-en-3-one  
20-H was prepared following the same procedure as 20-Cl from benzaldehyde (5.31g, 
50mmol). As 20-H is a liquid, the work-up was modified as follow: water (100mL) was added 
to the reaction mixture and the product was extracted by diethyl ether (3x50mL). The 
combined organic layers were dried with MgSO4 then the solvent was evaporated and the 
product was dried under vacuum to give 8.64g (92%) of a colourless liquid. 1H NMR 
(300MHz, CDCl3): δ (ppm) = 1.23 (s, 9H), 7.10-7.16 (d, J=15.6Hz, 1H), 7.38-7.40 (m, 3H), 
7.56-7.59 (m, 2H), 7.66-7.71 (d, J=15.6Hz, 1H) 13C NMR (75MHz, CDCl3): δ (ppm) = 
26.09, 43.00, 120.484, 128.06, 128.68, 129.98, 134.69, 142.69, 203.86 Chemical ionisation 
MS
+
 (calc. for C13H16O 188.12): m/z = 189.0 [M+H]+, 206.1 [M+NH4]+ 
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20-Me (E)-1-(p-toluyl)-4,4-dimethylpent-1-en-3-one  
20-Me was prepared following the same procedure as 20-Cl from p-tolualdehyde (20.03g, 
200mmol) to give 30.1g (75%) of a pale yellow solid. 1H NMR (300MHz, CDCl3): δ (ppm) 
= 1.23 (s, 9H), 2.38 (s, 3H), 7.06-7.11 (d, J=15.60Hz, 1H), 7.18-7.21 (d, J=8.0Hz, 2H), 7.46-
7.49 (d, J=8.01Hz, 2), 7.63-7.67 (d, J=15.60Hz, 1H). 13C NMR (75MHz, CDCl3): δ (ppm) = 
21.46, 26.35, 43.18, 119.71, 128.26, 129.55, 132.17, 140.59, 142.90, 204.31. ESI-MS+ (calc. 
for C14H18O 202.14): m/z = 203.1 [M+H]+. Melting point: 83°C. 
 
20-Br (E)-1-(4-bromophenyl)-4,4-dimethylpent-1-en-3-one  
20-Br was prepared following the same procedure as 20-Cl from 4-bromobenzaldehyde 
(37.00g, 200mmol) to give 41.04g (75%) of a pale yellow solid. 1H NMR (300MHz, CDCl3): 
δ (ppm) = 1.22 (s, 9H), 7.07-7.12 (d, J=15.6Hz, 1H), 7.41-7.44 (d, J=8.6Hz, 2H), 7.50-7.52 
(d, J=8.6Hz, 2), 7.57-7.62 (d, J=15.6Hz, 1H) 13C NMR (75MHz, CDCl3): δ (ppm) = 26.23, 
43.26, 121.21, 124.33, 129.62, 132.04, 133.81, 141.51, 203.98. ESI-MS+ (calc. for 
C13H15BrO 266.03): m/z = 266.94 [M+H]+, 268.87 [M+H+2]+. Melting point: 92°C. 
 
20-tBu (E)-1-(4-tertbuthylphenyl)-4,4-dimethylpent-1-en-3-one  
20-tBu was prepared following the same procedure as 20-Cl from 4-tert-butylbenzaldehyde 
(23.36g, 144mmol). As 20-tBu is a liquid, the work-up was modified as follow: water 
(100mL) was added to the reaction mixture and the product was extracted by ethyl acetate 
(3x50mL). The combined organic layers were washed with water (3x), dried with MgSO4 
then the solvent was evaporated. The product was dried under vacuum to give 33.40g (95%) 
of a pale yellow liquid. 1H NMR (300MHz, CDCl3): δ (ppm) = 1.23 (s, 9H), 1.33 (s, 9H), 
7.07-7.12 (d, J=15.6Hz, 1H), 7.39-7.42 (d, J=8.4Hz, 2H), 7.50-7.53 (d, J=8.4Hz, 2H), 7.65-
7.70 (d, J=15.5Hz, 1H). 13C NMR (75MHz, CDCl3): δ (ppm) = 26.34, 31.15, 34.87, 43.20, 
119.93, 125.81, 128.11, 132.15, 142.78, 153.75, 204.37. ESI-MS+ (calc. for C17H24O 
244.18): m/z = 244.24 [M+H]+. 
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21-Cl 1-(4-chlorophenyl)-4,4-dimethylpentan-3-one  
3g of Raney Nickel, 50% slurry in water were placed in a round bottom flask and were 
washed with ethanol (3x10mL) then with ethyl acetate (3x10mL). A solution of 20-Cl 
(10.67g, 47mmol) in ethyl acetate (75mL) was added to the nickel. The reaction mixture was 
stirred under vacuum for 5 minutes then flushed with hydrogen gaz and stirred at room 
temperature overnight under hydrogen atmosphere using a rubber balloon. The conversion of 
the reaction was controlled by NMR. After complete conversion of the starting material, the 
solution was filtered through a pad of celite. The filtrate was evaporated and the product was 
dried under vacuum to give 10.32g (46mmol, 96%) of 21-Cl as a colourless liquid. 1H NMR 
(300MHz, CDCl3): δ (ppm) = 1.14 (s, 9H), 2.78-2.83 (m, 2H), 2.86-2.912 (m, 2H), 7.13-7.18 
(m, 2H), 7.25-7.30 (m, 2H) 13C NMR (75MHz, CDCl3): δ (ppm) = 26.26, 29.31, 38.16, 
44.02, 128.46, 129.76, 131.70, 140.00, 214.53. ESI-MS+ (calc. for C13H17ClO 224.10): m/z 
= 225.13 [M+H]+, 227.18 [M+H+2]+. 
 
21-H 4,4-dimethyl-1-phenylpentan-3-one  
21-H was prepared following the same procedure as 21-Cl from 10,23g (54mmol) of 20-H to 
give 10.07g (53mmol, 97%) of as a colorless liquid. 1H NMR (300MHz, CDCl3): δ (ppm) = 
1.11 (s, 9H), 2.77-2.83 (m, 2H), 2.86-2.91 (m, 2H), 7.16-7.21 (m, 3H), 7.30-7.31 (m, 2H). 13C 
NMR (75MHz, CDCl3): δ (ppm) = 26.16, 29.95, 38.33, 43.91, 125.85, 128.34, 141.42, 
142.76, 214,76. Chemical ionisation MS+ (calc. for C13H18O 190.28): m/z = 208.1 
[M+NH4]+. 
 
21-Me 4,4-dimethyl-1-(p-tolyl)pentan-3-one  
21-Me was prepared following the same procedure as 21-Cl from 30.1g (149mmol) of 20-Me 
to give 26.0g (127mmol, 86%) of a colourless liquid. For a complete conversion of the 
starting material, the rubber balloon was refilled with Hydrogen and the reaction mixture was 
Experimental part 
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stirred another night at room temperature. 1H NMR (300MHz, CDCl3): δ (ppm) = 1.12 (s, 
9H), 2.32 (s, 3H), 2.75-2.88 (m, 4H), 7.09-7.11 (m, 4H). 13C NMR (75MHz, CDCl3): δ 
(ppm) = 20.87, 26.21, 29.55, 38.52, 60.24, 128.13, 128.98, 135.30, 138.37, 214.82. ESI-MS+ 
(calc. for C14H20O 204.15): m/z = 205.07 [M+H]+. 
 
21-Br 1-(4-bromophenyl)-4,4-dimethylpentan-3-one  
16.6g (154mmol) of 20-Br were hydrogenated. However the hydrolyse of the Br-Ar bond was 
significant and, after refilling the rubber balloon six times and changing the catalyst twice, the 
conversion stopped around 50%. 10.55g of crude product was obtained. It was composed of 4 
molecules: 21-Br (≈35%, 16mmol), unreacted 20-Br (≈35%, 16mmol) and the corresponding 
non-brominated products 20-H (≈15%, 7mmol) and 21-H (≈15%, 7mmol). Relative 
proportions of products were determined by NMR. The crude product was used in the 
following step  without purification. 1H NMR (300MHz, CDCl3): δ (ppm) = 1.09 (s, 9H), 
2.73-2.87 (m, 4H). Peaks of aromatic hydrogens are superimposed with those of the by-
products. 13C NMR (75MHz, CDCl3): δ (ppm) = 25.88, 29.69, 37.98, 43.53, 129.83, 130.97, 
133.42, 140.15, 213,73. ESI-MS+ (calc. for C13H17BrO 268.05): m/z = 269.07 [M+H]+, 
271.10 [M+H+2]+, 290.96 [M+Na]+, 293.02 [M+Na+2]+. 
 
21-tBu 1-(4-tert-butylphenyl)-4,4-dimethylpentan-3-one  
21-tBu was prepared following the same procedure as 21-Cl from 35.7g (146mmol) of 20-
tBu to give 26.0g (146mmol, quant.) of a pale yellow solid. For a complete conversion of the 
starting material, the rubber balloon was refilled twice with hydrogen and the reaction mixture 
was stirred two other nights at room temperature. 1H NMR (300MHz, CDCl3): δ (ppm) = 
1.15 (s, 9H), 1.34 (s, 9H), 2.79-2.91 (m, 4H), 7.15-7.18 (d, J=8.3 Hz, 2H), 7.33-7.36 (d, 
J=8.3Hz, 2H). 13C NMR (75MHz, CDCl3): δ (ppm) = 26.32, 29.50, 31.35, 34.31, 38.48, 
44.04, 125.27, 127.95, 138.41, 148.77, 215.12. ESI-MS+ (calc. for C17H26O 246.20): m/z = 
246.92 [M+H]+. 
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22-Cl 2-bromo-1-(4-chlorophenyl)-4,4-dimethylpentan-3-one  
21-Cl (13.46g, 59.89mmol) was dissolved in glacial acetic acid (120mL) then tetrabutyl 
ammonium tribromide (31.80g, 65.88mmol) was added. The reaction mixture was stirred at 
room temperature for 5h then water (350mL) was added. The combined organic and aqueous 
phases were transferred in a separating funnel then the product was extracted with ethyl 
acetate (4x150mL). Organics layers were combined, then washed with water (2x150mL) and 
with a sodium hydroxide aqueous solution (around 2,5.10-1mol.L-1) until all acetic acid was 
removed. The organic layer was dried with MgSO4, the solvent was evaporated and the 
product was dried under vacuum to give 17.52g (57.7mmol, 96%) of 22-Cl as a white solid. 
1
H NMR (300MHz, CDCl3): δ (ppm) = 1.01 (s, 9H), 3.12-3.18 (dd, J=5.7Hz, J=13.5Hz, 1H), 
3.40-3.48 (dd, J=9.3Hz, J=13.2Hz, 1H), 4.68-4.73 (dd, J=5.7Hz, J=9.3Hz, 1H), 7.07-7.12 (d, 
J=8.6Hz, 2H), 7.23-7.28 (d, J=8.6Hz, 2H). 13C NMR (75MHz, CDCl3): δ (ppm) = 26.27, 
39.90, 43.67, 44.08, 128.75, 130.96, 133.12, 135.71, 208.32. ESI-MS+ (calc. for 
C13H16BrClO 302.01): m/z = 325.07 [M+Na]+, 327.07 [M+Na+2]+, 329.07 [M+Na+4]+. 
 
22-H 2-bromo-4,4-dimethyl-1-phenylpentan-3-one  
22-H was prepared following the same procedure as 22-Cl from 10.00g (53mmol) of 21-H to 
give 13.66g (51mmol, 97%) of a white solid. 1H NMR (300MHz, CDCl3): δ (ppm) = 0.98 (s, 
9H), 3.16-3.22 (dd, J=5.6Hz, J=13.3Hz, 1H), 3.43-3.51 (dd, J=9.7Hz, J=13.3Hz, 1H), 4.73-
4.78 (dd, J=5.6Hz, J=9.7Hz, 1H), 7.14-7.17 (m, 2H), 7.22-7.31 (m, 3H). 13C NMR (75MHz, 
CDCl3): δ (ppm) = 26.18, 40.73, 44.09, 44.32, 127.19, 128.60, 129.63, 137.24, 208.60. ESI-
MS
+
 (calc. for C13H16BrO 268.05): m/z = 291.12 [M+Na]+, 293.12 [M+Na+2]+. 
 
22-Me 2-bromo-4,4-dimethyl-1-(p-tolyl)pentan-3-one  
22-Me was prepared following the same procedure as 22-Cl from 26.0g (127mmol) of 21-Me 
to give 32.5g (115.6mmol, 91%) of a white solid. 1H NMR (300MHz, CDCl3): δ (ppm) = 
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0.99 (s, 9H), 2.30 (s, 3H), 3.11-3.18 (dd, J=5.6Hz, J=13.4Hz, 1H), 3.39-3.52 (m, 2H), 4.71-
4.76 (dd, J=5.7Hz, J=9.5Hz, 1H), 7.02-7.11 (m, 4H) (CDCl3 = 7.26ppm). 13C NMR (75MHz, 
CDCl3): δ (ppm) = 21.03, 26.22, 33.53, 40.28, 44.27, 129.22, 129.45, 134.12, 136.75, 208.59. 
ESI-MS
+
 (calc. for C13H19BrO 282.06): m/z = 283.10 [M+H]+, 285.03 [M+H+2]+. 
 
22-Br 2-bromo-1-(4-bromophenyl)-4,4-dimethylpentan-3-one  
22-Br was prepared following the same procedure as 22-Cl from 10.55g of the crude product 
containing 21-Br by using 1.4 equivalent of TBA.Br3 (instead of 1.1 equivalent). 16.2g of 
crude product, containing 22-Br, were obtained. The crude product was used in the following 
step without purification. 1H NMR (300MHz, CDCl3): δ (ppm) = 1.01, 3.10-3.16 (dd, 
J=5.7Hz, J=13.5Hz, 1H), 3.38-3.46 (dd, J=9.5Hz, J=13.6Hz, 1H), 4.68-4.73 (dd, J=5.7Hz, 
J=9.5Hz, 1H), 7.02-7.05 (d, J=8.3Hz, 2H), 7.38-7.43 (d, J=8.4Hz, 2H). ESI-MS+ (calc. for 
C13H16Br2O 345.96): m/z = 348.24 [M+H+2]+. 
 
22-tBu 2-bromo-1-(4-tert-butylphenyl)-4,4-dimethylpentan-3-one  
22-tBu was prepared following the same procedure than 22-Cl from 38.00g (154mmol) of 21-
tBu to give 50.1g (154mmol, quant.) of a white solid. 1H NMR (300MHz, CDCl3): δ (ppm) 
= 0.97 (s, 9H), 1.28 (s, 9H), 3.13-3.20 (dd, J=5.7Hz, J=13.4Hz, 1H), 3.39-3.47 (dd, J=9.6Hz, 
J=13.4Hz, 1H), 4.72-4.77 (dd, J=5.7Hz, J=10.2Hz, 1H), 7.04-7.10 (d, J=8.2Hz, 2H), 7.28-
7.30 (d, J=8.3Hz, 2H). 13C NMR (75MHz, CDCl3): δ (ppm) = 26.09, 31.27, 34.41, 40.18, 
44.24, 44.33, 125.42, 129.25, 134.10, 150.19, 208.72. ESI-MS+ (calc. for C17H25BrO 
324.11): m/z = 324.89 [M+H]+, 326.82 [M+H+2]+. 
 
17-Cl 1-(4-chlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pentan-3-one  
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22-Cl (24.7g, 81mmol) was dissolved in acetone (170mL) then 1,2,4-1H-triazole (5.62g, 
81mmol) and K2CO3 (22.5g, 163mmol) were added. The reaction mixture was stirred at 45°C 
for 4h. After cooling to room temperature, the solution was filtered. The solid was washed 
with acetone (3x100mL). The filtrate was evaporated; a pale orange solid was obtained. It was 
washed with diisopropyl ether (3x50mL) then with a small amount of methanol (2x10mL) and 
dried. The filtrate was evaporated and the solid obtained was washed as previously described. 
The two solids were combined to give 19.7g (67mmol, 83%) of 17-Cl as a white solid. 1H 
NMR (300MHz, CDCl3): δ (ppm) = 0.97 (s, 9H), 3.12-3.19 (dd, J=7.8Hz, J=13.7Hz, 1H), 
3.25-3.32 (dd, J=7.5Hz, J=13.7Hz), 5.61-5.66 (t, 1H), 6.93-6.95 (d, J=8.4Hz, 2H), 7.15-7.18 
(d, J=8.4Hz, 2H), 7.82 (s, 1H), 8.17 (s, 1H). 13C NMR (75MHz, CDCl3): δ (ppm) = 25.35, 
38.35, 44.68, 62.33, 128.96, 130.33, 133.22, 133.51, 142.15, 151.19, 208.67. ESI-MS+ (calc. 
for C15H18ClN3O 291.11): m/z = 292.25 [M+H]+, 294.19 [M+H+2]+, 314.13 [M+Na]+, 
316.13 [M+Na+2]+. Elementary analysis (calc. for C15H18ClN3O: %C=61.75, %H=6.22, 
%N=14.40): %C=61.73, %H=6.24, %N=14.47%. Melting point (by DSC): 120.9°C. 
 
17-H 4,4-dimethyl-1-phenyl-2-(1,2,4-triazol-1-yl)pentan-3-one  
17-H was prepared following the same procedure as 17-Cl from 13.66g (51mmol) of 22-H to 
give 9.24g (36mmol, 71%) of a white solid. 1H NMR (300MHz, CDCl3): δ (ppm) = 1.03 (s, 
9H), 3.21-3.29 (dd, J=7.7Hz, J=13.6Hz, 1H), 3.36-3.43 (dd, J=6.6Hz, J=13.6Hz, 1H), 5.72-
5.77 (t, J=7.7Hz, 1H), 7.07-7.10 (m, 2H), 7.24-7.31 (m, 3H+CHCl3), 7.90 (s, 1H), 8.28 (m, 
1H). 13C NMR (75MHz, CDCl3): δ (ppm) = 25.38, 39.17, 44.73, 62.68, 127.36, 128.74, 
129.05, 135.01, 142.18, 151.08. ESI-MS+ (calc. for C15H19N3O 257.15): m/z = 258.23 
[M+H]+, 280.25 [M+Na]+, 537.05 [2M+Na]+. Elementary analysis (calc. for C15H19N3O: 
%C=70.01, %H=7.44, %N=16.33): %C=69.94, %H=7.42, %N=16.27. Melting point (by 
DSC): 71.0°C. 
 
17-Me 4,4-dimethyl-1-(p-tolyl)-2-(1,2,4-triazol-1-yl)pentan-3-one  
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17-Me was prepared following the same procedure as 17-Cl from 23.10g (81.6mmol) of 22-
Me to give 17.00g (63mmol, 77%) of a white solid. 1H NMR (300MHz, CDCl3): δ (ppm) = 
0.99 (s, 9H), 2.26 (s, 3H), 3.12-3.19 (dd, 2H, J=7.9Hz, J=13.7Hz), 3.27-3.46 (dd, 2H, 
J=7.5Hz, J=13.7Hz), 5.65-5.70 (t, 1H, J=7.7Hz), 6.90-6.93 (d, 2H, J=8.0Hz), 7.02-7.04 (d, 
2H, J=7.9Hz), 7.83 (s, 1H), 8.20 (s, 1H) (CDCl3 = 7.26ppm). 13C NMR (75MHz, CDCl3): δ 
(ppm) = 20.96, 25.46, 38.80, 44.74, 62.82, 128.90, 129.42, 131.89, 137.02, 142.24, 151.09, 
209.28. ESI-MS+ (calc. for C16H21N3O 271.17): m/z = 272.27 [M+H]+, 294.27 [M+Na]+, 
565.13 [2M+Na]+. Elementary analysis (calc. for C16H21N3O: %C=70.82, %H=7.80, 
%N=15.49): %C=70.21, %H=7.77, %N=17.07. Melting point (by DSC): 96.2°C. 
 
17-Br 1-(4-bromophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pentan-3-one  
17-Br was prepared following the same procedure as 17-Cl from 16.2g of crude material 
containing 22-Br to give 2.8g (8.3mmol) of 17-Br as a white solid. The work-up was 
modified as follow: after filtration, the mixture was recrystallized in diisopropyl ether then the 
solid was stirred in methanol (15mL) for 1h, then filtered and dried under vacuum. 1H NMR 
(300MHz, CDCl3): δ (ppm) = 1.01 (s, 9H), 3.14-3.21 (dd, J=7.7Hz, J=13.7Hz, 1H), 3.27-3.34 
(dd, J=7.5Hz, J=13.7Hz, 1H), 5.64-5.69 (t, 7.7Hz, 1H), 6.91-6.45 (d, J=8.4Hz, 1H), 7.36-7.39 
(d, J=  7.4Hz, 1H), 7.86 (s, 2H), 8.20 (s, 1H). 13C NMR (75MHz, CDCl3): δ (ppm) = 25.30, 
38.30, 44.62, 62.17, 121.21, 130.63, 131.70, 133.98, 142.14, 151.44, 208.57. ESI-MS+ (calc. 
for C15H18BrN3O 335.06): m/z = 336.20 [M+H]+, 338.13 [M+H+2]+, 358.13 [M+Na]+, 
360.07 [M+Na+2]+. Elementary analysis (calc. for C15H18BrN3O: %C=53.58, %H=5.40, 
%N=12.50): %C=53.47, %H=5.74, %N=12.58. Melting point (by DSC): 139.3°C. 
 
17-tBu 1-(4-tert-butylphenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pentan-3-one  
17-tBu was prepared following the same procedure as 17-Cl from 50.00g (154mmol) of 22-
tBu. This compound is difficult to crystallize and can not be purified as 17-Cl. Around a half 
of the crude product (30.00g) was purified by chromatography on silicagel with petroleum 
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ether/ethyl acetate from 9/1 to 7/3 as eluent. 18.5g of pure 17-tBu were obtained as a pale 
yellow solid. 1H NMR (300MHz, CDCl3): δ (ppm) = 1.00 (s, 9H), 1.26 (s, 9H), 3.17-3.24 
(dd, J=7.9Hz, J=13.8Hz, 1H), 3.29-3.36 (dd, J=7.5Hz, J=13.7Hz, 1H), 5.69-5.73 (t, 7.7Hz, 
1H), 6.97-6.99 (d, J=8.2Hz, 1H), 7.25-7.28 (d, J=8.2Hz, 1H), 7.87 (s, 2H), 8.24 (s, 1H). 13C 
NMR (75MHz, CDCl3): δ (ppm) = 25.39, 31.21, 34.39, 38.62, 44.77, 62.74, 125.67, 128.72, 
131.88, 142.26, 150.44, 151.06, 209.34. ESI-MS+ (calc. for C19H27N3O 313.22): m/z = 
314.31 [M+H]+, 336.20 [M+Na]+. Elementary analysis (calc. for C19H27N3O: %C=72.81, 
%H=8.68, %N=13.41): %C=72.75, %H=8.67, %N=13.77. Melting point (by DSC): 47.4°C. 
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IV - Synthesis of pure enantiomer of Prasugrel by deracemisation 
 
41 Boc-2-fluorophenylglycine, 2-(tert-butoxycarbonylamino)-2-(2-fluorophenyl)acetic acid 
10g (59.1mmol) of 2-fluorophenylglycine 40 were dissolved in a 1/1 THF/water mixture 
(350mL) then NaHCO3 (14.9g, 177.0mmol) was added. The reaction mixture was cooled 
down to 0°C then Boc2O (15.5g, 71.0mmol) was added. The reaction mixture was stirred for 
30 minutes at 0°C then overnight at RT. The product was extracted with Et2O (2x250mL) 
then the combined organic layers were washed with brine (250mL). The first aqueous layer 
was acidified with half saturated aqueous citric acid then the product was extracted with 
CH2Cl2 (3x120mL). The combined organic layers were washed with brine (100mL). Both 
organic layers were combined, dried (MgSO4) then the solvent was evaporated to give 16.31g 
(quant.) of 41 as a pale yellow powder. 1H NMR (300MHz, methanol-d4): δ (ppm) = 1.44 
(s, 9H), 5.51, 7.08-7.19 (m, 2H), 7.31-7.42 (m, 2H). 13C NMR (75MHz, methanol-d4): δ 
(ppm) = 28.71, 52.86, 80.92, 116.41-116.70 (d, J=22.0Hz), 125.53-125.58 (d, J=3.5Hz), 
126.28-126.47 (d, J=14.4Hz), 130.34-130.37 (d, J=2.9Hz), 131.16-131.27 (d, J=8.3Hz), 
157.49, 160.23-163.50 (d, J=246.8Hz), 173.52. MS ESI- (calc. for C13H16FNO4 269.11): 
268.08 [M-H]-. Melting point: 136°C. 
F
BocHN
N
O
O
42
 
42 Tert-butyl 1-(2-fluorophenyl)-2-(methoxy(methyl)amino)-2-oxoethylcarbamate 
41 (5g, 18.57mmol) was dissolved in THF (35mL) then carbonyldiimidazole (CDI, 3.01g, 
18.57mmol) was added. The reaction mixture was stirred for 2h at RT then N-O-
dimethylhydroxylamine hydrochloride (1.81g, 18.57mmol) and triethylamine (TEA, 2.6mL, 
18.57mmol) were added. The reaction mixture was stirred overnight at RT then the solvent 
was evaporated. The residue was dissolved in AcOEt then washed with saturated aqueous 
NaHCO3 (3x75ml), water (3x75ml) then with brine (1x75mL). The organic layer was dried 
(MgSO4) then the solvent was evaporated to give 4.83g (15.41mmol, 83%) of 42 as a white 
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powder. 1H NMR (300MHz, CDCl3): δ (ppm) = 1.34 (s, 9H), 3.09 (s, 3H), 3.41 (s, 3H), 
5.76-5.86 (m, 1H), 6.99-7.07 (m, 2H), 7.17-7.29 (m, 2H). 13C NMR (75MHz, CDCl3): δ 
(ppm) = 28.23, 49.11, 61.00, 79.76n 115.54-115.83 (d, J=21.9Hz), 124.32-124.36 (d, 
J=3.4Hz), 125.09-125.29 (d, J=15.4Hz), 128.92-128.96 (d, J=3.9Hz), 129.62-129.73 (d, 
J=8.2Hz), 154.75, 158.53-161.84 (d, J=249.2Hz), 170.49. MS ESI+ (calc. for C15H21FN2O4 
312.15): 312.90 [M+H]+, 335.05 [M+Na]+. Melting point: 136°C. 
 
44 tert-butyl 1-(2-fluorophenyl)-2-morpholino-2-oxoethylcarbamate 
41 (19g, 70.6mmol) was dissolved in THF (140mL) then CDI (11.44g, 70.6mmol) was added. 
The reaction mixture was stirred for 1h45 at RT then cooled down to 0°C. Morpholine 
(6.15mL, 70.6mmol) was added dropwise at 0°C then the reaction mixture was stirred 
overnight at RT. The solvent was evaporated then the residue was dissolved in AcOEt. The 
organic layer was washed with saturated aqueous NaHCO3 (3x100ml), brine (3x100ml) and 
water (1x100mL) then dried (MgSO4) and the solvent was evaporated to give 22.65g 
(67.1mmol, 95%) of 44 as a white powder. 1H NMR (300MHz, CDCl3): δ (ppm) = 1.32 (s, 
9H), 3.08-3.34 (m, 1H), 3.40-3.59 (m, 7H), 5.77-5.79 (d, H), 6.97-7.09 (m, 2H), 7.19-7.32 (m, 
2H). 13C NMR (75MHz, CDCl3): δ (ppm) = 28.09, 42.62, 47.98, 53.26, 65.86, 66.24, 79.61, 
115.43-115.72 (d, J=22.0Hz), 124.67-124.71 (d, J=3.7Hz), 124.84, 128.50-128.54 (d, 
J=3.1Hz), 129.83-129.94 (d, J=8.3Hz), 154.54, 157.70-160.97 (d, J=247.4Hz), 167.97. MS 
ESI+ (calc. for C17H23FN2O4 312.15): 338.98 [M+H]+, 361.07 [M+Na]+. 
 
45 Tert-butyl 2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethylcarbamate 
Magnesium turnings (0.94mg, 38.42mmol) were suspended in dry THF (15ml) at 0°C under 
nitrogen then few drops of I2 in THF were added. The bromocyclopropane (7.02mL, 
38.42mmol) was dissolved in dry THF (30mL) then 5mL of this solution were added 
dropwise to the magnesium at 0°C. After the disappearance of the yellow colour, the rest of 
the solution was added dropwise at 0°C, under nitrogen. The reaction mixture was stirred for 
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2h at 0°C. 42 (3g, 9.60mmol), dissolved in dry THF (25mL), was added dropwise to the 
bromocyclopropyl magnesium at 0°C. The reaction mixture was stirred for 1h30 at 0°C the 
overnight at RT. The mixture was quenched with saturated aqueous NH4Cl at 0°C then the 
product was extracted with AcOEt (3x50mL). The combined organic layers were washed with 
brine (1x50mL), dried (MgSO4) then the solvents were evaporated. The crude product was 
purified on silicagel with n-heptane/AcOEt 9/1 as eluent (Rf = 0.3) to give 2.35g (7.97mmol, 
83%) of 45 as pale yellow oil. Exactly the same procedure was used to prepare 45 from the 
morpholine derivative 44. 1H NMR (300MHz, CDCl3): δ (ppm) = 0.71-0.79 (m, 1H), 0.87-
0.99 (m, 2H), 1.07-1.14  (m, 1H), 1.39 (s, 9H), 1.84-1.92 (m, 1H), 5.71-5.73 (d, 1H), 7.05-
7.17 (m, 2H), 7.26, 7.33 (m, 2H). 13C NMR (75MHz, CDCl3): δ (ppm) = 11.86, 12.02, 18.31, 
28.16, 58.84, 79.71, 115.68-115.97 (d, J=21.5Hz), 124.57-124.61 (d, J=3.5Hz), 125.37, 
129.66-129.69 (d, J=2.8Hz), 129.87-120.00 (d, J=8.3Hz), 154.67, 158.92-162.20 (d, 
J=247.6Hz), 204.77. MS ESI+ (calc. for C16H20FNO3 293.14): 294.09 [M+H]+. 
F
H3N
O
Cl
37.HCl
 
37.HCl 2-amino-1-cyclopropyl-2-(2-fluorophenyl)ethanone hydrochloride 
43 (14.15g, 49.43mmol) was dissolved in 1,4-dioxane (125mL) then HCl 4N in 1,4-dioxane 
(123mL, 494mmol) was added. The reaction mixture was stirred overnight at RT then the 
solid was filtered, washed with 1,4-dioxane (2x50mL) then dried under vacuum. The filtrate 
was concentrated. AcOEt was added to the residue and the solid was filtered, washed with 
AcOEt (2x50mL) then dried under vacuum. The two solids were combined to give 9.50g 
(41.52mmol, 84%) of 37H.HCl as a white powder. 1H NMR (300MHz, methanol-d4): δ 
(ppm) =  0.88, 1.24 (m, 4H), 1.88-1.95 (m, 1H), 5.67 (s, 1H), 7.31-7.39 (m, 2H), 7.50-7.63 
(m, 2H). 13C NMR (75MHz, methanol-d4): δ (ppm) = 13.07, 13.45, 19.37, 58.38, 117.50-
117.78 (d, J=21.3Hz), 120.26-120.45 (d, J=14.3Hz), 126.81-126.85 (d, J=3.6Hz), 132.02-
132.05 (d, J=2.5Hz), 133.97-134.08 (d, J=8.5Hz), 160.70-164.00 (d, J=248.7Hz), 203.71. MS 
ESI+ (calc. for C11H12FNO 193.09): 193.09 [M+H]+. 
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46 2,5-dicyclopropyl-3,6-bis(2-fluorophenyl)pyrazine 
1
H NMR (300MHz, CDCl3): δ (ppm) = 0.88-0.95 (m, 4H), 1.11-1.16 (m, 4H), 1.90-1.99 (m, 
2H), 7.18-7.24 (t, 2H), 7.28-7.33 (m, 2H), 7.42-7.50 (m, 2H), 7.55-7.61 (m, 2H). 13C NMR 
(75MHz, CDCl3): δ (ppm) = 10.04, 13.37, 13.42, 115.59-115.88 (d, J=21.9Hz), 124.17-
124.21 (d, J=3.6Hz), 126.71-126.91 (d, J=15.3Hz), 130.26-130.37 (d, J=8.1Hz), 131.99-
132.04 (d, J=3.3Hz), 146.38, 152.00, 158.40-161.70 (d, J = 248.9Hz). MS ESI+ (calc. for 
C22H18F2N2 348.14): 349.22 [M+H]+. Melting point: 178°C. 
 
48.HCl 2-amino-2-(2-fluorophenyl)-1-morpholinoethanone hydrochloride 
44 (35.5g, 105mmol) was dissolved in 1,4-dioxane (700mL) then HCl 4N in 1,4-dioxane 
(210mL, 840mmol) was added. The reaction mixture was stirred overnight at RT then the 
solid was filtered, washed with 1,4-dioxane (3x100mL) then dried under vacuum. The filtrate 
was concentrated; the solid was filtered then washed with acetone (3x50mL) and dried under 
vacuum. The two solids were combined to give 24.68g (89.3mmol, 85%) of 48.HCl as a 
white powder. 1H NMR (300MHz, methanol-d4): δ (ppm) =  3.05-3.17 (m, 2H), 3.39-3.70 
(m, 6H), 5.75 (s, 1H), 7.30-7.39 (m, 2H), 7.49-7.60 (m, 2H). 13C NMR (75MHz, methanol-
d4): δ (ppm) = 44.15, 46.87, 49.54, 67.00, 67.47, 117.52-117.80 (d, J=21.6Hz), 120.57-
120.76 (d, J=14.1Hz), 126.96-127.01 (d, J=3.6Hz), 130.77, 134.06-134.17 (d, J=8.7Hz) 
159.87-163.16 (d, J=248.9Hz), 166.40. MS ESI+ (calc. for C12H15FN2O2 238.11): 239.12 
[M+H]+. 
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48 2-amino-2-(2-fluorophenyl)-1-morpholinoethanone 
48.HCl (22.97g, 81.1mmol) was dissolved in water then 150mL of 1N NaOH were added. 
The reaction mixture was stirred 19 minutes at RT then the product was extracted with 
CH2Cl2 (4x50mL). The combined organic layers were dried (Na2SO4) then the solvent was 
evaporated to give 18.01g (75.6mmol, 93%) of the free amine 48. 
 
49a-j 2-(R-benzylideneamino)-2-(2-fluorophenyl)-1-morpholinoethanone 
48 (1g, 4.20mmol), were dissolved in CH2Cl2 (10mL) then the corresponding substituted 
benzaldehyde (4.20mmol) and Na2SO4 (1.19g, 8.40mmol) were added. The reaction mixture 
was stirred overnight at room temperature then the solution was filtered and the solvent was 
evaporated to give the imines 49a-j as oils with quantitative yields. 
49a: 1H NMR (300MHz, CDCl3): δ (ppm) =  3.34-3.75 (m, 8H), 5.80 (s, 1H), 7.04-7.18 (m, 
2H), 7.23-30 (m, 1H), 7.40-7.51 (m, 4), 7.78-7.81 (d, 2H), 8.35 (s, 1H). 13C NMR (75MHz, 
CDCl3): δ (ppm) = 42.70, 46.03, 66.39, 66.65, 68.49, 115.23-115.52 (d, J=21.6Hz), 124.40-
124.44 (d, J=3.Hz), 125.09-125.27 (d, J=13.8Hz), 128.48, 128.51, 128.84, 129.01-129.06 (d, 
J=3.7Hz), 129.44-129.55 (d, J=8.3Hz), 131.17, 134.31, 135.45, 158.20-161.47 (d, 
J=246.7Hz), 163.89, 168.18. MS ESI+ (calc. for C19H19FN2O2 326.14): 327.20 [M+H]+. 
49b: 1H NMR (300MHz, CDCl3): δ (ppm) = 2.40 (s, 3H), 3.45-3.80 (m, 8H), 5.80 (s, 1H), 
7.05-7.4 (m, 6H), 7.25-7.35 (d, 1H), 7.70 (s, 1H), 9.40 (s, 1H). 
49c: 1H NMR (300MHz, CDCl3): δ (ppm) = 3.40-3.80 (m, 8H), 5.9 (s, 1H), 7.10-7.15 (t, 
1H), 7.15-7.25 (t, 1H), 7.25-7.40 (m, 4H), 7.50-7.60 (m, 1H), 8.20 (d, 1H), 8.80 (s, 1H). 
49d: 1H NMR (300MHz, CDCl3): δ (ppm) = 3.40-3.80 (m, 8H), 6.85 (s, 1H), 7.10-7.15 (t, 
1H), 7.15-7.20 (t, 1H), 7.30-7.50 (m, 4H), 7.60-7.65 (m, 1H), 7.85 (d, 1H). 
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49e: 1H NMR (300MHz, CDCl3): δ (ppm) = 3.40-3.80 (m, 8H), 5.90 (s, 1H), 7.10-7.15 (t, 
1H), 7.15-7.25 (t, 1H), 7.25-7.40 (m, 3H), 7.45-7.60 (m, 2H), 8.15-8.20 (d, 1H), 8.75 (s, 1H). 
49f: 1H NMR (300MHz, CDCl3): δ (ppm) = 3.40-3.80 (m, 8H), 3.90 (s, 3H), 5.80 (s, 1H), 
6.90-7.00 (d, 1H), 7.00-7.20 (m, 4H), 7.25-7.35 (m, 1H), 7.50-7.55 (t, 1H), 7.75-7.80 (d, 1H), 
8.30 (s, 1H). 
49g: 1H NMR (300MHz, CDCl3): δ (ppm) = 3.50-3.80 (m, 8H), 3.90 (s, 3H), 5.80 (s, 1H), 
6.90-7.20 (m, 4H), 7.25-7.30 (m, 1H), 7.40-7.45 (t, 1H), 7.50-7.55 (t, 1H), 8.05-8.10 (d, 1H), 
8.90 (s, 1H). 
49h: 1H NMR (300MHz, CDCl3): δ (ppm) = 3.40-3.80 (m, 8H), 5.90 (s, 1H), 7.10-7.20 (t, 
1H), 7.10-7.15 (t, 1H), 7.20-7.30 (m, 1H), 7.45-7.55 (t, 1H), 7.65-7.75 (m, 2H), 7.90-7.95 (m, 
2H), 8.40 (s, 1H). 
49i: 1H NMR (300MHz, CDCl3): δ (ppm) = 3.40-3.80 (m, 8H), 6.90 (s, 1H), 7.10-7.15 (t, 
1H), 7.20-7.25 (t, 1H), 7.30-7.40 (m, 3H), 7.45-7.55 (t, 1H), 8.10-8.15 (d, 1H), 8.70 (s, 1H). 
49j: 1H NMR (300MHz, CDCl3): δ (ppm) = 3.40-3.80 (m, 8H), 5.90 (s, 1H), 7.10-7.15 (m, 
1H), 7.20-7.25 (t, 1H), 7.30-7.40 (m, 1H), 7.40-7.50 (m, 1H), 8.25 (s, 1H). 
F
H2N
N
O
O
42'
 
42’ 2-amino-2-(2-fluorophenyl)-N-methoxy-N-methylacetamide 
42 (750mg, 2.40mmol) were dissolved in 1,4-dioxane (10mL) then HCl 4N in 1,4-dioxane 
(4.8mL, 19.21mmol) was added. The reaction mixture was stirred overnight at RT then the 
solid was filtered, washed with 1,4-dioxane (2x5mL) and with acetone (1x5mL) then dried 
under vacuum to give 434mg of 42’.HCl. This product was dissolved in water (10mL) then 
NaOH 1N in water was added. The reaction mixture was stirred 10 minutes at RT then the 
free amine was extracted with CH2Cl2 (4x10mL). The combined organic layers were dried 
(Na2SO4) then the solvent was evaporated to give 331mg (1.56mmol, 65%) of 42’. 
F
N
N
O
O
50a-c
R  
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50a-c 2-(R-benzylideneamino)-2-(2-fluorophenyl)-N-methoxy-N-methylacetamide 
41’ (100mg, 0.47mmol), were dissolved in CH2Cl2 (1mL) then the corresponding substituted 
benzaldehyde (0.47mmol) and Na2SO4 (134mg, 0.94mmol) were added. The reaction mixture 
was stirred overnight at room temperature then the solution was filtered and the solvent was 
evaporated to give the imines 50a-c as oils with quantitative yields. 
50a: 1H NMR (300MHz, CDCl3): δ (ppm) = 3.15 (s, 3H), 3.65 (s, 3H), 6.10 (s, 1H), 7.05-
7.10 (t, 1H), 7.15-7.20 (t, 1H), 7.25-7.30 (m, 2H), 7.35-7.45 (m, 2H), 7.60-7.65 (t, 1H), 8.80-
8.85 (m, 2H), 8.35 (s, 1H). 
50b: 1H NMR (300MHz, CDCl3): δ (ppm) = 2.40 (s, 3H), 3.25 (s, 3H), 3.65 (s, 3H), 6.10 (s, 
1H), 7.05-7.10 (t, 1H), 7.15-7.35 (m, 4H), 7.60-7.65 (t, 1H), 7.70-7.75 (dd, 2H), 8.30 (s, 1H). 
50c: 1H NMR (300MHz, CDCl3): δ (ppm) = 3.15 (s, 3H), 3.65 (s, 3H), 6.15 (s, 1H), 7.05-
7.15 (t, 1H), 7.15-7.25 (t, 1H), 7.15-7.20 (m, 3H), 7.55-7.60 (d, 1H), 7.20-7.30 (m, 1H), 8.15-
8.20 (dd, 1H), 8.70 (s, 1H). 
H2N
NH2
O
F
51
 
51 2-fluorophenylglycinamide 
10g (59.12mmol) of 2-fluorophenylglycine were suspended in methanol (60ml) then SOCl2 
(5.2mL, 70.94mmol) was added dropwise at 0°C. The reaction mixture was stirred overnight 
at RT. Additional 1mL of SOCl2 was added. The reaction mixture was stirred 2h at RT then 
40-50mL of methanol were evaporated. TBME (400mL) was added to the residue then the 
solid was filtered, washed with TBME (3x75mL) and dried under vacuum to give 12.58g 
(57.35mmol, 97%) of the 2-fluorophenylglycine methyl ester hydrochloride as a pale yellow 
powder. 1H NMR (300MHz, methanol-d4): δ (ppm) =  3.83 (s, 3H), 5.44 (s, 1H), 7.26-7.35 
(m, 2H), 7.48-7.60  (m, 2H). 
10.39g (47.3mmol) of the 2-fluorophenylglycine methyl ester hydrochloride were stirred 
overnight in 33%wt aqueous NH3 (41.5mL) then the product was extracted with CH2Cl2 
(15x15mL). The combined organic layers were dried (MgSO4) then the solvent was 
evaporated to give 5.91g (35.00mmol, 75%) of 51 as a white powder. 1H NMR (300MHz, 
MeOH-d4): δ (ppm) =  4.74 (s, 1H), 7.08-7.20 (m, 2H), 7.29-7.37 (m, 1H), 7.43-7.48 (m, 
1H). 13C NMR (75MHz, DMSO-d6): δ (ppm) = 52.75, 114.89-115.18 (d, J=22.0Hz), 
124.16-124.21 (d, J=3.4Hz), 128.65-128.73 (d, J=5.9Hz), 128.76-128.79 (d, J=1.2Hz), 
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130.05-130.25 (d, J=14.7Hz), 150.20-161.44 (d, J=244.4Hz), 174.67. MS ESI+ (calc. for 
C8H9FN2O 168.07): 169.07 [M+H]+. Melting point: 104°C. 
 
52a 2-(benzylideneamino)-2-(2-fluorophenyl)acetamide 
51 (5.5g, 32.7mmol) was dissolved in CH2Cl2 then benzaldehyde (3.8g, 36.0mmol) and 
Na2SO4 (8.4g, 58.6mmol) were added. The reaction mixture was stirred overnight at RT then 
the suspension was filtered and the solvent was evaporated. The solid was washed with 
TBME (3x10mL) then was dried under vacuum to give 8.03g (31.4mmol, 96%) of 52a as a 
white solid. 1H NMR (300MHz, CDCl3): δ (ppm) =  5.37 (s, 1H), 7.06-7.3 (m, 3H), 7.40-
7.48 (m, 4H), 7.76-7.78 (m, 2H), 8.29 (s, 1H). 13C NMR (75MHz, CDCl3): δ (ppm) = 69.43, 
115.56-11585 (d, J=21.9Hz), 124.45-124.50 (d, J=3.5Hz), 125.88, 126.07, 128.41, 128.59, 
129.41-129.46 (d, J=3.7Hz), 129.63-129.74 (d, J=8.3Hz), 131.48, 135.22, 158.85-162.13 (d, 
J=247.5Hz), 163.68, 173.94. MS ESI+ (calc. for C15H13FN2O 256.10): 257.15 [M+H]+. 
Elementary analysis (calc. for C15H13FN2O: %C=70.30, %H=5.11, %N=10.93): 
%C=70.04, %H=5.12, %N=10.91. 
 
52b-j 2-(R-benzylideneamino)-2-(2-fluorophenyl)acetamide 
The imines 52b-j were synthesised with quantitative yields following the same protocol as 
52a from 100mg (0.59mmol) of 51. 
52b: 1H NMR (300MHz, CDCl3): δ (ppm) = 2.40 (s, 1H), 5.35 (s, 1H), 7.05-7.35 (m, 5H), 
7.45-7.50 (t, 1H), 7.65-7.70 (d, 2H), 8.25 (s, 1H). 
52c: 1H NMR (300MHz, CDCl3): δ (ppm) = 5.45 (s, 1H), 7.05-7.20 (m, 3H), 7.25-7.40 (m, 
3H), 7.45-7.50 (t, 1H), 8.05-8.10 (d, 1H), 8.80 (s, 1H). 
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52d: 1H NMR (300MHz, CDCl3): δ (ppm) = 5.40 (s, 1H), 7.05-7.20 (m, 3H), 7.25-7.50 (m, 
3H), 7.55-7.60 (d, 1H), 7.80 (s, 1H), 8.25 (s, 1H). 
52e: 1H NMR (300MHz, CDCl3): δ (ppm) = 5.45 (s, 1H), 7.10-7.20 (m, 3H), 7.25-7.40 (m, 
2H), 7.45-7.50 (m, 1H), 7.55-7.65 (d, 1H), 8.05-8.10 (d, 1H), 8.70 (s, 1H). 
52f: 1H NMR (300MHz, CDCl3): δ (ppm) = 3.85 (s, 3H), 5.35 (s, 1H), 6.90-6.95 (d, 2H), 
7.05-7.35 (m, 3H), 7.40-7.45 (t, 1H), 7.70-7.75 (d, 2H), 8.20 (s, 1H). 
52g: 1H NMR (300MHz, CDCl3): δ (ppm) = 4.85 (s, 3H), 5.40 (s, 1H), 6.90-7.30 (m, 5H), 
7.40-7.55 (m, 2H), 8.00 (d, 1H), 8.80 (s, 1H). 
52h: 1H NMR (300MHz, CDCl3): δ (ppm) = 5.40 (s, 1H), 7.05-7.20 (m, 2H), 7.25-7.35 (m, 
1H), 7.45-7.50 (t, 1H), 7.70-7.75 (d, 2H), 7.90-7.95 (d, 2H), 8.35 (s, 1H). 
52i: 1H NMR (300MHz, CDCl3): δ (ppm) = 5.40 (s, 1H), 7.05-7.20 (m, 3H), 7.30-7.35 (m, 
2H), 7.45-7.50 (t, 1H), 8.00-8.05 (d, 1H), 8.65 (s, 1H). 
52j: 1H NMR (300MHz, CDCl3): δ (ppm) = 5.40 (s, 1H), 7.10-7.15 (m, 1H), 7.20-7.25 (t, 
1H), 7.30-7.40 (m, 1H), 7.40-7.50 (m, 1H), 8.30 (s, 1H). 
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I - ClTAK 
 
Figure 32. Asymmetric unit of ClTAK, in ellipsoid thermal representation (50% of probability). 
The two positions of the tBu are represented in grey (sof: 78%) and light grey (sof: 22%). 
 
Table 1 a. Crystal data. 
Chemical Formula C15H18ClN3O 
Molecular Weight / g.mol-1 291.77 
Crystal System Orthorhombic 
Space group P212121 
Z , Z’ (asymmetric units per unit cell) 4, 1 
a / Å 5.8076(5) 
b / Å 19.661(2) 
c / Å 13.553(1) 
V / Å3 1547.5(2) 
dcalc / g.cm-3 1.252 
R factor (with I>2σI) 
R1 = 0.0367 
wR2 = 0.0871 
R factor (all data) R1 = 0.0483, wR2 = 0.0938 
F(000) / e- 616 
Extinction Coefficient 0.017(2) 
Absolute structure parameter -0.06(7) 
Absorption coefficient µ (MoKα1) mm-1 0.246 
Number of reflections (n) (with FO>4.0σ(FO)) 3162 / 2621 
Number of refined parameters (p) / restraints 216 
Goodness of fit indicator (restrainted GooF) 1.024 
Maximum peak in final difference map / e-Ǻ-3 0.123 
Maximum hole in final difference map / e-Ǻ-3 -0.135 
 
Table 1 b. Atomic coordinates (x104) and equivalent isotropic displacement parameters (Å2 x 103). U(eq) is 
defined as one third of the trace of the orthogonalized  Uij tensor. 
 x y z U(eq) 
Cl(1) 9584(2) 8044(1) 2056(1) 94(1) 
N(1) 13829(2) 4927(1) 1474(1) 44(1) 
N(2) 15709(3) 4860(1) 2054(1) 62(1) 
N(3) 12449(4) 4766(1) 2950(1) 86(1) 
O(1) 17732(2) 4672(1) -157(1) 68(1) 
C(1) 11595(4) 6532(1) 309(1) 54(1) 
C(2) 10324(4) 7055(1) 718(2) 59(1) 
C(3) 11141(4) 7376(1) 1541(2) 60(1) 
C(4) 13192(4) 7188(1) 1955(2) 68(1) 
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C(5) 14430(4) 6660(1) 1545(1) 62(1) 
C(6) 13659(3) 6329(1) 708(1) 47(1) 
C(7) 15082(3) 5771(1) 245(1) 50(1) 
C(8) 14126(3) 5061(1) 425(1) 41(1) 
C(9) 15765(3) 4514(1) 12(1) 47(1) 
C(10) 14953(4) 3785(1) -142(2) 57(1) 
C(11) 16125(7) 3520(2) -1088(3) 88(1) 
C(12) 15853(9) 3382(2) 738(3) 87(1) 
C(13) 12404(5) 3724(2) -241(4) 84(2) 
C(12A) 13080(30) 3544(7) 709(14) 119(8) 
C(11A) 13440(40) 3757(9) -1084(14) 149(11) 
C(13A) 16680(40) 3266(9) -100(20) 210(20) 
C(14) 11926(4) 4869(1) 2021(2) 63(1) 
C(15) 14752(5) 4761(1) 2925(2) 80(1) 
In italic, the atoms of the tert-butyl with a sof of 22%. 
 
Table 1 c. Hydrogen coordinates (x104) and equivalent isotropic displacement parameters (Å2 x 103). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
H(1) 11039 6312 -250 65 
H(2) 8933 7187 437 71 
H(4) 13748 7414 2509 82 
H(5) 15806 6526 1836 74 
H(7A) 16635 5794 506 60 
H(7B) 15169 5849 -461 60 
H(8) 12631 5020 96 49 
H(11A) 15654 3060 -1208 132 
H(11B) 17767 3536 -1008 132 
H(11C) 15685 3800 -1637 132 
H(12A) 15213 3563 1336 130 
H(12B) 17502 3414 762 130 
H(12C) 15411 2913 671 130 
H(13A) 11681 3876 357 126 
H(13B) 12002 3258 -361 126 
H(13C) 11889 3999 -783 126 
H(12D) 12234 3156 476 178 
H(12E) 12027 3910 841 178 
H(12F) 13881 3427 1304 178 
H(11D) 14280 3944 -1630 223 
H(11E) 12061 4016 -980 223 
H(11F) 13044 3293 -1224 223 
H(13D) 15957 2827 -125 315 
H(13E) 17521 3308 509 315 
H(13F) 17714 3316 -644 315 
H(14) 10433 4897 1776 76 
H(15) 15629 4692 3490 96 
In italic, the atoms of the tert-butyl with a sof of 22%. 
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Table 1 d. Bond lengths (Å). 
Cl(1)-C(3) 1.741(2)  C(9)-C(10) 1.523(3)  C(12)-H(12A) 0.96 
N(1)-C(14) 1.336(2)  C(10)-C(13A) 1.430(17)  C(12)-H(12B) 0.96 
N(1)-N(2) 1.351(2)  C(10)-C(13) 1.491(4)  C(12)-H(12C) 0.96 
N(1)-C(8) 1.456(2)  C(10)-C(12) 1.525(4)  C(13)-H(13A) 0.96 
N(2)-C(15) 1.320(3)  C(10)-C(11) 1.542(4)  C(13)-H(13B) 0.96 
N(3)-C(14) 1.310(3)  C(10)-C(11A) 1.550(17)  C(13)-H(13C) 0.96 
N(3)-C(15) 1.337(3)  C(10)-C(12A) 1.656(14)  C(12A)-H(12D) 0.96 
O(1)-C(9) 1.206(2)  C(1)-H(1) 0.93  C(12A)-H(12E) 0.96 
C(1)-C(6) 1.375(3)  C(2)-H(2) 0.93  C(12A)-H(12F) 0.96 
C(1)-C(2) 1.382(3)  C(4)-H(4) 0.93  C(11A)-H(11D) 0.96 
C(2)-C(3) 1.367(3)  C(5)-H(5) 0.93  C(11A)-H(11E) 0.96 
C(3)-C(4) 1.368(3)  C(7)-H(7A) 0.97  C(11A)-H(11F) 0.96 
C(4)-C(5) 1.379(3)  C(7)-H(7B) 0.97  C(13A)-H(13D) 0.9643 
C(5)-C(6) 1.383(3)  C(8)-H(8) 0.98  C(13A)-H(13E) 0.9642 
C(6)-C(7) 1.509(2)  C(11)-H(11A) 0.96  C(13A)-H(13F) 0.9643 
C(7)-C(8) 1.523(2)  C(11)-H(11B) 0.96  C(14)-H(14) 0.93 
C(8)-C(9) 1.542(2)  C(11)-H(11C) 0.96  C(15)-H(15) 0.93 
In italic, the atoms of the tert-butyl with a sof of 22%. 
 
Table 1 e. Angles (°). 
C(14)-N(1)-N(2) 109.75(14)  C(12)-C(10)-C(11) 108.9(3)  C(10)-C(11)-H(11B) 109.5 
C(14)-N(1)-C(8) 130.95(16)  C(13A)-C(10)-C(11A) 114.0(12)  C(10)-C(11)-H(11C) 109.5 
N(2)-N(1)-C(8) 119.27(14)  C(13)-C(10)-C(11A) 50.2(10)  C(10)-C(12)-H(12A) 109.5 
C(15)-N(2)-N(1) 101.18(18)  C(9)-C(10)-C(11A) 108.8(7)  C(10)-C(12)-H(12B) 109.5 
C(14)-N(3)-C(15) 102.07(19)  C(12)-C(10)-C(11A) 145.0(7)  C(10)-C(12)-H(12C) 109.5 
C(6)-C(1)-C(2) 121.63(19)  C(11)-C(10)-C(11A) 63.5(9)  C(10)-C(13)-H(13A) 109.5 
C(3)-C(2)-C(1) 119.1(2)  C(13A)-C(10)-C(12A) 103.2(13)  C(10)-C(13)-H(13B) 109.5 
C(2)-C(3)-C(4) 120.80(19)  C(13)-C(10)-C(12A) 52.1(8)  C(10)-C(13)-H(13C) 109.5 
C(2)-C(3)-Cl(1) 119.72(18)  C(9)-C(10)-C(12A) 112.2(5)  C(10)-C(12A)-H(12D) 109.5 
C(4)-C(3)-Cl(1) 119.47(16)  C(12)-C(10)-C(12A) 62.1(8)  C(10)-C(12A)-H(12E) 109.5 
C(3)-C(4)-C(5) 119.47(19)  C(11)-C(10)-C(12A) 140.7(5)  H(12D)-C(12A)-H(12E) 109.5 
C(4)-C(5)-C(6) 121.1(2)  C(11A)-C(10)-C(12A) 101.0(12)  C(10)-C(12A)-H(12F) 109.4 
C(1)-C(6)-C(5) 117.87(18)  N(3)-C(14)-N(1) 110.7(2)  H(12D)-C(12A)-H(12F) 109.5 
C(1)-C(6)-C(7) 121.69(17)  N(2)-C(15)-N(3) 116.3(2)  H(12E)-C(12A)-H(12F) 109.5 
C(5)-C(6)-C(7) 120.43(18)  C(6)-C(1)-H(1) 119.2  C(10)-C(11A)-H(11D) 109.6 
C(6)-C(7)-C(8) 113.57(15)  C(2)-C(1)-H(1) 119.2  C(10)-C(11A)-H(11E) 109.4 
N(1)-C(8)-C(7) 111.45(13)  C(3)-C(2)-H(2) 120.5  H(11D)-C(11A)-H(11E) 109.5 
N(1)-C(8)-C(9) 107.57(13)  C(1)-C(2)-H(2) 120.5  C(10)-C(11A)-H(11F) 109.4 
C(7)-C(8)-C(9) 110.91(14)  C(3)-C(4)-H(4) 120.3  H(11D)-C(11A)-H(11F) 109.5 
O(1)-C(9)-C(10) 120.67(17)  C(5)-C(4)-H(4) 120.3  H(11E)-C(11A)-H(11F) 109.5 
O(1)-C(9)-C(8) 118.27(16)  C(4)-C(5)-H(5) 119.4  C(10)-C(13A)-H(13D) 110 
C(10)-C(9)-C(8) 121.02(16)  C(6)-C(5)-H(5) 119.4  C(10)-C(13A)-H(13E) 109.8 
C(13A)-C(10)-C(13) 129.9(8)  C(6)-C(7)-H(7A) 108.9  H(13D)-C(13A)-H(13E) 109 
C(13A)-C(10)-C(9) 116.6(8)  C(8)-C(7)-H(7A) 108.9  C(10)-C(13A)-H(13F) 109.9 
C(13)-C(10)-C(9) 113.27(19)  C(6)-C(7)-H(7B) 108.9  H(13D)-C(13A)-H(13F) 109 
C(13A)-C(10)-C(12) 49.9(14)  C(8)-C(7)-H(7B) 108.8  H(13E)-C(13A)-H(13F) 109 
C(13)-C(10)-C(12) 111.7(3)  H(7A)-C(7)-H(7B) 107.7  N(3)-C(14)-H(14) 124.6 
C(9)-C(10)-C(12) 106.0(2)  N(1)-C(8)-H(8) 109  N(1)-C(14)-H(14) 124.6 
C(13A)-C(10)-C(11) 59.1(14)  C(7)-C(8)-H(8) 109  N(2)-C(15)-H(15) 121.9 
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C(13)-C(10)-C(11) 109.7(3)  C(9)-C(8)-H(8) 109  N(3)-C(15)-H(15) 121.9 
C(9)-C(10)-C(11) 107.12(19)  C(10)-C(11)-H(11A) 109.5    
In italic, the atoms of the ter-butyl with a sof of 22%. 
 
Table 1 f. Anisotropic displacement parameters (Å² x 103) The anisotropic displacement factor exponent 
takes the form: -2 π² [ h² a*² U11 + ... + 2 h k a* b* U12 ]. 
 U11 U22 U33 U23 U13 U12 
Cl(1) 134(1) 65(1) 83(1) -10(1) 14(1) 33(1) 
N(1) 45(1) 47(1) 40(1) 1(1) -1(1) -5(1) 
N(2) 63(1) 76(1) 48(1) 3(1) -14(1) -5(1) 
N(3) 98(2) 108(2) 52(1) 8(1) 14(1) -27(1) 
O(1) 55(1) 60(1) 91(1) -1(1) 22(1) 2(1) 
C(1) 61(1) 46(1) 54(1) -3(1) -6(1) -1(1) 
C(2) 64(1) 49(1) 64(1) 2(1) -4(1) 4(1) 
C(3) 84(2) 41(1) 57(1) 5(1) 13(1) 6(1) 
C(4) 92(2) 57(1) 55(1) -12(1) -8(1) 1(1) 
C(5) 70(1) 60(1) 56(1) -1(1) -10(1) 4(1) 
C(6) 57(1) 37(1) 45(1) 5(1) 5(1) -5(1) 
C(7) 56(1) 44(1) 50(1) 6(1) 7(1) 0(1) 
C(8) 43(1) 42(1) 37(1) 2(1) -2(1) -1(1) 
C(9) 49(1) 48(1) 43(1) 2(1) -1(1) 4(1) 
C(10) 57(1) 43(1) 70(1) -6(1) -7(1) 7(1) 
C(11) 86(3) 86(2) 91(2) -42(2) 5(2) 4(2) 
C(12) 129(4) 43(2) 88(2) 9(2) -15(2) 4(2) 
C(13) 63(2) 45(2) 145(5) -20(2) -7(2) -7(1) 
C(12A) 165(18) 68(8) 122(14) 2(8) 30(13) -59(10) 
C(11A) 240(30) 101(12) 105(13) -40(10) -50(17) -24(15) 
C(13A) 142(19) 66(10) 420(60) -40(20) -160(30) 31(10) 
C(14) 60(1) 74(1) 56(1) 2(1) 12(1) -15(1) 
C(15) 105(2) 91(2) 42(1) 8(1) -15(1) -21(2) 
In italic, the atoms of the tert-butyl with a sof of 22%. 
 
Table 1 g. Torsion angles (°) 
C(14)-N(1)-N(2)-C(15) 0.3(2)  C(7)-C(8)-C(9)-O(1) 18.2(2) 
C(8)-N(1)-N(2)-C(15) 178.73(17)  N(1)-C(8)-C(9)-C(10) 73.75(19) 
C(6)-C(1)-C(2)-C(3) -0.2(3)  C(7)-C(8)-C(9)-C(10) -164.14(16) 
C(1)-C(2)-C(3)-C(4) 0.4(3)  O(1)-C(9)-C(10)-C(13A) 24.5(16) 
C(1)-C(2)-C(3)-Cl(1) 179.06(15)  C(8)-C(9)-C(10)-C(13A) -153.1(16) 
C(2)-C(3)-C(4)-C(5) -1.1(3)  O(1)-C(9)-C(10)-C(13) -160.0(3) 
Cl(1)-C(3)-C(4)-C(5) -179.73(17)  C(8)-C(9)-C(10)-C(13) 22.4(3) 
C(3)-C(4)-C(5)-C(6) 1.5(3)  O(1)-C(9)-C(10)-C(12) 77.2(3) 
C(2)-C(1)-C(6)-C(5) 0.7(3)  C(8)-C(9)-C(10)-C(12) -100.4(2) 
C(2)-C(1)-C(6)-C(7) -178.19(17)  O(1)-C(9)-C(10)-C(11) -39.0(3) 
C(4)-C(5)-C(6)-C(1) -1.3(3)  C(8)-C(9)-C(10)-C(11) 143.5(2) 
C(4)-C(5)-C(6)-C(7) 177.53(19)  O(1)-C(9)-C(10)-C(11A) -106.1(10) 
C(1)-C(6)-C(7)-C(8) -75.3(2)  C(8)-C(9)-C(10)-C(11A) 76.3(11) 
C(5)-C(6)-C(7)-C(8) 105.9(2)  O(1)-C(9)-C(10)-C(12A) 143.1(9) 
C(14)-N(1)-C(8)-C(7) 109.1(2)  C(8)-C(9)-C(10)-C(12A) -34.5(9) 
N(2)-N(1)-C(8)-C(7) -69.0(2)  C(15)-N(3)-C(14)-N(1) -0.4(3) 
C(14)-N(1)-C(8)-C(9) -129.2(2)  N(2)-N(1)-C(14)-N(3) 0.1(2) 
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N(2)-N(1)-C(8)-C(9) 52.75(19)  C(8)-N(1)-C(14)-N(3) -178.12(18) 
C(6)-C(7)-C(8)-N(1) -55.3(2)  N(1)-N(2)-C(15)-N(3) -0.6(3) 
C(6)-C(7)-C(8)-C(9) -175.10(15)  C(14)-N(3)-C(15)-N(2) 0.7(3) 
N(1)-C(8)-C(9)-O(1) -103.87(18)    
In italic, the atoms of the tert-butyl with a sof of 22%. 
 
 
 
 
II - HTAK 
 
Figure 33. Asymmetric unit of HTAK, in ellipsoid thermal representation (50% of probability). 
 
Table 2 a. Crystal data. 
Chemical Formula C15H19N3O 
Molecular Weight / g.mol-1 257.33 
Crystal System Monoclinic 
Space group P21 (n°4) 
Z , Z’ (asymmetric units per unit cell) 4, 2 
a / Å 5.747(1) 
b / Å 19.183(1) 
c / Å 13.437(1) 
β / ° 96.561(1) 
V / Å3 1471.8(2) 
dcalc / g.cm-3 1.161 
R factor (with I>2σI) 
R1 = 0.0623 
wR2 = 0.1142 
R factor (all data) R1 = 0.0623 wR2 = 0.1142 
F(000) / e- 552 
Absolute structure parameter 0.8(12) 
Absorption coefficient µ (MoKα1) mm-1 552 
Number of reflections (n) (with FO>4.0σ(FO)) 5980 / 4664 
Number of refined parameters (p) / restraints 349 / 1 
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Reflection / parameter ratio  
Goodness of fit indicator (restrainted GooF) 1.024 
Maximum peak in final difference map / e-Ǻ-3 0.139 
Maximum hole in final difference map / e-Ǻ-3 -0.167 
 
Table 2 b. Atomic coordinates (x104) and equivalent isotropic displacement parameters (Å2 x 103). U(eq) is 
defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z U(eq)   x y z U(eq) 
N(1) 6240(3) 2216(1) 2703(1) 44(1)  N(1A) 8784(3) 1714(1) 7552(1) 44(1) 
N(2) 4248(3) 2364(1) 2098(1) 62(1)  N(3A) 7490(4) 1298(1) 6086(2) 71(1) 
N(3) 7423(5) 2478(1) 1269(2) 82(1)  N(2A) 10721(3) 1642(1) 7069(1) 57(1) 
O(1) 2479(3) 1582(1) 4107(1) 60(1)  O(1A) 12514(3) 2620(1) 8910(1) 74(1) 
C(1) 6414(4) 3847(1) 3616(2) 64(1)  C(1A) 6741(4) 713(1) 9797(2) 66(1) 
C(2) 7903(6) 4403(1) 3528(2) 81(1)  C(2A) 5362(5) 122(2) 9724(2) 82(1) 
C(3) 10058(6) 4417(1) 4075(2) 82(1)  C(3A) 5912(6) -424(2) 9143(2) 82(1) 
C(4) 10741(5) 3880(2) 4703(2) 73(1)  C(4A) 7826(6) -377(1) 8622(2) 81(1) 
C(5) 9249(4) 3319(1) 4789(2) 59(1)  C(5A) 9193(5) 216(1) 8689(2) 66(1) 
C(6) 7066(4) 3298(1) 4240(2) 48(1)  C(6A) 8664(4) 773(1) 9276(2) 51(1) 
C(7) 5437(4) 2690(1) 4326(2) 51(1)  C(7A) 10087(4) 1432(1) 9316(2) 54(1) 
C(8) 6108(3) 2050(1) 3752(1) 40(1)  C(8A) 9006(4) 1979(1) 8580(1) 44(1) 
C(9) 4327(3) 1453(1) 3804(1) 43(1)  C(9A) 10461(4) 2653(1) 8612(2) 48(1) 
C(10) 4870(3) 717(1) 3459(2) 51(1)  C(10A) 9273(4) 3337(1) 8303(2) 56(1) 
C(11) 3896(4) 198(1) 4175(2) 69(1)  C(12A) 11078(5) 3853(2) 8006(3) 111(1) 
C(12) 3573(5) 618(2) 2404(2) 77(1)  C(11A) 7269(5) 3256(2) 7443(2) 81(1) 
C(13) 7473(4) 584(1) 3473(3) 86(1)  C(13A) 8201(6) 3601(2) 9219(2) 90(1) 
C(14) 8071(4) 2296(1) 2201(2) 60(1)  C(14A) 9811(5) 1393(1) 6197(2) 66(1) 
C(15) 5083(5) 2512(2) 1255(2) 76(1)  C(15A) 6917(4) 1506(1) 6956(2) 58(1) 
 
Table 2 c. Hydrogen coordinates (x104) and equivalent isotropic displacement parameters (Å2 x 103). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z U(eq)   x y z U(eq) 
H(1) 4944 3845 3247 77  H(1A) 6366 1077 10206 80 
H(2) 7439 4768 3095 97  H(2A) 4055 96 10072 99 
H(3) 11056 4792 4017 98  H(3A) 4997 -825 9100 99 
H(4) 12208 3889 5075 88  H(4A) 8202 -746 8222 97 
H(5) 9726 2954 5220 71  H(5A) 10489 241 8335 79 
H(7A) 3856 2829 4074 61  H(7A1) 11656 1324 9163 65 
H(7B) 5445 2569 5028 61  H(7A2) 10210 1620 9990 65 
H(8) 7650 1887 4049 47  H(8A) 7439 2093 8753 53 
H(11A) 4235 -269 3979 104  H(12D) 12261 3925 8562 166 
H(11B) 2231 258 4148 104  H(12E) 10326 4289 7822 166 
H(11C) 4611 281 4845 104  H(12F) 11789 3672 7448 166 
H(12A) 4118 957 1959 115  H(11D) 7862 3041 6878 122 
H(12B) 1922 678 2427 115  H(11E) 6642 3707 7253 122 
H(12C) 3869 158 2167 115  H(11F) 6056 2970 7663 122 
H(13A) 8253 693 4125 129  H(13D) 7015 3282 9381 135 
H(13B) 8084 874 2981 129  H(13E) 7513 4052 9077 135 
H(13C) 7729 103 3323 129  H(13F) 9399 3637 9776 135 
H(14) 9618 2231 2473 72  H(14A) 10727 1288 5690 79 
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H(15) 4111 2635 681 91  H(15A) 5398 1507 7131 70 
 
Table 2 d Bond lengths (Å). 
N(1)-C(14) 1.322(3)  C(1)-H(1) 0.93  N(1A)-C(15A) 1.325(3)  C(1A)-H(1A) 0.93 
N(1)-N(2) 1.356(2)  C(2)-H(2) 0.93  N(1A)-N(2A) 1.358(2)  C(2A)-H(2A) 0.93 
N(1)-C(8) 1.456(2)  C(3)-H(3) 0.93  N(1A)-C(8A) 1.464(2)  C(3A)-H(3A) 0.93 
N(2)-C(15) 1.310(3)  C(4)-H(4) 0.93  N(3A)-C(15A) 1.312(3)  C(4A)-H(4A) 0.93 
N(3)-C(14) 1.312(3)  C(5)-H(5) 0.93  N(3A)-C(14A) 1.337(3)  C(5A)-H(5A) 0.93 
N(3)-C(15) 1.345(4)  C(7)-H(7A) 0.97  N(2A)-C(14A) 1.317(3)  C(7A)-H(7A1) 0.97 
O(1)-C(9) 1.205(2)  C(7)-H(7B) 0.97  O(1A)-C(9A) 1.204(3)  C(7A)-H(7A2) 0.97 
C(1)-C(6) 1.371(3)  C(8)-H(8) 0.98  C(1A)-C(6A) 1.379(3)  C(8A)-H(8A) 0.98 
C(1)-C(2) 1.381(4)  C(11)-H(11A) 0.96  C(1A)-C(2A) 1.380(4)  C(12A)-H(12D) 0.96 
C(2)-C(3) 1.366(4)  C(11)-H(11B) 0.96  C(2A)-C(3A) 1.364(4)  C(12A)-H(12E) 0.96 
C(3)-C(4) 1.360(4)  C(11)-H(11C) 0.96  C(3A)-C(4A) 1.373(4)  C(12A)-H(12F) 0.96 
C(4)-C(5) 1.389(3)  C(12)-H(12A) 0.96  C(4A)-C(5A) 1.379(4)  C(11A)-H(11D) 0.96 
C(5)-C(6) 1.382(3)  C(12)-H(12B) 0.96  C(5A)-C(6A) 1.382(3)  C(11A)-H(11E) 0.96 
C(6)-C(7) 1.508(3)  C(12)-H(12C) 0.96  C(6A)-C(7A) 1.503(3)  C(11A)-H(11F) 0.96 
C(7)-C(8) 1.524(3)  C(13)-H(13A) 0.96  C(7A)-C(8A) 1.525(3)  C(13A)-H(13D) 0.96 
C(8)-C(9) 1.543(3)  C(13)-H(13B) 0.96  C(8A)-C(9A) 1.538(3)  C(13A)-H(13E) 0.96 
C(9)-C(10) 1.531(3)  C(13)-H(13C) 0.96  C(9A)-C(10A) 1.515(3)  C(13A)-H(13F) 0.96 
C(10)-C(13) 1.515(3)  C(14)-H(14) 0.93  C(10A)-C(12A) 1.520(3)  C(14A)-H(14A) 0.93 
C(10)-C(11) 1.533(3)  C(15)-H(15) 0.93  C(10A)-C(13A) 1.525(4)  C(15A)-H(15A) 0.93 
C(10)-C(12) 1.536(3)     C(10A)-C(11A) 1.543(4)    
 
Table 2 e. Angles (°). 
C(14)-N(1)-N(2) 109.66(16)  O(1A)-C(9A)-C(8A) 118.32(19)  N(3)-C(14)-H(14) 124.4 
C(14)-N(1)-C(8) 130.69(17)  C(10A)-C(9A)-C(8A) 119.60(18)  N(1)-C(14)-H(14) 124.4 
N(2)-N(1)-C(8) 119.52(16)  C(9A)-C(10A)-C(12A) 109.6(2)  N(2)-C(15)-H(15) 121.9 
C(15)-N(2)-N(1) 101.31(19)  C(9A)-C(10A)-C(13A) 106.12(19)  N(3)-C(15)-H(15) 121.9 
C(14)-N(3)-C(15) 101.6(2)  C(12A)-C(10A)-C(13A) 110.3(3)  C(6A)-C(1A)-H(1A) 119.3 
C(6)-C(1)-C(2) 121.1(2)  C(9A)-C(10A)-C(11A) 113.1(2)  C(2A)-C(1A)-H(1A) 119.3 
C(3)-C(2)-C(1) 120.1(3)  C(12A)-C(10A)-C(11A) 110.0(2)  C(3A)-C(2A)-H(2A) 119.9 
C(4)-C(3)-C(2) 119.9(3)  C(13A)-C(10A)-C(11A) 107.6(2)  C(1A)-C(2A)-H(2A) 119.9 
C(3)-C(4)-C(5) 120.0(3)  N(2A)-C(14A)-N(3A) 116.0(2)  C(2A)-C(3A)-H(3A) 120.2 
C(6)-C(5)-C(4) 120.7(2)  N(3A)-C(15A)-N(1A) 111.2(2)  C(4A)-C(3A)-H(3A) 120.2 
C(1)-C(6)-C(5) 118.1(2)  C(6)-C(1)-H(1) 119.4  C(3A)-C(4A)-H(4A) 119.9 
C(1)-C(6)-C(7) 120.8(2)  C(2)-C(1)-H(1) 119.4  C(5A)-C(4A)-H(4A) 119.9 
C(5)-C(6)-C(7) 121.1(2)  C(3)-C(2)-H(2) 119.9  C(4A)-C(5A)-H(5A) 119.5 
C(6)-C(7)-C(8) 112.87(16)  C(1)-C(2)-H(2) 119.9  C(6A)-C(5A)-H(5A) 119.5 
N(1)-C(8)-C(7) 110.98(16)  C(4)-C(3)-H(3) 120  C(6A)-C(7A)-H(7A1) 109.2 
N(1)-C(8)-C(9) 108.36(15)  C(2)-C(3)-H(3) 120  C(8A)-C(7A)-H(7A1) 109.2 
C(7)-C(8)-C(9) 111.53(15)  C(3)-C(4)-H(4) 120  C(6A)-C(7A)-H(7A2) 109.2 
O(1)-C(9)-C(10) 120.64(17)  C(5)-C(4)-H(4) 120  C(8A)-C(7A)-H(7A2) 109.2 
O(1)-C(9)-C(8) 118.59(17)  C(6)-C(5)-H(5) 119.7  H(7A1)-C(7A)-H(7A2) 107.9 
C(10)-C(9)-C(8) 120.77(15)  C(4)-C(5)-H(5) 119.7  N(1A)-C(8A)-H(8A) 108.5 
C(13)-C(10)-C(9) 112.70(17)  C(6)-C(7)-H(7A) 109  C(7A)-C(8A)-H(8A) 108.5 
C(13)-C(10)-C(11) 108.3(2)  C(8)-C(7)-H(7A) 109  C(9A)-C(8A)-H(8A) 108.5 
C(9)-C(10)-C(11) 107.87(17)  C(6)-C(7)-H(7B) 109  C(10A)-C(12A)-H(12D) 109.5 
C(13)-C(10)-C(12) 111.4(2)  C(8)-C(7)-H(7B) 109  C(10A)-C(12A)-H(12E) 109.5 
C(9)-C(10)-C(12) 107.38(19)  H(7A)-C(7)-H(7B) 107.8  H(12D)-C(12A)-H(12E) 109.5 
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C(11)-C(10)-C(12) 109.02(18)  N(1)-C(8)-H(8) 108.6  C(10A)-C(12A)-H(12F) 109.5 
N(3)-C(14)-N(1) 111.2(2)  C(7)-C(8)-H(8) 108.6  H(12D)-C(12A)-H(12F) 109.5 
N(2)-C(15)-N(3) 116.2(2)  C(9)-C(8)-H(8) 108.6  H(12E)-C(12A)-H(12F) 109.5 
C(15A)-N(1A)-N(2A) 109.41(16)  C(10)-C(11)-H(11B) 109.5  C(10A)-C(11A)-H(11D) 109.5 
C(15A)-N(1A)-C(8A) 130.69(17)  H(11A)-C(11)-H(11B) 109.5  C(10A)-C(11A)-H(11E) 109.5 
N(2A)-N(1A)-C(8A) 119.90(16)  C(10)-C(11)-H(11C) 109.5  H(11D)-C(11A)-H(11E) 109.5 
C(15A)-N(3A)-C(14A) 102.02(19)  H(11A)-C(11)-H(11C) 109.5  C(10A)-C(11A)-H(11F) 109.5 
C(14A)-N(2A)-N(1A) 101.40(18)  H(11B)-C(11)-H(11C) 109.5  H(11D)-C(11A)-H(11F) 109.5 
C(6A)-C(1A)-C(2A) 121.3(2)  C(10)-C(12)-H(12A) 109.5  H(11E)-C(11A)-H(11F) 109.5 
C(3A)-C(2A)-C(1A) 120.1(3)  C(10)-C(12)-H(12B) 109.5  C(10A)-C(13A)-H(13D) 109.5 
C(2A)-C(3A)-C(4A) 119.6(2)  H(12A)-C(12)-H(12B) 109.5  C(10A)-C(13A)-H(13E) 109.5 
C(3A)-C(4A)-C(5A) 120.3(3)  C(10)-C(12)-H(12C) 109.5  H(13D)-C(13A)-H(13E) 109.5 
C(4A)-C(5A)-C(6A) 120.9(2)  H(12A)-C(12)-H(12C) 109.5  C(10A)-C(13A)-H(13F) 109.5 
C(1A)-C(6A)-C(5A) 117.8(2)  H(12B)-C(12)-H(12C) 109.5  H(13D)-C(13A)-H(13F) 109.5 
C(1A)-C(6A)-C(7A) 121.1(2)  C(10)-C(13)-H(13A) 109.5  H(13E)-C(13A)-H(13F) 109.5 
C(5A)-C(6A)-C(7A) 121.1(2)  C(10)-C(13)-H(13B) 109.5  N(2A)-C(14A)-H(14A) 122 
C(6A)-C(7A)-C(8A) 112.12(17)  H(13A)-C(13)-H(13B) 109.5  N(3A)-C(14A)-H(14A) 122 
N(1A)-C(8A)-C(7A) 110.98(16)  C(10)-C(13)-H(13C) 109.5  N(3A)-C(15A)-H(15A) 124.4 
N(1A)-C(8A)-C(9A) 107.86(15)  H(13A)-C(13)-H(13C) 109.5  N(1A)-C(15A)-H(15A) 124.4 
C(7A)-C(8A)-C(9A) 112.39(17)  H(13B)-C(13)-H(13C) 109.5    
O(1A)-C(9A)-C(10A) 122.0(2)  C(10)-C(11)-H(11A) 109.5    
 
Table 2 f. Anisotropic displacement parameters (Å² x 103) The anisotropic displacement factor exponent 
takes the form: -2 π² [ h² a*² U11 + ... + 2 h k a* b* U12 ]. 
 U11 U22 U33 U23 U13 U12   U11 U22 U33 U23 U13 U12 
N(1) 42(1) 49(1) 40(1) -1(1) 6(1) 1(1)  N(1A) 42(1) 45(1) 43(1) 2(1) 5(1) 1(1) 
N(2) 58(1) 73(1) 54(1) 10(1) -4(1) 0(1)  N(3A) 78(2) 76(2) 54(1) -10(1) -5(1) -4(1) 
N(3) 95(2) 104(2) 51(1) 12(1) 24(1) 0(1)  N(2A) 51(1) 72(1) 48(1) -3(1) 14(1) -2(1) 
O(1) 45(1) 57(1) 81(1) -5(1) 26(1) -2(1)  O(1A) 63(1) 68(1) 86(1) 11(1) -15(1) -14(1) 
C(1) 74(2) 52(1) 67(1) 6(1) 14(1) 2(1)  C(1A) 82(2) 54(1) 67(1) 7(1) 27(1) 2(1) 
C(2) 106(2) 52(2) 89(2) 12(1) 34(2) -6(2)  C(2A) 91(2) 71(2) 90(2) 12(2) 32(2) -15(2) 
C(3) 93(2) 51(2) 109(2) -18(2) 49(2) -22(1)  C(3A) 106(2) 57(2) 84(2) 9(1) 8(2) -22(2) 
C(4) 63(2) 66(2) 92(2) -29(2) 18(1) -14(1)  C(4A) 109(2) 55(2) 78(2) -10(1) 11(2) -1(2) 
C(5) 68(2) 47(1) 64(1) -10(1) 13(1) 0(1)  C(5A) 75(2) 61(2) 65(2) -2(1) 18(1) 2(1) 
C(6) 59(1) 40(1) 49(1) -9(1) 20(1) -3(1)  C(6A) 62(1) 49(1) 43(1) 9(1) 5(1) 4(1) 
C(7) 55(1) 49(1) 52(1) -6(1) 18(1) -3(1)  C(7A) 61(1) 56(1) 44(1) 4(1) 3(1) 0(1) 
C(8) 39(1) 40(1) 40(1) 1(1) 7(1) 0(1)  C(8A) 46(1) 47(1) 42(1) -1(1) 12(1) 2(1) 
C(9) 37(1) 47(1) 46(1) -2(1) 7(1) -2(1)  C(9A) 52(1) 55(1) 40(1) 0(1) 10(1) -2(1) 
C(10) 42(1) 46(1) 68(1) -12(1) 13(1) -6(1)  C(10A) 64(1) 47(1) 61(1) 5(1) 20(1) 0(1) 
C(11) 71(2) 50(1) 87(2) 7(1) 10(1) -2(1)  C(12A) 86(2) 69(2) 183(4) 51(2) 43(2) -2(2) 
C(12) 99(2) 68(2) 65(2) -19(1) 16(1) -15(2)  C(11A) 91(2) 68(2) 83(2) 15(1) 6(2) 26(2) 
C(13) 51(1) 54(2) 157(3) -32(2) 28(2) -1(1)  C(13A) 114(2) 72(2) 90(2) -13(2) 34(2) 10(2) 
C(14) 57(1) 77(2) 51(1) 2(1) 20(1) 2(1)  C(14A) 78(2) 73(2) 50(1) -4(1) 17(1) -1(1) 
C(15) 93(2) 82(2) 48(1) 12(1) -10(1) -4(2)  C(15A) 49(1) 64(1) 60(1) -1(1) 0(1) -1(1) 
 
Table 2 g. Torsion angles (°). 
C(14)-N(1)-N(2)-C(15) 1.0(3)  O(1)-C(9)-C(10)-C(13) -158.8(2)  C(5A)-C(6A)-C(7A)-C(8A) 94.9(2) 
C(8)-N(1)-N(2)-C(15) 177.23(19)  C(8)-C(9)-C(10)-C(13) 22.5(3)  C(15A)-N(1A)-C(8A)-C(7A) 105.8(2) 
C(6)-C(1)-C(2)-C(3) -0.7(4)  O(1)-C(9)-C(10)-C(11) -39.3(3)  N(2A)-N(1A)-C(8A)-C(7A) -73.2(2) 
C(1)-C(2)-C(3)-C(4) 0.4(4)  C(8)-C(9)-C(10)-C(11) 142.03(18)  C(15A)-N(1A)-C(8A)-C(9A) -130.7(2) 
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C(2)-C(3)-C(4)-C(5) 0.0(4)  O(1)-C(9)-C(10)-C(12) 78.1(2)  N(2A)-N(1A)-C(8A)-C(9A) 50.3(2) 
C(3)-C(4)-C(5)-C(6) 0.0(3)  C(8)-C(9)-C(10)-C(12) -100.6(2)  C(6A)-C(7A)-C(8A)-N(1A) -58.8(2) 
C(2)-C(1)-C(6)-C(5) 0.8(3)  C(15)-N(3)-C(14)-N(1) 1.0(3)  C(6A)-C(7A)-C(8A)-C(9A) -179.65(17) 
C(2)-C(1)-C(6)-C(7) -179.5(2)  N(2)-N(1)-C(14)-N(3) -1.4(3)  N(1A)-C(8A)-C(9A)-O(1A) -98.7(2) 
C(4)-C(5)-C(6)-C(1) -0.4(3)  C(8)-N(1)-C(14)-N(3) -177.0(2)  C(7A)-C(8A)-C(9A)-O(1A) 24.0(3) 
C(4)-C(5)-C(6)-C(7) 179.89(19)  N(1)-N(2)-C(15)-N(3) -0.5(3)  N(1A)-C(8A)-C(9A)-C(10A) 83.2(2) 
C(1)-C(6)-C(7)-C(8) 103.0(2)  C(14)-N(3)-C(15)-N(2) -0.3(3)  C(7A)-C(8A)-C(9A)-C(10A) -154.12(17) 
C(5)-C(6)-C(7)-C(8) -77.3(2)  C(15A)-N(1A)-N(2A)-C(14A) 0.3(2)  O(1A)-C(9A)-C(10A)-C(12A) 23.9(3) 
C(14)-N(1)-C(8)-C(7) 105.9(2)  C(8A)-N(1A)-N(2A)-C(14A) 179.49(18)  C(8A)-C(9A)-C(10A)-C(12A) -158.1(2) 
N(2)-N(1)-C(8)-C(7) -69.3(2)  C(6A)-C(1A)-C(2A)-C(3A) 1.2(4)  O(1A)-C(9A)-C(10A)-C(13A) -95.1(3) 
C(14)-N(1)-C(8)-C(9) -131.3(2)  C(1A)-C(2A)-C(3A)-C(4A) -0.9(5)  C(8A)-C(9A)-C(10A)-C(13A) 82.9(2) 
N(2)-N(1)-C(8)-C(9) 53.4(2)  C(2A)-C(3A)-C(4A)-C(5A) 0.4(4)  O(1A)-C(9A)-C(10A)-C(11A) 147.2(2) 
C(6)-C(7)-C(8)-N(1) -55.7(2)  C(3A)-C(4A)-C(5A)-C(6A) -0.2(4)  C(8A)-C(9A)-C(10A)-C(11A) -34.8(3) 
C(6)-C(7)-C(8)-C(9) -176.64(17)  C(2A)-C(1A)-C(6A)-C(5A) -1.1(3)  N(1A)-N(2A)-C(14A)-N(3A) -0.2(3) 
N(1)-C(8)-C(9)-O(1) -109.35(19)  C(2A)-C(1A)-C(6A)-C(7A) 176.8(2)  C(15A)-N(3A)-C(14A)-N(2A) 0.0(3) 
C(7)-C(8)-C(9)-O(1) 13.1(3)  C(4A)-C(5A)-C(6A)-C(1A) 0.6(4)  C(14A)-N(3A)-C(15A)-N(1A) 0.2(3) 
N(1)-C(8)-C(9)-C(10) 69.4(2)  C(4A)-C(5A)-C(6A)-C(7A) -177.3(2)  N(2A)-N(1A)-C(15A)-N(3A) -0.3(2) 
C(7)-C(8)-C(9)-C(10) -168.19(17)  C(1A)-C(6A)-C(7A)-C(8A) -82.9(2)  C(8A)-N(1A)-C(15A)-N(3A) -179.38(18) 
 
 
 
 
III - MeTAK 
 
Figure 34. Asymmetric unit of MeTAK, in ellipsoid thermal representation (50% of probability). 
The two positions of the tertbuthyl are represented in grey (sof: 69%) and light grey (sof: 31%). 
 
Table 3 a. Crystal data. 
Chemical Formula C16 H21 N3 O 
Molecular Weight / g.mol-1 271.36 
Crystal System Orthorhombic 
Space group P212121 
Z , Z’ (asymmetric units per unit cell) 4, 1 
a / Å 5.808(1) 
b / Å 13.641(1) 
c / Å 19.789(1) 
V / Å3 1567.9(2) 
dcalc / g.cm-3 1.150 
R factor (with I>2σI) 
R1 = 0.0389 
wR2 = 0.1142 
R factor (all data) R1 = 0.0444 wR2 = 0.1210 
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F(000) / e- 584 
Absorption coefficient µ (MoKα1) mm-1 0.074 
Number of reflections (n) (with FO>4.0σ(FO)) 1880 
Number of refined parameters (p) / restraints 216 / 0 
Goodness of fit indicator (restrainted GooF) 0.965 
Maximum peak in final difference map / e-Ǻ-3 0.128 
Maximum hole in final difference map / e-Ǻ-3 -0.108 
 
Table 3 b. Atomic coordinates (x104) and equivalent isotropic displacement parameters (Å2 x 103). U(eq) is 
defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z U(eq)   x y z U(eq) 
O(1) 5280(3) 7423(1) 2178(1) 76(1)  C(9) 1663(3) 7995(1) 2558(1) 46(1) 
N(1) 1344(3) 9041(1) 2414(1) 49(1)  C(10) 3314(3) 7583(1) 2021(1) 52(1) 
N(2) 3203(3) 9624(1) 2339(1) 68(1)  C(11) 2492(4) 7400(2) 1293(1) 63(1) 
N(3) -82(5) 10491(2) 2255(1) 91(1)  C(12) 3446(10) 8232(4) 886(2) 89(2) 
C(1) -2889(7) 9509(2) 5438(1) 93(1)  C(13) 3668(9) 6442(4) 1064(3) 94(2) 
C(2) -1491(5) 9073(2) 4873(1) 66(1)  C(14) -37(6) 7290(5) 1237(2) 85(2) 
C(3) -2201(5) 8248(2) 4533(1) 68(1)  C(12B) 4250(30) 7286(19) 788(6) 159(11) 
C(4) -915(4) 7858(2) 4014(1) 62(1)  C(13B) 990(50) 6472(16) 1300(9) 181(12) 
C(5) 1148(4) 8275(1) 3817(1) 53(1)  C(14B) 650(30) 8231(12) 1043(7) 131(7) 
C(6) 1852(4) 9110(2) 4152(1) 70(1)  C(15) -562(4) 9571(2) 2369(1) 68(1) 
C(7) 560(5) 9493(2) 4671(1) 75(1)  C(16) 2230(6) 10478(2) 2241(2) 83(1) 
C(8) 2616(4) 7832(2) 3266(1) 58(1)       
In italic, the atoms of the tert-butyl with a sof of 22%. 
 
Table 3 c. Hydrogen coordinates (x104) and equivalent isotropic displacement parameters (Å2 x 103). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor 
 x y z U(eq)   x y z U(eq) 
H(1A) -4382 9207 5448 139  H(13C) 5303 6498 1125 141 
H(1B) -3057 10201 5366 139  H(14A) -437 7131 780 128 
H(1C) -2121 9397 5861 139  H(14B) -770 7893 1364 128 
H(3) -3577 7947 4655 81  H(14C) -543 6774 1532 128 
H(4) -1444 7301 3792 75  H(12D) 4889 6639 818 239 
H(6) 3216 9416 4026 84  H(12E) 5438 7762 861 239 
H(7) 1083 10052 4892 90  H(12F) 3587 7380 348 239 
H(8A) 2753 7132 3345 69  H(13D) -429 6600 1069 271 
H(8B) 4148 8112 3291 69  H(13E) 679 6287 1759 271 
H(9) 175 7661 2519 55  H(13F) 1796 5949 1077 271 
H(12A) 5096 8195 882 134  H(14D) 1305 8871 1101 196 
H(12B) 2976 8843 1084 134  H(14E) -735 8181 1308 196 
H(12C) 2877 8193 432 134  H(14F) 285 8129 575 196 
H(13A) 3336 6327 595 141  H(15) -2044 9321 2413 82 
H(13B) 3097 5905 1329 141  H(16) 3090 11043 2167 100 
In italic, the atoms of the tert-butyl with a sof of 31%. 
 
Table 3 d. Bond lengths (Å). 
O(1)-C(10) 1.203(3)  C(5)-C(6) 1.380(3) 
N(1)-C(15) 1.326(3)  C(5)-C(8) 1.510(3) 
N(1)-N(2) 1.349(2)  C(6)-C(7) 1.374(3) 
N(1)-C(9) 1.467(2)  C(8)-C(9) 1.522(2) 
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N(2)-C(16) 1.309(3)  C(9)-C(10) 1.538(3) 
N(3)-C(15) 1.305(3)  C(10)-C(11) 1.538(3) 
N(3)-C(16) 1.343(4)  C(11)-C(12) 1.498(5) 
C(1)-C(2) 1.506(3)  C(11)-C(13) 1.543(5) 
C(2)-C(3) 1.375(3)  C(11)-C(14) 1.481(4) 
C(2)-C(7) 1.381(4)  C(11)-C(12B) 1.435(15) 
C(3)-C(4) 1.376(3)  C(11)-C(13B) 1.536(18) 
C(4)-C(5) 1.383(3)  C(11)-C(14B) 1.637(14) 
 
Table 3 e. Angles (°). 
C(15)-N(1)-N(2) 109.82(16)  C(5)-C(8)-C(9) 113.60(16)  C(12)-C(11)-C(10) 105.4(2) 
C(15)-N(1)-C(9) 130.51(18)  N(1)-C(9)-C(8) 111.54(15)  C(13B)-C(11)-C(10) 107.5(7) 
N(2)-N(1)-C(9) 119.59(15)  N(1)-C(9)-C(10) 107.44(14)  C(12B)-C(11)-C(13) 52.4(10) 
C(16)-N(2)-N(1) 101.3(2)  C(8)-C(9)-C(10) 110.85(15)  C(14)-C(11)-C(13) 109.3(3) 
C(15)-N(3)-C(16) 101.7(2)  O(1)-C(10)-C(9) 118.62(18)  C(12)-C(11)-C(13) 108.7(4) 
C(3)-C(2)-C(7) 117.2(2)  O(1)-C(10)-C(11) 120.50(19)  C(13B)-C(11)-C(13) 63.6(11) 
C(3)-C(2)-C(1) 121.7(3)  C(9)-C(10)-C(11) 120.87(17)  C(10)-C(11)-C(13) 105.9(3) 
C(7)-C(2)-C(1) 121.1(2)  C(12B)-C(11)-C(14) 129.9(6)  C(12B)-C(11)-C(14B) 109.3(12) 
C(2)-C(3)-C(4) 121.2(2)  C(12B)-C(11)-C(12) 56.4(10)  C(14)-C(11)-C(14B) 53.0(7) 
C(3)-C(4)-C(5) 121.5(2)  C(14)-C(11)-C(12) 113.8(4)  C(12)-C(11)-C(14B) 63.6(7) 
C(6)-C(5)-C(4) 117.4(2)  C(12B)-C(11)-C(13B) 108.6(11)  C(13B)-C(11)-C(14B) 101.7(15) 
C(6)-C(5)-C(8) 120.7(2)  C(14)-C(11)-C(13B) 49.8(12)  C(10)-C(11)-C(14B) 111.9(5) 
C(4)-C(5)-C(8) 121.92(19)  C(12)-C(11)-C(13B) 147.1(8)  C(13)-C(11)-C(14B) 142.0(5) 
C(7)-C(6)-C(5) 120.8(2)  C(12B)-C(11)-C(10) 116.7(6)  N(3)-C(15)-N(1) 111.0(2) 
C(6)-C(7)-C(2) 121.9(2)  C(14)-C(11)-C(10) 113.2(2)  N(2)-C(16)-N(3) 116.2(2) 
In italic, the atoms of the tert-butyl with a sof of 31%. 
 
Table 3 f. Anisotropic displacement parameters (Å² x 103) The anisotropic displacement factor exponent 
takes the form: -2 π² [ h² a*² U11 + ... + 2 h k a* b* U12 ]. 
 U11 U22 U33 U23 U13 U12 
O(1) 60(1) 98(1) 70(1) -5(1) 0(1) 23(1) 
N(1) 51(1) 44(1) 51(1) 1(1) -5(1) 0(1) 
N(2) 68(1) 53(1) 82(1) 2(1) -4(1) -14(1) 
N(3) 104(2) 57(1) 112(2) 9(1) -22(2) 18(1) 
C(1) 124(2) 89(2) 65(1) 1(1) 23(2) 19(2) 
C(2) 90(2) 63(1) 45(1) 6(1) 1(1) 13(1) 
C(3) 71(1) 72(1) 61(1) 5(1) 7(1) -3(1) 
C(4) 72(1) 61(1) 54(1) -2(1) -3(1) -5(1) 
C(5) 62(1) 53(1) 44(1) 4(1) -5(1) 6(1) 
C(6) 74(1) 66(1) 70(1) -3(1) 4(1) -11(1) 
C(7) 97(2) 62(1) 66(1) -15(1) 2(1) -8(1) 
C(8) 63(1) 59(1) 51(1) 6(1) -3(1) 12(1) 
C(9) 47(1) 41(1) 49(1) 0(1) -1(1) -1(1) 
C(10) 54(1) 48(1) 54(1) 1(1) 4(1) -1(1) 
C(11) 63(1) 76(1) 50(1) -9(1) 10(1) -7(1) 
C(12) 121(4) 98(3) 49(2) 12(2) 1(2) -19(3) 
C(13) 93(3) 90(3) 99(3) -42(2) 8(3) -1(3) 
C(14) 62(2) 141(5) 53(2) -23(3) -7(2) -13(2) 
C(12B) 151(13) 260(30) 62(6) -59(11) 15(7) -71(17) 
C(13B) 280(30) 139(15) 119(13) -66(11) -10(16) -72(19) 
Appendix 
 
- 288 - 
C(14B) 188(17) 127(12) 78(7) -1(7) -64(9) 29(12) 
C(15) 64(1) 59(1) 81(2) 5(1) -10(1) 12(1) 
C(16) 104(2) 46(1) 99(2) 7(1) -11(2) -10(1) 
In italic, the atoms of the tert-butyl with a sof of 31%. 
 
Table 3 g. Torsion angles (°). 
C(15)-N(1)-N(2)-C(16) -1.0(2)  C(8)-C(9)-C(10)-O(1) -18.1(3) 
C(9)-N(1)-N(2)-C(16) -178.1(2)  N(1)-C(9)-C(10)-C(11) -74.6(2) 
C(7)-C(2)-C(3)-C(4) 0.2(3)  C(8)-C(9)-C(10)-C(11) 163.34(18) 
C(1)-C(2)-C(3)-C(4) 179.7(2)  O(1)-C(10)-C(11)-C(12B) -15.7(12) 
C(2)-C(3)-C(4)-C(5) 0.4(4)  C(9)-C(10)-C(11)-C(12B) 162.9(12) 
C(3)-C(4)-C(5)-C(6) -1.1(3)  O(1)-C(10)-C(11)-C(14) 159.6(4) 
C(3)-C(4)-C(5)-C(8) 177.7(2)  C(9)-C(10)-C(11)-C(14) -21.9(4) 
C(4)-C(5)-C(6)-C(7) 1.2(3)  O(1)-C(10)-C(11)-C(12) -75.4(3) 
C(8)-C(5)-C(6)-C(7) -177.5(2)  C(9)-C(10)-C(11)-C(12) 103.2(3) 
C(5)-C(6)-C(7)-C(2) -0.7(4)  O(1)-C(10)-C(11)-C(13B) 106.5(13) 
C(3)-C(2)-C(7)-C(6) 0.0(4)  C(9)-C(10)-C(11)-C(13B) -75.0(13) 
C(1)-C(2)-C(7)-C(6) -179.5(2)  O(1)-C(10)-C(11)-C(13) 39.8(4) 
C(6)-C(5)-C(8)-C(9) -106.6(2)  C(9)-C(10)-C(11)-C(13) -141.7(3) 
C(4)-C(5)-C(8)-C(9) 74.7(2)  O(1)-C(10)-C(11)-C(14B) -142.7(8) 
C(15)-N(1)-C(9)-C(8) -107.0(2)  C(9)-C(10)-C(11)-C(14B) 35.9(8) 
N(2)-N(1)-C(9)-C(8) 69.4(2)  C(16)-N(3)-C(15)-N(1) -0.6(3) 
C(15)-N(1)-C(9)-C(10) 131.4(2)  N(2)-N(1)-C(15)-N(3) 1.0(3) 
N(2)-N(1)-C(9)-C(10) -52.3(2)  C(9)-N(1)-C(15)-N(3) 177.7(2) 
C(5)-C(8)-C(9)-N(1) 56.8(2)  N(1)-N(2)-C(16)-N(3) 0.7(4) 
C(5)-C(8)-C(9)-C(10) 176.43(17)  C(15)-N(3)-C(16)-N(2) -0.1(4) 
N(1)-C(9)-C(10)-O(1) 104.0(2)    
In italic, the atoms of the tert-butyl with a sof of 31%. 
 
 
 
 
IV - BrTAK 
 
Figure 35. Asymmetric unit of BrTAK, in ellipsoid thermal representation (50% of probability). 
The two positions of the tertbuthyl are represented in grey (sof: 68%) and light grey (sof: 32%). 
Table 4 a. Crystal data. 
Chemical Formula C15 H18 Br N3 O 
Molecular Weight / g.mol-1 336.23 
Crystal System Orthorhombic 
Space group P212121 
Z , Z’ (asymmetric units per unit cell) 4, 1 
a / Å 5.7875(5) 
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b / Å 13.629(1) 
c / Å 19.882(2) 
V / Å3 1568.3(2) 
dcalc / g.cm-3 1.424 
R factor (with I>2σI) 
R1 = 0.0371 
wR2 = 0.0848 
R factor (all data) R1 = 0.0544 wR2 = 0.0913 
F(000) / e- 688 
Absorption coefficient µ (MoKα1) mm-1 2.621 
Number of reflections (n) (with FO>4.0σ(FO)) 3192 / 2447 
Number of refined parameters (p) / restraints 215 
Goodness of fit indicator (restrainted GooF) 1.030 
Maximum peak in final difference map / e-Ǻ-3 0.405 
Maximum hole in final difference map / e-Ǻ-3 -0.161 
 
Table 4 b. Atomic coordinates (x104) and equivalent isotropic displacement parameters (Å2 x 103). U(eq) is 
defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
Br(1) 7287(1) 417(1) 590(1) 85(1) 
O(1) 15344(4) 2661(2) -2849(1) 72(1) 
N(1) 11433(4) 1041(2) -2599(1) 44(1) 
N(2) 13303(5) 468(2) -2673(1) 62(1) 
N(3) 10045(7) -422(2) -2773(2) 85(1) 
C(1) 8917(6) 969(2) -150(1) 57(1) 
C(2) 10952(6) 562(2) -348(2) 66(1) 
C(3) 12137(6) 972(2) -876(2) 61(1) 
C(4) 11332(5) 1802(2) -1205(1) 46(1) 
C(5) 9270(5) 2189(2) -991(2) 54(1) 
C(6) 8061(5) 1778(2) -458(1) 57(1) 
C(7) 12709(6) 2259(2) -1761(1) 51(1) 
C(8) 11736(5) 2090(2) -2464(1) 42(1) 
C(9) 13364(5) 2503(2) -3002(1) 47(1) 
C(10) 12528(6) 2689(2) -3716(1) 57(1) 
C(13) 13377(13) 1824(5) -4132(3) 84(2) 
C(11) 9979(10) 2813(7) -3770(3) 87(3) 
C(12) 13701(13) 3653(6) -3959(4) 100(3) 
C(11A) 10780(30) 1849(14) -3999(7) 105(7) 
C(13A) 11140(40) 3632(13) -3721(8) 116(8) 
C(12A) 14460(30) 2820(20) -4227(7) 133(10) 
C(14) 12346(8) -396(2) -2774(2) 77(1) 
C(15) 9518(6) 512(3) -2656(2) 63(1) 
In italic, the atoms of the tert-butyl with a sof of 32%. 
 
Table 4 c. Hydrogen coordinates (x104) and equivalent isotropic displacement parameters (Å2 x 103). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
H(2) 11534 13 -128 79 
H(3) 13513 686 -1017 73 
H(5) 8670 2738 -1208 64 
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H(6) 6679 2056 -313 68 
H(7A) 14268 1999 -1745 61 
H(7B) 12802 2960 -1682 61 
H(8) 10235 2418 -2500 50 
H(13A) 13077 1946 -4599 125 
H(13B) 12582 1240 -3994 125 
H(13C) 15008 1741 -4064 125 
H(11A) 9557 2887 -4234 131 
H(11B) 9513 3385 -3523 131 
H(11C) 9223 2245 -3587 131 
H(12A) 15349 3582 -3935 151 
H(12B) 13223 4187 -3677 151 
H(12C) 13255 3783 -4416 151 
H(11D) 10368 1997 -4455 158 
H(11E) 9415 1832 -3726 158 
H(11F) 11535 1222 -3982 158 
H(13D) 11996 4140 -3497 175 
H(13E) 9700 3530 -3491 175 
H(13F) 10839 3825 -4177 175 
H(12D) 13843 3105 -4630 199 
H(12E) 15129 2194 -4329 199 
H(12F) 15622 3246 -4044 199 
H(14) 13228 -958 -2841 92 
H(15) 8025 758 -2618 76 
In italic, the atoms of the tert-butyl with a sof of 32%. 
 
Table 4 d. Bond lengths (Å). 
Br(1)-C(1) 1.903(3)  C(9)-C(10) 1.521(4)  C(11)-H(11A) 0.96 
O(1)-C(9) 1.205(4)  C(10)-C(11) 1.489(7)  C(11)-H(11B) 0.96 
N(1)-C(15) 1.327(4)  C(10)-C(13) 1.521(6)  C(11)-H(11C) 0.96 
N(1)-N(2) 1.343(3)  C(10)-C(12) 1.555(7)  C(12)-H(12A) 0.96 
N(1)-C(8) 1.464(4)  C(10)-C(13A) 1.516(18)  C(12)-H(12B) 0.96 
N(2)-C(14) 1.317(4)  C(10)-C(12A) 1.520(16)  C(12)-H(12C) 0.96 
N(3)-C(15) 1.329(4)  C(10)-C(11A) 1.627(15)  C(11A)-H(11D) 0.96 
N(3)-C(14) 1.332(5)  C(2)-H(2) 0.93  C(11A)-H(11E) 0.96 
C(1)-C(6) 1.356(4)  C(3)-H(3) 0.93  C(11A)-H(11F) 0.96 
C(1)-C(2) 1.360(5)  C(5)-H(5) 0.93  C(13A)-H(13D) 0.96 
C(2)-C(3) 1.373(4)  C(6)-H(6) 0.93  C(13A)-H(13E) 0.96 
C(3)-C(4) 1.387(4)  C(7)-H(7A) 0.97  C(13A)-H(13F) 0.96 
C(4)-C(5) 1.373(4)  C(7)-H(7B) 0.97  C(12A)-H(12D) 0.96 
C(4)-C(7) 1.498(4)  C(8)-H(8) 0.98  C(12A)-H(12E) 0.96 
C(5)-C(6) 1.389(4)  C(13)-H(13A) 0.96  C(12A)-H(12F) 0.96 
C(7)-C(8) 1.524(3)  C(13)-H(13B) 0.96  C(14)-H(14) 0.93 
C(8)-C(9) 1.532(4)  C(13)-H(13C) 0.96  C(15)-H(15) 0.93 
In italic, the atoms of the tert-butyl with a sof of 32%. 
 
Table 4 e. Angles (°). 
C(15)-N(1)-N(2) 110.3(2)  C(11)-C(10)-C(13) 111.6(5)  C(8)-C(7)-H(7B) 108.6 
C(15)-N(1)-C(8) 130.2(3)  C(13A)-C(10)-C(13) 145.6(7)  H(7A)-C(7)-H(7B) 107.6 
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N(2)-N(1)-C(8) 119.4(2)  C(12A)-C(10)-C(13) 59.4(11)  N(1)-C(8)-H(8) 109 
C(14)-N(2)-N(1) 101.4(3)  C(9)-C(10)-C(13) 105.9(3)  C(7)-C(8)-H(8) 109 
C(15)-N(3)-C(14) 101.8(3)  C(11)-C(10)-C(12) 108.4(5)  C(9)-C(8)-H(8) 109 
C(6)-C(1)-C(2) 121.2(3)  C(13A)-C(10)-C(12) 60.9(9)  C(10)-C(13)-H(13A) 109.5 
C(6)-C(1)-Br(1) 119.3(3)  C(12A)-C(10)-C(12) 51.1(10)  C(10)-C(13)-H(13B) 109.5 
C(2)-C(1)-Br(1) 119.5(2)  C(9)-C(10)-C(12) 107.0(4)  C(10)-C(13)-H(13C) 109.5 
C(1)-C(2)-C(3) 119.2(3)  C(13)-C(10)-C(12) 110.1(5)  C(10)-C(11)-H(11A) 109.5 
C(2)-C(3)-C(4) 121.6(3)  C(11)-C(10)-C(11A) 55.9(8)  C(10)-C(11)-H(11B) 109.5 
C(5)-C(4)-C(3) 117.4(3)  C(13A)-C(10)-C(11A) 105.4(11)  C(10)-C(11)-H(11C) 109.5 
C(5)-C(4)-C(7) 122.1(3)  C(12A)-C(10)-C(11A) 108.0(12)  C(10)-C(12)-H(12A) 109.5 
C(3)-C(4)-C(7) 120.6(3)  C(9)-C(10)-C(11A) 113.7(6)  C(10)-C(12)-H(12B) 109.5 
C(4)-C(5)-C(6) 121.3(3)  C(13)-C(10)-C(11A) 57.8(8)  C(10)-C(12)-H(12C) 109.5 
C(1)-C(6)-C(5) 119.3(3)  C(12)-C(10)-C(11A) 139.3(6)  H(11D)-C(11A)-H(11E) 109.5 
C(4)-C(7)-C(8) 114.7(2)  N(2)-C(14)-N(3) 116.3(3)  H(11D)-C(11A)-H(11F) 109.5 
N(1)-C(8)-C(7) 111.1(2)  N(1)-C(15)-N(3) 110.1(3)  H(11E)-C(11A)-H(11F) 109.5 
N(1)-C(8)-C(9) 107.7(2)  C(1)-C(2)-H(2) 120.4  H(13D)-C(13A)-H(13E) 109.5 
C(7)-C(8)-C(9) 110.9(2)  C(3)-C(2)-H(2) 120.4  H(13D)-C(13A)-H(13F) 109.5 
O(1)-C(9)-C(10) 120.5(3)  C(2)-C(3)-H(3) 119.2  H(13E)-C(13A)-H(13F) 109.5 
O(1)-C(9)-C(8) 118.3(3)  C(4)-C(3)-H(3) 119.2  H(12D)-C(12A)-H(12E) 109.5 
C(10)-C(9)-C(8) 121.1(3)  C(4)-C(5)-H(5) 119.4  H(12D)-C(12A)-H(12F) 109.5 
C(11)-C(10)-C(13A) 51.5(9)  C(6)-C(5)-H(5) 119.4  H(12E)-C(12A)-H(12F) 109.5 
C(11)-C(10)-C(12A) 131.8(7)  C(1)-C(6)-H(6) 120.4  N(2)-C(14)-H(14) 121.8 
C(13A)-C(10)-C(12A) 106.6(12)  C(5)-C(6)-H(6) 120.4  N(3)-C(14)-H(14) 121.8 
C(11)-C(10)-C(9) 113.7(3)  C(4)-C(7)-H(7A) 108.6  N(1)-C(15)-H(15) 124.9 
C(13A)-C(10)-C(9) 108.4(6)  C(8)-C(7)-H(7A) 108.6  N(3)-C(15)-H(15) 124.9 
C(12A)-C(10)-C(9) 114.2(7)       
In italic, the atoms of the tert-butyl with a sof of 32%. 
 
Table 4 f. Anisotropic displacement parameters (Å² x 103) The anisotropic displacement factor exponent 
takes the form: -2 π² [ h² a*² U11 + ... + 2 h k a* b* U12 ]. 
 U11 U22 U33 U23 U13 U12 
Br(1) 121(1) 75(1) 60(1) 8(1) 26(1) -10(1) 
O(1) 60(2) 97(2) 58(1) 5(1) 1(1) -23(1) 
N(1) 46(1) 44(1) 42(1) -2(1) -5(1) 1(1) 
N(2) 63(2) 51(2) 71(2) -2(1) -6(1) 11(2) 
N(3) 98(3) 54(2) 102(2) -9(2) -22(2) -13(2) 
C(1) 84(2) 49(2) 37(2) -4(1) 5(2) -9(2) 
C(2) 83(2) 53(2) 60(2) 13(2) 2(2) 12(2) 
C(3) 61(2) 61(2) 61(2) -3(1) 5(2) 12(2) 
C(4) 56(2) 46(2) 37(1) -8(1) -5(1) -6(1) 
C(5) 60(2) 51(2) 50(2) 7(1) -3(2) 7(2) 
C(6) 57(2) 61(2) 53(2) -1(1) 5(1) 2(2) 
C(7) 58(2) 52(1) 43(1) -5(1) -1(2) -12(2) 
C(8) 44(2) 38(1) 44(1) -2(1) -1(1) 3(1) 
C(9) 46(2) 47(2) 48(2) -2(1) 4(1) 0(1) 
C(10) 58(2) 68(2) 43(1) 8(1) 8(2) 11(2) 
C(13) 107(6) 96(5) 48(3) -5(3) 8(3) 22(4) 
C(11) 62(4) 149(9) 50(3) 27(4) -3(3) 20(4) 
C(12) 89(5) 112(6) 100(6) 56(5) 1(4) -9(4) 
C(11A) 127(15) 124(15) 65(8) 6(9) -55(9) -23(12) 
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C(13A) 180(20) 81(11) 91(11) 28(9) -9(12) 4(12) 
C(12A) 104(12) 260(30) 38(7) 13(11) 20(7) 44(17) 
C(14) 93(3) 48(2) 88(2) -10(2) -15(2) 16(3) 
C(15) 56(2) 59(2) 75(2) -7(2) -10(2) -11(2) 
In italic, the atoms of the tert-butyl with a sof of 32%. 
 
Table 4 g. Torsion angles (°) 
C(15)-N(1)-N(2)-C(14) 0.2(3)  C(7)-C(8)-C(9)-O(1) 18.6(4) 
C(8)-N(1)-N(2)-C(14) 179.1(2)  N(1)-C(8)-C(9)-C(10) 75.6(3) 
C(6)-C(1)-C(2)-C(3) -1.0(5)  C(7)-C(8)-C(9)-C(10) -162.7(2) 
Br(1)-C(1)-C(2)-C(3) -179.1(3)  O(1)-C(9)-C(10)-C(11) -159.0(5) 
C(1)-C(2)-C(3)-C(4) 1.2(5)  C(8)-C(9)-C(10)-C(11) 22.4(5) 
C(2)-C(3)-C(4)-C(5) -1.4(4)  O(1)-C(9)-C(10)-C(13A) -103.7(10) 
C(2)-C(3)-C(4)-C(7) 177.4(3)  C(8)-C(9)-C(10)-C(13A) 77.6(10) 
C(3)-C(4)-C(5)-C(6) 1.3(4)  O(1)-C(9)-C(10)-C(12A) 15.0(13) 
C(7)-C(4)-C(5)-C(6) -177.4(3)  C(8)-C(9)-C(10)-C(12A) -163.7(12) 
C(2)-C(1)-C(6)-C(5) 1.0(5)  O(1)-C(9)-C(10)-C(13) 78.1(5) 
Br(1)-C(1)-C(6)-C(5) 179.0(2)  C(8)-C(9)-C(10)-C(13) -100.6(4) 
C(4)-C(5)-C(6)-C(1) -1.1(4)  O(1)-C(9)-C(10)-C(12) -39.4(5) 
C(5)-C(4)-C(7)-C(8) -74.9(3)  C(8)-C(9)-C(10)-C(12) 141.9(4) 
C(3)-C(4)-C(7)-C(8) 106.4(3)  O(1)-C(9)-C(10)-C(11A) 139.4(9) 
C(15)-N(1)-C(8)-C(7) 109.3(3)  C(8)-C(9)-C(10)-C(11A) -39.2(9) 
N(2)-N(1)-C(8)-C(7) -69.4(3)  N(1)-N(2)-C(14)-N(3) 0.2(4) 
C(15)-N(1)-C(8)-C(9) -129.0(3)  C(15)-N(3)-C(14)-N(2) -0.5(5) 
N(2)-N(1)-C(8)-C(9) 52.3(3)  N(2)-N(1)-C(15)-N(3) -0.5(4) 
C(4)-C(7)-C(8)-N(1) -55.2(3)  C(8)-N(1)-C(15)-N(3) -179.3(3) 
C(4)-C(7)-C(8)-C(9) -174.9(2)  C(14)-N(3)-C(15)-N(1) 0.6(4) 
N(1)-C(8)-C(9)-O(1) -103.1(3)    
In italic, the atoms of the tert-butyl with a sof of 32%. 
 
 
 
 
V – Imine monohydrate 52a 
 
Figure 36. Asymmetric unit of the monohydrate of 52a. 
Table 5 a. Crystal data. 
 
Chemical Formula C15H15FN2O2 
Molecular Weight / g.mol-1 274.29 
Crystal System Monoclinic 
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Space group P21/c 
Z , Z’ (asymmetric units per unit cell) 4, 1 
a / Å 13.9829(14) 
b / Å 6.6374(7) (1) 
c / Å 15.8034 (1) 
β / ° 100.202(2) 
V / Å3 1443.5(3) 
dcalc / g.cm-3 1.262 
R factor (with I>2σI) 
R1 = 0.0659 
wR2 = 0.1907 
R factor (all data) R1 = 0.0719 wR2 = 0.1965 
F(000) / e- 576 
Absorption coefficient µ (MoKα1) mm-1 0.094 
Number of reflections (n) (with FO>4.0σ(FO)) 11022 / 2960 
Number of refined parameters (p) / restraints 189 
Goodness of fit indicator (restrainted GooF) 1.093 
Maximum peak in final difference map / e-Ǻ-3 0.941 
Maximum hole in final difference map / e-Ǻ-3 -0.286 
 
Table 5 b. Atomic coordinates (x104) and equivalent isotropic displacement parameters (Å2 x 103). U(eq) is 
defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
OW1 5837(1) 741(3) 7659(2) 72(1) 
F(1) 2000(2) 5783(3) 8946(1) 99(1) 
O(1) 3926(1) 1637(2) 7779(1) 62(1) 
N(1) 1739(1) 826(3) 8637(1) 46(1) 
N(2) 3133(1) -1160(3) 8056(1) 61(1) 
C(1) 2748(2) 4953(4) 9471(2) 63(1) 
C(2) 3160(3) 6002(5) 10188(2) 94(1) 
C(3) 3917(3) 5144(7) 10730(2) 106(1) 
C(4) 4238(2) 3261(6) 10558(2) 92(1) 
C(5) 3816(2) 2231(5) 9826(2) 68(1) 
C(6) 3047(1) 3090(3) 9254(1) 47(1) 
C(7) 2545(1) 2064(3) 8447(1) 42(1) 
C(8) 890(1) 1512(3) 8424(1) 48(1) 
C(9) 23(1) 470(3) 8597(1) 50(1) 
C(10) 78(2) -1392(4) 8997(2) 65(1) 
C(11) -758(2) -2337(5) 9149(2) 80(1) 
C(12) -1648(2) -1419(5) 8914(2) 78(1) 
C(13) -1708(2) 421(5) 8524(2) 74(1) 
C(14) -880(2) 1374(4) 8362(2) 62(1) 
C(15) 3264(1) 790(3) 8059(1) 44(1) 
 
Table 5 c. Hydrogen coordinates (x104) and equivalent isotropic displacement parameters (Å2 x 103). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
HW1 5270(20) 810(50) 7702(19) 81(9) 
HW2 5920(30) -460(70) 7500(20) 104(12) 
H(2A) 3524 -1941 7848 73 
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H(2B) 2655 -1662 8262 73 
H(2) 2930 7269 10303 113 
H(3) 4216 5837 11217 127 
H(4) 4745 2670 10938 110 
H(5) 4045 961 9714 82 
H(7) 2279 3100 8029 50 
H(8) 810 2747 8142 58 
H(10) 679 -2011 9164 78 
H(11) -718 -3596 9412 96 
H(12) -2208 -2054 9020 94 
H(13) -2311 1038 8366 89 
H(14) -928 2627 8094 75 
 
Table 5 d. Bond lengths (Å). 
OW1-HW1 0.81(3)  C(5)-H(5) 0.93 
OW1-HW2 0.85(4)  C(6)-C(7) 1.506(3) 
F(1)-C(1) 1.333(3)  C(7)-C(15) 1.523(3) 
O(1)-C(15) 1.231(2)  C(7)-H(7) 0.98 
N(1)-C(8) 1.260(2)  C(8)-C(9) 1.463(3) 
N(1)-C(7) 1.468(2)  C(8)-H(8) 0.93 
N(2)-C(15) 1.307(3)  C(9)-C(10) 1.384(4) 
N(2)-H(2A) 0.86  C(9)-C(14) 1.388(3) 
N(2)-H(2B) 0.86  C(10)-C(11) 1.385(3) 
C(1)-C(6) 1.368(3)  C(10)-H(10) 0.93 
C(1)-C(2) 1.368(4)  C(11)-C(12) 1.377(4) 
C(2)-C(3) 1.362(6)  C(11)-H(11) 0.93 
C(2)-H(2) 0.93  C(12)-C(13) 1.364(4) 
C(3)-C(4) 1.372(6)  C(12)-H(12) 0.93 
C(3)-H(3) 0.93  C(13)-C(14) 1.383(4) 
C(4)-C(5) 1.382(4)  C(13)-H(13) 0.93 
C(4)-H(4) 0.93  C(14)-H(14) 0.93 
C(5)-C(6) 1.398(3)    
 
Table 5 e. Angles (°). 
HW1-OW1-HW2 106(3)  C(6)-C(7)-H(7) 108.5 
C(8)-N(1)-C(7) 117.65(17)  C(15)-C(7)-H(7) 108.5 
C(15)-N(2)-H(2A) 120  N(1)-C(8)-C(9) 123.5(2) 
C(15)-N(2)-H(2B) 120  N(1)-C(8)-H(8) 118.3 
H(2A)-N(2)-H(2B) 120  C(9)-C(8)-H(8) 118.3 
F(1)-C(1)-C(6) 117.3(2)  C(10)-C(9)-C(14) 118.9(2) 
F(1)-C(1)-C(2) 118.3(3)  C(10)-C(9)-C(8) 121.75(19) 
C(6)-C(1)-C(2) 124.4(3)  C(14)-C(9)-C(8) 119.4(2) 
C(3)-C(2)-C(1) 118.3(3)  C(9)-C(10)-C(11) 120.2(2) 
C(3)-C(2)-H(2) 120.8  C(9)-C(10)-H(10) 119.9 
C(1)-C(2)-H(2) 120.8  C(11)-C(10)-H(10) 119.9 
C(2)-C(3)-C(4) 120.1(3)  C(12)-C(11)-C(10) 120.2(3) 
C(2)-C(3)-H(3) 119.9  C(12)-C(11)-H(11) 119.9 
C(4)-C(3)-H(3) 119.9  C(10)-C(11)-H(11) 119.9 
C(3)-C(4)-C(5) 120.7(3)  C(13)-C(12)-C(11) 119.9(2) 
C(3)-C(4)-H(4) 119.7  C(13)-C(12)-H(12) 120 
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C(5)-C(4)-H(4) 119.7  C(11)-C(12)-H(12) 120 
C(4)-C(5)-C(6) 120.3(3)  C(12)-C(13)-C(14) 120.4(2) 
C(4)-C(5)-H(5) 119.8  C(12)-C(13)-H(13) 119.8 
C(6)-C(5)-H(5) 119.8  C(14)-C(13)-H(13) 119.8 
C(1)-C(6)-C(5) 116.2(2)  C(13)-C(14)-C(9) 120.3(3) 
C(1)-C(6)-C(7) 120.3(2)  C(13)-C(14)-H(14) 119.9 
C(5)-C(6)-C(7) 123.6(2)  C(9)-C(14)-H(14) 119.9 
N(1)-C(7)-C(6) 109.86(15)  O(1)-C(15)-N(2) 124.36(19) 
N(1)-C(7)-C(15) 110.91(16)  O(1)-C(15)-C(7) 118.95(18) 
C(6)-C(7)-C(15) 110.50(15)  N(2)-C(15)-C(7) 116.69(17) 
N(1)-C(7)-H(7) 108.5    
 
Table 5 f. Anisotropic displacement parameters (Å² x 103) The anisotropic displacement factor exponent 
takes the form: -2 π² [ h² a*² U11 + ... + 2 h k a* b* U12 ]. 
 U11 U22 U33 U23 U13 U12 
OW1 46(1) 51(1) 125(2) 6(1) 31(1) -3(1) 
F(1) 108(1) 59(1) 136(2) 0(1) 38(1) 27(1) 
O(1) 53(1) 57(1) 86(1) -5(1) 38(1) -4(1) 
N(1) 36(1) 47(1) 58(1) 1(1) 16(1) 2(1) 
N(2) 55(1) 45(1) 91(1) -9(1) 35(1) 0(1) 
C(1) 72(2) 47(1) 79(2) -2(1) 37(1) -1(1) 
C(2) 137(3) 66(2) 96(2) -31(2) 63(2) -29(2) 
C(3) 135(3) 122(3) 67(2) -32(2) 37(2) -59(3) 
C(4) 83(2) 129(3) 61(2) -2(2) 3(1) -25(2) 
C(5) 61(1) 86(2) 57(1) 1(1) 7(1) -3(1) 
C(6) 46(1) 46(1) 54(1) 0(1) 24(1) -5(1) 
C(7) 37(1) 39(1) 53(1) 6(1) 16(1) 4(1) 
C(8) 40(1) 50(1) 56(1) 1(1) 10(1) 4(1) 
C(9) 37(1) 62(1) 53(1) -9(1) 12(1) 1(1) 
C(10) 46(1) 71(2) 81(2) 5(1) 21(1) 2(1) 
C(11) 68(2) 89(2) 89(2) 7(2) 28(1) -15(2) 
C(12) 47(1) 121(3) 71(2) -11(2) 22(1) -22(1) 
C(13) 35(1) 113(2) 75(2) -12(2) 9(1) 3(1) 
C(14) 40(1) 76(2) 70(1) -4(1) 7(1) 7(1) 
C(15) 38(1) 47(1) 50(1) -4(1) 14(1) -1(1) 
 
Table 5 g. Torsion angles (°). 
F(1)-C(1)-C(2)-C(3) 179.3(3)  C(5)-C(6)-C(7)-C(15) -34.0(3) 
C(6)-C(1)-C(2)-C(3) -0.3(4)  C(7)-N(1)-C(8)-C(9) -178.12(18) 
C(1)-C(2)-C(3)-C(4) -1.1(5)  N(1)-C(8)-C(9)-C(10) -1.4(3) 
C(2)-C(3)-C(4)-C(5) 1.5(5)  N(1)-C(8)-C(9)-C(14) 178.0(2) 
C(3)-C(4)-C(5)-C(6) -0.7(5)  C(14)-C(9)-C(10)-C(11) 0.7(4) 
F(1)-C(1)-C(6)-C(5) -178.5(2)  C(8)-C(9)-C(10)-C(11) -179.9(2) 
C(2)-C(1)-C(6)-C(5) 1.1(3)  C(9)-C(10)-C(11)-C(12) -0.8(4) 
F(1)-C(1)-C(6)-C(7) 0.6(3)  C(10)-C(11)-C(12)-C(13) 0.4(5) 
C(2)-C(1)-C(6)-C(7) -179.8(2)  C(11)-C(12)-C(13)-C(14) 0.1(4) 
C(4)-C(5)-C(6)-C(1) -0.6(4)  C(12)-C(13)-C(14)-C(9) -0.2(4) 
C(4)-C(5)-C(6)-C(7) -179.6(2)  C(10)-C(9)-C(14)-C(13) -0.2(4) 
C(8)-N(1)-C(7)-C(6) 102.5(2)  C(8)-C(9)-C(14)-C(13) -179.6(2) 
C(8)-N(1)-C(7)-C(15) -135.03(19)  N(1)-C(7)-C(15)-O(1) 172.32(18) 
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C(1)-C(6)-C(7)-N(1) -90.3(2)  C(6)-C(7)-C(15)-O(1) -65.6(2) 
C(5)-C(6)-C(7)-N(1) 88.7(2)  N(1)-C(7)-C(15)-N(2) -8.2(2) 
C(1)-C(6)-C(7)-C(15) 147.00(19)  C(6)-C(7)-C(15)-N(2) 113.8(2) 
 
 
 
 
VI – Dimer 46 
 
Figure 37. The two fully regenerated molecules of the asymmetric unit (in light grey the part regenerated 
by the inversion centre - red dot). The molecule to the left exhibits a partial disorder on the fluorine atom 
which is divided onto two positions with s.o.f. of 79% and 21%. 
 
Table 6 a. Crystal data. 
Chemical Formula C22H18F2N2 
Molecular Weight / g.mol-1 348.38 
Crystal System Triclinic 
Space group P-1 
Z , Z’ (asymmetric units per unit cell) 2, 2x0.5 
a / Å 9.2668(10) 
b / Å 9.6027(10) 
c / Å 11.3518(12) 
α / ° 65.849(2) 
β / ° 77.487(2) 
γ / ° 86.079(2) 
V / Å3 899.61(17) 
dcalc / g.cm-3 1.286 
R factor (with I>2σI) 
R1 = 0.0514, 
wR2 = 0.1340 
R factor (all data) R1 = 0.0580, wR2 = 0.1394 
F(000) / e- 364 
Absorption coefficient µ (MoKα1) mm-1 0.09 
Number of reflections (n) (with Fo>4.0σ(Fo)) 3609 / 3129 
Number of refined parameters (p) / restraints 245 
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Goodness of fit indicator (restrainted GooF) 1.046 
Maximum peak in final difference map / e-Ǻ-3 0.280 
Maximum hole in final difference map / e-Ǻ-3 -0.215 
 
Table 6 b. Atomic coordinates (x104) and equivalent isotropic displacement parameters (Å2 x 103). U(eq) is 
defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z U(eq)   x y z U(eq) 
F(1) 10241(1) 6417(1) 2577(1) 71(1)  F(1A) 5451(2) -1532(2) 3511(1) 80(1) 
N(1) 9715(1) 3648(2) 1111(1) 42(1)  F(2A) 1199(6) -376(8) 1988(6) 73(2) 
C(1) 12186(2) 3049(2) 2597(2) 50(1)  N(1A) 4055(1) 954(2) 420(1) 39(1) 
C(2) 12812(2) 2683(2) 3687(2) 63(1)  C(1A) 1829(2) -829(2) 2862(2) 53(1) 
C(3) 12584(2) 3597(2) 4377(2) 63(1)  C(2A) 1011(2) -1237(2) 4140(2) 70(1) 
C(4) 11733(2) 4863(2) 3999(2) 57(1)  C(3A) 1703(3) -1772(3) 5182(2) 76(1) 
C(5) 11121(2) 5197(2) 2919(2) 47(1)  C(4A) 3201(3) -1888(3) 4965(2) 75(1) 
C(6) 11335(2) 4330(2) 2184(2) 40(1)  C(5A) 3997(2) -1468(2) 3701(2) 58(1) 
C(7) 10638(2) 4716(2) 1023(2) 39(1)  C(6A) 3345(2) -951(2) 2616(2) 42(1) 
C(8) 9062(2) 3922(2) 99(2) 41(1)  C(7A) 4230(2) -479(2) 1241(1) 37(1) 
C(9) 7984(2) 2755(2) 256(2) 54(1)  C(8A) 4821(2) 1461(2) -827(1) 38(1) 
C(10) 7097(3) 1839(3) 1578(2) 88(1)  C(9A) 4638(2) 3074(2) -1691(2) 51(1) 
C(11) 8246(3) 1119(3) 938(3) 96(1)  C(10A) 4221(3) 4221(2) -1110(2) 71(1) 
      C(11A) 3132(3) 3743(3) -1636(2) 78(1) 
 
Table 6 c. Hydrogen coordinates (x104) and equivalent isotropic displacement parameters (Å2 x 103). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
H(1) 12341 2425 2137 60 
H(2) 13386 1821 3952 76 
H(3) 13011 3353 5105 75 
H(4) 11574 5483 4463 69 
H(9) 7471 3021 -475 65 
H(10A) 7281 2003 2322 105 
H(10B) 6076 1600 1640 105 
H(11A) 7937 430 604 115 
H(11B) 9141 833 1286 115 
H(1A) 1344 -467 2160 63 
H(2A) -11 -1145 4285 84 
H(3A) 1154 -2056 6037 92 
H(4A) 3680 -2250 5671 90 
H(5A) 5021 -1535 3566 69 
H(9A) 5297 3452 -2563 61 
H(10C) 4072 3866 -159 86 
H(10D) 4652 5242 -1607 86 
H(11C) 2892 4467 -2458 93 
H(11D) 2312 3091 -1010 93 
 
Table 6 d. Bond lengths (Å). 
F(1)-C(5) 1.350(2)  C(9)-C(11) 1.470(3)  C(4A)-C(5A) 1.370(3) 
N(1)-C(8) 1.337(2)  C(9)-C(10) 1.478(3)  C(4A)-H(4A) 0.93 
N(1)-C(7) 1.338(2)  C(9)-H(9) 0.98  C(5A)-C(6A) 1.381(2) 
C(1)-C(6) 1.382(2)  C(10)-C(11) 1.455(4)  C(5A)-H(5A) 0.93 
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C(1)-C(2) 1.385(3)  C(10)-H(10A) 0.97  C(6A)-C(7A) 1.494(2) 
C(1)-H(1) 0.93  C(10)-H(10B) 0.97  C(7A)-C(8A)#2 1.398(2) 
C(2)-C(3) 1.376(3)  C(11)-H(11A) 0.97  C(8A)-C(7A)#2 1.398(2) 
C(2)-H(2) 0.93  C(11)-H(11B) 0.97  C(8A)-C(9A) 1.477(2) 
C(3)-C(4) 1.368(3)  N(1A)-C(7A) 1.3321(19)  C(9A)-C(10A) 1.491(3) 
C(3)-H(3) 0.93  N(1A)-C(8A) 1.3384(19)  C(9A)-C(11A) 1.495(3) 
C(4)-C(5) 1.372(2)  C(1A)-C(6A) 1.379(2)  C(9A)-H(9A) 0.98 
C(4)-H(4) 0.93  C(1A)-C(2A) 1.389(3)  C(10A)-C(11A) 1.462(3) 
C(5)-C(6) 1.379(2)  C(1A)-H(1A) 0.93  C(10A)-H(10C) 0.97 
C(6)-C(7) 1.493(2)  C(2A)-C(3A) 1.364(3)  C(10A)-H(10D) 0.97 
C(7)-C(8)#1 1.394(2)  C(2A)-H(2A) 0.93  C(11A)-H(11C) 0.97 
C(8)-C(7)#1 1.394(2)  C(3A)-C(4A) 1.361(3)  C(11A)-H(11D) 0.97 
C(8)-C(9) 1.483(2)  C(3A)-H(3A) 0.93    
 
Table 6 e. Angles (°). 
C(8)-N(1)-C(7) 118.40(14)  C(7)#1-C(8)-C(9) 122.72(14)  N(1A)-C(7A)-C(8A)#2 121.55(13) 
C(6)-C(1)-C(2) 120.87(17)  C(11)-C(9)-C(10) 59.12(18)  N(1A)-C(7A)-C(6A) 115.47(13) 
C(6)-C(1)-H(1) 119.6  C(11)-C(9)-C(8) 120.89(17)  C(8A)#2-C(7A)-C(6A) 122.98(14) 
C(2)-C(1)-H(1) 119.6  C(11)-C(9)-H(9) 115.2  N(1A)-C(8A)-C(7A)#2 119.63(14) 
C(3)-C(2)-C(1) 119.95(18)  C(10)-C(9)-H(9) 115.2  N(1A)-C(8A)-C(9A) 117.07(13) 
C(3)-C(2)-H(2) 120  C(8)-C(9)-H(9) 115.2  C(7A)#2-C(8A)-C(9A) 123.29(14) 
C(1)-C(2)-H(2) 120  C(11)-C(10)-C(9) 60.14(16)  C(8A)-C(9A)-C(10A) 120.10(16) 
C(4)-C(3)-C(2) 120.41(17)  C(2A)-C(1A)-H(1A) 119.4  C(8A)-C(9A)-C(11A) 119.63(16) 
C(4)-C(3)-H(3) 119.8  C(3A)-C(2A)-C(1A) 120.2(2)  C(10A)-C(9A)-C(11A) 58.59(15) 
C(2)-C(3)-H(3) 119.8  C(3A)-C(2A)-H(2A) 119.9  C(8A)-C(9A)-H(9A) 115.5 
C(3)-C(4)-C(5) 118.49(18)  C(1A)-C(2A)-H(2A) 119.9  C(10A)-C(9A)-H(9A) 115.5 
C(3)-C(4)-H(4) 120.8  C(4A)-C(3A)-C(2A) 119.79(18)  C(11A)-C(9A)-H(9A) 115.5 
C(5)-C(4)-H(4) 120.8  C(4A)-C(3A)-H(3A) 120.1  C(11A)-C(10A)-C(9A) 60.84(14) 
F(1)-C(5)-C(4) 118.27(16)  C(2A)-C(3A)-H(3A) 120.1  C(11A)-C(10A)-H(10C) 117.7 
F(1)-C(5)-C(6) 118.44(14)  C(3A)-C(4A)-C(5A) 119.5(2)  C(9A)-C(10A)-H(10C) 117.7 
C(4)-C(5)-C(6) 123.27(17)  C(3A)-C(4A)-H(4A) 120.2  C(11A)-C(10A)-H(10D) 117.7 
C(5)-C(6)-C(1) 116.99(15)  C(5A)-C(4A)-H(4A) 120.2  C(9A)-C(10A)-H(10D) 117.7 
C(5)-C(6)-C(7) 121.90(15)  C(4A)-C(5A)-C(6A) 122.9(2)  H(10C)-C(10A)-H(10D) 114.8 
C(1)-C(6)-C(7) 121.08(14)  C(4A)-C(5A)-H(5A) 118.6  C(10A)-C(11A)-C(9A) 60.57(14) 
N(1)-C(7)-C(8)#1 121.46(14)  C(6A)-C(5A)-H(5A) 118.6  C(10A)-C(11A)-H(11C) 117.7 
N(1)-C(7)-C(6) 115.54(14)  C(1A)-C(6A)-C(5A) 116.40(16)  C(9A)-C(11A)-H(11C) 117.7 
C(8)#1-C(7)-C(6) 122.98(13)  C(1A)-C(6A)-C(7A) 121.31(15)  C(10A)-C(11A)-H(11D) 117.7 
N(1)-C(8)-C(7)#1 120.13(14)  C(5A)-C(6A)-C(7A) 122.23(15)  C(9A)-C(11A)-H(11D) 117.7 
N(1)-C(8)-C(9) 117.11(14)  C(6A)-C(1A)-H(1A) 119.4  H(11C)-C(11A)-H(11D) 114.8 
C(10)-C(9)-C(8) 119.76(16)       
 
Table 6 f. Anisotropic displacement parameters (Å² x 103) The anisotropic displacement factor exponent 
takes the form: -2 π² [ h² a*² U11 + ... + 2 h k a* b* U12 ]. 
 U11 U22 U33 U23 U13 U12   U11 U22 U33 U23 U13 U12 
F(1) 86(1) 75(1) 76(1) -49(1) -34(1) 31(1)  F(2A) 43(3) 102(5) 68(4) -30(3) -11(3) 8(3) 
N(1) 44(1) 43(1) 39(1) -18(1) -8(1) -4(1)  N(1A) 37(1) 42(1) 36(1) -15(1) -3(1) 2(1) 
C(1) 51(1) 46(1) 52(1) -19(1) -10(1) 0(1)  C(1A) 48(1) 52(1) 54(1) -24(1) 4(1) -1(1) 
C(2) 60(1) 56(1) 65(1) -13(1) -22(1) 7(1)  C(2A) 58(1) 67(1) 79(2) -39(1) 25(1) -10(1) 
C(3) 65(1) 74(1) 48(1) -15(1) -24(1) -5(1)  C(3A) 104(2) 68(1) 44(1) -26(1) 24(1) -20(1) 
C(4) 63(1) 70(1) 47(1) -30(1) -14(1) -5(1)  C(4A) 100(2) 78(2) 37(1) -18(1) -2(1) -11(1) 
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C(5) 48(1) 51(1) 47(1) -24(1) -12(1) 3(1)  C(5A) 66(1) 62(1) 37(1) -15(1) -5(1) -4(1) 
C(6) 38(1) 44(1) 39(1) -16(1) -6(1) -5(1)  C(6A) 45(1) 39(1) 37(1) -16(1) 1(1) -2(1) 
C(7) 38(1) 45(1) 39(1) -23(1) -6(1) 0(1)  C(7A) 33(1) 42(1) 34(1) -14(1) -4(1) -1(1) 
C(8) 42(1) 44(1) 41(1) -20(1) -7(1) -3(1)  C(8A) 34(1) 40(1) 36(1) -14(1) -4(1) 1(1) 
C(9) 64(1) 53(1) 47(1) -17(1) -16(1) -17(1)  C(9A) 53(1) 45(1) 41(1) -10(1) 2(1) 6(1) 
C(10) 103(2) 100(2) 59(1) -28(1) -4(1) -56(2)  C(10A) 88(2) 43(1) 70(1) -20(1) 2(1) 5(1) 
C(11) 113(2) 45(1) 138(3) -26(1) -67(2) -8(1)  C(11A) 65(1) 60(1) 84(2) -10(1) -15(1) 23(1) 
F(1A) 59(1) 116(2) 52(1) -18(1) -22(1) 4(1)         
 
Table 6 g. Torsion angles (°). 
C(6)-C(1)-C(2)-C(3) 0.3(3)  C(8)-C(9)-C(11)-C(10) 108.4(2) 
C(1)-C(2)-C(3)-C(4) 0.4(3)  C(6A)-C(1A)-C(2A)-C(3A) -0.1(3) 
C(2)-C(3)-C(4)-C(5) -0.1(3)  C(1A)-C(2A)-C(3A)-C(4A) 0.8(3) 
C(3)-C(4)-C(5)-F(1) 177.77(17)  C(2A)-C(3A)-C(4A)-C(5A) -0.1(4) 
C(3)-C(4)-C(5)-C(6) -0.9(3)  C(3A)-C(4A)-C(5A)-C(6A) -1.3(3) 
F(1)-C(5)-C(6)-C(1) -177.13(15)  C(2A)-C(1A)-C(6A)-C(5A) -1.2(3) 
C(4)-C(5)-C(6)-C(1) 1.5(3)  C(2A)-C(1A)-C(6A)-C(7A) -178.55(16) 
F(1)-C(5)-C(6)-C(7) 0.7(2)  C(4A)-C(5A)-C(6A)-C(1A) 1.9(3) 
C(4)-C(5)-C(6)-C(7) 179.35(16)  C(4A)-C(5A)-C(6A)-C(7A) 179.23(19) 
C(2)-C(1)-C(6)-C(5) -1.2(3)  C(8A)-N(1A)-C(7A)-C(8A)#2 -0.8(2) 
C(2)-C(1)-C(6)-C(7) -179.04(16)  C(8A)-N(1A)-C(7A)-C(6A) 179.50(13) 
C(8)-N(1)-C(7)-C(8)#1 -0.9(3)  C(1A)-C(6A)-C(7A)-N(1A) 56.0(2) 
C(8)-N(1)-C(7)-C(6) -179.64(13)  C(5A)-C(6A)-C(7A)-N(1A) -121.25(18) 
C(5)-C(6)-C(7)-N(1) -119.16(17)  C(1A)-C(6A)-C(7A)-C(8A)#2 -123.74(18) 
C(1)-C(6)-C(7)-N(1) 58.6(2)  C(5A)-C(6A)-C(7A)-C(8A)#2 59.0(2) 
C(5)-C(6)-C(7)-C(8)#1 62.1(2)  C(7A)-N(1A)-C(8A)-C(7A)#2 0.8(2) 
C(1)-C(6)-C(7)-C(8)#1 -120.12(18)  C(7A)-N(1A)-C(8A)-C(9A) -177.73(14) 
C(7)-N(1)-C(8)-C(7)#1 0.9(2)  N(1A)-C(8A)-C(9A)-C(10A) 26.8(2) 
C(7)-N(1)-C(8)-C(9) -176.79(15)  C(7A)#2-C(8A)-C(9A)-C(10A) -151.60(18) 
N(1)-C(8)-C(9)-C(11) -38.2(3)  N(1A)-C(8A)-C(9A)-C(11A) -41.9(2) 
C(7)#1-C(8)-C(9)-C(11) 144.2(2)  C(7A)#2-C(8A)-C(9A)-C(11A) 139.70(19) 
N(1)-C(8)-C(9)-C(10) 31.5(3)  C(8A)-C(9A)-C(10A)-C(11A) -108.4(2) 
C(7)#1-C(8)-C(9)-C(10) -146.1(2)  C(8A)-C(9A)-C(11A)-C(10A) 109.2(2) 
C(8)-C(9)-C(10)-C(11) -110.3(2)    
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Abstract 
 The purification of enantiomers by crystallisation is widely used in industry, but 
cannot be applied to all compounds. The improvement and optimization of existing 
techniques is therefore a major issue for scientists. 
 Thus, the synthesis of new chiral selectors has been proposed. A small library of 
monosubstituted β-cyclodextrins was synthesized to enhance the host-guest interactions. No 
chiral discrimination was visible so far and the existence of a large range of hydrates was 
highlighted. Structural studies and the determination of the host/guest/solvents phase 
diagrams may rationalise the chiral discrimination. 
 A second method to access to pure enantiomers was studied: the deracemisation. It 
quantitatively transforms a racemic suspension into pure enantiomer by action of glass beads. 
Unfortunately, this process is limited to chiral components easily racemisable in solution and 
crystallising as conglomerates. The crystallisation of conglomerates is uncommon and 
unpredictable. But, some families of compounds exhibit a high tendency to crystallise as 
conglomerates. Two new families were studied and it appeared that limited modifications of 
substituents do not disturb too much the crystal packing so that the full chiral discrimination 
in the solid state is preserved. 
 It has also been shown that ultrasounds can replace the action of the glass beads, 
making the process more efficient. In addition, studies carried out on the 1-(4-X-phenyl)-4,4-
dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-one (X = Cl, Me, Br and H) allowed to shed light 
on the deracemisation mechanism. 
 An additional study allowed to apply the deracemization process to the synthesis of 
enantiomerically pure active pharmaceutical compounds. 
 
Résumé 
 La purification d’énantiomères par cristallisation est largement utilisée en industrie, 
mais ne peut pas être appliquée à tous les composés. L’amélioration et l’optimisation de 
techniques déjà existantes est un donc enjeu considérable pour les scientifiques. 
 Ainsi, la synthèse de nouveaux sélecteurs chiraux a été proposée. Une petite librairie 
de β-cyclodextrines monosubstituées a été synthétisée, afin de consolider les interactions 
hote-invité. Aucune discrimination chirale n’a pu être mise en évidence et l’existence d’une 
large gamme d’hydrates a été observée. Les études structurales et la détermination des 
diagrammes de phases hôte/invité/solvant pourraient rationnaliser la discrimination chirale. 
 Un second procédé d’obtention d’énantiomères purs a été étudié : la déracemisation, 
permettant de transformer quantitativement une suspension racémique en énantiomère pur par 
action de billes de verre. Malheureusement, ce procédé est limité aux composés chiraux 
facilement racémisables en solution et cristallisant comme des conglomérats. Or la 
cristallisation de conglomérats est peu fréquente et surtout imprévisible. Cependant, certaines 
familles de composés ont une tendance prononcée à former des conglomérats. Deux nouvelles 
familles ont été étudiées et il est apparu que la modification modérée des substituents ne 
modifiait pas trop l’empilement cristallin, de telle sorte que la discrimination totale a l’état 
solide est préservée. 
 Il a aussi été prouvé que les ultrasons pouvaient remplacer l’action des billes de verre, 
rendant le procédé plus performant. De plus, les études menées sur les 1-(4-Xphenyl)-4,4-
dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-one (X = Cl, Me, Br, et H) ont permis d’éclaircir 
le mécanisme de déracémisation. 
 Une seconde étude à permis d’appliquer le procédé de déracémisation à la synthèse de 
l’énantiomère pur de composés pharmaceutiquement actifs. 
